U.S. patent application number 10/066500 was filed with the patent office on 2002-11-28 for secreted and transmembrane polypeptides and nucleic acids encoding.
This patent application is currently assigned to Genentech, Inc.. Invention is credited to Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, Gao, Wei-Qiang, Gerber, Hanspeter, Gerritsen, Mary E., Goddard, Audrey, Godowski, Paul J., Gurney, Austin L., Kljavin, Ivar J., Mather, Jennie P., Napier, Mary A., Pan, James, Paoni, Nicholas F., Roy, Margaret Ann, Stewart, Timothy A., Tumas, Daniel, Watanabe, Colin K., Williams, P Mickey, Wood, William I., Zhang, Zemin.
Application Number | 20020177165 10/066500 |
Document ID | / |
Family ID | 56290219 |
Filed Date | 2002-11-28 |
United States Patent
Application |
20020177165 |
Kind Code |
A1 |
Ashkenazi, Avi J. ; et
al. |
November 28, 2002 |
Secreted and transmembrane polypeptides and nucleic acids
encoding
Abstract
The present invention is directed to novel polypeptides and to
nucleic acid molecules encoding those polypeptides. Also provided
herein are vectors and host cells comprising those nucleic acid
sequences, chimeric polypeptide molecules comprising the
polypeptides of the present invention fused to heterologous
polypeptide sequences, antibodies which bind to the polypeptides of
the present invention and to methods for producing the polypeptides
of the present invention.
Inventors: |
Ashkenazi, Avi J.; (San
Mateo, CA) ; Baker, Kevin P.; (Darnestown, MD)
; Botstein, David A.; (Belmont, CA) ; Desnoyers,
Luc; (San Francisco, CA) ; Eaton, Dan L.; (San
Rafael, CA) ; Ferrara, Napoleone; (San Francisco,
CA) ; Fong, Sherman; (Alameda, CA) ; Gao,
Wei-Qiang; (Palo Alto, CA) ; Gerber, Hanspeter;
(San Francisco, CA) ; Gerritsen, Mary E.; (San
Mateo, CA) ; Goddard, Audrey; (San Francisco, CA)
; Godowski, Paul J.; (Hillsborough, CA) ; Gurney,
Austin L.; (Belmont, CA) ; Kljavin, Ivar J.;
(Layfayette, CA) ; Mather, Jennie P.; (Millbrae,
CA) ; Napier, Mary A.; (Hillsborough, CA) ;
Pan, James; (Belmont, CA) ; Paoni, Nicholas F.;
(Belmont, CA) ; Roy, Margaret Ann; (San Francisco,
CA) ; Stewart, Timothy A.; (San Francisco, CA)
; Tumas, Daniel; (Orinda, CA) ; Watanabe, Colin
K.; (Moraga, CA) ; Williams, P Mickey; (Half
Moon Bay, CA) ; Wood, William I.; (Hillsborough,
CA) ; Zhang, Zemin; (Foster City, CA) |
Correspondence
Address: |
Ginger R. Dreger
Knobbe Martens Olson & Bear
Suite 1150
201 California Street
San Francisco
CA
94111
US
|
Assignee: |
Genentech, Inc.
|
Family ID: |
56290219 |
Appl. No.: |
10/066500 |
Filed: |
February 1, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10066500 |
Feb 1, 2002 |
|
|
|
10002796 |
Nov 15, 2001 |
|
|
|
60056974 |
Aug 26, 1997 |
|
|
|
60059115 |
Sep 17, 1997 |
|
|
|
60059263 |
Sep 18, 1997 |
|
|
|
60059588 |
Sep 19, 1997 |
|
|
|
60062285 |
Oct 17, 1997 |
|
|
|
60062816 |
Oct 24, 1997 |
|
|
|
60063082 |
Oct 24, 1997 |
|
|
|
60063329 |
Oct 27, 1997 |
|
|
|
60063733 |
Oct 29, 1997 |
|
|
|
60066364 |
Nov 21, 1997 |
|
|
|
60066840 |
Nov 25, 1997 |
|
|
|
60069694 |
Dec 16, 1997 |
|
|
|
60074086 |
Feb 9, 1998 |
|
|
|
60074092 |
Feb 9, 1998 |
|
|
|
60079294 |
Mar 25, 1998 |
|
|
|
60081049 |
Apr 8, 1998 |
|
|
|
60095998 |
Aug 10, 1998 |
|
|
|
60097000 |
Aug 18, 1998 |
|
|
|
60099601 |
Sep 9, 1998 |
|
|
|
60099803 |
Sep 10, 1998 |
|
|
|
60099811 |
Sep 10, 1998 |
|
|
|
60099812 |
Sep 10, 1998 |
|
|
|
60100858 |
Sep 17, 1998 |
|
|
|
60101922 |
Sep 24, 1998 |
|
|
|
60106032 |
Oct 28, 1998 |
|
|
|
60109304 |
Nov 20, 1998 |
|
|
|
60125778 |
Mar 23, 1999 |
|
|
|
60139695 |
Jun 15, 1999 |
|
|
|
60145070 |
Jul 20, 1999 |
|
|
|
60145698 |
Jul 26, 1999 |
|
|
|
60149396 |
Aug 17, 1999 |
|
|
|
60169495 |
Dec 7, 1999 |
|
|
|
Current U.S.
Class: |
435/7.1 ;
435/183; 435/320.1; 435/325; 435/69.1; 514/19.8; 514/8.3; 514/9.6;
530/350; 530/388.1; 536/23.2 |
Current CPC
Class: |
C07H 21/04 20130101;
A61K 38/17 20130101; G01N 33/53 20130101; C12P 21/06 20130101; Y02A
50/473 20180101; C07K 14/435 20130101; C12N 9/00 20130101; C07K
16/40 20130101; C12P 21/02 20130101; C12N 5/06 20130101 |
Class at
Publication: |
435/7.1 ;
435/69.1; 435/320.1; 435/325; 435/183; 514/12; 530/350; 530/388.1;
536/23.2 |
International
Class: |
G01N 033/53; C07H
021/04; C12N 009/00; C12P 021/02; C12N 005/06; C07K 014/435; C07K
016/40; A61K 038/17 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 14, 1998 |
US |
PCT/US98/14552 |
Sep 10, 1998 |
US |
PCT/US98/18824 |
Sep 14, 1998 |
US |
PCT/US98/19093 |
Sep 16, 1998 |
US |
PCT/US98/19330 |
Sep 17, 1998 |
US |
PCT/US98/19437 |
Nov 20, 1998 |
US |
PCT/US98/24855 |
Dec 1, 1998 |
US |
PCT/US98/25108 |
Nov 25, 1998 |
US |
PCT/US98/25190 |
Mar 8, 1999 |
US |
PCT/US99/05028 |
Jun 2, 1999 |
US |
PCT/US99/12252 |
Sep 1, 1999 |
US |
PCT/US99/20111 |
Sep 8, 1999 |
US |
PCT/US99/20594 |
Sep 15, 1999 |
US |
PCT/US99/21090 |
Sep 15, 1999 |
US |
PCT/US99/21547 |
Dec 1, 1999 |
US |
PCT/US99/28301 |
Nov 30, 1999 |
US |
PCT/US99/28313 |
Dec 2, 1999 |
US |
PCT/US99/28565 |
Dec 20, 1999 |
US |
PCT/US99/30999 |
Jan 5, 2000 |
US |
PCT/US00/00219 |
Feb 18, 2000 |
US |
PCT/US00/04341 |
Feb 18, 2000 |
US |
PCT/US00/04342 |
Feb 22, 2000 |
US |
PCT/US00/04414 |
Mar 1, 2000 |
US |
PCT/US00/05601 |
Mar 2, 2000 |
US |
PCT/US00/05841 |
Mar 9, 2000 |
US |
PCT/US00/06471 |
Mar 20, 2000 |
US |
PCT/US00/07377 |
Mar 30, 2000 |
US |
PCT/US00/08439 |
May 15, 2000 |
US |
PCT/US00/13358 |
May 17, 2000 |
US |
PCT/US00/13705 |
May 22, 2000 |
US |
PCT/US00/14042 |
May 30, 2000 |
US |
PCT/US00/14941 |
Jun 2, 2000 |
US |
PCT/US00/15264 |
Aug 11, 2000 |
US |
PCT/US00/22031 |
Aug 24, 2000 |
US |
PCT/US00/23328 |
Aug 23, 2000 |
US |
PCT/US00/23522 |
Dec 1, 2000 |
US |
PCT/US00/32678 |
Feb 28, 2001 |
US |
PCT/US01/06520 |
May 30, 2001 |
US |
PCT/US01/17443 |
Jun 1, 2001 |
US |
PCT/US01/17800 |
Jun 20, 2001 |
US |
PCT/US01/19692 |
Jun 29, 2001 |
US |
PCT/US01/21066 |
Jul 9, 2001 |
US |
PCT/US01/21735 |
Claims
What is claimed is:
1. Isolated nucleic acid having at least 80% nucleic acid sequence
identity to a nucleotide sequence that encodes an amino acid
sequence selected from the group consisting of the amino acid
sequence shown in FIG. 2 (SEQ ID NO:4), FIG. 4 (SEQ ID NO:9), FIG.
6 (SEQ ID NO:11), FIG. 8 (SEQ ID NO:13), FIG. 10 (SEQ ID NO:15),
FIG. 12 (SEQ ID NO:17), FIG. 14 (SEQ ID NO:22), FIG. 16 (SEQ ID
NO:24), FIG. 18 (SEQ ID NO:29), FIG. 20 (SEQ ID NO:32), FIG. 22
(SEQ ID NO:39), FIG. 24 (SEQ ID NO:41), FIG. 26 (SEQ ID NO:52),
FIG. 28 (SEQ ID NO:54), FIG. 30 (SEQ ID NO:56), FIG. 32 (SEQ ID
NO:58), FIG. 34 (SEQ ID NO:63), FIG. 36 (SEQ ID NO:65), FIG. 38
(SEQ ID NO:73), FIG. 40 (SEQ ID NO:78), FIG. 42 (SEQ ID NO:80),
FIG. 44 (SEQ ID NO:84), FIG. 46 (SEQ ID NO:86), FIG. 48 (SEQ ID
NO:91), FIG. 50 (SEQ ID NO:99), FIG. 52 (SEQ ID NO:104), FIG. 54
(SEQ ID NO:106), FIG. 56 (SEQ ID NO:108), FIG. 58 (SEQ ID NO:110),
FIG. 60 (SEQ ID NO:115), FIG. 62 (SEQ ID NO:121), FIG. 64 (SEQ ID
NO:126), FIG. 66 (SEQ ID NO:128), FIG. 68 (SEQ ID NO:130), FIG. 70
(SEQ ID NO:132), FIG. 72 (SEQ ID NO:137) and FIG. 74 (SEQ ID
NO:139).
2. Isolated nucleic acid having at least 80% nucleic acid sequence
identity to a nucleotide sequence selected from the group
consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID
NO:3), FIG. 3 (SEQ ID NO:8), FIG. 5 (SEQ ID NO:10), FIG. 7 (SEQ ID
NO:12), FIG. 9 (SEQ ID NO:14), FIG. 11 (SEQ ID NO:16), FIG. 13 (SEQ
ID NO:21), FIG. 15 (SEQ ID NO:23), FIG. 17 (SEQ ID NO:28), FIG. 19
(SEQ ID NO:31), FIG. 21 (SEQ ID NO:38), FIG. 23 (SEQ ID NO:40),
FIG. 25 (SEQ ID NO:51), FIG. 27 (SEQ ID NO:53), FIG. 29 (SEQ ID
NO:55), FIG. 31 (SEQ ID NO:57), FIG. 33 (SEQ ID NO:62), FIG. 35
(SEQ ID NO:64), FIG. 37 (SEQ ID NO:72), FIG. 39 (SEQ ID NO:77),
FIG. 41 (SEQ ID NO:79), FIG. 43 (SEQ ID NO:83), FIG. 45 (SEQ ID
NO:85), FIG. 47 (SEQ ID NO:90), FIG. 49 (SEQ ID NO:98), FIG. 51
(SEQ ID NO:103), FIG. 53 (SEQ ID NO:105), FIG. 55 (SEQ ID NO:107),
FIG. 57 (SEQ ID NO:109), FIG. 59 (SEQ ID NO:114), FIG. 61 (SEQ ID
NO:120), FIG. 63 (SEQ ID NO:125), FIG. 65 (SEQ ID NO:127), FIGS.
67A-B (SEQ ID NO:129), FIG. 69 (SEQ ID NO:131), FIG. 71 (SEQ ID
NO:136) and FIG. 73 (SEQ ID NO:138).
3. Isolated nucleic acid having at least 80% nucleic acid sequence
identity to a nucleotide sequence selected from the group
consisting of the full-length coding sequence of the nucleotide
sequence shown in FIG. 1 (SEQ ID NO:3), FIG. 3 (SEQ ID NO:8), FIG.
5 (SEQ ID NO:10), FIG. 7 (SEQ ID NO:12), FIG. 9 (SEQ ID NO:14),
FIG. 11 (SEQ ID NO:16), FIG. 13 (SEQ ID NO:21), FIG. 15 (SEQ ID
NO:23), FIG. 17 (SEQ ID NO:28), FIG. 19 (SEQ ID NO:31), FIG. 21
(SEQ ID NO:38), FIG. 23 (SEQ ID NO:40), FIG. 25 (SEQ ID NO:51),
FIG. 27 (SEQ ID NO:53), FIG. 29 (SEQ ID NO:55), FIG. 31 (SEQ ID
NO:57), FIG. 33 (SEQ ID NO:62), FIG. 35 (SEQ ID NO:64), FIG. 37
(SEQ ID NO:72), FIG. 39 (SEQ ID NO:77), FIG. 41 (SEQ ID NO:79),
FIG. 43 (SEQ ID NO:83), FIG. 45 (SEQ ID NO:85), FIG. 47 (SEQ ID
NO:90), FIG. 49 (SEQ ID NO:98), FIG. 51 (SEQ ID NO:103), FIG. 53
(SEQ ID NO:105), FIG. 55 (SEQ ID NO:107), FIG. 57 (SEQ ID NO:109),
FIG. 59 (SEQ ID NO:114), FIG. 61 (SEQ ID NO:120), FIG. 63 (SEQ ID
NO:125), FIG. 65 (SEQ ID NO:127), FIGS. 67A-B (SEQ ID NO:129), FIG.
69 (SEQ ID NO:131), FIG. 71 (SEQ ID NO:136) and FIG. 73 (SEQ ID
NO:138).
4. Isolated nucleic acid having at least 80% nucleic acid sequence
identity to the full-length coding sequence of the DNA deposited
under any ATCC accession number shown in Table 10.
5. A vector comprising the nucleic acid of any one of claims 1 to
4.
6. The vector of claim 5 operably linked to control sequences
recognized by a host cell transformed with the vector.
7. A host cell comprising the vector of claim 5.
8. The host cell of claim 7, wherein said cell is a CHO cell.
9. The host cell of claim 7, wherein said cell is an E. coli.
10. The host cell of claim 7, wherein said cell is a yeast
cell.
11. A process for producing a PRO polypeptides comprising culturing
the host cell of claim 7 under conditions suitable for expression
of said PRO polypeptide and recovering said PRO polypeptide from
the cell culture.
12. An isolated polypeptide having at least 80% amino acid sequence
identity to an amino acid sequence selected from the group
consisting of the amino acid sequence shown in FIG. 2 (SEQ ID
NO:4), FIG. 4 (SEQ ID NO:9), FIG. 6 (SEQ ID NO:11), FIG. 8 (SEQ ID
NO:13), FIG. 10 (SEQ ID NO:15), FIG. 12 (SEQ ID NO:17), FIG. 14
(SEQ ID NO:22), FIG. 16 (SEQ ID NO:24), FIG. 18 (SEQ ID NO:29),
FIG. 20 (SEQ ID NO:32), FIG. 22 (SEQ ID NO:39), FIG. 24 (SEQ ID
NO:41), FIG. 26 (SEQ ID NO:52), FIG. 28 (SEQ ID NO:54), FIG. 30
(SEQ ID NO:56), FIG. 32 (SEQ ID NO:58), FIG. 34 (SEQ ID NO:63),
FIG. 36 (SEQ ID NO:65), FIG. 38 (SEQ ID NO:73), FIG. 40 (SEQ ID
NO:78), FIG. 42 (SEQ ID NO:80), FIG. 44 (SEQ ID NO:84), FIG. 46
(SEQ ID NO:86), FIG. 48 (SEQ ID NO:91), FIG. 50 (SEQ ID NO:99),
FIG. 52 (SEQ ID NO:104), FIG. 54 (SEQ ID NO:106), FIG. 56 (SEQ ID
NO:108), FIG. 58 (SEQ ID NO:110), FIG. 60 (SEQ ID NO:115), FIG. 62
(SEQ ID NO:121), FIG. 64 (SEQ ID NO:126), FIG. 66 (SEQ ID NO:128),
FIG. 68 (SEQ ID NO:130), FIG. 70 (SEQ ID NO:132), FIG. 72 (SEQ ID
NO:137) and FIG. 74 (SEQ ID NO:139).
13. An isolated polypeptide scoring at least 80% positives when
compared to an amino acid sequence selected from the group
consisting of the amino acid sequence shown in FIG. 2 (SEQ ID
NO:4), FIG. 4 (SEQ ID NO:9), FIG. 6 (SEQ ID NO:11), FIG. 8 (SEQ ID
NO:13), FIG. 10 (SEQ ID NO:15), FIG. 12 (SEQ ID NO:17), FIG. 14
(SEQ ID NO:22), FIG. 16 (SEQ ID NO:24), FIG. 18 (SEQ ID NO:29),
FIG. 20 (SEQ ID NO:32), FIG. 22 (SEQ ID NO:39), FIG. 24 (SEQ ID
NO:41), FIG. 26 (SEQ ID NO:52), FIG. 28 (SEQ ID NO:54), FIG. 30
(SEQ ID NO:56), FIG. 32 (SEQ ID NO:58), FIG. 34 (SEQ ID NO:63),
FIG. 36 (SEQ ID NO:65), FIG. 38 (SEQ ID NO:73), FIG. 40 (SEQ ID
NO:78), FIG. 42 (SEQ ID NO:80), FIG. 44 (SEQ ID NO:84), FIG. 46
(SEQ ID NO:86), FIG. 48 (SEQ ID NO:91), FIG. 50 (SEQ ID NO:99),
FIG. 52 (SEQ ID NO:104), FIG. 54 (SEQ ID NO:106), FIG. 56 (SEQ ID
NO:108), FIG. 58 (SEQ ID NO.110), FIG. 60 (SEQ ID NO:115), FIG. 62
(SEQ ID NO:121), FIG. 64 (SEQ ID NO:126), FIG. 66 (SEQ ID NO:128),
FIG. 68 (SEQ ID NO:130), FIG. 70 (SEQ ID NO:132), FIG. 72 (SEQ ID
NO:137) and FIG. 74 (SEQ ID NO:139).
14. An isolated polypeptide having at least 80% amino acid sequence
identity to an amino acid sequence encoded by the full-length
coding sequence of the DNA deposited under any ATCC accession
number shown in Table 10.
15. A chimeric molecule comprising a polypeptide according to any
one of claims 12 to 14 fused to a heterologous amino acid
sequence.
16. The chimeric molecule of claim 15, wherein said heterologous
amino acid sequence is an epitope tag sequence.
17. The chimeric molecule of claim 15, wherein said heterologous
amino acid sequence is a Fc region of an immunoglobulin.
18. An antibody which specifically binds to a polypeptide according
to any one of claims 12 to 14.
19. The antibody of claim 18, wherein said antibody is a monoclonal
antibody, a humanized antibody or a single-chain antibody.
20. Isolated nucleic acid having at least 80% nucleic acid sequence
identity to: (a) a nucleotide sequence encoding the polypeptide
shown in FIG. 2 (SEQ ID NO:4), FIG. 4 (SEQ ID NO:9), FIG. 6 (SEQ ID
NO:11), FIG. 8 (SEQ ID NO:13), FIG. 10 (SEQ ID NO:15), FIG. 12 (SEQ
ID NO:17), FIG. 14 (SEQ ID NO:22), FIG. 16 (SEQ ID NO:24), FIG. 18
(SEQ ID NO:29), FIG. 20 (SEQ ID NO:32), FIG. 22 (SEQ ID NO:39),
FIG. 24 (SEQ ID NO:41), FIG. 26 (SEQ ID NO:52), FIG. 28 (SEQ ID
NO:54), FIG. 30 (SEQ ID NO:56), FIG. 32 (SEQ ID NO:58), FIG. 34
(SEQ ID NO:63), FIG. 36 (SEQ ID NO:65), FIG. 38 (SEQ ID NO:73),
FIG. 40 (SEQ ID NO:78), FIG. 42 (SEQ ID NO:80), FIG. 44 (SEQ ID
NO:84), FIG. 46 (SEQ ID NO:86), FIG. 48 (SEQ ID NO:91), FIG. 50
(SEQ ID NO:99), FIG. 52 (SEQ ID NO:104), FIG. 54 (SEQ ID NO:106),
FIG. 56 (SEQ ID NO:108), FIG. 58 (SEQ ID NO:110), FIG. 60 (SEQ ID
NO:115), FIG. 62 (SEQ ID NO:121), FIG. 64 (SEQ ID NO:126), FIG. 66
(SEQ ID NO:128), FIG. 68 (SEQ ID NO:130), FIG. 70 (SEQ ID NO:132),
FIG. 72 (SEQ ID NO:137) or FIG. 74 (SEQ ID NO:139), lacking its
associated signal peptide; (b) a nucleotide sequence encoding an
extracellular domain of the polypeptide shown in FIG. 2 (SEQ ID
NO:4), FIG. 4 (SEQ ID NO:9), FIG. 6 (SEQ ID NO:11), FIG. 8 (SEQ ID
NO:13), FIG. 10 (SEQ ID NO:15), FIG. 12 (SEQ ID NO:17), FIG. 14
(SEQ ID NO:22), FIG. 16 (SEQ ID NO:24), FIG. 18 (SEQ ID NO:29),
FIG. 20 (SEQ ID NO:32), FIG. 22 (SEQ ID NO:39), FIG. 24 (SEQ ID
NO:41), FIG. 26 (SEQ ID NO:52), FIG. 28 (SEQ ID NO:54), FIG. 30
(SEQ ID NO:56), FIG. 32 (SEQ ID NO:58), FIG. 34 (SEQ ID NO:63),
FIG. 36 (SEQ ID NO:65), FIG. 38 (SEQ ID NO:73), FIG. 40 (SEQ ID
NO:78), FIG. 42 (SEQ ID NO:80), FIG. 44 (SEQ ID NO:84), FIG. 46
(SEQ ID NO:86), FIG. 48 (SEQ ID NO:91), FIG. 50 (SEQ ID NO:99),
FIG. 52 (SEQ ID NO:104), FIG. 54 (SEQ ID NO:106), FIG. 56 (SEQ ID
NO:108), FIG. 58 (SEQ ID NO:110), FIG. 60 (SEQ ID NO:115), FIG. 62
(SEQ ID NO:121), FIG. 64 (SEQ ID NO:126), FIG. 66 (SEQ ID NO:128),
FIG. 68 (SEQ ID NO:130), FIG. 70 (SEQ ID NO:132), FIG. 72 (SEQ ID
NO:137) or FIG. 74 (SEQ ID NO:139), with its associated signal
peptide; or (c) a nucleotide sequence encoding an extracellular
domain of the polypeptide shown in FIG. 2 (SEQ ID NO:4), FIG. 4
(SEQ ID NO:9), FIG. 6 (SEQ ID NO:11), FIG. 8 (SEQ ID NO:13), FIG.
10 (SEQ ID NO:15), FIG. 12 (SEQ ID NO:17), FIG. 14 (SEQ ID NO:22),
FIG. 16 (SEQ ID NO:24), FIG. 18 (SEQ ID NO:29), FIG. 20 (SEQ ID
NO:32), FIG. 22 (SEQ ID NO:39), FIG. 24 (SEQ ID NO:41), FIG. 26
(SEQ ID NO:52), FIG. 28 (SEQ ID NO:54), FIG. 30 (SEQ ID NO:56),
FIG. 32 (SEQ ID NO:58), FIG. 34 (SEQ ID NO:63), FIG. 36 (SEQ ID
NO:65), FIG. 38 (SEQ ID NO:73), FIG. 40 (SEQ ID NO:78), FIG. 42
(SEQ ID NO:80), FIG. 44 (SEQ ID NO:84), FIG. 46 (SEQ ID NO:86),
FIG. 48 (SEQ ID NO:91), FIG. 50 (SEQ ID NO:99), FIG. 52 (SEQ ID
NO:104), FIG. 54 (SEQ ID NO:106), FIG. 56 (SEQ ID NO:108), FIG. 58
(SEQ ID NO:110), FIG. 60 (SEQ ID NO:115), FIG. 62 (SEQ ID NO:121),
FIG. 64 (SEQ ID NO:126), FIG. 66 (SEQ ID NO:128), FIG. 68 (SEQ ID
NO:130), FIG. 70 (SEQ ID NO:132), FIG. 72 (SEQ ID NO:137) or FIG.
74 (SEQ ID NO:139), lacking its associated signal peptide.
21. An isolated polypcptide having at least 80% amino acid sequence
identity to: (a) the polypeptide shown in FIG. 2 (SEQ ID NO:4),
FIG. 4 (SEQ ID NO:9), FIG. 6 (SEQ ID NO:11), FIG. 8 (SEQ ID NO:13),
FIG. 10 (SEQ ID NO:15), FIG. 12 (SEQ ID NO:17), FIG. 14 (SEQ ID
NO:22), FIG. 16 (SEQ ID NO:24), FIG. 18 (SEQ ID NO:29), FIG. 20
(SEQ ID NO:32), FIG. 22 (SEQ ID NO:39), FIG. 24 (SEQ ID NO:41),
FIG. 26 (SEQ ID NO:52), FIG. 28 (SEQ ID NO:54), FIG. 30 (SEQ ID
NO:56), FIG. 32 (SEQ ID NO:58), FIG. 34 (SEQ ID NO:63), FIG. 36
(SEQ ID NO:65), FIG. 38 (SEQ ID NO:73), FIG. 40 (SEQ ID NO:78),
FIG. 42 (SEQ ID NO:80), FIG. 44 (SEQ ID NO:84), FIG. 46 (SEQ ID
NO:86), FIG. 48 (SEQ ID NO:91), FIG. 50 (SEQ ID NO:99), FIG. 52
(SEQ ID NO:104), FIG. 54 (SEQ ID NO:106), FIG. 56 (SEQ ID NO:108),
FIG. 58 (SEQ ID NO:110), FIG. 60 (SEQ ID NO:115), FIG. 62 (SEQ ID
NO:121), FIG. 64 (SEQ ID NO:126), FIG. 66 (SEQ ID NO:128), FIG. 68
(SEQ ID NO:130), FIG. 70 (SEQ ID NO:132), FIG. 72 (SEQ ID NO:137)
or FIG. 74 (SEQ ID NO:139), lacking its associated signal peptide;
(b) an extracellular domain of the polypeptide shown in FIG. 2 (SEQ
ID NO:4), FIG. 4 (SEQ ID NO:9), FIG. 6 (SEQ ID NO:11), FIG. 8 (SEQ
ID NO:13), FIG. 10 (SEQ ID NO:15), FIG. 12 (SEQ ID NO:17), FIG. 14
(SEQ ID NO:22), FIG. 16 (SEQ ID NO:24), FIG. 18 (SEQ ID NO:29),
FIG. 20 (SEQ ID NO:32), FIG. 22 (SEQ ID NO:39), FIG. 24 (SEQ ID
NO:41), FIG. 26 (SEQ ID NO:52), FIG. 28 (SEQ ID NO:54), FIG. 30
(SEQ ID NO:56), FIG. 32 (SEQ ID NO:58), FIG. 34 (SEQ ID NO:63),
FIG. 36 (SEQ ID NO:65), FIG. 38 (SEQ ID NO:73), FIG. 40 (SEQ ID
NO:78), FIG. 42 (SEQ ID NO:80), FIG. 44 (SEQ ID NO:84), FIG. 46
(SEQ ID NO:86), FIG. 48 (SEQ ID NO:91), FIG. 50 (SEQ ID NO:99),
FIG. 52 (SEQ ID NO:104), FIG. 54 (SEQ ID NO:106), FIG. 56 (SEQ ID
NO:108), FIG. 58 (SEQ ID NO:110), FIG. 60 (SEQ ID NO:115), FIG. 62
(SEQ ID NO:121), FIG. 64 (SEQ ID NO:126), FIG. 66 (SEQ ID NO:128),
FIG. 68 (SEQ ID NO:130), FIG. 70 (SEQ ID NO:132), FIG. 72 (SEQ ID
NO:137) or FIG. 74 (SEQ ID NO:139), with its associated signal
peptide; or (c) an extracellular domain of the polypeptide shown in
FIG. 2 (SEQ ID NO:4), FIG. 4 (SEQ ID NO:9), FIG. 6 (SEQ ID NO:11),
FIG. 8 (SEQ ID NO:13), FIG. 10 (SEQ ID NO:15), FIG. 12 (SEQ ID
NO:17), FIG. 14 (SEQ ID NO:22), FIG. 16 (SEQ ID NO:24), FIG. 18
(SEQ ID NO:29), FIG. 20 (SEQ ID NO:32), FIG. 22 (SEQ ID NO:39),
FIG. 24 (SEQ ID NO:41), FIG. 26 (SEQ ID NO:52), FIG. 28 (SEQ ID
NO:54), FIG. 30 (SEQ ID NO:56), FIG. 32 (SEQ ID NO:58), FIG. 34
(SEQ ID NO:63), FIG. 36 (SEQ ID NO:65), FIG. 38 (SEQ ID NO:73),
FIG. 40 (SEQ ID NO:78), FIG. 42 (SEQ ID NO:80), FIG. 44 (SEQ ID
NO:84), FIG. 46 (SEQ ID NO:86), FIG. 48 (SEQ ID NO:91), FIG. 50
(SEQ ID NO:99), FIG. 52 (SEQ ID NO:104), FIG. 54 (SEQ ID NO:106),
FIG. 56 (SEQ ID NO:108), FIG. 58 (SEQ ID NO:110), FIG. 60 (SEQ ID
NO:115), FIG. 62 (SEQ ID NO:121), FIG. 64 (SEQ ID NO:126), FIG. 66
(SEQ ID NO:128), FIG. 68 (SEQ ID NO:130), FIG. 70 (SEQ ID NO:132),
FIG. 72 (SEQ ID NO:137) or FIG. 74 (SEQ ID NO:139), lacking its
associated signal peptide.
22. A method of detecting a polypeptide designaed as A, B, C, D, E,
F, G, H, or I in a sample suspected of containing an A, B, C, D, E,
F, G, H, or I polypeptide, said method comprising contacting said
sample with a polypeptide designated herein as J, K, L, M, N, O, P,
Q, R, S or T and determining the formation of a A/J, B/K, C/L, C/M,
C/N, C/J, D/O, E/P, F/Q, G/R, H/S or I/T polypeptide conjugate in
said sample, wherein the formation of said conjugate is indicative
of the presence of an A, B, C, D, E, F, G, H, or I polypeptide in
said sample and wherein A is a PRO533 polypeptide, B is a PRO301
polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide,
E is a PRO1411 polypeptide, F is a PRO 10096 polypeptide, G is a
PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003
polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide,
L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an
FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356
polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide,
S is a PRO265 polypeptide and T is a PRO941 polypeptide.
23. The method according to claim 22, wherein said sample comprises
cells suspected of expressing said A, B, C, D, E, F, G, H, or I
polypeptide.
24. The method according to claim 22, wherein said J, K, L, M, N,
O, P, Q, R, S or T polypeptide is labeled with a detectable
label.
25. The method according to claim 22, wherein said J, K, L, M, N,
O, P, Q, R, S or T polypeptide is attached to a solid support.
26. A method of detecting a polypeptide designated as J, K, L, M,
N, O, P, Q, R, S or T in a sample suspected of containing a J, K,
L, M, N, O, P, Q, R, S or T polypeptide, said method comprising
contacting said sample with a polypeptide designated herein as A,
B, C, D, E, F, G, H, or I and determining the formation of a A/J,
B/K, C/L, C/M, C/N, C/J, D/O, E/P, F/Q, G/R, H/S or I/T polypeptide
conjugate in said sample, wherein the formation of said conjugate
is indicative of the presence of a J, K, L, M, N, O, P, Q, R, S or
T polypeptide in said sample and wherein A is a PRO533 polypeptide,
B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337
polypeptide, E is a PRO1411 polypeptide, F is a PRO10096
polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide,
I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a
PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1
polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004
polypeptide, P is a PRO4356 polypeptide, Q is a PRO2630
polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide
and T is a PRO941 polypeptide.
27. The method according to claim 26, wherein said sample comprises
cells suspected of expressing said J, K, L, M, N, O, P, Q, R, S or
T polypeptide.
28. The method according to claim 26, wherein said A, B, C, D, E,
F, G, H, or I polypeptide is labeled with a detectable label.
29. The method according to claim 26, wherein said A, B, C, D, E,
F, G, H, or I polypeptide is attached to a solid support.
30. A method of linking a bioactive molecule to a cell expressing a
polypeptide designated as A, B, C, D, E, F, G, H, or I, said method
comprising contacting said cell with a polypeptide designated as J,
K, L, M, N, O, P, Q, R, S or T that is bound to said bioactive
molecule and allowing said A, B, C, D, E, F, G, H, or I and said J,
K, L, M, N, O, P, Q, R, S or T polypeptides to bind to one another,
thereby linking said bioactive molecules to said cell, wherein A is
a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187
polypeptide, D is a PRO337 polypeptide, E is a PRO141 1
polypeptide, F is a PRO10096 polypeptide, G is a PRO246
polypeptide, H is a PRO6307 polypeptide, I is a PRO6003
polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide,
L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an
FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356
polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide,
S is a PRO265 polypeptide and T is a PRO941 polypeptide.
31. The method according to claim 30, wherein said bioactive
molecule is a toxin, a radiolabel or an antibody.
32. The method according to claim 30, wherein said bioactive
molecule causes the death of said cell.
33. A method of linking a bioactive molecule to a cell expressing a
polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T, said
method comprising contacting said cell with a polypeptide
designated as A, B, C, D, E, F, G, H, or I that is bound to said
bioactive molecule and allowing said A, B, C, D, E, F, G, H, or I
and said J, K, L, M, N, O, P, Q, R, S or T polypeptides to bind to
one another, thereby linking said bioactive molecules to said cell,
wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is
a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411
polypeptide, F is a PRO10096 polypeptide, G is a PRO246
polypeptide, H is a PRO6307 polypeptide, I is a PRO6003
polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide,
L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an
FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356
polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide,
S is a PRO265 polypeptide and T is a PRO941 polypeptide.
34. The method according to claim 33, wherein said bioactive
molecule is a toxin, a radiolabel or an antibody.
35. The method according to claim 33, wherein said bioactive
molecule causes the death of said cell.
36. A method of modulating at least one biological activity of a
cell expressing a polypeptide designated as A, B, C, D, E, F, G, H,
or I, said method comprising contacting said cell with a
polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T or an
anti-A, B, C, D, E, F, G, H, or I polypeptide antibody, whereby
said J, K, L, M, N, O, P, Q, R, S or T polypeptide or anti-A, B, C,
D, E, F, G, H, or I polypeptide antibody binds to said A, B, C, D,
E, F, G, H, or I polypeptide, thereby modulating at least one
biological activity of said cell.
37. The method according to claim 36, wherein said cell is
killed.
38. A method of modulating at least one biological activity of a
cell expressing a polypeptide designated as J, K, L, M, N, O, P, Q,
R, S or T, said method comprising contacting said cell with a
polypeptide designated as A, B, C, D, E, F, G, H, or I or an
anti-J, K, L, M, N, O, P, Q, R, S or T polypeptide antibody,
whereby said anti-J, K, L, M, N, O, P, Q, R, S or T polypeptide
antibody or A, B, C, D, E, F, G, H, or I polypeptide antibody binds
to said J, K, L, M, N, O, P, Q, R, S or T polypeptide, thereby
modulating at least one biological activity of said cell.
39. The method according to claim 36, wherein said cell is killed.
Description
FIELD OF THE INVENTION
[0001] The present invention relates generally to the
identification and isolation of novel DNA and to the recombinant
production of novel polypeptides.
BACKGROUND OF THE INVENTION
[0002] Extracellular proteins play important roles in, among other
things, the formation, differentiation and maintenance of
multicellular organisms. The fate of many individual cells, e.g.,
proliferation, migration, differentiation, or interaction with
other cells, is typically governed by information received from
other cells and/or the immediate environment. This information is
often transmitted by secreted polypeptides (for instance, mitogenic
factors, survival factors, cytotoxic factors, differentiation
factors, neuropeptides, and hormones) which are, in turn, received
and interpreted by diverse cell receptors or membrane-bound
proteins. These secreted polypeptides or signaling molecules
normally pass through the cellular secretory pathway to reach their
site of action in the extracellular environment.
[0003] Secreted proteins have various industrial applications,
including as pharmaceuticals, diagnostics, biosensors and
bioreactors. Most protein drugs available at present, such as
thrombolytic agents, interferons, interleukins, erythropoietins,
colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors, which are membrane proteins,
also have potential as therapeutic or diagnostic agents. Efforts
are being undertaken by both industry and academia to identify new,
native secreted proteins. Many efforts are focused on the screening
of mammalian recombinant DNA libraries to identify the coding
sequences for novel secreted proteins. Examples of screening
methods and techniques are described in the literature [see, for
example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996);
U.S. Pat. No. 5,536,637)].
[0004] Membrane-bound proteins and receptors can play important
roles in, among other things, the formation, differentiation and
maintenance of multicellular organisms. The fate of many individual
cells, e.g., proliferation, migration, differentiation, or
interaction with other cells, is typically governed by information
received from other cells and/or the immediate environment. This
information is often transmitted by secreted polypeptides (for
instance, mitogenic factors, survival factors, cytotoxic factors,
differentiation factors, neuropeptides, and hormones) which are, in
turn, received and interpreted by diverse cell receptors or
membrane-bound proteins. Such membrane-bound proteins and cell
receptors include, but are not limited to, cytokine receptors,
receptor kinases, receptor phosphatases, receptors involved in
cell-cell interactions, and cellular adhesin molecules like
selectins and integrins. For instance, transduction of signals that
regulate cell growth and differentiation is regulated in part by
phosphorylation of various cellular proteins. Protein tyrosine
kinases, enzymes that catalyze that process, can also act as growth
factor receptors. Examples include fibroblast growth factor
receptor and nerve growth factor receptor.
[0005] Membrane-bound proteins and receptor molecules have various
industrial applications, including as pharmaceutical and diagnostic
agents. Receptor immunoadhesins, for instance, can be employed as
therapeutic agents to block receptor-ligand interactions. The
membrane-bound proteins can also be employed for screening of
potential peptide or small molecule inhibitors of the relevant
receptor/ligand interaction.
[0006] Efforts are being undertaken by both industry and academia
to identify new, native receptor or membrane-bound proteins. Many
efforts are focused on the screening of mammalian recombinant DNA
libraries to identify the coding sequences for novel receptor or
membrane-bound proteins.
[0007] 1. PRO196
[0008] The abbreviations "TIE" or "tie" are acronyms, which stand
for "tyrosine kinase containing Ig and EGF homology domains" and
were coined to designate a new family of receptor tyrosine kinases
which arc almost exclusively expressed in vascular endothelial
cells and early hemopoietic cells, and are characterized by the
presence of an EGF-like domain, and extracellular folding units
stabilized by intra-chain disulfide bonds, generally referred to as
"immunoglobulin (IG)-like" folds. A tyrosine kinase homologous cDNA
fragment from human leukemia cells (tie) was described by Partanen
et al., Proc. Natl. Acad. Sci. USA 87, 8913-8917 (1990). The mRNA
of this human "tie" receptor has been detected in all human fetal
and mouse embryonic tissues, and has been reported to be localized
in the cardiac and vascular endothelial cells. Korhonen et al.,
Blood 80 2548-2555 (1992); PCT Application Publication No. WO
93/14124 (published Jul. 22, 1993). The rat homolog of human tie,
referred to as "tie-1", was identified by Maisonpierre et al.,
Oncogene 8, 1631-1637 (1993)). Another tie receptor, designated
"tie-2" was originally identified in rats ( Dumont et al., Oncogene
8, 1293-1301 (1993)), while the human homolog of tie-2, referred to
as "ork" was described in U.S. Pat. No. 5,447,860 (Ziegler). The
murine homolog of tie-2 was originally tenned "tek." The cloning of
a mouse tie-2 receptor from a brain capillary cDNA library is
disclosed in PCT Application Publication No. WO 95/13387 (published
May 18, 1995). The TIE receptors are believed to be actively
involved in angiogenesis, and may play a role in hemopoiesis as
well.
[0009] The expression cloning of human TIE-2 ligands has been
described in PCT Application Publication No. WO 96/11269 (published
Apr. 18, 1996) and in U.S. Pat. No. 5,521,073 (published May 28,
1996). A vector designated as .lambda.gt10 encoding a TIE-2 ligand
named "htie-2 ligand 1" or "hTL1" has been deposited under ATCC
Accession No. 75928. A plasmid encoding another TIE-2 ligand
designated "htie-2 2" or "hTL2" is available under ATCC Accession
No. 75928. This second ligand has been described as an antagonist
of the TAI-2 receptor. The identification of secreted human and
mouse ligands for the TIE-2 receptor has been reported by Davis et
al., Cell 87, 1161-1169 (1996). The human ligand designated
"Angiopoietin-1", to reflect its role in angiogenesis and potential
action during hemopoiesis, is the same ligand as the ligand
variously designated as "htie-2 1" or "hTL-1" in WO 96/11269.
Angiopoietin-1 has been described to play an angiogenic role later
and distinct from that of VEGF (Suri et al., Cell 87, 1171-1180
(1996)). Since TIE-2 is apparently upregulated during the
pathologic angiogenesis requisite for tumor growth (Kaipainen et
al., Cancer Res. 54, 6571-6577 (1994)) angiopoietin-1 has been
suggested to be additionally useful for specifically targeting
tumor vasculature (Davis et al., supra).
[0010] 2. PRO444
[0011] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel secreted proteins. We herein
describe the identification and isolation of cDNA molecules
encoding novel secreted polypeptides, designated herein as PRO444
polypeptides.
[0012] 3. PRO183
[0013] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel secreted proteins. We herein
describe the identification and isolation of cDNA molecules
encoding novel polypeptides, designated herein as PRO183
polypeptides.
[0014] 4. PRO185
[0015] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel secreted proteins. We herein
describe the identification and isolation of cDNA molecules
encoding novel polypeptides, designated herein as PRO185
polypeptides.
[0016] 5. PRO210 and PRO217
[0017] Epidermal growth factor (EGF) is a conventional mitogenic
factor that stimulates the proliferation of various types of cells
including epithelial cells and fibroblasts. EGF binds to and
activates the EGF receptor (EGFR), which initiates intracellular
signaling and subsequent effects. The EGFR is expressed in neurons
of the cerebral cortex, cerebellum, and hippocampus in addition to
other regions of the central nervous system (CNS). In addition, EGF
is also expressed in various regions of the CNS. Therefore, EGF
acts not only on mitotic cells, but also on postmitotic neurons. In
fact, many studies have indicated that EGF has neurotrophic or
neuromodulatory effects on various types of neurons in the CNS. For
example, EGF acts directly on cultured cerebral cortical and
cerebellar neurons, enhancing neurite outgrowth and survival. On
the other hand, EGF also acts on other cell types, including septal
cholinergic and mesencephalic dopaminergic neurons, indirectly
through glial cells. Evidence of the effects of EGF on neurons in
the CNS is accumulating, but the mechanisms of action remain
essentially unknown. EGF-induced signaling in mitotic cells is
better understood than in postmitotic neurons. Studies of cloned
pheochromocytoma PC12 cells and cultured cerebral cortical neurons
have suggested that the EGF-induced neurotrophic actions are
mediated by sustained activation of the EGFR and mitogen-activated
protein kinase (MAPK) in response to EGF. The sustained
intracellular signaling correlates with the decreased rate of EGFR
down-regulation, which might determine the response of neuronal
cells to EGF. It is likely that EGF is a multi-potent growth factor
that acts upon various types of cells including mitotic cells and
postmitotic neurons.
[0018] EGF is produced by the salivary and Brunner's glands of the
gastrointestinal system, kidney, pancreas, thyroid gland, pituitary
gland, and the nervous system, and is found in body fluids such as
saliva, blood, cerebrospinal fluid (CSF), urine, amniotic fluid,
prostatic fluid, pancreatic juice, and breast milk, Plata-Salaman,
CR Peptides 12: 653-663 (1991).
[0019] EGF is mediated by its membrane specific receptor, which
contains an intrinsic tyrosine kinase. Stoscheck C M et al., J.
Cell Biochem. 31: 135-152 (1986). EGF is believed to function by
binding to the extracellular portion of its receptor which induces
a transmembrane signal that activates the intrinsic tyrosine
kinase.
[0020] Purification and sequence analysis of the EGF-like domain
has revealed the presence of six conserved cysteine residues which
cross-bind to create three peptide loops, Savage C R et al., J.
Biol. Chem. 248: 7669-7672 (1979). It is now generally known that
several other peptides can react with the EGF receptor which share
the same generalized motif XnCX7CX4/5CX10CXCX5GX2CXn, where X
represents any non-cysteine amino acid, and n is a variable repeat
number. Non isolated peptides having this motif include TGF-a,
amphiregulin, schwannoma-derived growth factor (SDGF),
heparin-binding EGF-like growth factors and certain virally encoded
peptides (e.g., Vaccinia virus, Reisner A H, Nature 313: 801-803
(1985), Shope fibroma virus, Chang W., et al., Mol Cell Biol. 7:
535-540 (1987), Molluscum contagiosum, Porter C D & Archard L
C, J. Gen. Virol. 68: 673-682 (1987), and Myxoma virus, Upton C et
al., J. Virol. 61: 1271-1275 (1987). Prigent S A & Lemoine N.
R., Prog. Growth Factor Res. 4: 1-24 (1992).
[0021] EGF-like domains are not confined to growth factors but have
been observed in a variety of cell-surface and extracellular
proteins which have interesting properties in cell adhesion,
protein-protein interaction and development, Laurence D J R &
Gusterson B A, Tumor Biol. 11: 229-261 (1990). These proteins
include blood coagulation factors (factors VI, IX, X, XII, protein
C, protein S, protein Z, tissue plasminogen activator, urokinase),
extracellular matrix components (laminin, cytotactin, entactin),
cell surface receptors (LDL receptor, thrombomodulin receptor) and
immunity-related proteins (complement Clr, uromodulin).
[0022] Even more interesting, the general structure pattern of
EGF-like precursors is preserved through lower organisms as well as
in mammalian cells. A number of genes with developmental
significance have been identified in invertebrates with EGF-like
repeats. For example, the notch gene of Drosophila encodes 36
tandemly arranged 40 amino acid repeats which show homology to EGF,
Wharton W et al., Cell 43: 557-581 (1985). Hydropathy plots
indicate a putative membrane spanning domain, with the EGF-related
sequences being located on the extracellular side of the membrane.
Other homeotic genes with EGF-like repeats include Delta, 95F and
5ZD which were identified using probes based on Notch, and the
nematode gene Lin-12 which encodes a putative receptor for a
developmental signal transmitted between two specified cells.
[0023] Specifically, EGF has been shown to have potential in the
preservation and maintenance of gastrointestinal mucosa and the
repair of acute and chronic mucosal lesions, Konturek, P C et al.,
Eur. J. Gastroenterol Hepatol. 7 (10), 933-37 (1995), including the
treatment of necrotizing enterocolitis, Zollinger-Ellison syndrome,
gastrointestinal ulceration gastrointestinal ulcerations and
congenital microvillus atrophy, A. Guglietta & P B Sullivan,
Eur. J. Gastroenterol Hepatol, 7(10), 945-50 (1995). Additionally,
EGF has been implicated in hair follicle differentiation; C. L. du
Cros, J. Invest. Dermatol. 101 (1 Suppl.), 106S-113S (1993), S G
Hillier, Clin. Endocrinol. 33(4), 427-28 (1990); kidney function,
L. L. Hamm et al., Semin. Nephrol. 13 (1): 109-15 (1993), R C
Harris, Am. J. Kidney Dis. 17(6): 627-30 (1991); tear fluid, G B
van Setten et al., Int. Ophthalmol 15(6); 359-62 (1991); vitamin K
mediated blood coagulation, J. Stenflo et al., Blood 78(7): 1637-51
(1991). EGF is also implicated various skin disease characterized
by abnormal keratinocyte differentiation, e.g., psoriasis,
epithelial cancers such as squamous cell carcinomas of the lung,
epidermoid carcinoma of the vulva and gliomas. King, L E et al.,
Am. J. Med. Sci. 296: 154-158 (1988).
[0024] Of great interest is mounting evidence that genetic
alterations in growth factors signaling pathways are closely linked
to developmental abnormalities and to chronic diseases including
cancer. Aaronson S A, Science 254: 1146-1153 (1991). For example,
c-erb-2 (also known as HER-2), a proto-oncogene with close
structural similarity to EGF receptor protein, is overexpressed in
human breast cancer. King et al., Science 229: 974-976 (1985);
Gullick, W J, Hormones and their actions, Cooke B A et al., eds,
Amsterdam, Elsevier, pp 349-360 (1986).
[0025] 6. PRO215
[0026] Protein-protein interactions include receptor and antigen
complexes and signaling mechanisms. As more is known about the
structural and functional mechanisms underlying protein-protein
interactions, protein-protein interactions can be more easily
manipulated to regulate the particular result of the
protein-protein interaction. Thus, the underlying mechanisms of
protein-protein interactions are of interest to the scientific and
medical community.
[0027] All proteins containing leucine-rich repeats are thought to
be involved in protein-protein interactions. Leucine-rich repeats
are short sequence motifs present in a number of proteins with
diverse functions and cellular locations. The crystal structure of
ribonuclease inhibitor protein has revealed that leucine-rich
repeats correspond to beta-alpha structural units. These units are
arranged so that they form a parallel beta-sheet with one surface
exposed to solvent, so that the protein acquires an unusual,
nonglubular shape. These two features have been indicated as
responsible for the protein-binding functions of proteins
containing leucine-rich repeats. See, Kobe and Deisenhofer, Trends
Biochem. Sci., 19(10):415-421 (October 1994).
[0028] A study has been reported on leucine-rich proteoglycans
which serve as tissue organizers, orienting and ordering collagen
fibrils during ontogeny and are involved in pathological processes
such as wound healing, tissue repair, and tumor stroma formation.
Iozzo, R. V., Crit. Rev. Biochem. Mol. Biol., 32(2):141-174 (1997).
Others studies implicating leucine rich proteins in wound healing
and tissue repair are De La Salle, C., et al., Vouv. Rev. Fr.
Hematol. (Germany), 37(4):215-222 (1995), reporting mutations in
the leucine rich motif in a complex associated with the bleeding
disorder Bernard-Soulier syndrome and Chlemetson, K. J., Thromb.
Haemost. (Germany), 74(1):111-116 (July 1995), reporting that
platelets have leucine rich repeats. Another protein of particular
interest which has been reported to have leucine-rich repeats is
the SLIT protein which has been reported to be useful in treating
neuro-degenerative diseases such as Alzheimer's disease, nerve
damage such as in Parkinson's disease, and for diagnosis of cancer,
see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by
Yale University. Other studies reporting on the biological
functions of proteins having leucine-rich repeats include: Tayar,
N., et al., Mol. Cell Endocrinol., (Ireland), 125(1-2):65-70
(December 1996) (gonadotropin receptor involvement); Miura, Y., et
al., Nippon Rinsho (Japan), 54(7):1784-1789 (July 1996) (apoptosis
involvement); Harris, P. C., et al., J. Am. Soc. Nephrol.,
6(4):1125-1133 (October 1995) (kidney disease involvement); and
Ruoslahti, E. I., et al., WO9110727-A by La Jolla Cancer Research
Foundation (decorin binding to transforming growth factor.beta.
involvement for treatment for cancer, wound healing and
scarring).
[0029] 7. PRO242, PRO1318 and PRO1600
[0030] Leukocytes include monocytes, macrophages, basophils, and
eosinophils and play an important role in the immune response.
These cells are important in the mechanisms initiated by T and/or B
lymphocytes and secrete a range of cytokines which recruit and
activate other inflammatory cells and contribute to tissue
destruction.
[0031] Thus, investigation of the regulatory processes by which
leukocytes move to their appropriate destination and interact with
other cells is critical. Currently, leukocytes are thought to move
from the blood to injured or inflamed tissues by rolling along the
endothelial cells of the blood vessel wall. This movement is
mediated by transient interactions between selectins and their
ligands. Next, the leukocyte must move through the vessel wall and
into the tissues. This diapedesis and extravasation step involves
cell activation which promotes a more stable leukocyte-endothelial
cell interaction, again mediated by integrins and their
ligands.
[0032] Chemokines are a large family of structurally related
polypeptide cytokines. These molecules stimulate leukocyte movement
and may explain leukocyte trafficking in different inflammatory
situations. Chemokines mediate the expression of particular
adhesion molecules on endothelial cells, and they produce
chemoattractants which activate specific cell types. In addition,
the chemokines stimulate proliferation and regulate activation of
specific cell types. In both of these activities, chemokines
demonstrate a high degree of target cell specificity.
[0033] The chemokine family is divided into two subfamilies based
on whether two amino terminal cysteine residues are immediately
adjacent (C-C) or separated by one amino acid (C-X-C). Chemokines
of the C-X-C family generally activate neutrophils and fibroblasts
while the C-C chemokines act on a more diverse group of target
cells including monocytes/macrophages, basophils, cosinophils and T
lymphocytes. The known chemokines of both subfamilies are
synthesized by many diverse cell types as reviewed in Thomson A.
(1994) The Cytokine Handbook, 2 d Ed. Academic Press, N.Y.
[0034] Known chemokines include macrophage inflammatory proteins
alpha and beta (MIP-1 alpha and beta ), I-309, RANTES, and monocyte
chemotactic protein (MCP-1).
[0035] MIP-1 alpha and MIP-1 beta were first purified from a
stimulated mouse macrophage cell line and elicited an inflammatory
response when injected into normal tissues. MIP-1 alpha and MIP-1
beta consist of 68-69 amino acids and share approximately 70%
identity in their mature secreted forms. Both are expressed in T
cells, B cells and monocytes which are stimulated by mitogens,
anti-CD3 and endotoxin, and both polypeptides bind heparin and
stimulate monocytes. MIP-1 alpha acts as a chemoattractant for the
CD-8 subset of T lymphocytes and eosinophils, while MIP-1 beta
chemoattracts the CD-4 subset of T lymphocytes. In addition, these
proteins are known to stimulate myelopoiesis in mice.
[0036] RANTES is regulated by interleukins-1 and -4, transforming
nerve factor and interferon-gamma and is expressed in T cells,
platelets, stimulated rheumatoid synovial fibroblasts, and in some
tumor cell lines. RANTES affects lymphocytes, monocytes, basophils
and eosinophils. RANTES expression is substantially reduced upon T
cell stimulation.
[0037] Monocyte chemotactic protein (MCP-1) is a 76 amino acid
protein which appears to be expressed in almost all cells and
tissues upon stimulation by a variety of agents. However, the
targets of MCP-1 are limited to monocytes and basophils. In these
cells, MCP-1 induces a MCP-1 receptor. Two related proteins, MCP-2
and MCP-3, have 62% and 73% identity, respectively, with MCP-1 and
share its chemoattractant specificity or monocytes.
[0038] Current techniques for diagnosis of abnormalities in
inflamed or diseased issues mainly rely on observation of clinical
symptoms or serological analyses of body tissues or fluids for
hormones, polypeptides or various metabolites. Problems exist with
these diagnostic techniques. First, patients may not manifest
clinical symptoms at early stages of disease. Second, serological
tests do not always differentiate between invasive diseases and
genetic syndromes. Thus, the identification of expressed chemokines
is important to the development of new diagnostic techniques,
effective therapies, and to aid in the understanding of molecular
pathogenesis.
[0039] The chemokine molecules were reviewed in Schall T J (1994)
Chemotactic Cytokines: Targets for Therapeutic Development.
International Business Communications, Southborough Mass. pp
180-270; and in Paul W E (1993) Fundamental Immunology, 3rd Ed.
Raven Press, N.Y. pp 822-826.
[0040] 8. PRO288
[0041] Control of cell numbers in mammals is believed to be
determined, in part, by a balance between cell proliferation and
cell death. One forn of cell death, sometimes referred to as
necrotic cell death, is typically characterized as a pathologic
form of cell death resulting from some trauma or cellular injury.
In contrast, there is another, "physiologic" form of cell death
which usually proceeds in an orderly or controlled manner. This
orderly or controlled form of cell death is often referred to as
"apoptosis" [see, e.g., Barr et al., Bio/Technology, 12:487-493
(1994); Steller et al., Science, 267:1445-1449 (1995)]. Apoptotic
cell death naturally occurs in many physiological processes,
including embryonic development and clonal selection in the immune
system [Itoh et al., Cell, 66:233-243 (1991)]. Decreased levels of
apoptotic cell death have been associated with a variety of
pathological conditions, including cancer, lupus, and herpes virus
infection [Thompson, Science, 267:1456-1462 (1995)]. Increased
levels of apoptotic cell death may be associated with a variety of
other pathological conditions, including AIDS, Alzheimer's disease,
Parkinson's disease, amyotrophic lateral sclerosis, multiple
sclerosis, retinitis pigmentosa, cerebellar degeneration, aplastic
anemia, myocardial infarction, stroke, reperfusion injury, and
toxin-induced liver disease [see, Thompson, supra].
[0042] Apoptotic cell death is typically accompanied by one or more
characteristic morphological and biochemical changes in cells, such
as condensation of cytoplasm, loss of plasma membrane microvilli,
segmentation of the nucleus, degradation of chromosomal DNA or loss
of mitochondrial function. A variety of extrinsic and intrinsic
signals are believed to trigger or induce such morphological and
biochemical cellular changes [Raff, Nature, 356:397-400 (1992);
Steller, supra; Sachs et al., Blood, 82:15 (1993) ]. For instance,
they can be triggered by hormonal stimuli, such as glucocorticoid
hormones for immature thymocytes, as well as withdrawal of certain
growth factors [Watanabe-Fukunaga et al., Nature, 356:314-317
(1992)]. Also, some identified oncogenes such as myc, rel, and E1A,
and tumor suppressors, like p53, have been reported to have a role
in inducing apoptosis. Certain chemotherapy drugs and some forms of
radiation have likewise been observed to have apoptosis-inducing
activity [Thompson, supra].
[0043] Various molecules, such as tumor necrosis factor-.alpha.
("TNF-.alpha."), tumor necrosis factor-.beta. ("TNF-.beta." or
"lymphotoxin"), CD30 ligand, CD27 ligand, CD40 ligand, OX-40
ligand, 4-1BB ligand, Apo-1ligand (also referred to as Fas ligand
or CD95 ligand), and Apo-2 ligand (also referred to as TRAIL) have
been identified as members of the tumor necrosis factor ("TNF")
family of cytokines [See, e.g., Gruss and Dower, Blood,
85:3378-3404 (1995); Wiley et al., Immunity, 3:673-682 (1995);
Pitti et al., J. Biol. Chem., 271:12687-12690 (1996)]. Among these
molecules, TNF-.alpha., TNF-.beta., CD30 ligand, 4-1BB ligand,
Apo-1 ligand, and Apo-2 ligand (TRAIL) have been reported to be
involved in apoptotic cell death. Both TNF-.alpha. and TNF-.beta.
have been reported to induce apoptotic death in susceptible tumor
cells [Schmid et al., Proc. Natl. Acad. Sci., 83:1881 (1986);
Dealtry et al., Eur. J. Immunol., 17:689 (1987)]. Zheng et al. have
reported that TNF-.alpha. is involved in post-stimulation apoptosis
of CD8-positive T cells [Zheng et al., Nature, 377:348-351 (1995)].
Other investigators have reported that CD30 ligand may be involved
in deletion of self-reactive T cells in the thymus [Amakawa et al.,
Cold Spring Harbor Laboratory Symposium on Programmed Cell Death,
Abstr. No. 10, (1995)].
[0044] Mutations in the mouse Fas/Apo-1 receptor or ligand genes
(called lpr and gld, respectively) have been associated with some
autoimmune disorders, indicating that Apo-1 ligand may play a role
in regulating the clonal deletion of self-reactive lymphocytes in
the periphery [Krammer et al., Curr. Op. Immunol., 6:279-289
(1994); Nagata et al., Science, 267:1449-1456 (1995)]. Apo-1 ligand
is also reported to induce post-stimulation apoptosis in
CD4-positive T lymphocytes and in B lymphocytes, and may be
involved in the elimination of activated lymphocytes when their
function is no longer needed [Krammer et al., supra; Nagata et al.,
supra]. Agonist mouse monoclonal antibodies specifically binding to
the Apo-1 receptor have been reported to exhibit cell killing
activity that is comparable to or similar to that of TNF-.alpha.
[Yonehara et al., J. Exp. Med., 169:1747-1756 (1989)].
[0045] Induction of various cellular responses mediated by such TNF
family cytokines is believed to be initiated by their binding to
specific cell receptors. Two distinct TNF receptors of
approximately 55-kDa (TNFR1) and 75-kDa (TNFR2) have been
identified [Hohman et al., J. Biol. Chem., 264:14927-14934 (1989);
Brockhaus et al., Proc. Natl. Acad. Sci., 87:3127-3131 (1990); EP
417,563, published Mar. 20, 1991] and human and mouse cDNAs
corresponding to both receptor types have been isolated and
characterized [Loetscher et al., Cell, 61:351 (1990); Schall et
al., Cell, 61:361 (1990); Smith et al., Science, 248:1019-1023
(1990); Lewis et al., Proc. Natl. Acad. Sci., 88:2830-2834 (1991);
Goodwin et al., Mol. Cell. Biol., 11:3020-3026 (1991)]. Extensive
polymorphisms have been associated with both TNF receptor genes
[see, e.g., Takao et al., Immunogenetics, 37:199-203 (1993)]. Both
TNFRs share the typical structure of cell surface receptors
including extracellular, transmembrane and intracellular regions.
The extracellular portions of both receptors are found naturally
also as soluble TNF-binding proteins [Nophar, Y. et al., EMBO J.,
9:3269 (1990); and Kohno, T. et al., Proc. Natl. Acad. Sci. U.S.A.,
87:8331 (1990)]. More recently, the cloning of recombinant soluble
TNF receptors was reported by Hale et al. [J. Cell. Biochem.
Supplement 15F, 1991, p. 113 (P424)].
[0046] The extracellular portion of type 1 and type 2 TNFRs (TNFR1
and TNFR2) contains a repetitive amino acid sequence pattern of
four cysteine-rich domains (CRDs) designated 1 through 4, starting
from the NH.sub.2-terminus. Each CRD is about 40 amino acids long
and contains 4 to 6 cysteine residues at positions which are well
conserved [Schall et al., supra; Loetscher et al., supra; Smith et
al., supra; Nophar et al., supra; Kohno et al., supra]. In TNFR1,
the approximate boundaries of the four CRDs are as follows:
CRD1-amino acids 14 to about 53; CRD2-amino acids from about 54 to
about 97; CRD3-amino acids from about 98 to about 138; CRD4-amino
acids from about 139 to about 167. In TNFR2, CRD1 includes amino
acids 17 to about 54; CRD2-amino acids from about 55 to about 97;
CRD3-amino acids from about 98 to about 140; and CRD4-amino acids
from about 141 to about 179 [Banner et al., Cell, 73:431-435
(1993)]. The potential role of the CRDs in ligand binding is also
described by Banner et al., supra.
[0047] A similar repetitive pattern of CRDs exists in several other
cell-surface proteins, including the p75 nerve growth factor
receptor (NGFR) [Johnson et al., Cell, 47:545 (1986); Radeke et
al., Nature, 325:593 (1987)], the B cell antigen CD40 [Stamenkovic
et al., EMBO J., 8:1403 (1989)], the T cell antigen OX40 [Mallet et
al., EMBO J., 9:1063 (1990)] and the Fas antigen [Yonehara et al.,
supra and Itoh et al., supra]. CRDs are also found in the soluble
TNFR (sTNFR)-like T2 proteins of the Shope and myxoma poxviruses
[Upton etal., Virology, 160:20-29(1987); Smith et al., Biochem.
Biophys. Res. Commun., 176:335 (1991); Upton et al., Virology,
184:370 (1991)]. Optimal alignment of these sequences indicates
that the positions of the cysteine residues are well conserved.
These receptors are sometimes collectively referred to as members
of the TNF/NGF receptor superfamily. Recent studies on p75NGFR
showed that the deletion of CRD1 [Welcher, A. A. et al., Proc.
Natl. Acad. Sci. USA, 88:159-163 (1991)] or a 5-amino acid
insertion in this domain [Yan, H. and Chao, M. V., J. Biol. Chem.,
266:12099-12104 (1991)] had little or no effect on NGF binding
[Yan, H. and Chao, M. V., supra]. p75 NGFR contains a proline-rich
stretch of about 60 amino acids, between its CRD4 and transmembrane
region, which is not involved in NGF binding [Peetre, C. et al.,
Eur. J. Hematol., 41:414-419 (1988); Seckinger, P. et al., J. Biol.
Chem., 264:11966-11973 (1989); Yan, H. and Chao, M. V., supra]. A
similar proline-rich region is found in TNFR2 but not in TNFR1.
[0048] Itoh et al. disclose that the Apo-1 receptor can signal an
apoptotic cell death similar to that signaled by the 55-kDa TNFR1
[Itoh et al., supra]. Expression of the Apo-1 antigen has also been
reported to be down-regulated along with that of TNFR1 when cells
are treated with either TNF-.alpha. or anti-Apo-1 mouse monoclonal
antibody [Krammer et al., supra; Nagata et al., supra].
Accordingly, some investigators have hypothesized that cell lines
that co-express both Apo-1 and TNFR1 receptors may mediate cell
killing through common signaling pathways [Id.].
[0049] The TNF family ligands identified to date, with the
exception of lymphotoxin-.alpha., are type II transmembrane
proteins, whose C-terminus is extracellular. In contrast, the
receptors in the TNF receptor (TNFR) family identified to date are
type I transmembrane proteins. In both the TNF ligand and receptor
families, however, homology identified between family members has
been found mainly in the extracellular domain ("ECD"). Several of
the TNF family cytokines, including TNF-.alpha., Apo-1 ligand and
CD40 ligand, are cleaved proteolytically at the cell surface; the
resulting protein in each case typically forms a homotrimeric
molecule that functions as a soluble cytokine. TNF receptor family
proteins are also usually cleaved proteolytically to release
soluble receptor ECDs that can function as inhibitors of the
cognate cytokines.
[0050] Recently, other members of the TNFR family have been
identified. In Marsters et al., Curr. Biol., 6:750 (1996),
investigators describe a full length native sequence human
polypeptide, called Apo-3, which exhibits similarity to the TNFR
family in its extracellular cysteine-rich repeats and resembles
TNFR1 and CD95 in that it contains a cytoplasmic death domain
sequence [see also Marsters et al., Curr. Biol., 6:1669 (1996)].
Apo-3 has also been referred to by other investigators as DR3,
wsl-1 and TRAMP [Chinnaiyan et al., Science, 274:990 (1996); Kitson
et al., Nature, 384:372 (1996); Bodmer et al., Immunity, 6:79
(1997)].
[0051] Pan et al. have disclosed another TNF receptor family member
referred to as "DR4" [Pan et al., Science, 276:111-113 (1997)]. The
DR4 was reported to contain a cytoplasmic death domain capable of
engaging the cell suicide apparatus. Pan et al. disclose that DR4
is believed to be a receptor for the ligand known as Apo-2 ligand
or TRAIL.
[0052] In Sheridan et al., Science, 277:818-821 (1997) and Pan et
al., Science, 277:815-818 (1997), another molecule believed to be a
receptor for the Apo-2 ligand (TRAIL) is described. That molecule
is referred to as DR5 (it has also been alternatively referred to
as Apo-2). Like DR4, DR5 is reported to contain a cytoplasmic death
domain and be capable of signaling apoptosis.
[0053] In Sheridan et al., supra, a receptor called DcR1 (or
alternatively, Apo-2DcR) is disclosed as being a potential decoy
receptor for Apo-2 ligand (TRAIL). Sheridan et al. report that DcR1
can inhibit Apo-2 ligand function in vitro. See also, Pan et al.,
supra, for disclosure on the decoy receptor referred to as
TRID.
[0054] As presently understood, the cell death program contains at
least three important elements--activators, inhibitors, and
effectors; in C. elegans, these elements are encoded respectively
by three genes, Ced-4, Ced-9 and Ced-3 [Steller, Science, 267:1445
(1995); Chinnaiyan et al., Science, 275:1122-1126 (1997); Wang et
al., Cell, 90:1-20 (1997)]. Two of the TNFR family members, TNFR1
and Fas/Apo1 (CD95), can activate apoptotic cell death [Chinnaiyan
and Dixit, Current Biology, 6:555-562 (1996); Fraser and Evan,
Cell; 85:781-784 (1996)]. TNFR1 is also known to mediate activation
of the transcription factor, NF-.kappa.B [Tartaglia et al., Cell,
74:845-853 (1993); Hsu et al., Cell, 84:299-308 (1996)]. In
addition to some ECD homology, these two receptors share homology
in their intracellular domain (ICD) in an oligomerization interface
known as the death domain [Tartaglia et al., supra; Nagata, Cell,
88:355 (1997)]. Death domains are also found in several metazoan
proteins that regulate apoptosis, namely, the Drosophila protein,
Reaper, and the mammalian proteins referred to as FADD/MORTI,
TRADD, and RIP [Cleaveland and Ihle, Cell, 81:479-482 (1995)].
Using the yeast-two hybrid system, Raven et al. report the
identification of protein, wsl-1, which binds to the TNFR1 death
domain [Raven et al., Programmed Cell Death Meeting, Sep. 20-24,
1995, Abstract at page 127; Raven et al., European Cytokine
Network, 7:Abstr. 82 at page 210 (April-June 1996); see also,
Kitson et al., Nature, 384:372-375 (1996)]. The wsl-1 protein is
described as being homologous to TNFR1 (48% identity) and having a
restricted tissue distribution. According to Raven et al., the
tissue distribution of wsl-1 is significantly different from the
TNFR1 binding protein, TRADD.
[0055] Upon ligand binding and receptor clustering, TNFR1 and CD95
are believed to recruit FADD into a death-inducing signalling
complex. CD95 purportedly binds FADD directly, while TNFR1 binds
FADD indirectly via TRADD [Chinnaiyan et al., Cell, 81:505-512
(1995); Boldin et al., J. Biol. Chem., 270:387-391 (1995); Hsu et
al., supra; Chinnaiyan et al., J. Biol. Chem., 271:4961-4965
(1996)]. It has been reported that FADD serves as an adaptor
protein which recruits the Ced-3-related protease,
MACH.alpha./FLICE (caspase 8), into the death signalling complex
[Boldin et al., Cell, 85:803-815 (1996); Muzio et al., Cell,
85:817-827 (1996)]. MACH.alpha./FLICE appears to be the trigger
that sets off a cascade of apoptotic proteases, including the
interleukin-1.beta. converting enzyme (ICE) and CPP32/Yama, which
may execute some critical aspects of the cell death programme
[Fraser and Evan, supra].
[0056] It was recently disclosed that programmed cell death
involves the activity of members of a family of cysteine proteases
related to the C. elegans cell death gene, ced-3, and to the
mammalian IL-1-converting enzyme, ICE. The activity of the ICE and
CPP32/Yama proteases can be inhibited by the product of the cowpox
virus gene, crmA [Ray et al., Cell, 69:597-604 (1992); Tewari et
al., Cell, 81:801-809 (1995)]. Recent studies show that CrmA can
inhibit TNRF1- and CD95-induced cell death [Enari et al., Nature,
375:78-81 (1995); Tewari et al., J. Biol. Chem., 270:3255-3260
(1995)].
[0057] As reviewed recently by Tewari et al., TNFR1, TNFR2 and CD40
modulate the expression of proinflammatory and costimulatory
cytokines, cytokine receptors, and cell adhesion molecules through
activation of the transcription factor, NF-.kappa.B [Tewari et al.,
Curr. Op. Genet. Develop., 6:39-44 (1996)]. NF-.kappa.B is the
prototype of a family of dimeric transcription factors whose
subunits contain conserved Rel regions [Verma et al., Genes
Develop., 9:2723-2735 (1996); Baldwin, Ann. Rev. Immunol.,
14:649-681 (1996)]. In its latent form, NF-.kappa.B is complexed
with members of the I.kappa.B inhibitor family; upon inactivation
of the I.kappa.B in response to certain stimuli, released
NF-.kappa.B translocates to the nucleus where it binds to specific
DNA sequences and activates gene transcription.
[0058] For a review of the TNF family of cytokines and their
receptors, see Gruss and Dower, supra.
[0059] 9. PRO365
[0060] Polypeptides such as human 2-19 protein may function as
cytokines. Cytokines are low molecular weight proteins which
function to stimulate or inhibit the differentiation, proliferation
or function of immune cells. Cytokines often act as intercellular
messengers and have multiple physiological effects. Given the
physiological importance of immune mechanisms in vivo, efforts are
currently being under taken to identify new, native proteins which
are involved in effecting the imnune system. We describe herein the
identification of a novel polypeptide which has homology to the
human 2-19 protein.
[0061] 10. PRO1361
[0062] Efforts are being undertaken by both industry and academia
to identify new, native transmembrane receptor proteins. Many
efforts are focused on the screening of mammalian recombinant DNA
libraries to identify the coding sequences for novel receptor
proteins. We herein describe the identification and
characterization of novel transmembrane polypeptides, designated
herein as PRO1361 polypeptides.
[0063] 11. PRO1308
[0064] Follistatin is a secreted protein that regulates secretion
of pituitary follicle-stimulating hormone (FSH). It functions by
binding to, and thereby inhibiting, proteins such as activin and
other members of the transforming growth factor beta (TGF.beta.)
family, that stimulate the production and secretion of FSH from the
anterior pituitary. Follistatin is also involved in mechanisms that
control basic development, including the induction of neural
development. Follistatin also exhibits angiogenic properties,
particularly in combination with basic fibroblast growth factor
(bFGF). As such, there is strong interest in identifying new
members of the follistatin family of proteins. The identification
and characterization of follistatins is the topic of the following
references which are incorporated herein by reference: Sugino et
al. J. Med Invest (1997)44:(1-2): 1-14; Mather et al., Proc. Soc.
Exp. biol. Med. (1997) 215(3):209-222; Thomsen, G. H., Trends Genet
(1997) 13(6): 209-211; DePaolo, L. V., Proc. Soc. Exp. Biol. Med.
(1997)214(4):328-339; Peng et al., Biol. Signals (1996) 5(2):81-89,
and Halvorson et al. Fertil Steril (1996) 65(3):459-469.
[0065] 12. PRO1183
[0066] Protoporphyrinogen oxidase catalyzes the penultimate step in
the heme biosynthetic pathway. Deficiency in activity of this
enzyme results in the human genetic disease variegate porphyria.
Thus, protoporphyrinogen oxidases and molecules which either
modulate or are related to these oxidases are of interest.
Moreover, oxidases, and related molecules in general are also of
interest. Oxidases are further described in at least Birchfield, et
al., Biochemistry, 37(19):6905-6910 (1998); Fingar, et al., Cancer
Res., 57(20):4551-4556(1997); Arnould, et al., Biochemistry,
36(33):10178-10184 (1997); and Dailey and Dailey, Cell Mol. Biol.,
43(1):67-73 (1997).
[0067] 13. PRO1272
[0068] The cement gland is an ectodermal organ in the head of frog
embryos, lying anterior to any neural tissue. The cement gland,
like neural tissue, has been shown to be induced by the dorsal
mesoderm. XAG-1 is a cement gland specific protein that is useful
as a marker of cement gland induction during development. See,
Sive, et al., Cell, 58(1):171-180 (1989); Itoh, et al.,
Development, 121(12):3979-3988 (1995). XAG-2 and other proteins
related to the XAG family are further described in Aberger, et al.,
Mech. Dev., 72(1-2):115-130 (1998) and Gammill and Sive,
Development, 124(2):471-481 (1997). Thus, novel polypeptides having
sequence identity with XAG proteins are of interest.
[0069] 14. PRO1419
[0070] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel secreted proteins. We herein
describe the identification and characterization of novel secreted
polypeptides, designated herein as PRO1419 polypeptides.
[0071] 15. PRO4999
[0072] Uromodulin is synthesized in the kidney and is the most
abundant protein in normal human urine. The amino acid sequence
encoded by one of the exons of the uromodulin gene has homology to
the low-density-lipoprotein receptor and the epidermal growth
factor precursor. Pennica et al., Science 236:83-88 (1987). The
function of uromodulin is not known; however, it may function as a
unique renal regulatory glycoprotein that specifically binds to and
regulates the circulating activity of a number of potent cytokines,
as it binds to IL-1, IL-2 and TNF with high affinity. See Hession
et al., Science 237:1479-1484 (1987). Su et al. suggest that
uromodulin plays a significant role in the innate immunity of the
urinary system and that the immunostimulatory activity of
uromodulin is potentially useful for immunotherapy. Su et al., J.
Immunology, 158:3449-3456 (1997).
[0073] We herein describe the identification and characterization
of novel polypeptides having sequence similarity to uromodulin,
designated herein as PRO4999 polypeptides.
[0074] 16. PRO7170
[0075] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel secreted proteins. We herein
describe the identification and characterization of novel secreted
polypeptides, designated herein as PRO7170 polypeptides.
[0076] 17. PRO248
[0077] Cytokines have been implicated in the pathogenesis of a
number of brain diseases in which neurological dysfuntion has been
attributed to a change in amino acid neurotransmitter metabolism.
In particular, members of the transforming growth factor.beta.s
(TGFB) have been implicated. Transforming growth peptides are small
polypeptides that were first identified by their ability to induce
proliferation and transformation in noncancerous cells in culture.
Although initially defined as a growth factor, TGF.beta. also
inhibits proliferation of epithelial, endothelial, lymphoid, and
hematopoictic cells. This cytokine is thought to play an important
role in regulating the duration of the inflammatory response,
allowing the healing process to proceed. It is also a potent
immunomodulator, which has many pleiotrophic effects, including
regulating many other cytokines.
[0078] The TGF.beta. family includes basic myelin proteins (BMP-2,
BMP-4, BMP-5, BMP-6, BMP-7), activins A & B, decapentaplegic
(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs)
1, 3, and 9, nodal, MIS, Inhibin .alpha., transforming growth
factors betas (TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, TGF-.beta.5),
and glial-derived neurotrophic factor (GDNF), Atrisano, et al., J.
Biochemica et Biophysica Acta, 1222:71-80 (1994). Of particuar
interest are the growth differentiation factors, for as their name
implies, these factors are implicated in the differentiation of
cells.
[0079] Thus, identifying proteins having homology to the TGF.beta.
family members, particularly growth differentiation factor (GDF) 3,
is of importance to the medical and industrial community.
Generally, proteins having homology to each other have similar
function. It is also of interest when proteins having homology do
not have similar functions, indicating that certain structural
motifs identify information other than function, such as locality
of function.
[0080] 18. PRO353
[0081] The complement proteins comprise a large group of serum
proteins some of which act in an enzymatic cascade, producing
effector molecules involved in inflammation. The complement
proteins are of particular importance in regulating movement and
function of cells involved in inflammation. Given the physiological
importance of inflammation and related mechanisms in vivo, efforts
are currently being under taken to identify new, native proteins
which are involved in inflamation. We describe herein the
identification and characterization of novel polypeptides which
have homology to complement proteins, designated herein as PRO353
polypeptides.
[0082] 19. PRO533
[0083] Growth factors are molecular signals or mediators that
enhance cell growth or proliferation, alone or in concert, by
binding to specific cell surface receptors. however, there are
other cellular reactions than only growth upon expression to growth
factors. As a result, growth factors are better characterized as
multifunctional and potent cellular regulators. Their biological
effects include proliferation, chemotaxis and stimulation of
extracellular matrix production. Growth factors can have both
stimulatory and inhibitory effects. For example, transforming
growth factors (TGF-.beta.) is highly pleiotropic and can stimulate
proliferation in some cells, especially connective tissues, while
being a potent inhibitor of proliferation in others, such as
lymphocytes and epithelial cells.
[0084] The physiological effect of growth stimulation or inhibition
by growth factors depends upon the state of development and
differentiation of the target tissue. The mechanism of local
cellular regulation by classical endocrine molecules comprehends
autocrine (same cell), juxtacrine (neighbor cell), and paracrine
(adjacent cell) pathways. Peptide growth factors are elements of a
complex biological language, providing the basis for intercellular
communication. They permit cells to convey information between each
other, mediate interaction between cells and change gene
expression. the effect of these multifunctional and pluripotent
factors is dependent on the presence or absence of other
peptides.
[0085] Fibroblast growth factors (FGFs) are a family of
heparin-binding, potent mitogens for both normal diploid
fibroblasts and established cell lines, Godpodarowicz, D. et al.
(1984), Proc. Natl. Acad. Sci. USA 81: 6983. the FGF family
comprises acidic FGF (FGF-1), basic FGF (FGF-2), INT-2(FGF-3),
K-FGF/HST (FGF-4), FGF-5, FGF-6, KGF (FGF-7), AIGF (FGF-8) among
others. All FGFs have two conserved cysteine residues and share
30-50% sequence homology at the amino acid level. These factors are
mitogenic for a wide variety of normal diploid mesoderm-derived and
neural crest-derived cells, inducing granulosa cells, adrenal
cortical cells, chrondocytes, myoblasts, corneal and vascular
endothelial cells (bovine or human), vascular smooth muscle cells,
lens, retina and prostatic epithelial cells, oligodendrocytes,
astrocytes, chrondocytes, myoblasts and osteoblasts.
[0086] Fibroblast growth factors can also stimulate a large number
of cell types in a non-mitogenic manner. These activities include
promotion of cell migration into a wound area (chemotaxis),
initiation of new blood vessel formulation (angiogenesis),
modulation of nerve regeneration and survival (neurotrophism),
modulation of endocrine functions, and stimulation or suppression
of specific cellular protein expression, extracellular matrix
production and cell survival. Baird, A. & Bohlen, P., Handbook
of Exp. Phrmacol. 95(1): 369-418 (1990). These properties provide a
basis for using fibroblast growth factors in therapeutic approaches
to accelerate wound healing, nerve repair, collateral blood vessel
formation, and the like. For example, fibroblast growth factors,
have been suggested to minimize myocardium damage in heart disease
and surgery (U.S. Pat. No. 4,378,437).
[0087] We herein describe the identification and characterization
of novel polypeptides having homology to FGF, herein designated
PRO533 polypeptides.
[0088] 20. PRO301
[0089] The widespread occurrence of cancer has prompted the
devotion of considerable resources and discovering new treatments
of treatment. One particular method involves the creation of tumor
or cancer specific monoclonal antibodies (mAbs) which are specific
to tumor antigens. Such mAbs, which can distinguish between normal
and cancerous cells are useful in the diagnosis, prognosis and
treatment of the disease. Particular antigens are known to be
associated with neoplastic diseases, such as colorectal cancer.
[0090] One particular antigen, the A33 antigen is expressed in more
than 90% of primary or metastatic colon cancers as well as normal
colon epithelium. Since colon cancer is a widespread disease, early
diagnosis and treatment is an important medical goal. Diagnosis and
treatment of colon cancer can be implemented using monoclonal
antibodies (mAbs) specific therefore having fluorescent, nuclear
magnetic or radioactive tags. Radioactive gene, toxins and/or drug
tagged mAbs can be used for treatment in situ with minimal patient
description. mAbs can also be used to diagnose during the diagnosis
and treatment of colon cancers. For example, when the serum levels
of the A33 antigen are elevated in a patient, a drop of the levels
after surgery would indicate the tumor resection was successful. On
the other hand, a subsequent rise in serum A33 antigen levels after
surgery would indicate that metastases of the original tumor may
have formed or that new primary tumors may have appeared. Such
monoclonal antibodies can be used in lieu of, or in conjunction
with surgery and/or other chemotherapies. For example, U.S. Pat.
No. 4,579,827 and U.S. Ser. No. 424,991 (E.P. 199,141) are directed
to therapeutic administration of monoclonal antibodies, the latter
of which relates to the application of anti-A33 mAb.
[0091] Many cancers of epithelial origin have adenovirus receptors.
In fact, adenovirus-derived vectors have been proposed as a means
of inserting antisense nucleic acids into tumors (U.S. Pat. No.
5,518,885). Thus, the association of viral receptors with
neoplastic tumors is not unexpected.
[0092] We herein describe the identification and characterization
of novel polypeptides having homology to certain cancer-associated
antigens, designated herein as PRO301 polypeptides.
[0093] 21. PRO187
[0094] Growth factors are molecular signals or mediators that
enhance cell growth or proliferation, alone or in concert, by
binding to specific cell surface receptors. However, there are
other cellular reactions than only growth upon expression to growth
factors. As a result, growth factors are better characterized as
multifunctional and potent cellular regulators. Their biological
effects include proliferation, chemotaxis and stimulation of
extracellular matrix production. Growth factors can have both
stimulatory and inhibitory effects. For example, transforming
growth factor (TGF-.beta.) is highly pleiotropic and can stimulate
proliferation in some cells, especially connective tissue, while
being a potent inhibitor of proliferation in others, such as
lymphocytes and epithelial cells.
[0095] The physiological effect of growth stimulation or inhibition
by growth factors depends upon the state of development and
differentiation of the target tissue. The mechanism of local
cellular regulation by classical endocrine molecules involves
comprehends autocrine (same cell), juxtacrine (neighbor cell), and
paracrine (adjacent cells) pathways. Peptide growth factors are
elements of a complex biological language, providing the basis for
intercellular communication. They permit cells to convey
information between each other, mediate interaction between cells
and change gene expression. The effect of these multifunctional and
pluripotent factors is dependent on the presence or absence of
other peptides.
[0096] FGF-8 is a member of the fibroblast growth factors (FGFs)
which are a family of heparin-binding, potent mitogens for both
normal diploid fibroblasts and established cell lines,
Gospodarowicz et al. (1984), Proc. Natl. Acad. Sci. USA 81:6963.
The FGF family comprises acidic FGF (FGF-1), basic FGF (FGF-2),
INT-2 (FGF-3), K-FGF/HST (FGF-4), FGF-5, FGF-6, KGF (FGF-7), AIGF
(FGF-8) among others. All FGFs have two conserved cysteine residues
and share 30-50% sequence homology at the amino acid level. These
factors are mitogenic for a wide variety of normal diploid
mesoderm-derived and neural crest-derived cells, including
granulosa cells, adrenal cortical cells, chondrocytes, myoblasts,
corneal and vascular endothelial cells (bovine or human), vascular
smooth muscle cells, lens, retina and prostatic epithelial cells,
oligodendrocytes, astrocytes, chrondocytes, myoblasts and
osteoblasts.
[0097] Fibroblast growth factors can also stimulate a large number
of cell types in a non-mitogenic manner. These activities include
promotion of cell migration into wound area (chemotaxis),
initiation of new blood vessel formulation (angiogenesis),
modulation of nerve regeneration and survival (neurotrophism),
modulation of endocrine functions, and stimulation or suppression
of specific cellular protein expression, extracellular matrix
production and cell survival. Baird & Bohlen, Handbook of Exp.
Pharmacol. 95(1): 369-418, Springer, (1990). These properties
provide a basis for using fibroblast growth factors in therapeutic
approaches to accelerate wound healing, nerve repair, collateral
blood vessel formation, and the like. For example, fibroblast
growth factors have been suggested to minimize myocardium damage in
heart disease and surgery (U.S. Pat. No. 4,378,347).
[0098] FGF-8, also known as androgen-induced growth factor (AIGF),
is a 215 amino acid protein which shares 30-40% sequence homology
with the other members of the FGF family. FGF-8 has been proposed
to be under androgenic regulation and induction in the mouse
mammary carcinoma cell line SC3. Tanaka et al., Proc. Natl. Acad.
Sci. USA 89: 8928-8932 (1992); Sato et al., J. Steroid Biochem.
Molec. Biol. 47: 91-98 (1993). As a result, FGF-8 may have a local
role in the prostate, which is known to be an androgen-responsive
organ. FGF-8 can also be oncogenic, as it displays transforming
activity when transfected into NIH-3T3 fibroblasts. Kouhara et al.,
Oncogene 9 455-462 (1994). While FGF-8 has been detected in heart,
brain, lung, kidney, testis, prostate and ovary, expression was
also detected in the absence of exogenous androgens. Schmitt et
al., J. Steroid Biochem. Mol. Biol. 57 (3-4): 173-78 (1996).
[0099] FGF-8 shares the property with several other FGFs of being
expressed at a variety of stages of murine embryogenesis, which
supports the theory that the various FGFs have multiple and perhaps
coordinated roles in differentiation and embryogenesis. Moreover,
FGF-8 has also been identified as a protooncogene that cooperates
with Wnt-1 in the process of mammary tumorigenesis (Shackleford et
al., Proc. Natl. Acad. Sci. USA 90, 740-744 (1993); Heikinheimo et
al., Mech. Dev. 48: 129-138 (1994)).
[0100] In contrast to the other FGFs, FGF-8 exists as three protein
isoforms, as a result of alternative splicing of the primary
transcript. Tanaka et al., supra. Normal adult expression of FGF-8
is weak and confined to gonadal tissue, however northern blot
analysis has indicated that FGF-8 mRNA is present from day 10
through day 12 or murine gestation, which suggests that FGF-8 is
important to normal development. Heikinheimo et al., Mech Dev.
48(2): 129-38 (1994). Further in situ hybridization assays between
day 8 and 16 of gestation indicated initial expression in the
surface ectoderm of the first bronchial arches, the frontonasal
process, the forebrain and the midbrain-hindbrain junction. At days
10-12, FGF-8 was expressed in the surface ectoderm of the forelimb
and hindlimb buds, the nasal its and nasopharynx, the infundibulum
and in the telencephalon, diencephalon and metencephalon.
Expression continues in the developing hindlimbs through day 13 of
gestation, but is undetectable thereafter. The results suggest that
FGF-8 has a unique temporal and spatial pattern in embryogenesis
and suggests a role for this growth factor in multiple regions of
ectodermal differentiation in the post-gastrulation embryo.
[0101] We herein describe the identification of novel poypeptides
having homology to FGF-8, wherein those polypeptides are hecin
designated PRO187 polypeptides.
[0102] 22. PRO337
[0103] Neuronal development in higher vertebrates is characterized
by processes that must successfully navigate distinct cellular
environment en route to their synaptic targets. The result is a
functionally precise formation of neural circuits. The precision is
believed to result form mechanisms that regulate growth cone
pathfinding and target recognition, followed by latter refinement
and remodeling of such projections by events that require neuronal
activity, Goodman and Shatz, Cell/Neuron [Suppl.] 72(10): 77-98
(1993). It is further evident that different neurons extend nerve
fibers that are biochemically distinct and rely on specific
guidance cues provided by cell-cell, cell-matrix, and chemotrophic
interactions to reach their appropriate synaptic targets, Goodman
et al., supra.
[0104] One particular means by which diversity of the neuronal cell
surface may be generated is through differential expression of cell
surface proteins referred to as cell adhesion molecules (CAMs).
Neuronally expressed CAMs have been implicated in diverse
developmental processes, including migration of neurons along
radial glial cells, providing permissive or repulsive substrates
for neurite extension, and in promoting the selective fasciculation
of axons in projectional pathways. Jessel, Neuron 1: 3-13 (1988);
Edelman and Crossin, Annu. Rev. Biochem. 60: 155-190 (1991).
Interactions between CAMs present on the growth cone membrane and
molecules on opposing cell membranes or in the extracellular matrix
are thought to provide the specific guidance cues that direct nerve
fiber outgrowth along appropriate projectional pathways. Such
interactions are likely to result in the activation of various
second messenger systems within the growth cone that regulate
neurite outgrowth. Doherty and Walsh, Curr. Opin Neurobiol. 2:
595-601 (1992).
[0105] In higher vertebrates, most neural CAMs have been found to
be members of three major structural families of proteins: the
integrins, the cadherins, and the immunoglobulin gene superfamily
(IgSF). Jessel, supra.; Takeichi, Annu. Rev. Biochem. 59: 237-252
(1990); Reichardt and Tomaselli, Annu. Rev. Neurosci. 14: 531-570
(1991). Cell adhesion molecules of the IgSF (or Ig-CAMs), in
particular, constitute a large family of proteins frequently
implicated in neural cell interactions and nerve fiber outgrowth
during development, Salzer and Colman, Dev. Neurosci. 11: 377-390
(1989); Brummendorf and Rathjen, J. Neurochem. 61: 1207-1219
(1993). However, the majority of mammalian Ig-CAMs appear to be too
widely expressed to specify navigational pathways or synaptic
targets suggesting that other CAMs, yet to be identified, have role
in these more selective interactions of neurons.
[0106] Many of the known neural Ig-CAMs have been found to be
attached to the plasma membrane via a glycosylphosphatidylinositol
(GPI) anchor. Additionally, many studies have implicated
GPI-anchored proteins in providing specific guidance cues during
the outgrowth on neurons in specific pathways. In studies of the
grasshopper nervous system, treatment of embryos with
phosphatidylinositol-specific phopholipase C (PIPLC), which
selectively removes GPI-anchored proteins from the surfaces of
cells, resulted in misdirection and faulty navigation among subsets
of pioneering growth cones, as well as inhibited migratory patterns
of a subset of early neurons, Chang et al., Devel. 114: 507-519
(1992). The projection of retinal fibers to the optic tectum
appears to depend, in part, on a 33 kDa GPI-anchored protein,
however, the precise nature of this protein is unknown. Stahl et
al., Neuron 5: 735-743 (1990).
[0107] The expression of various GPI-anchored proteins has been
characterized amongst the different populations of primary rat
neurons amongst dorsal root ganglion, sympathetic neurons of the
cervical ganglion, sympathetic neurons of the superior cervical
ganglion, and cerebellar granule neurons. Rosen et al., J. Cell
Biol. 117: 617-627 (1992). In contrast to the similar pattern of
total membrane protein expression by these different types of
neurons, striking differences were observed in the expression of
GPI-anchored proteins between these neurons. Recently, a 65 kDa
protein band known as neurotrimin was discovered and found to be
differentially expressed by primary neurons (Rosen et al., supra),
and restricted to the nervous system and found to be the most
abundant and earliest expressed of the GPI-anchored species in the
CNS. Struyk et al., J. Neuroscience 15(3): 2141-2156 (1995). The
discovery of neurotrimin has further lead to the identification of
a family of IgSF members, each containing three Ig-like domains
that share significant amino acid identity, now termed IgLON.
Struyk et al., supra; Pimenta et al., Gene 170(2): 189-95
(1996).
[0108] Additional members of the IgLON subfamily include opiate
binding cell adhesion molecule (OBCAM), Schofield et al., EMBO J.
8: 489-495 (1989); limbic associated membrane protein (LAMP),
Pimenta et al., supra; CEPU-1; GP55, Wilson et al., J. Cell Sci.
109: 3129-3138 (1996); Eur. J. Neurosci. 9(2): 334-41 (1997); and
AvGp50, Hancox et al., Brain Res. Mol. Brain Res. 44(2): 273-85
(1997).
[0109] While the expression of neurotrimin appears to be
widespread, it does appear to correlated with the development of
several neural circuits. For example, between E18 and P10,
neurotimin mRNA expression within the forebrain is maintained at
high levels in neurons of the developing thalamus, cortical
subplate, and cortex, particularly laminae V and VI (with less
intense expression in II, II, and IV, and minimal expression in
lamina I). Cortical subplate neurons may provide an early,
temporary scaffold for the ingrowing thalamic afferents en route to
their final synaptic targets in the cortex. Allendoerfer and Shatz,
Annu. Rev. Neurosci. 17: 185-218 (1994). Conversely, subplate
neurons have been suggested to be required for cortical neurons
from layer V to select VI to grow into the thalamus, and neurons
from layer V to select their targets in the colliculus, pons, and
spinal cord (McConnell et al., J. Neurosci. 14: 1892-1907 (1994).
The high level expression of neurotrimin in many of these
projections suggests that it could be involved in their
development.
[0110] In the hindbrain, high levels of neurotrimin message
expression were observed within the pontine nucleus and by the
internal granule cells and Purkinje cells of the cerebellum. The
pontine nucleus received afferent input from a variety of sources
including corticopontine fibers of layer V, and is a major source
of afferent input, via mossy fibers, to the granule cells which, in
turn, are a major source of afferent input via parallel fibers to
Purkinje cells. [Palay and Chan-Palay, The cerebellar cortex:
cytology and organization. New York: Springer (1974]. High level
expression of neurotrimin these neurons again suggests potential
involvement in the establishment of these circuits.
[0111] Neurotrimin also exhibits a graded expression pattern in the
early postnatal striatum. Increased neurotrimin expression is found
overlying the dorsolateral striatum of the rat, while lesser
hybridization intensity is seen overlying the ventromedial
striatum. Struyk et al., supra. This region of higher neurotrimin
hybridization intensity does not correspond to a
cytoarchitecturally differentiable region, rather it corresponds to
the primary area of afferent input from layer VI of the
contralateral sensorimotor cortex (Gerfen, Nature 311: 461-464
(1984); Donoghue and Herkenham, Brain Res. 365: 397-403 (1986)).
The ventromedial striatum, by contrast, receives the majority of
its afferent input from the perirhinal and association cortex. It
is noteworthy that a complementary graded pattern of LAMP
expression, has been observed within the striatum, with highest
expression in ventromedial regions, and lowest expression
dorsolaterally. Levitt, Science 223: 299-301 (1985); Chesselet et
al., Neuroscience 40: 725-733 (1991).
[0112] 23. PRO1411
[0113] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel secreted proteins. We herein
describe the identification and characterization of a novel
secreted protein designated herein as PRO1411.
[0114] 24. PRO4356
[0115] Glycosylphosphatidylinositol (GPI) anchored proteoglycans
are generally localized to the cell surface and are thus known to
be involved in the regulation of responses of cells to numerous
growth factors, cell adhesion molecules and extracellular matrix
components. The metastasis-associated GPI-anchored protein
(MAGPIAP) is one of these cell surface proteins which appears to be
involved in metastasis. Metastasis is the form of cancer wherein
the transformed or malignant cells are traveling and spreading the
cancer from one site to another. Therefore, identifying the
polypeptides related to metastasis and MAGPIAP is of interest.
[0116] 25. PRO246
[0117] The cell surface protein HICAR is a membrane-bound protein
that acts as a receptor for subgroup C of the adenoviruses and
subgroup B of the coxsackieviruses. Thus, HCAR may provide a means
for mediating viral infection of cells in that the presence of the
HCAR receptor on the cellular surface provides a binding site for
viral particles, thereby facilitating viral infection.
[0118] In light of the physiological importance of membrane-bound
proteins and specficially those which serve a cell surface receptor
for viruses, efforts are currently being undertaken by both
industry and academia to identify new, native membrane-bound
receptor proteins. Many of these efforts are focused on the
screening of mammalian recombinant DNA libraries to identify the
coding sequences for novel receptor proteins. We herein describe a
novel membrane-bound polypeptide (designated herein as PRO246)
having homology to the cell surface protein HCAR and to various
tumor antigens including A33 and carcinoembryonic antigen, wherein
this polypeptide may be a novel cell surface virus receptor or
tumor antigen.
[0119] 26. PRO265
[0120] Protein-protein interactions include receptor and antigen
complexes and signaling mechanisms. As more is known about the
structural and functional mechanisms underlying protein-protein
interactions, protein-protein interactions can be more easily
manipulated to regulate the particular result of the
protein-protein interaction. Thus, the underlying mechanisms of
protein-protein interactions are of interest to the scientific and
medical community.
[0121] All proteins containing leucine-rich repeats are thought to
be involved in protein-protein interactions. Leucine-rich repeats
are short sequence motifs present in a number of proteins with
diverse functions and cellular locations. The crystal structure of
ribonuclease inhibitor protein has revealed that leucine-rich
repeats correspond to beta-alpha structural units. These units are
arranged so that they form a parallel beta-sheet with one surface
exposed to solvent, so that the protein acquires an unusual,
nonglubular shape. These two features have been indicated as
responsible for the protein-binding functions of proteins
containing leucine-rich repeats. See, Kobe and Deisenhofer, Trends
Biochem. Sci., 19(10):415-421 (October 1994).
[0122] A study has been reported on leucine-rich proteoglycans
which serve as tissue organizers, orienting and ordering collagen
fibrils during ontogeny and are involved in pathological processes
such as wound healing, tissue repair, and tumor stroma formation.
Iozzo, R. V., Crit. Rev. Biochem. Mol. Biol., 32(2):141-174 (1997).
Others studies implicating leucine rich proteins in wound healing
and tissue repair are De La Salle, C., et al., Vouv. Rev. Fr.
Hematol. (Germany), 37(4):215-222 (1995), reporting mutations in
the leucine rich motif in a complex associated with the bleeding
disorder Bernard-Soulier syndrome and Chlemetson, K. J., Thromb.
Haemost. (Germany), 74(1):111-116 (July 1995), reporting that
platelets have leucine rich repeats. Another protein of particular
interest which has been reported to have leucine-rich repeats is
the SLIT protein which has been reported to be useful in treating
neuro-degenerative diseases such as Alzheimer's disease, nerve
damage such as in Parkinson's disease, and for diagnosis of cancer,
see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by
Yale University. Other studies reporting on the biological
functions of proteins having leucine-rich repeats include: Tayar,
N., et al., Mol. Cell Endocrinol., (Ireland), 125(1-2):65-70 (Decem
1996) (gonadotropin receptor involvement); Miura, Y., et al.,
Nippon Rinsho (Japan), 54(7):1784-1789 (July 1996) (apoptosis
involvement); Harris, P. C., et al., J. Am. Soc. Nephrol.,
6(4):1125-1133 (October 1995) (kidney disease involvement); and
Ruoslahti, E. I., et al., WO91 10727-A by La Jolla Cancer Research
Foundation (decorin binding to transforming growth factor-.beta.
involvement for treatment for cancer, wound healing and scarring).
Also of particular interest is fibromodulin and its use to prevent
or reduce dermal scarring. A study of fibromodulin is found in U.S.
Pat. No. 5,654,270 to Ruoslahti, et al.
[0123] Efforts are therefore being undertaken by both industry and
academia to identify new proteins having leucine rich repeats to
better understand protein-protein interactions. Of particular
interest are those proteins having leucine rich repeats and
homology to known proteins having leucine rich repeats such as
fibromodulin, the SLIT protein and platelet glycoprotein V. Many
efforts are focused on the screening of mammalian recombinant DNA
libraries to identify the coding sequences for novel secreted and
membrane-bound proteins having leucine rich repeats. We herein
describe the identification and characterization of novel
polypeptides having homology to fibromodulin, herein designated as
PRO265 polypeptides.
[0124] 27. PRO941
[0125] Cadherins are a large family of transmembrane proteins.
Cadherins comprise a family of calcium-dependent glycoproteins that
function in mediating cell-cell adhesion in virtually all solid
tissues of multicellular organisms. At least cadherins 1-13 as well
as types B, E, EP, M, N, P and R have been identified and
characterized. Among the functions cadherins are known for, with
some exceptions, are that cadherins participate in cell aggregation
and are associated with cell-cell adhesion sites. Recently, it has
been reported that while all cadherins share multiple repeats of a
cadherin specific motif believed to correspond to folding of
extracellular domains, members of the cadherin superfamily have
divergent structures and, possibly, functions. In particular it has
been reported that members of the cadherin superfamily are involved
in signal transduction. See, Suzuki, J. Cell Biochem.,
61(4):531-542 (1996). Cadherins are further described in Tanihara
et al., J. Cell Sci., 107(6):1697-1704 (1994), Aberle et al., J.
Cell Biochem., 61(4):514-523 (1996) and Tanihara et al., Cell
Adhes. Commun., 2(1):15-26 (1994). We herein describe the
identification and characterization of a novel polypeptide having
homology to a cadherin protein, designated herein as PRO941.
[0126] 28. PRO10096
[0127] Interleukin-10 (IL-10) is a pleiotropic immunosuppressive
cytokine that has been implicated as an important regulator of the
functions of myeloid and lymphoid cells. It has been demonstrated
that IL-10 functions as a potent inhibitor of the activation of the
synthesis of various inflammatory cytokines including, for example,
IL-1, IL-6, IFN-.gamma. and TNF-.alpha. (Gesser et al., Proc. Natl.
Acad. Sci. USA 94:14620-14625 (1997)). Moreover, IL-10 has been
demonstrated to strongly inhibit several of the accessory
activities of macrophages, thereby functioning as a potent
suppressor of the effector functions of macrophages, T-cells and NK
cells (Kuhn et al., Cell 75:263-274 (1993)). Furthermore, IL-10 has
been strongly implicated in the regulation of B-cell, mast cell and
thymocyte differentiation.
[0128] IL-10 was independently identified in two separate lines of
experiments. First, cDNA clones encoding murine IL-10 were
identified based upon the expression of cytokine synthesis
inhibitory factor (Moore et al., Science 248:1230-1234 (1990)),
wherein the human IL-10 counterpart cDNAs were subsequently
identified by cross-hybridization with the murine IL-10 cDNA (Viera
et al., Proc. Natl. Acad. Sci. USA 88:1172-1176 (1991)).
Additionally, IL-10 was independently identified as a
B-cell-derived mediator which functioned to co-stimulate active
thymocytes (Suda et al., Cell Immunol. 129:228 (1990)).
[0129] We herein describe the identification and characterization
of novel polypeptides having sequence similarity to IL-10,
designated herein as PRO10096 polypeptides.
[0130] 29. PRO6003
[0131] Efforts are being undertaken by both industry and academia
to identify new, native receptor or membrane-bound proteins. Many
efforts are focused on the screening of mammalian recombinant DNA
libraries to identify the coding sequences for novel receptor or
membrane-bound proteins. We herein describe the identification and
characterization of novel polypeptides designated herein as PRO6003
polypeptides.
SUMMARY OF THE INVENTION
[0132] In one embodiments of the present invention, the invention
provides vectors comprising DNA encoding any of the herein
described polypeptides. Host cell comprising any such vector are
also provided. By way of example, the host cells may be CHO cells,
E. coli, or yeast. A process for producing any of the herein
described polypeptides is further provided and comprises culturing
host cells under conditions suitable for expression of the desired
polypeptide and recovering the desired polypeptide from the cell
culture.
[0133] In other embodiments, the invention provides chimeric
molecules comprising any of the herein described polypeptides fused
to a heterologous polypeptide or amino acid sequence. Example of
such chimeric molecules comprise any of the herein described
polypeptides fused to an epitope tag sequence or a Fc region of an
immunoglobulin.
[0134] In another embodiment, the invention provides an antibody
which specifically binds to any of the above or below described
polypeptides. Optionally, the antibody is a monoclonal antibody,
humanized antibody, antibody fragment or single-chain antibody.
[0135] In yet other embodiments, the invention provides
oligonucleotide probes useful for isolating genomic and cDNA
nucleotide sequences or as antisense probes, wherein those probes
may be derived from any of the above or below described nucleotide
sequences.
[0136] In other embodiments, the invention provides an isolated
nucleic acid molecule comprising a nucleotide sequence that encodes
a PRO polypeptide.
[0137] In one aspect, the isolated nucleic acid molecule comprises
a nucleotide sequence having at least about 80% nucleic acid
sequence identity, alternatively at least about 81% nucleic acid
sequence identity, alternatively at least about 82% nucleic acid
sequence identity, alternatively at least about 83% nucleic acid
sequence identity, alternatively at least about 84% nucleic acid
sequence identity, alternatively at least about 85% nucleic acid
sequence identity, alternatively at least about 86% nucleic acid
sequence identity, alternatively at least about 87% nucleic acid
sequence identity, alternatively at least about 88% nucleic acid
sequence identity, alternatively at least about 89% nucleic acid
sequence identity, alternatively at least about 90% nucleic acid
sequence identity, alternatively at least about 91% nucleic acid
sequence identity, alternatively at least about 92% nucleic acid
sequence identity, alternatively at least about 93% nucleic acid
sequence identity, alternatively at least about 94% nucleic acid
sequence identity, alternatively at least about 95% nucleic acid
sequence identity, alternatively at least about 96% nucleic acid
sequence identity, alternatively at least about 97% nucleic acid
sequence identity, alternatively at least about 98% nucleic acid
sequence identity and alternatively at least about 99% nucleic acid
sequence identity to (a) a DNA molecule encoding a PRO polypeptide
having a full-length amino acid sequence as disclosed herein, an
amino acid sequence lacking the signal peptide as disclosed herein,
an extracellular domain of a transmembrane protein, with or without
the signal peptide, as disclosed herein or any other specifically
defined fragment of the full-length amino acid sequence as
disclosed herein, or (b) the complement of the DNA molecule of
(a).
[0138] In other aspects, the isolated nucleic acid molecule
comprises a nucleotide sequence having at least about 80% nucleic
acid sequence identity, alternatively at least about 81% nucleic
acid sequence identity, alternatively at least about 82% nucleic
acid sequence identity, alternatively at least about 83% nucleic
acid sequence identity, alternatively at least about 84% nucleic
acid sequence identity, alternatively at least about 85% nucleic
acid sequence identity, alternatively at least about 86% nucleic
acid sequence identity, alternatively at least about 87% nucleic
acid sequence identity, alternatively at least about 88% nucleic
acid sequence identity, alternatively at least about 89% nucleic
acid sequence identity, alternatively at least about 90% nucleic
acid sequence identity, alternatively at least about 91% nucleic
acid sequence identity, alternatively at least about 92% nucleic
acid sequence identity, alternatively at least about 93% nucleic
acid sequence identity, alternatively at least about 94% nucleic
acid sequence identity, alternatively at least about 95% nucleic
acid sequence identity, alternatively at least about 96% nucleic
acid sequence identity, alternatively at least about 97% nucleic
acid sequence identity, alternatively at least about 98% nucleic
acid sequence identity and alternatively at least about 99% nucleic
acid sequence identity to (a) a DNA molecule comprising the coding
sequence of a full-length PRO polypeptide cDNA as disclosed herein,
the coding sequence of a PRO polypeptide lacking the signal peptide
as disclosed herein, the coding sequence of an extracellular domain
of a transmembrane PRO polypeptide, with or without the signal
peptide, as disclosed herein or the coding sequence of any other
specifically defined fragment of the full-length amino acid
sequence as disclosed herein, or (b) the complement of the DNA
molecule of (a).
[0139] In a further aspect, the invention concerns an isolated
nucleic acid molecule comprising a nucleotide sequence having at
least about 80% nucleic acid sequence identity, alternatively at
least about 81% nucleic acid sequence identity, alternatively at
least about 82% nucleic acid sequence identity, alternatively at
least about 83% nucleic acid sequence identity, alternatively at
least about 84% nucleic acid sequence identity, alternatively at
least about 85% nucleic acid sequence identity, alternatively at
least about 86% nucleic acid sequence identity, alternatively at
least about 87% nucleic acid sequence identity, alternatively at
least about 88% nucleic acid sequence identity, alternatively at
least about 89% nucleic acid sequence identity, alternatively at
least about 90% nucleic acid sequence identity, alternatively at
least about 91% nucleic acid sequence identity, alternatively at
least about 92% nucleic acid sequence identity, alternatively at
least about 93% nucleic acid sequence identity, alternatively at
least about 94% nucleic acid sequence identity, alternatively at
least about 95% nucleic acid sequence identity, alternatively at
least about 96% nucleic acid sequence identity, alternatively at
least about 97% nucleic acid sequence identity, alternatively at
least about 98% nucleic acid sequence identity and alternatively at
least about 99% nucleic acid sequence identity to (a) a DNA
molecule that encodes the same mature polypeptide encoded by any of
the human protein cDNAs deposited with the ATCC as disclosed
herein, or (b) the complement of the DNA molecule of (a).
[0140] Another aspect the invention provides an isolated nucleic
acid molecule comprising a nucleotide sequence encoding a PRO
polypeptide which is either transmembrane domain-deleted or
transmembrane domain-inactivated, or is complementary to such
encoding nucleotide sequence, wherein the transmembrane domain(s)
of such polypeptide are disclosed herein. Therefore, soluble
extracellular domains of the herein described PRO polypeptides are
contemplated.
[0141] Another embodiment is directed to fragments of a PRO
polypeptide coding sequence, or the complement thereof, that may
find use as, for example, hybridization probes, for encoding
fragments of a PRO polypeptide that may optionally encode a
polypeptide comprising a binding site for an anti-PRO antibody or
as antisense oligonucleotide probes. Such nucleic acid fragments
are usually at least about 20 nucleotides in length, alternatively
at least about 30 nucleotides in length, alternatively at least
about 40 nucleotides in length, alternatively at least about 50
nucleotides in length, alternatively at least about 60 nucleotides
in length, alternatively at least about 70 nucleotides in length,
alternatively at least about 80 nucleotides in length,
alternatively at least about 90 nucleotides in length,
alternatively at least about 100 nucleotides in length,
alternatively at least about 110 nucleotides in length,
alternatively at least about 120 nucleotides in length,
alternatively at least about 130 nucleotides in length,
alternatively at least about 140 nucleotides in length,
alternatively at least about 150 nucleotides in length,
alternatively at least about 160 nucleotides in length,
alternatively at least about 170 nucleotides in length,
alternatively at least about 180 nucleotides in length,
alternatively at least about 190 nucleotides in length,
alternatively at least about 200 nucleotides in length,
alternatively at least about 250 nucleotides in length,
alternatively at least about 300 nueleotides in length,
alternatively at least about 350 nucleotides in length,
alternatively at least about 400 nucleotides in length,
alternatively at least about 450 nucleotides in length,
alternatively at least about 500 nucleotides in length,
alternatively at least about 600 nucleotides in length,
alternatively at least about 700 nucleotides in length,
alternatively at least about 800 nucleotides in length,
alternatively at least about 900 nucleotides in length and
alternatively at least about 1000 nucleotides in length, wherein in
this context the term "about" means the referenced nucleotide
sequence length plus or minus 10% of that referenced length. It is
noted that novel fragments of a PRO polypeptide-encoding nucleotide
sequence may be determined in a routine manner by aligning the PRO
polypeptide-encoding nucleotide sequence with other known
nucleotide sequences using any of a number of well known sequence
alignment programs and determining which PRO polypeptide-encoding
nucleotide sequence fragment(s) are novel. All of such PRO
polypeptide-encoding nucleotide sequences are contemplated herein.
Also contemplated are the PRO polypeptide fragments encoded by
these nucleotide molecule fragments, preferably those PRO
polypeptide fragments that comprise a binding site for an anti-PRO
antibody.
[0142] In another embodiment, the invention provides isolated PRO
polypeptide encoded by any of the isolated nucleic acid sequences
hereinabove identified.
[0143] In a certain aspect, the invention concerns an isolated PRO
polypeptide, comprising an amino acid sequence having at least
about 80% amino acid sequence identity, alternatively at least
about 81% amino acid sequence identity, alternatively at least
about 82% amino acid sequence identity, alternatively at least
about 83% amino acid sequence identity, alternatively at least
about 84% amino acid sequence identity, alternatively at least
about 85% amino acid sequence identity, alternatively at least
about 86% amino acid sequence identity, alternatively at least
about 87% amino acid sequence identity, alternatively at least
about 88% amino acid sequence identity, alternatively at least
about 89% amino acid sequence identity, alternatively at least
about 90% amino acid sequence identity, alternatively at least
about 91% amino acid sequence identity, alternatively at least
about 92% amino acid sequence identity, alternatively at least
about 93% amino acid sequence identity, alternatively at least
about 94% amino acid sequence identity, alternatively at least
about 95% amino acid sequence identity, alternatively at least
about 96% amino acid sequence identity, alternatively at least
about 97% amino acid sequence identity, alternatively at least
about 98% amino acid sequence identity and alternatively at least
about 99% amino acid sequence identity to a PRO polypeptide having
a full-length amino acid sequence as disclosed herein, an amino
acid sequence lacking the signal peptide as disclosed herein, an
extracellular domain of a transmembrane protein, with or without
the signal peptide, as disclosed herein or any other specifically
defined fragment of the full-length amino acid sequence as
disclosed herein.
[0144] In a further aspect, the invention concerns an isolated PRO
polypeptide comprising an amino acid sequence having at least about
80% amino acid sequence identity, alternatively at least about 81%
amino acid sequence identity, alternatively at least about 82%
amino acid sequence identity, alternatively at least about 83%
amino acid sequence identity, alternatively at least about 84%
amino acid sequence identity, alternatively at least about 85%
amino acid sequence identity, alternatively at least about 86%
amino acid sequence identity, alternatively at least about 87%
amino acid sequence identity, alternatively at least about 88%
amino acid sequence identity, alternatively at least about 89%
amino acid sequence identity, alternatively at least about 90%
amino acid sequence identity, alternatively at least about 91%
amino acid sequence identity, alternatively at least about 92%
amino acid sequence identity, alternatively at least about 93%
amino acid sequence identity, alternatively at least about 94%
amino acid sequence identity, alternatively at least about 95%
amino acid sequence identity, alternatively at least about 96%
amino acid sequence identity, alternatively at least about 97%
amino acid sequence identity, alternatively at least about 98%
amino acid sequence identity and alternatively at least about 99%
amino acid sequence identity to an amino acid sequence encoded by
any of the human protein cDNAs deposited with the ATCC as disclosed
herein.
[0145] In a further aspect, the invention concerns an isolated PRO
polypeptide comprising an amino acid sequence scoring at least
about 80% positives, alternatively at least about 81% positives,
alternatively at least about 82% positives, alternatively at least
about 83% positives, alternatively at least about 84% positives,
alternatively at least about 85% positives, alternatively at least
about 86% positives, alternatively at least about 87% positives,
alternatively at least about 88% positives, alternatively at least
about 89% positives, alternatively at least about 90% positives,
alternatively at least about 91% positives, alternatively at least
about 92% positives, alternatively at least about 93% positives,
alternatively at least about 94% positives, alternatively at least
about 95% positives, alternatively at least about 96% positives,
alternatively at least about 97% positives, alternatively at least
about 98% positives and alternatively at least about 99% positives
when compared with the amino acid sequence of a PRO polypeptide
having a full-length amino acid sequence as disclosed herein, an
amino acid sequence lacking the signal peptide as disclosed herein,
an extracellular domain of a transmembrane protein, with or without
the signal peptide, as disclosed herein or any other specifically
defined fragment of the full-length amino acid sequence as
disclosed herein.
[0146] In a specific aspect, the invention provides an isolated PRO
polypeptide without the N-terminal signal sequence and/or the
initiating methionine and is encoded by a nucleotide sequence that
encodes such an amino acid sequence as hereinbefore described.
Processes for producing the same are also herein described, wherein
those processes comprise culturing a host cell comprising a vector
which comprises the appropriate encoding nucleic acid molecule
under conditions suitable for expression of the PRO polypeptide and
recovering the PRO polypeptide from the cell culture.
[0147] Another aspect the invention provides an isolated PRO
polypeptide which is either transmembrane domain-deleted or
transmembrane domain-inactivated. Processes for producing the same
are also herein described, wherein those processes comprise
culturing a host cell comprising a vector which comprises the
appropriate encoding nucleic acid molecule under conditions
suitable for expression of the PRO polypeptide and recovering the
PRO polypeptide from the cell culture.
[0148] In yet another embodiment, the invention concerns agonists
and antagonists of a native PRO polypeptide as defined herein. In a
particular embodiment, the agonist or antagonist is an anti-PRO
antibody or a small molecule.
[0149] In a further embodiment, the invention concerns a method of
identifying agonists or antagonists to a PRO polypeptide which
comprise contacting the PRO polypeptide with a candidate molecule
and monitoring a biological activity mediated by said PRO
polypeptide. Preferably, the PRO polypeptide is a native PRO
polypeptide.
[0150] In a still further embodiment, the invention concerns a
composition of matter comprising a PRO polypeptide, or an agonist
or antagonist of a PRO polypeptide as herein described, or an
anti-PRO antibody, in combination with a carrier. Optionally, the
carrier is a pharmaceutically acceptable carrier.
[0151] Another embodiment of the present invention is directed to
the use of a PRO polypeptide, or an agonist or antagonist thereof
as hereinbefore described, or an anti-PRO antibody, for the
preparation of a medicament useful in the treatment of a condition
which is responsive to the PRO polypeptide, an agonist or
antagonist thereof or an anti-PRO antibody.
BRIEF DESCRIPTION OF THE DRAWINGS
[0152] FIG. 1 shows a nucleotide sequence (SEQ ID NO:3) of a native
sequence PRO196 cDNA, wherein SEQ ID NO:3 is a clone designated
herein as "DNA22779-1130".
[0153] FIG. 2 shows the amino acid sequence (SEQ ID NO:4) derived
from the coding sequence of SEQ ID NO:3 shown in FIG. 1.
[0154] FIG. 3 shows a nucleotide sequence (SEQ ID NO:8) of a native
sequence PRO444 cDNA, wherein SEQ ID NO:8 is a clone designated
herein as "DNA26846-1397".
[0155] FIG. 4 shows the amino acid sequence (SEQ ID NO:9) derived
from the coding sequence of SEQ ID NO:8 shown in FIG. 3.
[0156] FIG. 5 shows a nucleotide sequence (SEQ ID NO:10) of a
native sequence PRO183 cDNA, wherein SEQ ID NO: 10 is a clone
designated herein as "DNA28498".
[0157] FIG. 6 shows the amino acid sequence (SEQ ID NO:11) derived
from the coding sequence of SEQ ID NO:10 shown in FIG. 5.
[0158] FIG. 7 shows a nucleotide sequence (SEQ ID NO:12) of a
native sequence PRO185 cDNA, wherein SEQ ID NO:12 is a clone
designated herein as "DNA28503".
[0159] FIG. 8 shows the amino acid sequence (SEQ ID NO:13) derived
from the coding sequence of SEQ ID NO:12 shown in FIG. 7.
[0160] FIG. 9 shows a nucleotide sequence (SEQ ID NO:14) of a
native sequence PRO210 cDNA, wherein SEQ ID NO:14 is a clone
designated herein as "DNA32279-1131".
[0161] FIG. 10 shows the amino acid sequence (SEQ ID NO:15) derived
from the coding sequence of SEQ ID NO:14 shown in FIG. 9.
[0162] FIG. 11 shows a nucleotide sequence (SEQ ID NO:16) of a
native sequence PRO215 cDNA, wherein SEQ ID NO:16 is a clone
designated herein as "DNA32288-1132".
[0163] FIG. 12 shows the amino acid sequence (SEQ ID NO:17) derived
from the coding sequence of SEQ ID NO:16 shown in FIG. 11.
[0164] FIG. 13 shows a nucleotide sequence (SEQ ID NO:21) of a
native sequence PRO217 cDNA, wherein SEQ ID NO:21 is a clone
designated herein as "DNA33094-1131".
[0165] FIG. 14 shows the amino acid sequence (SEQ ID NO:22) derived
from the coding sequence of SEQ ID NO:21 shown in FIG. 13.
[0166] FIG. 15 shows a nucleotide sequence (SEQ ID NO:23) of a
native sequence PRO242 cDNA, wherein SEQ ID NO:23 is a clone
designated herein as "DNA33785-1143".
[0167] FIG. 16 shows the amino acid sequence (SEQ ID NO:24) derived
from the coding sequence of SEQ ID NO:23 shown in FIG. 15.
[0168] FIG. 17 shows a nucleotide sequence (SEQ ID NO:28) of a
native sequence PRO288 cDNA, wherein SEQ ID NO:28 is a clone
designated herein as "DNA35663-1129".
[0169] FIG. 18 shows the amino acid sequence (SEQ ID NO:29) derived
from the coding sequence of SEQ ID NO:28 shown in FIG. 17.
[0170] FIG. 19 shows a nucleotide sequence (SEQ ID NO:31) of a
native sequence PRO365 cDNA, wherein SEQ ID NO:31 is a clone
designated herein as "DNA46777-1253".
[0171] FIG. 20 shows the amino acid sequence (SEQ ID NO:32) derived
from the coding sequence of SEQ ID NO:31 shown in FIG. 19.
[0172] FIG. 21 shows a nucleotide sequence (SEQ ID NO:38) of a
native sequence PRO1361 cDNA, wherein SEQ ID NO:38 is a clone
designated herein as "DNA60783-1611".
[0173] FIG. 22 shows the amino acid sequence (SEQ ID NO:39) derived
from the coding sequence of SEQ ID NO:38 shown in FIG. 21.
[0174] FIG. 23 shows a nucleotide sequence (SEQ ID NO:40) of a
native sequence PRO1308 cDNA, wherein SEQ ID NO:40 is a clone
designated herein as "DNA62306-1570".
[0175] FIG. 24 shows the amino acid sequence (SEQ ID NO:4 1)
derived from the coding sequence of SEQ ID NO:40 shown in FIG.
23.
[0176] FIG. 25 shows a nucleotide sequence (SEQ ID NO:51) of a
native sequence PRO1183 cDNA, wherein SEQ ID NO:51 is a clone
designated herein as "DNA62880-1513".
[0177] FIG. 26 shows the amino acid sequence (SEQ ID NO:52) derived
from the coding sequence of SEQ ID NO:51 shown in FIG. 25.
[0178] FIG. 27 shows a nucleotide sequence (SEQ ID NO:53) of a
native sequence PRO1272 cDNA, wherein SEQ ID NO:53 is a clone
designated herein as "DNA64896-1539".
[0179] FIG. 28 shows the amino acid sequence (SEQ ID NO:54) derived
from the coding sequence of SEQ ID NO:53 shown in FIG. 27.
[0180] FIG. 29 shows a nucleotide sequence (SEQ ID NO:55) of a
native sequence PRO1419 cDNA, wherein SEQ ID NO:55 is a clone
designated herein as "DNA71290-1630".
[0181] FIG. 30 shows the amino acid sequence (SEQ ID NO:56) derived
from the coding sequence of SEQ ID NO:55 shown in FIG. 29.
[0182] FIG. 31 shows a nucleotide sequence (SEQ ID NO:57) of a
native sequence PRO4999 cDNA, wherein SEQ ID NO:57 is a clone
designated herein as "DNA96031-2664".
[0183] FIG. 32 shows the amino acid sequence (SEQ ID NO:58) derived
from the coding sequence of SEQ ID NO:57 shown in FIG. 31.
[0184] FIG. 33 shows a nucleotide sequence (SEQ ID NO:62) of a
native sequence PRO7170 cDNA, wherein SEQ ID NO:62 is a clone
designated herein as "DNA108722-2743".
[0185] FIG. 34 shows the amino acid sequence (SEQ ID NO:63) derived
from the coding sequence of SEQ ID NO:62 shown in FIG. 33.
[0186] FIG. 35 shows a nucleotide sequence (SEQ ID NO:64) of a
native sequence PRO248 cDNA, wherein SEQ ID NO:64 is a clone
designated herein as "DNA35674-1142".
[0187] FIG. 36 shows the amino acid sequence (SEQ ID NO:65) derived
from the coding sequence of SEQ ID NO:64 shown in FIG. 35.
[0188] FIG. 37 shows a nucleotide sequence (SEQ ID NO:72) of a
native sequence PRO353 cDNA, wherein SEQ ID NO:72 is a clone
designated herein as "DNA41234".
[0189] FIG. 38 shows the amino acid sequence (SEQ ID NO:73) derived
from the coding sequence of SEQ ID NO:72 shown in FIG. 37.
[0190] FIG. 39 shows a nucleotide sequence (SEQ ID NO:77) of a
native sequence PRO1318 cDNA, wherein SEQ ID NO:77 is a clone
designated herein as "DNA73838-1674".
[0191] FIG. 40 shows the amino acid sequence (SEQ ID NO:78) derived
from the coding sequence of SEQ ID NO:77 shown in FIG. 39.
[0192] FIG. 41 shows a nucleotide sequence (SEQ ID NO:79) of a
native sequence PRO1600 cDNA, wherein SEQ ID NO:79 is a clone
designated herein as "DNA77503-1686".
[0193] FIG. 42 shows the amino acid sequence (SEQ ID NO:80) derived
from the coding sequence of SEQ ID NO:79 shown in FIG. 41.
[0194] FIG. 43 shows a nucleotide sequence (SEQ ID NO:83) of a
native sequence PRO9940 cDNA, wherein SEQ ID NO:83 is a clone
designated herein as "DNA92282".
[0195] FIG. 44 shows the amino acid sequence (SEQ ID NO:84) derived
from the coding sequence of SEQ ID NO:83 shown in FIG. 43.
[0196] FIG. 45 shows a nucleotide sequence (SEQ ID NO:85) of a
native sequence PRO533 cDNA, wherein SEQ ID NO:85 is a clone
designated herein as "DNA49435-1219".
[0197] FIG. 46 shows the amino acid sequence (SEQ ID NO:86) derived
from the coding sequence of SEQ ID NO:85 shown in FIG. 45.
[0198] FIG. 47 shows a nucleotide sequence (SEQ ID NO:90) of a
native sequence PRO301 cDNA, wherein SEQ ID NO:90 is a clone
designated herein as "DNA40628-1216".
[0199] FIG. 48 shows the amino acid sequence (SEQ ID NO:91) derived
from the coding sequence of SEQ ID NO:90 shown in FIG. 47.
[0200] FIG. 49 shows a nucleotide sequence (SEQ ID NO:98) of a
native sequence PRO187 cDNA, wherein SEQ ID NO:98 is a clone
designated herein as "DNA27864-1155".
[0201] FIG. 50 shows the amino acid sequence (SEQ ID NO:99) derived
from the coding sequence of SEQ ID NO:98 shown in FIG. 49.
[0202] FIG. 51 shows a nucleotide sequence (SEQ ID NO:103) of a
native sequence PRO337 cDNA, wherein SEQ ID NO:103 is a clone
designated herein as "DNA43316-1237".
[0203] FIG. 52 shows the amino acid sequence (SEQ ID NO:104)
derived from the coding sequence of SEQ ID NO:103 shown in FIG.
51.
[0204] FIG. 53 shows a nucleotide sequence (SEQ ID NO:105) of a
native sequence PRO1411 cDNA, wherein SEQ ID NO:105 is a clone
designated herein as "DNA59212-1627".
[0205] FIG. 54 shows the amino acid sequence (SEQ ID NO:106)
derived from the coding sequence of SEQ ID NO:105 shown in FIG.
53.
[0206] FIG. 55 shows a nucleotide sequence (SEQ ID NO:107) of a
native sequence PRO4356 cDNA, wherein SEQ ID NO:107 is a clone
designated herein as "DNA86576-2595".
[0207] FIG. 56 shows the amino acid sequence (SEQ ID NO:108)
derived from the coding sequence of SEQ ID NO:107 shown in FIG.
55.
[0208] FIG. 57 shows a nucleotide sequence (SEQ ID NO:109) of a
native sequence PRO246 cDNA, wherein SEQ ID NO:109 is a clone
designated herein as "DNA35639-1172".
[0209] FIG. 58 shows the amino acid sequence (SEQ ID NO:110)
derived from the coding sequence of SEQ ID NO:109 shown in FIG.
57.
[0210] FIG. 59 shows a nucleotide sequence (SEQ ID NO:114) of a
native sequence PRO265 cDNA, wherein SEQ ID NO:114 is a clone
designated herein as "DNA36350-1158".
[0211] FIG. 60 shows the amino acid sequence (SEQ ID NO:115)
derived from the coding sequence of SEQ ID NO:114 shown in FIG.
59.
[0212] FIG. 61 shows a nucleotide sequence (SEQ ID NO:120) of a
native sequence PRO941 cDNA, wherein SEQ ID NO:120 is a clone
designated herein as "DNA53906-1368".
[0213] FIG. 62 shows the amino acid sequence (SEQ ID NO:121)
derived from the coding sequence of SEQ ID NO:120 shown in FIG.
61.
[0214] FIG. 63 shows a nucleotide sequence (SEQ ID NO:125) of a
native sequence PRO10096 cDNA, wherein SEQ ID NO:125 is a clone
designated herein as "DNA25185-2806".
[0215] FIG. 64 shows the amino acid sequence (SEQ ID NO:126)
derived from the coding sequence of SEQ ID NO:125 shown in FIG.
63.
[0216] FIG. 65 shows a nucleotide sequence (SEQ ID NO:127) of a
native sequence PRO6003 cDNA, wherein SEQ ID NO:127 is a clone
designated herein as "DNA83568-2692".
[0217] FIG. 66 shows the amino acid sequence (SEQ ID NO:128)
derived from the coding sequence of SEQ ID NO:127 shown in FIG.
65.
[0218] FIGS. 67A-B show a nucleotide sequence (SEQ ID NO:129) of a
native sequence PRO6004 cDNA, wherein SEQ ID NO:129 is a clone
designated herein as "DNA92259".
[0219] FIG. 68 shows the amino acid sequence (SEQ ID NO:130)
derived from the coding sequence of SEQ ID NO:129 shown in FIGS.
67A-B.
[0220] FIG. 69 shows a nucleotide sequence (SEQ ID NO:131) of a
native sequence PRO350 cDNA, wherein SEQ ID NO:131 is a clone
designated herein as "DNA44175-1314".
[0221] FIG. 70 shows the amino acid sequence (SEQ ID NO:132)
derived from the coding sequence of SEQ ID NO:131 shown in FIG.
69.
[0222] FIG. 71 shows a nucleotide sequence (SEQ ID NO:136) of a
native sequence PRO2630 cDNA, wherein SEQ ID NO:136 is a clone
designated herein as "DNA83551".
[0223] FIG. 72 shows the amino acid sequence (SEQ ID NO:137)
derived from the coding sequence of SEQ ID NO:136 shown in FIG.
71.
[0224] FIG. 73 shows a nucleotide sequence (SEQ ID NO:138) of a
native sequence PRO6309 cDNA, wherein SEQ ID NO:138 is a clone
designated herein as "DNA116510".
[0225] FIG. 74 shows the amino acid sequence (SEQ ID NO:139)
derived from the coding sequence of SEQ ID NO:138 shown in FIG.
73.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0226] 1. Definitions
[0227] The terms "PRO polypeptide" and "PRO" as used herein and
when immediately followed by a numerical designation refer to
various polypeptides, wherein the complete designation (i.e.,
PRO/number) refers to specific polypeptide sequences as described
herein. The terms "PRO/number polypeptide" and "PRO/number" wherein
the tern "number" is provided as an actual numerical designation as
used herein encompass native sequence polypeptides and polypeptide
variants (which are further defined herein). The PRO polypeptides
described herein may be isolated from a variety of sources, such as
from human tissue types or from another source, or prepared by
recombinant or synthetic methods. The term "PRO polypeptide" refers
to each individual PRO/number polypeptide disclosed herein. All
disclosures in this specification which refer to the "PRO
polypeptide" refer to each of the polypeptides individually as well
as jointly. For example, descriptions of the preparation of,
purification of, derivation of, formation of antibodies to or
against, administration of, compositions containing, treatment of a
disease with, etc., pertain to each polypeptide of the invention
individually. The term "PRO polypeptide" also includes variants of
the PRO/number polypeptides disclosed herein.
[0228] A "native sequence PRO polypeptide" comprises a polypeptide
having the same amino acid sequence as the corresponding PRO
polypeptide derived from nature. Such native sequence PRO
polypeptides can be isolated from nature or can be produced by
recombinant or synthetic means. The term "native sequence PRO
polypeptide" specifically encompasses naturally-occurring truncated
or secreted forms of the specific PRO polypeptide (e.g., an
extracellular domain sequence), naturally-occurring variant forms
(e.g., alternatively spliced forms) and naturally-occurring allelic
variants of the polypeptide. In various embodiments of the
invention, the native sequence PRO polypeptides disclosed herein
are mature or full-length native sequence polypeptides comprising
the full-length amino acids sequences shown in the accompanying
figures. Start and stop codons are shown in bold font and
underlined in the figures. However, while the PRO polypeptide
disclosed in the accompanying figures are shown to begin with
methionine residues designated herein as amino acid position 1 in
the figures, it is conceivable and possible that other methionine
residues located either upstream or downstream from the amino acid
position 1 in the figures may be employed as the starting amino
acid residue for the PRO polypeptides.
[0229] The PRO polypeptide "extracellular domain" or "ECD" refers
to a form of the PRO polypeptide which is essentially free of the
transmembrane and cytoplasmic domains. Ordinarily, a PRO
polypeptide ECD will have less than 1% of such transmembrane and/or
cytoplasmic domains and preferably, will have less than 0.5% of
such domains. It will be understood that any transmembrane domains
identified for the PRO polypeptides of the present invention are
identified pursuant to criteria routinely employed in the art for
identifying that type of hydrophobic domain. The exact boundaries
of a transmembrane domain may vary but most likely by no more than
about 5 amino acids at either end of the domain as initially
identified herein. Optionally, therefore, an extracellular domain
of a PRO polypeptide may contain from about 5 or fewer amino acids
on either side of the transmembrane domain/extracellular domain
boundary as identified in the Examples or specification and such
polypeptides, with or without the associated signal peptide, and
nucleic acid encoding them, are comtemplated by the present
invention.
[0230] The approximate location of the "signal peptides" of the
various PRO polypeptides disclosed herein are shown in the present
specification and/or the accompanying figures. It is noted,
however, that the C-terminal boundary of a signal peptide may vary,
but most likely by no more than about 5 amino acids on either side
of the signal peptide C-terminal boundary as initially identified
herein, wherein the C-terminal boundary of the signal peptide may
be identified pursuant to criteria routinely employed in the art
for identifying that type of amino acid sequence element (e.g.,
Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al.,
Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also
recognized that, in some cases, cleavage of a signal sequence from
a secreted polypeptide is not entirely uniform, resulting in more
than one secreted species. These mature polypeptides, where the
signal peptide is cleaved within no more than about 5 amino acids
on either side of the C-terminal boundary of the signal peptide as
identified herein, and the polynucleotides encoding them, are
contemplated by the present invention.
[0231] "PRO polypeptide variant" means an active PRO polypeptide as
defined above or below having at least about 80% amino acid
sequence identity with a full-length native sequence PRO
polypeptide sequence as disclosed herein, a PRO polypeptide
sequence lacking the signal peptide as disclosed herein, an
extracellular domain of a PRO polypeptide, with or without the
signal peptide, as disclosed herein or any other fragment of a
full-length PRO polypeptide sequence as disclosed herein. Such PRO
polypeptide variants include, for instance, PRO polypeptides
wherein one or more amino acid residues are added, or deleted, at
the N- or C-terminus of the full-length native amino acid sequence.
Ordinarily, a PRO polypeptide variant will have at least about 80%
amino acid sequence identity, alternatively at least about 81%
amino acid sequence identity, alternatively at least about 82%
amino acid sequence identity, alternatively at least about 83%
amino acid sequence identity, alternatively at least about 84%
amino acid sequence identity, alternatively at least about 85%
amino acid sequence identity, alternatively at least about 86%
amino acid sequence identity, alternatively at least about 87%
amino acid sequence identity, alternatively at least about 88%
amino acid sequence identity, alternatively at least about 89%
amino acid sequence identity, alternatively at least about 90%
amino acid sequence identity, alternatively at least about 91%
ainino acid sequence identity, alternatively at least about 92%
amino acid sequence identity, alternatively at least about 93%
amino acid sequence identity, alternatively at least about 94%
amino acid sequence identity, alternatively at least about 95%
amino acid sequence identity, alternatively at least about 96%
amino acid sequence identity, alternatively at least about 97%
amino acid sequence identity, alternatively at least about 98%
amino acid sequence identity and alternatively at least about 99%
amino acid sequence identity to a full-length native sequence PRO
polypeptide sequence as disclosed herein, a PRO polypeptide
sequence lacking the signal peptide as disclosed herein, an
extracellular domain of a PRO polypeptide, with or without the
signal peptide, as disclosed herein or any other specifically
defined fragment of a full-length PRO polypeptide sequence as
disclosed herein. Ordinarily, PRO variant polypeptides are at least
about 10 amino acids in length, alternatively at least about 20
amino acids in length, alternatively at least about 30 amino acids
in length, alternatively at least about 40 amino acids in length,
alternatively at least about 50 amino acids in length,
alternatively at least about 60 amino acids in length,
alternatively at least about 70 amino acids in length,
alternatively at least about 80 amino acids in length,
alternatively at least about 90 amino acids in length,
alternatively at least about 100 amino acids in length,
alternatively at least about 150 amino acids in length,
alternatively at least about 200 amino acids in length,
alternatively at least about 300 amino acids in length, or
more.
[0232] "Percent (%) amino acid sequence identity" with respect to
the PRO polypeptide sequences identified herein is defined as the
percentage of amino acid residues in a candidate sequence that are
identical with the amino acid residues in the specific PRO
polypeptide sequence, after aligning the sequences and introducing
gaps, if necessary, to achieve the maximum percent sequence
identity, and not considering any conservative substitutions as
part of the sequence identity. Alignment for purposes of
determining percent amino acid sequence identity can be achieved in
various ways that are within the skill in the art, for instance,
using publicly available computer software such as BLAST, BLAST-2,
ALIGN or Megalign (DNASTAR) software. Those skilled in the art can
determine appropriate parameters for measuring alignment, including
any algorithms needed to achieve maximal alignment over the full
length of the sequences being compared. For purposes herein,
however, % amino acid sequence identity values are generated using
the sequence comparison computer program ALIGN-2, wherein the
complete source code for the ALIGN-2 program is provided in Table 1
below. The ALIGN-2 sequence comparison computer program was
authored by Genentech, Inc. and the source code shown in Table 1
below has been filed with user documentation in the U.S. Copyright
Office, Washington D.C., 20559, where it is registered under U.S.
Copyright Registration No. TXU510087. The ALIGN-2 program is
publicly available through Genentech, Inc., South San Francisco,
Calif. or may be compiled from the source code provided in Table 1
below. The ALIGN-2 program should be compiled for use on a UNIX
operating system, preferably digital UNIX V4.0D. All sequence
comparison parameters are set by the ALIGN-2 program and do not
vary.
[0233] In situations where ALIGN-2 is employed for amino acid
sequence comparisons, the % amino acid sequence identity of a given
amino acid sequence A to, with, or against a given amino acid
sequence B (which can alternatively be phrased as a given amino
acid sequence A that has or comprises a certain % amino acid
sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows:
100 times the fraction X/Y
[0234] where X is the number of amino acid residues scored as
identical matches by the sequence alignment program ALIGN-2 in that
program's alignment of A and B, and where Y is the total number of
amino acid residues in B. It will be appreciated that where the
length of amino acid sequence A is not equal to the length of amino
acid sequence B, the % amino acid sequence identity of A to B will
not equal the % amino acid sequence identity of B to A. As examples
of % amino acid sequence identity calculations using this method,
Tables 2 and 3 demonstrate how to calculate the % amino acid
sequence identity of the amino acid sequence designated "Comparison
Protein" to the amino acid sequence designated "PRO", wherein "PRO"
represents the amino acid sequence of a hypothetical PRO
polypeptide of interest, "Comparison Protein" represents the amino
acid sequence of a polypeptide against which the "PRO" polypeptide
of interest is being compared, and "X, "Y" and "Z" each represent
different hypothetical amino acid residues.
[0235] Unless specifically stated otherwise, all % amino acid
sequence identity values used herein are obtained as described in
the immediately preceding paragraph using the ALIGN-2 computer
program. However, % amino acid sequence identity values may also be
obtained as described below by using the WU-BLAST-2 computer
program (Altschul et al., Methods in Enzymology 266:460-480
(1996)). Most of the WU-BLAST-2 search parameters are set to the
default values. Those not set to default values, i.e., the
adjustable parameters, are set with the following values: overlap
span=1, overlap fraction=0.125, word threshold (T)=11, and scoring
matrix=BLOSUM62. When WU-BLAST-2 is employed, a % amino acid
sequence identity value is determined by dividing (a) the number of
matching identical amino acid residues between the amino acid
sequence of the PRO polypeptide of interest having a sequence
derived from the native PRO polypeptide and the comparison amino
acid sequence of interest (i.e., the sequence against which the PRO
polypeptide of interest is being compared which may be a PRO
variant polypeptide) as determined by WU-BLAST-2 by (b) the total
number of amino acid residues of the PRO polypeptide of interest.
For example, in the statement "a polypeptide comprising an the
amino acid sequence A which has or having at least 80% amino acid
sequence identity to the amino acid sequence B", the amino acid
sequence A is the comparison amino acid sequence of interest and
the amino acid sequence B is the amino acid sequence of the PRO
polypeptide of interest.
[0236] Percent amino acid sequence identity may also be determined
using the sequence comparison program NCBI-BLAST2 (Altschul et al.,
Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence
comparison program may be downloaded from
http://www.ncbi.nlm.nih.gov or otherwise obtained from the National
Institute of Health, Bethesda, Md. NCBI-BLAST2 uses several search
parameters, wherein all of those search parameters are set to
default values including, for example, unmask=yes, strand=all,
expected occurrences=10, minimum low complexity length=15/5,
multi-pass e-value=0.01, constant for multi-pass=25, dropoff for
final gapped alignment=25 and scoring matrix=BLOSUM62.
[0237] In situations where NCBI-BLAST2 is employed for amino acid
sequence comparisons, the % amino acid sequence identity of a given
amino acid sequence A to, with, or against a given amino acid
sequence B (which can alternatively be phrased as a given amino
acid sequence A that has or comprises a certain % amino acid
sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows:
100 times the fraction X/Y
[0238] where X is the number of amino acid residues scored as
identical matches by the sequence alignment program NCBI-BLAST2 in
that program's alignment of A and B, and where Y is the total
number of amino acid residues in B. It will be appreciated that
where the length of amino acid sequence A is not equal to the
length of amino acid sequence B, the % amino acid sequence identity
of A to B will not equal the % amino acid sequence identity of B to
A.
[0239] "PRO variant polynucleotide" or "PRO variant nucleic acid
sequence" means a nucleic acid molecule which encodes an active PRO
polypeptide as defined below and which has at least about 80%
nucleic acid sequence identity with a nucleotide acid sequence
encoding a full-length native sequence PRO polypeptide sequence as
disclosed herein, a full-length native sequence PRO polypeptide
sequence lacking the signal peptide as disclosed herein, an
extracellular domain of a PRO polypeptide, with or without the
signal peptide, as disclosed herein or any other fragment of a
full-length PRO polypeptide sequence as disclosed herein.
Ordinarily, a PRO variant polynucleotide will have at least about
80% nucleic acid sequence identity, alternatively at least about
81% nucleic acid sequence identity, alternatively at least about
82% nucleic acid sequence identity, alternatively at least about
83% nucleic acid sequence identity, alternatively at least about
84% nucleic acid sequence identity, alternatively at least about
85% nucleic acid sequence identity, alternatively at least about
86% nucleic acid sequence identity, alternatively at least about
87% nucleic acid sequence identity, alternatively at least about
88% nucleic acid sequence identity, alternatively at least about
89% nucleic acid sequence identity, alternatively at least about
90% nucleic acid sequence identity, alternatively at least about
91% nucleic acid sequence identity, alternatively at least about
92% nucleic acid sequence identity, alternatively at least about
93% nucleic acid sequence identity, alternatively at least about
94% nucleic acid sequence identity, alternatively at least about
95% nucleic acid sequence identity, alternatively at least about
96% nucleic acid sequence identity, alternatively at least about
97% nucleic acid sequence identity, alternatively at least about
98% nucleic acid sequence identity and alternatively at least about
99% nucleic acid sequence identity with a nucleic acid sequence
encoding a full-length native sequence PRO polypeptide sequence as
disclosed herein, a full-length native sequence PRO polypeptide
sequence lacking the signal peptide as disclosed herein, an
extracellular domain of a PRO polypeptide, with or without the
signal sequence, as disclosed herein or any other fragment of a
full-length PRO polypeptide sequence as disclosed herein. Variants
do not encompass the native nucleotide sequence.
[0240] Ordinarily, PRO variant polynucleotides are at least about
30 nucleotides in length, alternatively at least about 60
nucleotides in length, alternatively at least about 90 nucleotides
in length, alternatively at least about 120 nucleotides in length,
alternatively at least about 150 nucleotides in length,
alternatively at least about 180 nucleotides in length,
alternatively at least about 210 nucleotides in length,
alternatively at least about 240 nucleotides in length,
alternatively at least about 270 nucleotides in length,
alternatively at least about 300 nucleotides in length,
alternatively at least about 450 nucleotides in length,
alternatively at least about 600 nucleotides in length,
alternatively at least about 900 nucleotides in length, or
more.
[0241] "Percent (%) nucleic acid sequence identity" with respect to
PRO-encoding nucleic acid sequences identified herein is defined as
the percentage of nucleotides in a candidate sequence that are
identical with the nucleotides in the PRO nucleic acid sequence of
interest, after aligning the sequences and introducing gaps, if
necessary, to achieve the maximum percent sequence identity.
Alignment for purposes of determining percent nucleic acid sequence
identity can be achieved in various ways that are within the skill
in the art, for instance, using publicly available computer
software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software. For purposes herein, however, % nucleic acid sequence
identity values are generated using the sequence comparison
computer program ALIGN-2, wherein the complete source code for the
ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence
comparison computer program was authored by Genentech, Inc. and the
source code shown in Table 1 below has been filed with user
documentation in the U.S. Copyright Office, Washington D.C., 20559,
where it is registered under U.S. Copyright Registration No.
TXU510087. The ALIGN-2 program is publicly available through
Genentech, Inc., South San Francisco, Calif. or may be compiled
from the source code provided in Table 1 below. The ALIGN-2 program
should be compiled for use on a UNIX operating system, preferably
digital UNIX V4.0D. All sequence comparison parameters are set by
the ALIGN-2 program and do not vary.
[0242] In situations where ALIGN-2 is employed for nucleic acid
sequence comparisons, the % nucleic acid sequence identity of a
given nucleic acid sequence C to, with, or against a given nucleic
acid sequence D (which can alternatively be phrased as a given
nucleic acid sequence C that has or comprises a certain % nucleic
acid sequence identity to, with, or against a given nucleic acid
sequence D) is calculated as follows:
100 times the fraction W/Z
[0243] where W is the number of nucleotides scored as identical
matches by the sequence alignment program ALIGN-2 in that program's
alignment of C and D, and where Z is the total number of
nucleotides in D. It will be appreciated that where the length of
nucleic acid sequence C is not equal to the length of nucleic acid
sequence D, the % nucleic acid sequence identity of C to D will not
equal the % nucleic acid sequence identity of D to C. As examples
of % nucleic acid sequence identity calculations, Tables 4 and 5,
demonstrate how to calculate the % nucleic acid sequence identity
of the nucleic acid sequence designated "Comparison DNA" to the
nucleic acid sequence designated "PRO-DNA", wherein "PRO-DNA"
represents a hypothetical PRO-encoding nucleic acid sequence of
interest, "Comparison DNA" represents the nucieotide sequence of a
nucleic acid molecule against which the "PRO-DNA" nucleic acid
molecule of interest is being compared, and "N", "L" and "V" each
represent different hypothetical nucleotides.
[0244] Unless specifically stated otherwise, all % nucleic acid
sequence identity values used herein are obtained as described in
the immediately preceding paragraph using the ALIGN-2 computer
program. However, % nucleic acid sequence identity values may also
be obtained as described below by using the WU-BLAST-2 computer
program (Altschul et al., Methods in Enzymology 266:460-480
(1996)). Most of the WU-BLAST-2 search parameters are set to the
default values. Those not set to default values, i.e., the
adjustable parameters, are set with the following values: overlap
span=1, overlap fraction=0.125, word threshold (T)=11, and scoring
matrix=BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid
sequence identity value is determined by dividing (a) the number of
matching identical nucleotides between the nucleic acid sequence of
the PRO polypeptide-encoding nucleic acid molecule of interest
having a sequence derived from the native sequence PRO
polypeptide-encoding nucleic acid and the comparison nucleic acid
molecule of interest (i.e., the sequence against which the PRO
polypeptide-encoding nucleic acid molecule of interest is being
compared which may be a variant PRO polynucleotide) as determined
by WU-BLAST-2 by (b) the total number of nucleotides of the PRO
polypeptide-encoding nucleic acid molecule of interest. For
example, in the statement "an isolated nucleic acid molecule
comprising a nucleic acid sequence A which has or having at least
80% nucleic acid sequence identity to the nucleic acid sequence B",
the nucleic acid sequence A is the comparison nucleic acid molecule
of interest and the nucleic acid sequence B is the nucleic acid
sequence of the PRO polypeptide-encoding nucleic acid molecule of
interest.
[0245] Percent nucleic acid sequence identity may also be
determined using the sequence comparison program NCBI-BLAST2
(Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The
NCBI-BLAST2 sequence comparison program may be downloaded from
http://www.ncbi.nlm.nih.gov or otherwise obtained from the National
Institute of Health, Bethesda, Md. NCBI-BLAST2 uses several search
parameters, wherein all of those search parameters are set to
default values including, for example, unmask=yes, strand=all,
expected occurrences=10, minimum low complexity length=15/5,
multi-pass e-value=0.01, constant for multi-pass=25, dropoff for
final gapped alignment=25 and scoring matrix=BLOSUM62.
[0246] In situations where NCBI-BLAST2 is employed for sequence
comparisons, the % nucleic acid sequence identity of a given
nucleic acid sequence C to, with, or against a given nucleic acid
sequence D (which can alternatively be phrased as a given nucleic
acid sequence C that has or comprises a certain % nucleic acid
sequence identity to, with, or against a given nucleic acid
sequence D) is calculated as follows:
100 times the fraction W/Z
[0247] where W is the number of nucleotides scored as identical
matches by the sequence alignment program NCBI-BLAST2 in that
program's alignment of C and D, and where Z is the total number of
nucleotides in D. It will be appreciated that where the length of
nucleic acid sequence C is not equal to the length of nucleic acid
sequence D, the % nucleic acid sequence identity of C to D will not
equal the % nucleic acid sequence identity of D to C.
[0248] In other embodiments, PRO variant polynucleotides are
nucleic acid molecules that encode an active PRO polypeptide and
which are capable of hybridizing, preferably under stringent
hybridization and wash conditions, to nucleotide sequences encoding
a full-length PRO polypeptide as disclosed herein. PRO variant
polypeptides may be those that are encoded by a PRO variant
polynucleotide.
[0249] The term "positives", in the context of sequence comparison
performed as described above, includes residues in the sequences
compared that are not identical but have similar properties (e.g.
as a result of conservative substitutions, see Table 6 below). For
purposes herein, the % value of positives is determined by dividing
(a) the number of amino acid residues scoring a positive value
between the PRO polypeptide amino acid sequence of interest having
a sequence derived from the native PRO polypeptide sequence and the
comparison amino acid sequence of interest (i.e., the amino acid
sequence against which the PRO polypeptide sequence is being
compared) as determined in the BLOSUM62 matrix of WU-BLAST-2 by (b)
the total number of amino acid residues of the PRO polypeptide of
interest.
[0250] Unless specifically stated otherwise, the % value of
positives is calculated as described in the immediately preceding
paragraph. However, in the context of the amino acid sequence
identity comparisons performed as described for ALIGN-2 and
NCBI-BLAST-2 above, includes amino acid residues in the sequences
compared that are not only identical, but also those that have
similar properties. Amino acid residues that score a positive value
to an amino acid residue of interest are those that are either
identical to the amino acid residue of interest or are a preferred
substitution (as defined in Table 6 below) of the amino acid
residue of interest.
[0251] For amino acid sequence comparisons using ALIGN-2 or
NCBI-BLAST2, the % value of positives of a given amino acid
sequence A to, with, or against a given amino acid sequence B
(which can alternatively be phrased as a given amino acid sequence
A that has or comprises a certain % positives to, with, or against
a given amino acid sequence B) is calculated as follows:
100 times the fraction X/Y
[0252] where X is the number of amino acid residues scoring a
positive value as defined above by the sequence alignment program
ALIGN-2 or NCBI-BLAST2 in that program's alignment of A and B, and
where Y is the total number of amino acid residues in B. It will be
appreciated that where the length of amino acid sequence A is not
equal to the length of amino acid sequence B, the % positives of A
to B will not equal the % positives of B to A.
[0253] "Isolated,"when used to describe the various polypeptides
disclosed herein, means polypeptide that has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials that would typically interfere with diagnostic or
therapeutic uses for the polypeptide, and may include enzymes,
hormones, and other proteinaceous or non-proteinaceous solutes. In
preferred embodiments, the polypeptide will be purified (1) to a
degree sufficient to obtain at least 15 residues of N-terminal or
internal amino acid sequence by use of a spinning cup sequenator,
or (2) to homogeneity by SDS-PAGE under non-reducing or reducing
conditions using Coomassie blue or, preferably, silver stain.
Isolated polypeptide includes polypeptide in situ within
recombinant cells, since at least one component of the PRO
polypeptide natural environment will not be present. Ordinarily,
however, isolated polypeptide will be prepared by at least one
purification step.
[0254] An "isolated" PRO polypeptide-encoding nucleic acid or other
polypeptide-encoding nucleic acid is a nucleic acid molecule that
is identified and separated from at least one contaminant nucleic
acid molecule with which it is ordinarily associated in the natural
source of the polypeptide-encoding nucleic acid. An isolated
polypeptide-encoding nucleic acid molecule is other than in the
form or setting in which it is found in nature. Isolated
polypeptide-encoding nucleic acid molecules therefore are
distinguished from the specific polypeptide-encoding nucleic acid
molecule as it exists in natural cells. However, an isolated
polypeptide-encoding nucleic acid molecule includes
polypeptide-encoding nucleic acid molecules contained in cells that
ordinarily express the polypeptide where, for example, the nucleic
acid molecule is in a chromosomal location different from that of
natural cells.
[0255] The term "control sequences" refers to DNA sequences
necessary for the expression of an operably linked coding sequence
in a particular host organism. The control sequences that are
suitable for prokaryotes, for example, include a promoter,
optionally an operator sequence, and a ribosome binding site.
Eukaryotic cells are known to utilize promoters, polyadenylation
signals, and enhancers.
[0256] Nucleic acid is "operably linked" when it is placed into a
functional relationship with another nucleic acid sequence. For
example, DNA for a presequence or secretory leader is operably
linked to DNA for a polypeptide if it is expressed as a preprotein
that participates in the secretion of the polypeptide; a promoter
or enhancer is operably linked to a coding sequence if it affects
the transcription of the sequence; or a ribosome binding site is
operably linked to a coding sequence if it is positioned so as to
facilitate translation. Generally, "operably linked" means that the
DNA sequences being linked are contiguous, and, in the case of a
secretory leader, contiguous and in reading phase. However,
enhancers do not have to be contiguous. Linking is accomplished by
ligation at convenient restriction sites. If such sites do not
exist, the synthetic oligonucleotide adaptors or linkers are used
in accordance with conventional practice.
[0257] The term "antibody" is used in the broadest sense and
specifically covers, for example, single anti-PRO monoclonal
antibodies (including agonist, antagonist, and neutralizing
antibodies), anti-PRO antibody compositions with polyepitopic
specificity, single chain anti-PRO antibodies, and fragments of
anti-PRO antibodies (see below). The term "monoclonal antibody" as
used herein refers to an antibody obtained from a population of
substantially homogeneous antibodies, i.e., the individual
antibodies comprising the population are identical except for
possible naturally-occurring mutations that may be present in minor
amounts.
[0258] "Stringency" of hybridization reactions is readily
determinable by one of ordinary skill in the art, and generally is
an empirical calculation dependent upon probe length, washing
temperature, and salt concentration. In general, longer probes
require higher temperatures for proper annealing, while shorter
probes need lower temperatures. Hybridization generally depends on
the ability of denatured DNA to reanneal when complementary strands
are present in an environment below their melting temperature. The
higher the degree of desired homology between the probe and
hybridizable sequence, the higher the relative temperature which
can be used. As a result, it follows that higher relative
temperatures would tend to make the reaction conditions more
stringent, while lower temperatures less so. For additional details
and explanation of stringency of hybridization reactions, see
Ausubel et al., Current Protocols in Molecular Biology, Wiley
lnterscience Publishers, (1995).
[0259] "Stringent conditions" or "high stringency conditions", as
defined herein, may be identified by those that: (1) employ low
ionic strength and high temperature for washing, for example 0.015
M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl
sulfate at 50.degree. C.; (2) employ during hybridization a
denaturing agent, such as formamide, for example, 50% (v/v)
formamide with 0.1% bovine serum albumin/0. 1% Ficoll/0.1%
polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with
750 mM sodium chloride, 75 mM sodium citrate at 42.degree. C.; or
(3) employ 50% formamide, 5.times.SSC (0.75 M NaCl, 0.075 M sodium
citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium
pyrophosphate, 5.times.Denhardt's solution, sonicated salmon sperm
DNA (50 .mu.g/ml), 0.1% SDS, and 10% dextran sulfate at 42.degree.
C., with washes at 42.degree. C. in 0.2.times.SSC (sodium
chloride/sodium citrate) and 50% formamide at 55.degree. C.,
followed by a high-stringency wash consisting of 0.1.times.SSC
containing EDTA at 55.degree. C.
[0260] "Moderately stringent conditions" may be identified as
described by Sambrook et al., Molecular Cloning: A Laboratory
Manual, New York: Cold Spring Harbor Press, 1989, and include the
use of washing solution and hybridization conditions (e.g.,
temperature, ionic strength and % SDS) less stringent that those
described above. An example of moderately stringent conditions is
overnight incubation at 37 .degree. C. in a solution comprising:
20% formamide, 5.times.SSC (150 mM NaCl, 15 mM trisodium citrate),
50 mM sodium phosphate (pH 7.6), 5.times.Denhardt's solution, 10%
dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA,
followed by washing the filters in 1.times.SSC at about
37-50.degree. C. The skilled artisan will recognize how to adjust
the temperature, ionic strength, etc. as necessary to accommodate
factors such as probe length and the like.
[0261] The term "epitope tagged" when used herein refers to a
chimeric polypeptide comprising a PRO polypeptide fused to a "tag
polypeptide". The tag polypeptide has enough residues to provide an
epitope against which an antibody can be made, yet is short enough
such that it does not interfere with activity of the polypeptide to
which it is fused. The tag polypeptide preferably also is fairly
unique so that the antibody does not substantially cross-react with
other epitopes. Suitable tag polypeptides generally have at least
six amino acid residues and usually between about 8 and 50 amino
acid residues (preferably, between about 10 and 20 amino acid
residues).
[0262] As used herein, the term "immunoadhesin" designates
antibody-like molecules which combine the binding specificity of a
heterologous protein (an "adhesin") with the effector functions of
immunoglobulin constant domains. Structurally, the immunoadhesins
comprise a fusion of an amino acid sequence with the desired
binding specificity which is other than the antigen recognition and
binding site of an antibody (i.e., is "heterologous"), and an
immunoglobulin constant domain sequence. The adhesin part of an
immunoadhesin molecule typically is a contiguous amino acid
sequence comprising at least the binding site of a receptor or a
ligand. The immunoglobulin constant domain sequence in the
immunoadhesin may be obtained from any immunoglobulin, such as
IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and
IgA-1), IgE, IgD or IgM.
[0263] "Active" or "activity" for the purposes herein refers to
form(s) of a PRO polypeptide which retain a biological and/or an
immunological activity of native or naturally-occurring PRO,
wherein "biological" activity refers to a biological function
(either inhibitory or stimulatory) caused by a native or
naturally-occurring PRO other than the ability to induce the
production of an antibody against an antigenic epitope possessed by
a native or naturally-occurring PRO and an "immunological" activity
refers to the ability to induce the production of an antibody
against an antigenic epitope possessed by a native or
naturally-occurring PRO.
[0264] The term "antagonist" is used in the broadest sense, and
includes any molecule that partially or fully blocks, inhibits, or
neutralizes a biological activity of a native PRO polypeptide
disclosed herein. In a similar manner, the term "agonist" is used
in the broadest sense and includes any molecule that mimics a
biological activity of a native PRO polypeptide disclosed herein.
Suitable agonist or antagonist molecules specifically include
agonist or antagonist antibodies or antibody fragments, fragments
or amino acid sequence variants of native PRO polypeptides,
peptides, antisense oligonucleotides, small organic molecules, etc.
Methods for identifying agonists or antagonists of a PRO
polypeptide may comprise contacting a PRO polypeptide with a
candidate agonist or antagonist molecule and measuring a detectable
change in one or more biological activities normally associated
with the PRO polypeptide.
[0265] "Treatment" refers to both therapeutic treatment and
prophylactic or preventative measures, wherein the object is to
prevent or slow down (lessen) the targeted pathologic condition or
disorder. Those in need of treatment include those already with the
disorder as well as those prone to have the disorder or those in
whom the disorder is to be prevented.
[0266] "Chronic" administration refers to administration of the
agent(s) in a continuous mode as opposed to an acute mode, so as to
maintain the initial therapeutic effect (activity) for an extended
period of time. "Intermittent" administration is treatment that is
not consecutively done without interruption, but rather is cyclic
in nature.
[0267] "Mammal" for purposes of treatment refers to any animal
classified as a mammal, including humans, domestic and farm
animals, and zoo, sports, or pet animals, such as dogs, cats,
cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the
mammal is human.
[0268] Administration "in combination with" one or more further
therapeutic agents includes simultaneous (concurrent) and
consecutive administration in any order.
[0269] "Carriers" as used herein include pharmaceutically
acceptable carriers, excipients, or stabilizers which are nontoxic
to the cell or mammal being exposed thereto at the dosages and
concentrations employed. Often the physiologically acceptable
carrier is an aqueous pH buffered solution. Examples of
physiologically acceptable carriers include buffers such as
phosphate, citrate, and other organic acids; antioxidants including
ascorbic acid; low molecular weight (less than about 10 residues)
polypeptide; proteins, such as serum albumin, gelatin, or
immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;
amino acids such as glycine, glutamine, asparagine, arginine or
lysine; monosaccharides, disaccharides, and other carbohydrates
including glucose, mannose, or dextrins; chelating agents such as
EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming
counterions such as sodium; and/or nonionic surfactants such as
TWEEN.TM., polyethylene glycol (PEG), and PLURONICS.TM..
[0270] "Antibody fragments" comprise a portion of an intact
antibody, preferably the antigen binding or variable region of the
intact antibody. Examples of antibody fragments include Fab, Fab',
F(ab').sub.2, and Fv fragments; diabodies; linear antibodies
(Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain
antibody molecules; and multispecific antibodies formed from
antibody fragments.
[0271] Papain digestion of antibodies produces two identical
antigen-binding fragments, called "Fab" fragments, each with a
single antigen-binding site, and a residual "Fc" fragment, a
designation reflecting the ability to crystallize readily. Pepsin
treatment yields an F(ab').sub.2 fragment that has two
antigen-combining sites and is still capable of cross-linking
antigen.
[0272] "Fv" is the minimum antibody fragment which contains a
complete antigen-recognition and -binding site. This region
consists of a dimer of one heavy- and one light-chain variable
domain in tight, non-covalent association. It is in this
configuration that the three CDRs of each variable domain interact
to define an antigen-binding site on the surface of the
V.sub.H-V.sub.L dimer. Collectively, the six CDRs confer
antigen-binding specificity to the antibody. However, even a single
variable domain (or half of an Fv comprising only three CDRs
specific for an antigen) has the ability to recognize and bind
antigen, although at a lower affinity than the entire binding
site.
[0273] The Fab fragment also contains the constant domain of the
light chain and the first constant domain (CH1) of the heavy chain.
Fab fragments differ from Fab' fragments by the addition of a few
residues at the carboxy terminus of the heavy chain CH1 domain
including one or more cysteines from the antibody hinge region.
Fab'-SH is the designation herein for Fab' in which the cysteine
residue(s) of the constant domains bear a free thiol group.
F(ab').sub.2 antibody fragments originally were produced as pairs
of Fab' fragments which have hinge cysteines between them. Other
chemical couplings of antibody fragments are also known.
[0274] The "light chains" of antibodies (immunoglobulins) from any
vertebrate species can be assigned to one of two clearly distinct
types, called kappa and lambda, based on the amino acid sequences
of their constant domains.
[0275] Depending on the amino acid sequence of the constant domain
of their heavy chains, immunoglobulins can be assigned to different
classes. There are five major classes of immunoglobulins: IgA, IgD,
IgE, IgG, and IgM, and several of these may be further divided into
subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and
IgA2.
[0276] "Single-chain Fv" or "sFv" antibody fragments comprise the
V.sub.H and V.sub.L domains of antibody, wherein these domains are
present in a single polypeptide chain. Preferably, the Fv
polypeptide further comprises a polypeptide linker between the
V.sub.H and V.sub.L domains which enables the sFv to form the
desired structure for antigen binding. For a review of sFv, see
Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113,
Rosenburg and Moore eds., Springer-Verlag, N.Y., pp. 269-315
(1994).
[0277] The term "diabodies" refers to small antibody fragments with
two antigen-binding sites, which fragments comprise a heavy-chain
variable domain (V.sub.H) connected to a light-chain variable
domain (V.sub.L) in the same polypeptide chain (V.sub.H-V.sub.L).
By using a linker that is too short to allow pairing between the
two domains on the same chain, the domains are forced to pair with
the complementary domains of another chain and create two
antigen-binding sites. Diabodies are described more fully in, for
example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl.
Acad. Sci. USA, 90:6444-6448 (1993).
[0278] An "isolated" antibody is one which has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials which would interfere with diagnostic or therapeutic uses
for the antibody, and may include enzymes, hormones, and other
proteinaceous or nonproteinaceous solutes. In preferred
embodiments, the antibody will be purified (1) to greater than 95%
by weight of antibody as determined by the Lowry method, and most
preferably more than 99% by weight, (2) to a degree sufficient to
obtain at least 15 residues of N-terminal or internal amino acid
sequence by use of a spinning cup sequenator, or (3) to homogeneity
by SDS-PAGE under reducing or nonreducing conditions using
Coomassie blue or, preferably, silver stain. Isolated antibody
includes the antibody in situ within recombinant cells since at
least one component of the antibody's natural environment will not
be present. Ordinarily, however, isolated antibody will be prepared
by at least one purification step.
[0279] The word "label" when used herein refers to a detectable
compound or composition which is conjugated directly or indirectly
to the antibody so as to generate a "labeled" antibody. The label
may be detectable by itself (e.g. radioisotope labels or
fluorescent labels) or, in the case of an enzymatic label, may
catalyze chemical alteration of a substrate compound or composition
which is detectable.
[0280] By "solid phase" is meant a non-aqueous matrix to which the
antibody of the present invention can adhere. Examples of solid
phases encompassed herein include those formed partially or
entirely of glass (e.g., controlled pore glass), polysaccharides
(e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol
and silicones. In certain embodiments, depending on the context,
the solid phase can comprise the well of an assay plate; in others
it is a purification column (e.g., an affinity chromatography
column). This term also includes a discontinuous solid phase of
discrete particles, such as those described in U.S. Pat. No.
4,275,149.
[0281] A "liposome" is a small vesicle composed of various types of
lipids, phospholipids and/or surfactant which is useful for
delivery of a drug (such as a PRO polypeptide or antibody thereto)
to a mammal. The components of the liposome are commonly arranged
in a bilayer formation, similar to the lipid arrangement of
biological membranes.
[0282] A "small molecule" is defined herein to have a molecular
weight below about 500 Daltons.
[0283] "FGFR-1", "FGFR-2", "FGFR-3" and FGFR-4" refer to the
fibroblast growth factor receptors 1, 2, 3 and 4, respectively, as
disclosed by Isacchi et al., Nuc. Acids Res. 18(7):1906 (1990),
Dionne et al., EMBO J. 9(9):2685-2692 (1990), Keegan et al., Proc.
Natl. Acad. Sci. USA 88:1095-1099 (1991) and Partanen et al., EMBO
J. 10(6):1347-1354 (1991), respectively.
1TABLE 1 /* * * C-C increased from 12 to 15 * Z is average of EQ *
B is average of ND * match with stop is _M; stop-stop = 0; J
(joker) match = 0 */ #define _M -8 /* value of a match with a stop
*/ int _day[26][26] = { /* A B C D E F G H I J K L M N O P Q R S T
U V W X Y Z */ /* A */ {2, 0, -2, 0, 0, -4, 1, -1, -1, 0, -1, -2,
-1, 0, _M, 1, 0, -2, 1, 1, 0, 0, -6, 0, -3, 0}, /* B */ {0, 3, -4,
3, 2, -5, 0, 1, -2, 0, 0, -3, -2, 2, _M, -1, 1, 0, 0, 0, 0, -2, -5,
0, -3, 1}, /* C */ {-2, -4, 15, -5, -5, -4, -3, -3, -2, 0, -5, -6,
-5, -4, _M, -3, -5, -4, 0, -2, 0, -2, -8, 0, 0, -5}, /* D */ {0, 3,
-5, 4, 3, -6, 1, 1, -2, 0, 0, -4, -3, 2, _M, -1, 2, -1, 0, 0, 0,
-2, -7, 0, -4, 2}, /* E */ {0, 2, -5, 3, 4, -5, 0, 1, -2, 0, 0, -3,
-2, 1, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 3}, /* F */ {-4, -5,
-4, -6, -5, 9, -5, -2, 1, 0, -5, 2, 0, -4, _M, -5, -5, -4, -3, -3,
0, -1, 0, 0, 7, -5}, /* G */ {1, 0, -3, 1, 0, -5, 5, -2, -3, 0, -2,
-4, -3, 0, _M, -1, -1, -3, 1, 0, 0, -1, -7, 0, -5, 0}, /* H */ {-1,
1, -3, 1, 1, -2, -2, 6, -2, 0, 0, -2, -2, 2, _M, 0, 3, 2, -1, -1,
0, -2, -3, 0, 0, 2}, /* I */ {-1, -2, -2, -2, -2, 1, -3, -2, 5, 0,
-2, 2, 2, -2, _M, -2, -2, -2, -1, 0, 0, 4, -5, 0, -1, -2}, /* J */
{0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0}, /* K */ {-1, 0, -5, 0, 0, -5, -2, 0, -2, 0, 5, -3, 0,
1, _M, -1, 1, 3, 0, 0, 0, -2, -3, 0, -4, 0}, /* L */ {-2, -3, -6,
-4, -3, 2, -4, -2, 2, 0, -3, 6, 4, -3, _M, -3, -2, -3, -3 , -1, 0,
2, -2, 0, -1, -2} /* M */ {-1, -2, -5, -3, -2, 0, -3, -2, 2, 0, 0,
4, 6, -2, _M, -2, -1, 0, -2, -1, 0, 2, -4, 0, -2, -1}, /* N */ {0,
2, -4, 2, 1, -4, 0, 2, -2, 0, 1, -3, -2, 2, _M, -1, 1, 0, 1, 0, 0,
-2, -4, 0, -2, 1}, /* O */
{_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,
0,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,}, /* P */ {1, -1, -3, -1, -1,
-5, -1, 0, -2, 0, -1, -3, -2, -1,_M, 6, 0, 0, 1, 0, 0, -1, -6, 0,
-5, 0}, /* Q */ {0, 1, -5, 2, 2, -5, -1, 3, -2, 0, 1, -2, -1, 1,
_M, 0, 4, 1, -1, -1, 0, -2, -5, 0, -4, 3}, /* R */ {-2, 0, -4, -1,
-1, -4, -3, 2, -2, 0, 3, -3, 0, 0, _M, 0, 1, 6, 0, -1, 0, -2, 2, 0,
-4, 0}, /* S */ {1, 0, 0, 0, 0, -3, 1, -1, -1, 0, 0, -3, -2, 1, _M,
1, -1, 0, 2, 1, 0, -1, -2, 0, -3, 0}, /* T */ {1, 0, -2, 0, 0, -3,
0, -1, 0, 0, 0, -1, -1, 0, _M, 0, -1, -1, 1, 3, 0, 0, -5, 0, -3,
0}, /* U */ {0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,_M, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0}, /* V */ {0, -2, -2, -2, -2, -1, -1, -2, 4,
0, -2, 2, 2, -2,_M, -1, -2, -2, -1, 0, 0, 4, -6, 0, -2, -2}, /* W
*/ {-6, -5, -8, -7, -7, 0, -7, -3, -5, 0, -3, -2, -4, -4,_M, -6,
-5, 2, -2, -5, 0, -6, 17, 0, 0, -6}, /* X */ {0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0}, /* Y */
{-3, -3, 0, -4, -4, 7, -5, 0, -1, 0, -4, -1, -2, -2, _M, -5, -4,
-4, -3, -3, 0, -2, 0, 0, 10, -4}, /* Z */ {0, 1, -5, 2, 3, -5, 0,
2, -2, 0, 0, -2, -1, 1,_M, 0, 3, 0, 0, 0, 0, -2, -6, 0, -4, 4}, };
/* */ #include <stdio.h> #include <ctype.h> #define
MAXJMP 16 /* max jumps in a diag */ #define MAXGAP 24 /* don't
continue to penalize gaps larger than this */ #define JMPS 1024 /*
max jmps in an path */ #define MX 4 /* save if there's at least
MX-1 bases since last jmp */ #define DMAT 3 /* value of matching
bases */ #define DMIS 0 /* penalty for mismatched bases */ #define
DINS0 8 /* penalty for a gap */ #define DINS1 1 /* penalty per base
*/ #define PINS0 8 /* penalty for a gap */ #define PINS1 4 /*
penalty per residue */ struct jmp { short n[MAXJMP]; /* size of jmp
(neg for dely) */ unsigned short x[MAXJMP]; /* base no. of jmp in
seq x */ /* limits seq to 2{circumflex over ( )}16 -1 */ }; struct
diag { int score; /* score at last jmp */ long offset; /* offset of
prev block */ short ijmp; /* current jmp index */ struct jmp jp; /*
list of jmps */ }; struct path { int spc; /* number of leading
spaces */ short n[JMPS]; /* size of jmp (gap) */ int x[JMPS]; /*
loc of jmp (last elem before gap) */ }; char *ofile; /* output file
name */ char *namex[2]; /* seq names: getseqs() */ char *prog; /*
prog name for err msgs */ char *seqx[2]; /* seqs: getseqs() */ int
dmax; /* best diag: nw() */ int dmax0; /* final diag */ int dna; /*
set if dna: main() */ int endgaps; /* set if penalizing end gaps */
int gapx, gapy; /* total gaps in seqs */ int len0, len1; /* seq
lens */ int ngapx, ngapy; /* total size of gaps */ int smax; /* max
score: nw() */ int *xbm; /* bitmap for matching */ long offset; /*
current offset in jmp file */ struct diag *dx; /* holds diagonals
*/ struct path pp[2]; /* holds path for seqs */ char *calloc(),
*malloc(), *index(), *strcpy(); char *getseq(), *g_calloc(); /*
Needleman-Wunsch alignment program * * usage: progs file1 file2 *
where file1 and file2 are two dna or two protein sequences. * The
sequences can be in upper- or lower-case an may contain ambiguity *
Any lines beginning with `;`, `>` or `<` are ignored * Max
file length is 65535 (limited by unsigned short x in the jmp
struct) * A sequence with 1/3 or more of its elements ACGTU is
assumed to be DNA * Output is in the file "align.out" * * The
program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under BSD 4.3 on a vax 8650 */
#include "nw.h" #include "day.h" static _dbval[26] = {
1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0 }; static
_pbval[26] = { 1, 2.vertline.(1< <(`D`-`A`)).vertline.(1<
<(`N`-`A`)), 4, 8, 16, 32, 64, 128, 256, 0.times.FFFFFFF, 1<
<10, 1< <11, 1< <12, 1< <13, 1< <14,
1< <15, 1< <16, 1< <17, 1< <18, 1<
<19, 1< <20, 1< <21, 1< <22, 1< <23,
1< <24, 1< <25.vertline.(1<
<(`E`-`A`)).vertline.(1< <(`Q`-`A`)) }; main(ac, av) main
int ac; char *av[]; { prog = av[0]; if(ac != 3) { fprintf(stderr,
"usage: %s file1 file2.backslash.n", prog); fprintf(stderr, "where
file1 and file2 are two dna or two protein
sequences..backslash.n"); fprintf(stderr, "The sequences can be in
upper- or lower-case.backslash.n"); fprintf(stderr, "Any lines
beginning with `;` or `<` are ignored.backslash.n");
fprintf(stderr, "Output is in the file
.backslash."align.out.backslash.".backslash.n"); exit(1); }
namex[0] = av[1]; namex[1] = av[2]; seqx[0] = getseq(namex[0],
&len0); seqx[1] = getseq(namex[1], &len1); xbm = (dna)?
_dbval : _pbval; endgaps = 0; /* 1 to penalize endgaps */ ofile =
"align.out"; /* output file */ nw(); /* fill in the matrix, get the
possible jmps */ readjmps(); /* get the actual jmps */ print(); /*
print stats, alignment */ cleanup(0); /* unlink any tmp files */ }
/* do the alignment, return best score: main() * dna: values in
Fitch and Smith, PNAS, 80, 1382-1386, 1983 * pro: PAM 250 values *
When scores are equal, we prefer mismatches to any gap, prefer * a
new gap to extending an ongoing gap, and prefer a gap in seqx * to
a gap in seq y. */ nw() nw { char *px, *py; /* seqs and ptrs */ int
*ndely, *dely; /* keep track of dely */ int ndelx, delx; /* keep
track of delx */ int *tmp; /* for swapping row0, row1 */ int mis;
/* score for each type */ int ins0, ins1; /* insertion penalties */
register id; /* diagonal index */ register ij; /* jmp index */
register *col0, *col1; /* score for curr, last row */ register xx,
yy; /* index into seqs */ dx = (struct diag *)g_calloc("to get
diags", len0+len1+1, sizeof(struct diag)); ndely = (int
*)g_calloc("to get ndely", len1+1, sizeof(int)); dely = (int
*)g_calloc("to get dely", len1+1, sizeof(int)); col0 = (int
*)g_calloc("to get col0", len1+1, sizeof(int)); col1 = (int
*)g_calloc("to get col1", len1+1, sizeof(int)); ins0 = (dna)? DINS0
: PINS0; ins1 = (dna)? DINS1 : PlNS1; smax = -10000; if (endgaps) {
for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
col0[yy] = dely[yy] = col0[yy-1] - ins1; ndely[yy] = yy; } col0[0]
= 0; /* Waterman Bull Math Biol 84 */ } else for (yy= 1; yy <=
len1; yy++) dely[yy] = -ins0; /* fill in match matrix */ for (px =
seqx[0], xx = 1; xx <= len0; px++, xx++) { /* initialize first
entry in col */ if (endgaps) { if (xx == 1) col1[0] = delx =
-(ins0+ins1); else col1[0] = delx = col0[0]-ins1; ndelx = xx; }
else { col1[0] = 0; delx = -ins0; ndelx = 0; } ...nw for (py =
seqx[1], yy = 1; yy <= len1; py++, yy++) { mis = col0[yy-1]; if
(dna) mis + = (xbm[*px-`A`]&xbm[*py-`A`])? DMAT : DMIS; else
mis += _day[*px-`A`][*py-`A`]; /* update penalty for del in x seq;
* favor new del over ongong del * ignore MAXGAP if weighting
endgaps */ if (endgaps .vertline..vertline. ndely[yy] < MAXGAP)
{ if (col0[yy] - ins0 >= dely[yy]) { dely[yy] = col0[yy] -
(ins0+ins1); ndely[yy] = 1; } else { dely[yy] -= ins1; ndely[yy]++;
} } else { if (col0[yy] - (ins0+ins1) >= dely[yy]) { dely[yy] =
col0[yy] - (ins0+ins1); ndely[yy] = 1; } else ndely[yy]++; } /*
update penalty for del in y seq; * favor new del over ongong del */
if (endgaps .vertline..vertline. ndelx < MAXGAP) { if(col1[yy-1]
- ins0 >= delx) { delx = col1[yy-1] - (ins0+ins1); ndelx = 1; }
else { delx -= ins1; ndelx++; } } else { if (col1[yy-1] -
(ins0+ins1) >= delx) { delx = col1[yy-1] - (ins0+ins1); ndelx =
1; } else ndelx++; } /* pick the maximum score; we're favoring *
mis over any del and delx over dely */ ...nw id = xx - yy + len1 -
1; if (mis >= delx && mis >= dely[yy]) col1[yy] =
mis; else if (delx >= dely[yy]) { col1[yy] = delx; ij =
dx[id].ijmp; if (dx[id].jp.n[0] && (!dna
.vertline..vertline. (ndelx >= MAXJMP && xx >
dx[id].jp.x[ij]+MX) .vertline..vertline. mis >
dx[id].score+DINS0)) { dx[id].ijmp++; if (++ij >= MAXJMP) {
writejmps(id); ij = dx[id].ijmp = 0; dx[id].offset = offset; offset
+= sizeof(struct jmp) + sizeof(offset); } } dx[id].jp.n[ij] =
ndelx; dx[id].jp.x[ij] = xx; dx[id].score = delx; } else { col1[yy]
= dely[yy]; ij = dx[id].ijmp; if (dx[id].jp.n[0] && (!dna
.vertline..vertline. (ndely[yy] >= MAXJMP && xx >
dx[id].jp.x[ij]+MX) .vertline..vertline. mis >
dx[id].score+DINS0)) { dx[id].ijmp++; if (++ij >= MAXJMP) {
writejmps(id); ij = dx[id].ijmp = 0; dx[id].offset = offset; offset
+= sizeof(struct jmp) + sizeof(offset); } } dx[id].jp.n[ij]
=-ndely[yy]; dx[id].jp.x[ij] = xx; dx[id].score = dely[yy]; } if
(xx == len0 && yy < len1) { /* last col */ if (endgaps)
col1[yy] -= ins0+ins1*(len1-yy); if(col1[yy] > smax) { smax =
col1[yy]; dmax = id; } } } if (endgaps && xx < len0)
col1[yy-1] -= ins0+ins1*(len0-xx); if (col1[yy-1] > smax) { smax
= col1[yy-1]; dmax = id; } tmp = col0; col0 = col1; col1 = tmp; }
(void) free((char *)ndely); (void) free((char *)dely); (void)
free((char *)col0); (void) free((char *)col1); } /* * * print() --
only routine visible outside this module * * static: * getmat() --
trace back best path, count matches: print() * pr_align() -- print
alignment of described in array p[]: print() * dumpblock() -- dump
a block of lines with numbers, stars: pr_align() * nums() -- put
out a number line: dumpblock() * putline() -- put out a line (name,
[num], seq, [num]): dumpblock() * stars() - -put a line of stars:
dumpblock() * stripname() -- strip any path and prefix from a
seqname */ #include "nw.h" #define SPC 3 #define P_LINE 256 /*
maximum output line */ #define P_SPC 3 /* space between name or num
and seq */ extern _day[26][26]; int olen; /* set output line length
*/ FILE *fx; /* output file */ print() print { int lx, ly,
firstgap, lastgap; /* overlap */ if ((fx = fopen(ofile, "w")) == 0)
{ fprintf(stderr, "%s: can't write %s.backslash.n", prog, ofile);
cleanup(1); } fprintf(fx, "<first sequence: %s (length =
%d).backslash.n", namex[0], len0); fprintf(fx, "<second
sequence: %s (length = %d).backslash.n", namex[1], len1); olen =
60; lx = len0; ly = len1; firstgap = lastgap = 0; if (dmax <
len1 - 1) { /* leading gap in x */ pp[0].spc = firstgap = len1 -
dmax - 1; ly -= pp[0].spc; } else if (dmax > len1 - 1) { /*
leading gap in y */ pp[1].spc = firstgap = dmax - (len1 - 1); lx -=
pp[1].spc; } if (dmax0 < len0 - 1) { /* trailing gap in x */
lastgap = len0 - dmax0 -1; lx -= lastgap; } else if (dmax0 >
len0 - 1) { /* trailing gap in y */ lastgap = dmax0 - (len0 - 1);
ly -= lastgap; } getmat(lx, ly, firstgap, lastgap); pr_align(); }
/* * trace back the best path, count matches */ static getmat(lx,
ly, firstgap, lastgap) getmat int lx, ly; /* "core" (minus endgaps)
*/ int firstgap, lastgap; /* leading trailing overlap */ { int nm,
i0, i1, siz0, siz1; char outx[32]; double pct; register n0, n1;
register char *p0, *p1; /* get total matches, score */ i0 = i1 =
siz0 = siz1 = 0; p0 = seqx[0] + pp[1].spc; p1 = seqx[1] +
pp[0].spc; n0 = pp[1].spc + 1; n1 = pp[0].spc + 1; nm = 0; while (
*p0 && *p1 ) { if (siz0) { p1++; n1++; siz0--; } else if
(siz1) { p0++; n0++; siz1--; } else { if
(xbm[*p0-`A`]&xbm[*p1-`A- `]) nm++; if (n0++ == pp[0].x[i0])
siz0 = pp[0].n[i0++]; if (nl++ == pp[1].x[i1]) siz1 =
pp[1].n[il++]; p0++; p1++; } } /* pct homology: * if penalizing
endgaps, base is the shorter seq * else, knock off overhangs and
take shorter core */ if (endgaps) lx = (len0 < len1)? len0 :
len1; else lx = (lx < ly)? lx : ly; pct =
100.*(double)nm/(double- )lx; fprintf(fx, ".backslash.n");
fprintf(fx, "<%d match%s in an overlap of %d: %.2f percent
similarity.backslash.n", nm, (nm == 1)? "" : "es", lx, pct);
fprintf(fx, "<gaps in first sequence: %d", gapx); ...getmat if
(gapx) { (void) sprintf(outx, "(%d %s%s)", ngapx, (dna)? "base":
"residue", (ngapx == 1)? "":"s"); fprintf(fx, "% s", outx);
fprintf(fx, ", gaps in second sequence: %d", gapy); if (gapy) {
(void) sprintf(outx, "(%d %s%s)", ngapy, (dna)? "base":"residue",
(ngapy == 1)? "":"s"); fprintf(fx, "%s", outx); } if (dna)
fprintf(fx, ".backslash.n<score: %d (match = %d, mismatch = %d,
gap penalty = %d + %d per base).backslash.n", smax, DMAT, DMIS,
DINS0, DINS1); else fprintf(fx, ".backslash.n<score: %d (Dayhoff
PAM 250 matrix, gap penalty = %d + %d per residue).backslash.n",
smax, PINS0, PINS1); if (endgaps) fprintf(fx, "<endgaps
penalized. left endgap: %d %s%s, right endgap: %d
%s%s.backslash.n", firstgap, (dna)? "base" : "residue", (firstgap
== 1)? "" : "s", lastgap, (dna)? "base" : "residue", (lastgap ==
1)? "" : "s"); else fprintf(fx, "<endgaps not
penalized.backslash.n"); } static nm; /* matches in core -- for
checking */ static lmax; /* lengths of stripped file names */
static ij[2]; /* jmp index for a path */ static nc[2]; /* number at
start of current line */ static ni[2]; /* current elem
number -- for gapping */ static siz[2]; static char *ps[2]; /* ptr
to current element */ static char *po[2]; /* ptr to next output
char slot */ static char out[2][P_LINE]; /* output line */ static
char star[P_LINE]; /* set by stars() */ /* * print alignment of
described in struct path pp[] */ static pr_align() pr_align { int
nn; /* char count */ int more; register i; for (i = 0, lmax = 0; i
< 2++) { nn = stripname(namex[i]); if (nn > lmax) lmax = nn;
nc[i] = 1; ni[i] = 1; siz[i] = ij[i] = 0; ps[i] = seqx[i]; po[i] =
out[i]; } for (nn = nm = 0, more = 1; more;) { ...pr_align for (i =
more = 0; i < 2; i++) { /* * do we have more of this sequence?
*/ if (!*ps[i]) continue; more++; if (pp[i].spc) { /* leading space
*/ *po[i]++ = ` `; pp[i].spc--; } else if (siz[i]) { /* in a gap */
*po[i]++ = `-`; siz[i]--; } else { /* we're putting a seq element
*/ *po[i] = *ps[i]; if (islower(*ps[i])) *ps[i] = toupper(*ps[i]);
po[i]++; ps[i]++; /* * are we at next gap for this seq? */ if
(ni[i] == pp[i].x[ij[i]]) { /* * we need to merge all gaps * at
this location */ siz[i] == pp[i].n[ij[i]++]; while (ni[i] ==
pp[i].x[ij[i]]) siz[i] += pp[i].n[ij[i]++]; } ni[i]++; } } if (++nn
== olen .vertline..vertline. !more && nn) { dumpblock();
for (i = 0; i < 2; i++) po[i] = out[i]; nn = 0; } } } /* * dump
a block of lines, including numbers, stars: pr_align() */ static
dumpblock() dumpblock { register i; for(i = 0; i < 2; i++)
*po[i]-- = `.backslash.0`; ...dumpblock (void) putc(`.backslash.n`,
fx); for (i = 0; i < 2; i++) { if (*out[i] && (*out[i]
!= ` ` .vertline..vertline. *(po[i]) != ` `)) { if (i == 0)
nums(i); if (i == 0 && *out[1]) stars(); putline(i); if (i
== 0 && *out[1]) fprintf(fx, star); if (i == 1) nums(i); }
} } * put out a number line: dumpblock() */ static nums(ix) nums
int ix; /* index in out[] holding seq line */ { char nline[P_LINE];
register i, j; register char *pn, *px, *py; for(pn = nline, i = 0;
i < lmax+P_SPC; i++, pn++) *pn = ` `; for (i = nc[ix], py =
out[ix]; *py; py++, pn++) { if (*py == ` ` .vertline..vertline. *py
== `-`); *pn = ` `; else { if (i%10 == 0 .vertline..vertline. (i ==
1 && nc[ix] != 1)) { j = (i < 0)? -i : i; for (px = pn;
j; j/= 10, px--) *px = j%10 + `0`; if (i < 0) *px = `-`; } else
*pn = ` `; i++; } } *pn = `.backslash.0`; nc[ix] = i; for (pn =
nline; *pn; pn++) (void) putc(*pn, fx); (void) putc(`.backslash.n`,
fx); } /* * put out a line (name, [num], seq. [num]): dumpblock()
*/ static putline(ix) putline int ix; { ...putline int i; register
char *px; for (px = namex[ix], i = 0; *px && *px != `:`;
px++, i++) (void) putc(*px, fx); for (;i < lmax+P_SPC; i++)
(void) putc(` `, fx); /* these count from 1: * ni[] is current
element (from 1) * nc[] is number at start of current line */ for
(px = out[ix]; *px; px++) (void) putc(*px&0x7F, fx); (void)
putc(`.backslash.n`, fx); } /* * put a line of stars (seqs always
in out[0], out[1]): dumpblock() */ static stars() stars { int i;
register char *p0, *p1, cx, *px; if (!*out[0] .vertline..vertline.
(*out[0] == ` ` && *(p0[0]) == ` `) .vertline..vertline.
!*out[1] .vertline..vertline. (*out[1] == ` ` && *(po[1])
== ` `)) return; px = star; for (i = lmax+P_SPC; i; i--) *px++ = `
`; for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
if (isalpha(*p0) && isalpha(*p1)) { if
(xbm[*p0-`A`]&xbm[*p1-`A- `]) { cx = `*`; nm++; } else if (!dna
&& _day[*p0- `A`][*p1-`A`] > 0) cx = `.`; else cx = ` `;
} else cx = ` `; *px++ = cx; } *px++ = `.backslash.n`; *px =
`.backslash.0`; } /* * strip path or prefix from pn, return len:
pr_align() */ static stripname(pn) stripname char *pn; /* file name
(may be path) */ { register char *px, *py; py = 0; for (px = pn;
*px; px++) if (*px == `/`) py = px + 1; if (py) (void) strcpy(pn,
py); return(strlen(pn)); } /* * cleanup() -- cleanup any tmp file *
getseq() -- read in seq, set dna, len, maxlen * g_calloc() --
calloc() with error checkin * readjmps() -- get the good jmps, from
tmp file if necessary * writejmps() -- write a filled array of jmps
to a tmp file: nw() */ #include "nw.h" #include <sys/file.h>
char *jname = "/tmp/homgXXXXXX"; /* tmp file for jmps */ FILE *fj;
int cleanup(); /* cleanup tmp file */ long lseek(); /* * remove any
tmp file if we blow */ cleanup(i) cleanup int i; { if (fj) (void)
unlink(jname); exit(i); } /* * read, return ptr to seq, set dna,
len, maxlen * skip lines starting with `;`, `<`, or `>` * seq
in upper or lower case */ char * getseq(file, len) getseq char
*file; /* file name */ int *len; /* seq len */ { char line[1024],
*pseq; register char *px, *py; int natgc, tlen; FILE *fp; if ((fp =
fopen(file, "r")) == 0) { fprintf(stderr, "%s: can't read
%s.backslash.n", prog, file); exit(1); } tlen = natgc = 0; while
(fgets(line, 1024, fp)) { if (*line == `;` .vertline..vertline.
*line == `<` .vertline..vertline. *line == `>`) continue; for
(px = line; *px != `.backslash.n`; px++) if (isupper(*px)
.vertline..vertline. islower(*px)) tlen++; } if ((pseq =
malloc((unsigned)(tlen+6))) == 0) { fprintf(stderr, "%s: malloc()
failed to get %d bytes for %s.backslash.n", prog, tlen+6, file);
exit(1); } pseq[0] = pseq[1] = pseq[2] = pseq[3] = `.backslash.0`;
...getseq py = pseq + 4; *len = tlen; rewind(fp); while
(fgets(line, 1024, fp)) { if (*line == `;` .vertline..vertline.
*line == `<` .vertline..vertline. *line == `>`) continue; for
(px = line; *px != `.backslash.n`; px++) { if (isupper(*px)) *py++
= *px; else if (islower(*px)) *py++ = toupper(*px); if
(index("ATGCU", *(py-1))) natgc++; } } *py++ = `.backslash.0`; *py
= `.backslash.0`; (void) fclose(fp); dna = natgc > (tlen/3);
return(pseq+4); } char * g_calloc(msg, nx, sz) g_calloc char *msg;
/* program, calling routine */ int nx, sz; /* number and size of
elements */ { char *px, *calloc(); if ((px = calloc((unsigned)nx,
(unsigned)sz)) == 0) { if (*msg) { fprintf(stderr, "%s: g_calloc()
failed %s (n= %d, sz= %d).backslash.n", prog, msg, nx, sz);
exit(1); } } return(px); } /* * get final jmps from dx[] or tmp
file, set pp[], reset dmax: main() */ readjmps() readjmps { int fd
= -1; int siz, i0, i1; register i, j, xx; if (fj) { (void)
fclose(fj); if ((fd = open(jname, O_RDONLY, 0)) < 0) {
fprintf(stderr, "%s: can't open() %s.backslash.n", prog, jname);
cleanup(1); } } for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0;
;i++) { while (1) { for (j = dx[dmax].ijmp; j >= 0 &&
dx[dmax].jp.x[j] >= xx; j--) ; ...readjmps if (j < 0
&& dx[dmax].offset && fj) { (void) lseek(fd,
dx[dmax].offset, 0); (void) read(fd, (char *)&dx[dmax].jp,
sizeof(struct jmp)); (void) read(fd, (char *)&dx[dmax].offset,
sizeof(dx[dmax].offset)); dx[dmax].ijmp = MAXJMP-1; } else break; }
if (i >= JMPS) { fprintf(stderr, "%s: too many gaps in
alignment.backslash.n", prog); cleanup(1); } if (j >= 0) { siz =
dx[dmax].jp.n[j]; xx = dx[dmax].jp.x[j]; dmax += siz; if (siz <
0) { /* gap in second seq */ pp[1].n[il] = -siz; xx += siz; /* id =
xx - yy + len1 - 1 */ pp[1].x[il] = xx - dmax + len1 - 1; gapy++;
ngapy -= siz; /* ignore MAXGAP when doing endgaps */ siz = (-siz
< MAXGAP .vertline..vertline. endgaps)? -siz : MAXGAP; il++; }
else if (siz > 0) { /* gap in first seq */ pp[0] .n[i0] = siz;
pp[0] .x[i0] = xx; gapx++; ngapx += siz; /* ignore MAXGAP when
doing endgaps */ siz = (siz < MAXGAP .vertline..vertline.
endgaps)? siz : MAXGAP; i0++; } } else break; } /* reverse the
order of jmps */ for (j = 0, i0--; j < i0; j++, i0--) { i =
pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i; i =
pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i; } for (j =
0, i1--; j < i1; j++, i1--) { i = pp[1].n[j]; pp[1].n[j] =
pp[1].n[i1]; pp[1].n[i1] = i; i = pp[1].x[j]; pp[1].x[j] =
pp[1].x[i1]; pp[1].x[i1] = i; } if (fd >= 0) (void) close(fd);
if (fj) { (void) unlink(jname); fj = 0; offset = 0; } } /* * write
a filled jmp struct offset of the prev one (if any): nw() */
writejmps(ix) writejmps int ix; { char *mktemp(); if (!fj) { if
(mktemp(jname) < 0) { fprintf(stderr, "%s: can't mktemp()
%s.backslash.n", prog, jname); cleanup(1); } if ((fj = fopen(jname,
"w")) == 0) { fprintf(stderr, "%s: can't write %s.backslash.n",
prog, jname); exit(1); } } (void) fwrite((char *)&dx[ix].jp,
sizeof(struct jmp), 1, fj); (void) fwrite((char
*)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj); }
[0284]
2TABLE 2 PRO XXXXXXXXXXXXXXX (Length = 15 amino acids) Comparison
Protein XXXXXYYYYYYY (Length = 12 amino acids) % amino acid
sequence identity = (the number of identically matching amino acid
residues between the two polypeptide sequences as determined by
ALIGN-2) divided by (the total number of amino acid residues of the
PRO polypeptide) = 5 divided by 15 = 33.3%
[0285]
3TABLE 3 PRO XXXXXXXXXX (Length = 10 amino acids) Comparison
Protein XXXXXYYYYYYZZYZ (Length = 15 amino acids) % amino acid
sequence identity = (the number of identically matching amino acid
residues between the two polypeptide sequences as determined by
ALIGN-2) divided by (the total number of amino acid residues of the
PRO polypeptide) = 5 divided by 10 = 50%
[0286]
4TABLE 4 PRO-DNA NNNNNNNNNNNNNN (Length = 14 nucleotides)
Comparison NNNNNNLLLLLLLLLL (Length = 16 nucleotides) DNA % nucleic
acid sequence identity = (the number of identically matching
nucleotides between the two nucleic acid sequences as determined by
ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA
nucleic acid sequence) = 6 divided by 14 = 42.9%
[0287]
5TABLE 5 PRO-DNA NNNNNNNNNNNN (Length = 12 nucleotides) Comparison
DNA NNNNLLLVV (Length = 9 nucleotides) % nucleic acid sequence
identity = (the number of identically matching nucleotides between
the two nucleic acid sequences as determined by ALIGN-2) divided by
(the total number of nucleotides of the PRO-DNA nucleic acid
sequence) = 4 divided by 12 = 33.3%
[0288] II Compositions and Methods of the Invention
[0289] A. Full-Length PRO Polypeptides
[0290] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO polypeptides. In particular, cDNAs
encoding various PRO polypeptides have been identified and
isolated, as disclosed in further detail in the Examples below. It
is noted that proteins produced in separate expression rounds may
be given different PRO numbers but the UNQ number is unique for any
given DNA and the encoded protein, and will not be changed.
However, for sake of simplicity, in the present specification the
protein encoded by the full length native nucleic acid molecules
disclosed herein as well as all further native homologues and
variants included in the foregoing definition of PRO, will be
referred to as "PRO/number", regardless of their origin or mode of
preparation.
[0291] As disclosed in the Examples below, various cDNA clones have
been deposited with the ATCC. The actual nucleotide sequences of
those clones can readily be determined by the skilled artisan by
sequencing of the deposited clone using routine methods in the art.
The predicted amino acid sequence can be determined from the
nucleotide sequence using routine skill. For the PRO polypeptides
and encoding nucleic acids described herein, Applicants have
identified what is believed to be the reading frame best
identifiable with the sequence information available at the
time.
[0292] 1. Full-length PRO196 Polypeptides
[0293] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO196. In particular, Applicants have
identified and isolated cDNAs encoding a PRO196 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that a
cDNA sequence encoding full-length native sequence PRO196 encodes
for a polypeptide having an amino acid sequence which has identity
with the amino acid sequence of various TIE ligand
polypeptides.
[0294] 2. Full-length PRO444 Polypeptides
[0295] The DNA26846-1397 clone was isolated from a human fetal lung
library using a trapping technique which selects for nucleotide
sequences encoding secreted proteins. Thus, the DNA26846-1397 clone
encodes a secreted factor. As far as is known, the DNA26846-1397
sequence encodes a novel factor designated herein as PRO444.
Although, using WU-BLAST2 sequence alignment computer programs,
some sequence identities with known proteins were revealed.
[0296] 3. Full-length PRO183 Polypeptides
[0297] The DNA28498 clone was isolated from a human tissue library.
As far as is known, the DNA28498 sequence encodes a novel factor
designated herein as PRO183. Although, using WU-BLAST2 sequence
alignment computer programs, some sequence identities with known
proteins were revealed.
[0298] 4. Full-length PRO185 Polypeptides
[0299] The DNA28503 clone was isolated from a human tissue library.
As far as is known, the DNA28503 sequence encodes a novel factor
designated herein as PRO185. Although, using WU-BLAST2 sequence
alignment computer programs, some sequence identities with known
proteins were revealed.
[0300] 5. Full-length PRO210 and PRO217 Polypeptides
[0301] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO210 and PRO217. In particular, Applicants
have identified and isolated cDNAs encoding a PRO210 and PRO217
polypeptide, as disclosed in further detail in the Examples below.
Using BLAST (FastA format) sequence alignment computer programs,
Applicants found that cDNAs sequence encoding full-length native
sequence PRO210 and PRO217 have homologies to known proteins having
EGF-like domains. Accordingly, it is presently believed that the
PRO210 and PRO217 polypeptides disclosed in the present application
is a newly identified member of the EGF-like family and possesses
properties typical of the EGF-like protein family.
[0302] 6. Full-length PRO215 Polypeptides
[0303] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO215. In particular, Applicants have
identified and isolated cDNAs encoding a PRO215 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that a
cDNA sequence encoding full-length native sequence PRO215 (shown in
FIG. 11 and SEQ ID NO:16) encodes for a polypeptide having an amino
acid sequence which has identity with the amino acid sequence of
the SLIT protein precursor. PRO215 also has identity with a leucine
rich repeat protein.
[0304] 7. Full-length PRO242 Polypeptides
[0305] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO242. In particular, Applicants have
identified and isolated cDNA encoding a PRO242 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that a
cDNA sequence encoding full-length native sequence PRO242 (shown in
FIG. 15 and SEQ ID NO:23) has amino acid sequence identity with
human macrophage inflammatory protein 1-alpha, rabbit macrophage
inflammatory protein 1-beta, human LD78 and rabbit immune
activation gene 2. Accordingly, it is presently believed that
PRO242 polypeptide disclosed in the present application is a newly
identified member of the chemokine family and possesses activity
typical of the chemokine family.
[0306] 8. Full-length PRO288 Polypeptides
[0307] The present invention provides newly identified and isolated
PRO288 polypeptides. In particular, Applicants have identified and
isolated various human PRO288 polypeptides. The properties and
characteristics of some of these PRO288 polypeptides are described
in further detail in the Examples below. Based upon the properties
and characteristics of the PRO288 polypeptides disclosed herein, it
is Applicants' present belief that PRO288 is a member of the TNFR
family, and particularly, is a receptor for Apo-2 ligand.
[0308] 9. Full-length PRO365 Polypeptides
[0309] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO365. In particular, Applicants have
identified and isolated cDNA encoding a PRO365 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that
various portions of the PRO365 polypeptide have significant
homology with the human 2-19 protein. Accordingly, it is presently
believed that PRO365 polypeptide disclosed in the present
application is a newly identified member of the human 2-19 protein
family.
[0310] 10. Full-length PRO1361 Polypeptides
[0311] The DNA60783-1611 clone was isolated from a human B cell
library. As far as is known, the DNA60783-1611 sequence encodes a
novel factor designated herein as PRO1361; using the WU-BLAST2
sequence alignment computer program, no sequence identities to any
known proteins were revealed.
[0312] 11. Full-length PRO1308 Polypeptides
[0313] Using WU-BLAST2 sequence alignment computer programs, it has
been found that PRO1308 shares certain amino acid sequence identity
with the amino acid sequence of the follistatin protein designated
"S55369" in the Dayhoff database. Accordingly, it is presently
believed that PRO1308 disclosed in the present application is a
newly identified member of the follistatin protein family and may
possess activity or properties typical of that family of
proteins.
[0314] 12. Full-length PRO1183 Polypeptides
[0315] Using WU-BLAST2 sequence alignment computer programs, it has
been found that a full-length native sequence PRO183 (shown in FIG.
26 and SEQ ID NO:52) has certain amino acid sequence identity with
protoporphyrinogen oxidase. Accordingly, it is presently believed
that PRO1183 disclosed in the present application is a newly
identified member of the oxidase family and may possess enzymatic
activity typical of oxidases.
[0316] 13. Full-length PRO1272 Polypeptides
[0317] Using WU-BLAST2 sequence alignment computer programs, it has
been found that a full-length native sequence PRO1272 (shown in
FIG. 28 and SEQ ID NO:54) has certain amino acid sequence identity
with cement gland-specific protein from Xenopus laevis.
Accordingly, it is presently believed that PRO1272 disclosed in the
present application is a newly identified member of the XAG family
and may share at least one mechanism with the XAG proteins.
[0318] 14. Full-length PRO1419 Polypeptides
[0319] As far as is known, the DNA71290-1630 sequence encodes a
novel factor designated herein as PRO1419. Using WU-BLAST2 sequence
alignment computer programs, minimal sequence identities to known
proteins were revealed.
[0320] 15. Full-length PRO4999 Polypeptides
[0321] Using the ALIGN-2 sequence alignment computer program
referenced above, it has been found that the full-length native
sequence PRO4999 (shown in FIG. 32 and SEQ ID NO:58) has certain
amino acid sequence identity with UROM_HUMAN. Accordingly, it is
presently believed that the PRO4999 polypeptide disclosed in the
present application is a newly identified member of the uromodulin
protein family and may possess one or more biological and/or
immunological activities or properties typical of that protein
family.
[0322] 16. Full-length PRO7170 Polypeptides
[0323] The DNA108722-2743 clone was isolated from a human library
as described in the Examples below. As far as is known, the
DNA108722-2743 nucleotide sequence encodes a novel factor
designated herein as PRO7170; using the ALIGN-2 sequence alignment
computer program, no significant sequence identities to any known
proteins were revealed.
[0324] 17. Full-length PRO248 Polypeptides
[0325] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO248. In particular, Applicants have
identified and isolated cDNA encoding a PRO248 polypeptide, as
disclosed in further detail in the Examples below. Using known
programs such as BLAST and FastA sequence alignment computer
programs, Applicants found that a cDNA sequence encoding
full-length native sequence PRO248 (amino acid sequence shown in
FIG. 36 and SEQ ID NO:65) has certain amino acid sequence identity
with growth differentiation factor 3, from mouse and from homo
sapiens. Accordingly, it is presently believed that PRO248
polypeptide disclosed in the present application is a newly
identified member of the transforming growth factor .beta. family
and possesses growth and differentiation capabilities typical of
the this family.
[0326] 18. Full-length PRO353 Polypeptides
[0327] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO353. In particular, Applicants have
identified and isolated cDNA encoding PRO353 polypeptides, as
disclosed in further detail in the Examples below. Using BLAST and,
FastA sequence alignment computer programs, Applicants found that
various portions of the PRO353 polypeptides have certain homology
with the human and mouse complement proteins. Accordingly, it is
presently believed that the PRO353 polypeptides disclosed in the
present application are newly identified members of the complement
protein family and possesses the ability to effect the inflammation
process as is typical of the complement family of proteins.
[0328] 19. Full-length PRO1318 and PRO1600 Polypeptides
[0329] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO1318 and PRO1600. In particular,
Applicants have identified and isolated cDNAs encoding PRO1318 and
PRO1600 polypeptides, as disclosed in further detail in the
Examples below. Using BLAST and FastA sequence alignment computer
programs, Applicants found that cDNA sequence encoding full-length
native sequence PRO1318 and PRO1600 (shown in FIG. 40 and SEQ ID
NO:78 and FIG. 42 and SEQ ID NO:80, respectively) have amino acid
sequence identity with one or more chemokines. Accordingly, it is
presently believed that the PRO1318 and PRO1600 polypeptides
disclosed in the present application are newly identified members
of the chemokine family and possesses activity typical of the
chemokine family.
[0330] 20. Full-length PRO533 Polypeptides
[0331] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO533. In particular, Applicants have
identified and isolated cDNA encoding a PRO533 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST-2
and FastA sequence alignment computer programs, Applicants found
that a full-length native sequence PRO533 (shown in FIG. 46 and SEQ
ID NO:86) has a Blast score of 509 and 53% amino acid sequence
identity with fibroblast growth factor (FGF). Accordingly, it is
presently believed that PRO533 disclosed in the present application
is a newly identified member of the fibroblast growth factor family
and may possess activity typical of such polypeptides.
[0332] 21. Full-lenght PRO301 Polypeptides
[0333] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO301. In particular, Applicants have
identified and isolated cDNA encoding a PRO301 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that a
full-length native sequence PRO301 (shown in FIG. 48 and SEQ ID
NO:91) has a Blast score of 246 corresponding to 30% amino acid
sequence identity with human A33 antigen precursor. Accordingly, it
is presently believed that PRO301 disclosed in the present
application is a newly identified member of the A33 antigen protein
family and may be expressed in human neoplastic diseases such as
colorectal cancer.
[0334] 22. Full-lenght PRO187 Polypeptides
[0335] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO187. In particular, Applicants have
identified and isolated cDNA encoding a PRO187 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that a
full-length native sequence PRO187 (shown in FIG. 50) has 74% amino
acid sequence identity and BLAST score of 310 with various
androgen-induced growth factors and FGF-8. Accordingly, it is
presently believed that PRO187 polypeptide disclosed in the present
application is a newly identified member of the FGF-8 protein
family and may possess identify activity or property typical of the
FGF-8-like protein family.
[0336] 23. Full-length PRO337 Polypeptides
[0337] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO337. In particular, Applicants have
identified and isolated cDNA encoding a PRO337 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST,
BLAST-2 and FastA sequence alignment computer programs, Applicants
found that a full-length native sequence PRO337 has 97% amino acid
sequence identity with rat neurotrimin, 85% sequence identity with
chicken CEPU, 73% sequence identity with chicken G55, 59% homology
with human LAMP and 84% homology with human OPCAM. Accordingly, it
is presently believed that PRO337 disclosed in the present
application is a newly identified member of the IgLON sub family of
the immunoglobulin superfamily and may possess neurite growth and
differentiation potentiating properties.
[0338] 24. Full-length PRO1411 Polypeptides
[0339] As far as is known, the DNA59212-1627 sequence encodes a
novel factor designated herein as PRO1411. However, using WU-BLAST2
sequence alignment computer programs, some sequence identities to
known proteins were revealed.
[0340] 25. Full-length PRO4356 Polypeptides
[0341] Using WU-BLAST2 sequence alignment computer programs, it has
been found that a full-length native sequence PRO4356 (shown in
FIG. 56 and SEQ ID NO:108) has certain amino acid sequence identity
with metastasis associated GPI-anchored protein. Accordingly, it is
presently believed that PRO4356 disclosed in the present
application is a newly identified member of this family and shares
similar mechanisms.
[0342] 26. Full-length PRO246 Polypeptides
[0343] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO246. In particular, Applicants have
identified and isolated cDNA encoding a PRO246 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that a
portion of the PRO246 polypeptide has significant homology with the
human cell surface protein HCAR. Accordingly, it is presently
believed that PRO246 polypeptide disclosed in the present
application may be a newly identified membrane-bound virus receptor
or tumor cell-specific antigen.
[0344] 27. Full-length PRO265 Polypeptides
[0345] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO265. In particular, Applicants have
identified and isolated cDNA encoding a PRO265 polypeptide, as
disclosed in further detail in the Examples below. Using programs
such as BLAST and FastA sequence alignment computer programs,
Applicants found that various portions of the PRO265 polypeptide
have significant homology with the fibromodulin protein and
fibromodulin precursor protein. Applicants have also found that the
DNA encoding the PRO265 polypeptide has significant homology with
platelet glycoprotein V, a member of the leucine rich related
protein family involved in skin and wound repair. Accordingly, it
is presently believed that PRO265 polypeptide disclosed in the
present application is a newly identified member of the leucine
rich repeat family and possesses protein protein binding
capabilities, as well as be involved in skin and wound repair as
typical of this family.
[0346] 28. Full-length PRO941 Polypeptides
[0347] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO941. In particular, Applicants have
identified and isolated cDNA encoding a PRO941 polypeptide, as
disclosed in further detail in the Examples below. Using BLAST and
FastA sequence alignment computer programs, Applicants found that
the PRO941 polypeptide has significant similarity to one or more
cadherin proteins. Accordingly, it is presently believed that
PRO941 polypeptide disclosed in the present application is a newly
identified cadherin homolog.
[0348] 29. Full-length PRO10096 Polypeptides
[0349] Using the ALIGN-2 sequence alignment computer program
referenced above, it has been found that the full-length native
sequence PRO10096 (shown in FIG. 64 and SEQ ID NO:126) has certain
amino acid sequence identity with various interleukin-10-related
molecules. Accordingly, it is presently believed that the PRO10096
polypeptide disclosed in the present application is a newly
identified IL-10 homolog and may possess one or more biological
and/or immunological activities or properties typical of that
protein.
[0350] 30. Full-length PRO6003 Polypeptides
[0351] The DNA83568-2692 clone was isolated from a human fetal
kidney library as described in the Examples below. As far as is
known, the DNA83568-2692 nucleotide sequence encodes a novel factor
designated herein as PRO6003; using the ALIGN-2 sequence alignment
computer program, no significant sequence identities to any known
proteins were revealed.
[0352] B. PRO Polypeptide Variants
[0353] In addition to the full-length native sequence PRO
polypeptides described herein, it is contemplated that PRO variants
can be prepared. PRO variants can be prepared by introducing
appropriate nucleotide changes into the PRO DNA, and/or by
synthesis of the desired PRO polypeptide. Those skilled in the art
will appreciate that amino acid changes may alter
post-translational processes of the PRO, such as changing the
number or position of glycosylation sites or altering the membrane
anchoring characteristics.
[0354] Variations in the native full-length sequence PRO or in
various domains of the PRO described herein, can be made, for
example, using any of the techniques and guidelines for
conservative and non-conservative mutations set forth, for
instance, in U.S. Pat. No. 5,364,934. Variations may be a
substitution, deletion or insertion of one or more codons encoding
the PRO that results in a change in the amino acid sequence of the
PRO as compared with the native sequence PRO. Optionally the
variation is by substitution of at least one amino acid with any
other amino acid in one or more of the domains of the PRO. Guidance
in determining which amino acid residue may be inserted,
substituted or deleted without adversely affecting the desired
activity may be found by comparing the sequence of the PRO with
that of homologous known protein molecules and minimizing the
number of amino acid sequence changes made in regions of high
homology. Amino acid substitutions can be the result of replacing
one amino acid with another amino acid having similar structural
and/or chemical properties, such as the replacement of a leucine
with a serine, i.e., conservative amino acid replacements.
Insertions or deletions may optionally be in the range of about 1
to 5 amino acids. The variation allowed may be determined by
systematically making insertions, deletions or substitutions of
amino acids in the sequence and testing the resulting variants for
activity exhibited by the full-length or mature native
sequence.
[0355] PRO polypeptide fragments are provided herein. Such
fragments may be truncated at the N-terminus or C-terminus, or may
lack internal residues, for example, when compared with a full
length native protein. Certain fragments lack amino acid residues
that are not essential for a desired biological activity of the PRO
polypeptide.
[0356] PRO fragments may be prepared by any of a number of
conventional techniques. Desired peptide fragments may be
chemically synthesized. An alternative approach involves generating
PRO fragments by enzymatic digestion, e.g., by treating the protein
with an enzyme known to cleave proteins at sites defined by
particular amino acid residues, or by digesting the DNA with
suitable restriction enzymes and isolating the desired fragment.
Yet another suitable technique involves isolating and amplifying a
DNA fragment encoding a desired polypeptide fragment, by polymerase
chain reaction (PCR). Oligonucleotides that define the desired
termini of the DNA fragment are employed at the 5' and 3' primers
in the PCR. Preferably, PRO polypeptide fragments share at least
one biological and/or immunological activity with the native PRO
polypeptide disclosed herein.
[0357] In particular embodiments, conservative substitutions of
interest are shown in Table 6 under the heading of preferred
substitutions. If such substitutions result in a change in
biological activity, then more substantial changes, denominated
exemplary substitutions in Table 6, or as further described below
in reference to amino acid classes, are introduced and the products
screened.
6 TABLE 6 Original Exemplary Preferred Residue Substitutions
Substitutions Ala (A) val; leu; ile val Arg (R) lys; gln; asn lys
Asn (N) gln; his; lys; arg gln Asp (D) glu glu Cys (C) ser ser Gln
(Q) asn asn Glu (E) asp asp Gly (G) pro; ala ala His (H) asn; gln;
lys; arg arg Ile (I) leu; val; met; ala; phe; leu norleucine Leu
(L) norleucine; ile; val; ile met; ala; phe Lys (K) arg; gln; asn
arg Met (M) leu; phe; ile leu Phe (F) leu; val; ile; ala; tyr leu
Pro (P) ala ala Ser (S) thr thr Thr (T) ser ser Trp (W) tyr; phe
tyr Tyr (Y) trp; phe; thr; ser phe Val (V) ile; leu; met; phe; leu
ala; norleucine
[0358] Substantial modifications in function or immunological
identity of the PRO polypeptide are accomplished by selecting
substitutions that differ significantly in their effect on
maintaining (a) the structure of the polypeptide backbone in the
area of the substitution, for example, as a sheet or helical
conformation, (b) the charge or hydrophobicity of the molecule at
the target site, or (c) the bulk of the side chain. Naturally
occurring residues are divided into groups based on common
side-chain properties:
[0359] (1) hydrophobic: norleucine, met, ala, val, leu, ile;
[0360] (2) neutral hydrophilic: cys, ser, thr;
[0361] (3) acidic: asp, glu;
[0362] (4) basic: and, gln, his, lyes, arg;
[0363] (5) residues that influence chain orientation: gly, pro;
and
[0364] (6) aromatic: trp, tyr, phe.
[0365] Non-conservative substitutions will entail exchanging a
member of one of these classes for another class. Such substituted
residues also may be introduced into the conservative substitution
sites or, more preferably, into the remaining (non-conserved)
sites.
[0366] The variations can be made using methods known in the art
such as oligonucleotide-mediated (site-directed) mutagenesis,
alanine scanning, and PCR mutagenesis. Site-directed mutagenesis
[Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al.,
Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et
al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells
et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or
other known techniques can be performed on the cloned DNA to
produce the PRO variant DNA.
[0367] Scanning amino acid analysis can also be employed to
identify one or more amino acids along a contiguous sequence. Among
the preferred scanning amino acids are relatively small, neutral
amino acids. Such amino acids include alanine, glycine, serine, and
cysteine. Alanine is typically a preferred scanning amino acid
among this group because it eliminates the side-chain beyond the
beta-carbon and is less likely to alter the main-chain conformation
of the variant [Cunningham and Wells, Science, 244: 1081-1085
(1989)]. Alanine is also typically preferred because it is the most
common amino acid. Further, it is frequently found in both buried
and exposed positions [Creighton, The Proteins, (W. H. Freeman
& Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine
substitution does not yield adequate amounts of variant, an
isoteric amino acid can be used.
[0368] C. Modifications of PRO
[0369] Covalent modifications of PRO are included within the scope
of this invention. One type of covalent modification includes
reacting targeted amino acid residues of a PRO polypeptide with an
organic derivatizing agent that is capable of reacting with
selected side chains or the N- or C-terminal residues of the PRO.
Derivatization with bifunctional agents is useful, for instance,
for crosslinking PRO to a water-insoluble support matrix or surface
for use in the method for purifying anti-PRO antibodies, and
vice-versa. Commonly used crosslinking agents include, e.g.,
1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde,
N-hydroxysuccinimide esters, for example, esters with
4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters such as
3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides
such as bis-N-maleimido-1,8-octane and agents such as
methyl-3-[(p-azidophenyl- )dithio]propioimidate.
[0370] Other modifications include deamidation of glutaminyl and
asparaginyl residues to the corresponding glutamyl and aspartyl
residues, respectively, hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues,
methylation of the .alpha.-amino groups of lysine, arginine, and
histidine side chains [T. E. Creighton, Proteins: Structure and
Molecular Properties, W. H. Freeman & Co., San Francisco, pp.
79-86 (1983)], acetylation of the N-terminal amine, and amidation
of any C-terminal carboxyl group.
[0371] Another type of covalent modification of the PRO polypeptide
included within the scope of this invention comprises altering the
native glycosylation pattern of the polypeptide. "Altering the
native glycosylation pattern" is intended for purposes herein to
mean deleting one or more carbohydrate moieties found in native
sequence PRO (either by removing the underlying glycosylation site
or by deleting the glycosylation by chemical and/or enzymatic
means), and/or adding one or more glycosylation sites that are not
present in the native sequence PRO. In addition, the phrase
includes qualitative changes in the glycosylation of the native
proteins, involving a change in the nature and proportions of the
various carbohydrate moieties present.
[0372] Addition of glycosylation sites to the PRO polypeptide may
be accomplished by altering the amino acid sequence. The alteration
may be made, for example, by the addition of, or substitution by,
one or more serine or threonine residues to the native sequence PRO
(for O-linked glycosylation sites). The PRO amino acid sequence may
optionally be altered through changes at the DNA level,
particularly by mutating the DNA encoding the PRO polypeptide at
preselected bases such that codons are generated that will
translate into the desired amino acids.
[0373] Another means of increasing the number of carbohydrate
moieties on the PRO polypeptide is by chemical or enzymatic
coupling of glycosides to the polypeptide. Such methods are
described in the art, e.g., in WO 87/05330 published Sep. 11, 1987,
and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306
(1981).
[0374] Removal of carbohydrate moieties present on the PRO
polypeptide may be accomplished chemically or enzymatically or by
mutational substitution of codons encoding for amino acid residues
that serve as targets for glycosylation. Chemical deglycosylation
techniques are known in the art and described, for instance, by
Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by
Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of
carbohydrate moieties on polypeptides can be achieved by the use of
a variety of endo- and exo-glycosidases as described by Thotakura
et al., Meth. Enzymol., 138:350 (1987).
[0375] Another type of covalent modification of PRO comprises
linking the PRO polypeptide to one of a variety of nonproteinaceous
polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or
polyoxyalkylenes, in the mainer set forth in. U.S. Pat. Nos.
4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or
4,179,337.
[0376] The PRO of the present invention may also be modified in a
way to form a chimeric molecule comprising PRO fused to another,
heterologous polypeptide or amino acid sequence.
[0377] In one embodiment, such a chimeric molecule comprises a
fusion of the PRO with a tag polypeptide which provides an epitope
to which an anti-tag antibody can selectively bind. The epitope tag
is generally placed at the amino- or carboxyl-terminus of the PRO.
The presence of such epitope-tagged forms of the PRO can be
detected using an antibody against the tag polypeptide. Also,
provision of the epitope tag enables the PRO to be readily purified
by affinity purification using an anti-tag antibody or another type
of affinity matrix that binds to the epitope tag. Various tag
polypeptides and their respective antibodies are well known in the
art. Examples include poly-histidine (poly-his) or
poly-histidine-glycine (poly-his-gly) tags; the flu HA tag
polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol.,
8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7
and 9E10 antibodies thereto [Evan et al., Molecular and Cellular
Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus
glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein
Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include
the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)];
the KT3 epitope peptide [Martin et al., Science, 255:192-194
(1992)]; an .alpha.-tubulin epitope peptide [Skinner et al., J.
Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein
peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA,
87:6393-6397 (1990)].
[0378] In an alternative embodiment, the chimeric molecule may
comprise a fusion of the PRO with an immunoglobulin or a particular
region of an immunoglobulin. For a bivalent form of the chimeric
molecule (also referred to as an "immunoadhesin"), such a fusion
could be to the Fc region of an IgG molecule. The Ig fusions
preferably include the substitution of a soluble (transmembrane
domain deleted or inactivated) form of a PRO polypeptide in place
of at least one variable region within an Ig molecule. In a
particularly preferred embodiment, the immunoglobulin fusion
includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3
regions of an IgG1 molecule. For the production of immunoglobulin
fusions see also US Pat. No.5,428,130 issued Jun. 27, 1995.
[0379] D. Preparation of PRO
[0380] The description below relates primarily to production of PRO
by culturing cells transformed or transfected with a vector
containing PRO nucleic acid. It is, of course, contemplated that
alternative methods, which are well known in the art, may be
employed to prepare PRO. For instance, the PRO sequence, or
portions thereof, may be produced by direct peptide synthesis using
solid-phase techniques [see, e.g., Stewart et al., Solid-Phase
Peptide Synthesis, W. H. Freeman Co., San Francisco, Calif. (1969);
Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. In vitro
protein synthesis may be performed using manual techniques or by
automation. Automated synthesis may be accomplished, for instance,
using an Applied Biosystems Peptide Synthesizer (Foster City,
Calif.) using manufacturer's instructions. Various portions of the
PRO may be chemically synthesized separately and combined using
chemical or enzymatic methods to produce the full-length PRO.
[0381] 1. Isolation of DNA Encoding PRO
[0382] DNA encoding PRO may be obtained from a cDNA library
prepared from tissue believed to possess the PRO mRNA and to
express it at a detectable level. Accordingly, human PRO DNA can be
conveniently obtained from a cDNA library prepared from human
tissue, such as described in the Examples. The PRO-encoding gene
may also be obtained from a genomic library or by known synthetic
procedures (e.g., automated nucleic acid synthesis).
[0383] Libraries can be screened with probes (such as antibodies to
the PRO or oligonucleotides of at least about 20-80 bases) designed
to identify the gene of interest or the protein encoded by it.
Screening the cDNA or genomic library with the selected probe may
be conducted using standard procedures, such as described in
Sambrook et al., Molecular Cloning: A Laboratory Manual (New York:
Cold Spring Harbor Laboratory Press, 1989). An alternative means to
isolate the gene encoding PRO is to use PCR methodology [Sambrook
et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual
(Cold Spring Harbor Laboratory Press, 1995)].
[0384] The Examples below describe techniques for screening a cDNA
library. The oligonucleotide sequences selected as probes should be
of sufficient length and sufficiently unambiguous that false
positives are minimized. The oligonucleotide is preferably labeled
such that it can be detected upon hybridization to DNA in the
library being screened. Methods of labeling are well known in the
art, and include the use of radiolabels like .sup.32P-labeled ATP,
biotinylation or enzyme labeling. Hybridization conditions,
including moderate stringency and high stringency, are provided in
Sambrook et al., supra.
[0385] Sequences identified in such library screening methods can
be compared and aligned to other known sequences deposited and
available in public databases such as GenBank or other private
sequence databases. Sequence identity (at either the amino acid or
nucleotide level) within defined regions of the molecule or across
the full-length sequence can be determined using methods known in
the art and as described herein.
[0386] Nucleic acid having protein coding sequence may be obtained
by screening selected cDNA or genomic libraries using the deduced
amino acid sequence disclosed herein for the first time, and, if
necessary, using conventional primer extension procedures as
described in Sambrook et al., supra, to detect precursors and
processing intermediates of mRNA that may not have been
reverse-transcribed into cDNA.
[0387] 2. Selection and Transformation of Host Cells
[0388] Host cells are transfected or transformed with expression or
cloning vectors described herein for PRO production and cultured in
conventional nutrient media modified as appropriate for inducing
promoters, selecting transformants, or amplifying the genes
encoding the desired sequences. The culture conditions, such as
media, temperature, pH and the like, can be selected bv the skilled
artisan without undue experimentation. In general, principles,
protocols, and practical techniques for maximizing the productivity
of cell cultures can be found in Mammalian Cell Biotechnology: a
Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook
et al., supra.
[0389] Methods of eukaryotic cell transfection and prokaryotic cell
transformation are known to the ordinarily skilled artisan, for
example, CaCl.sub.2, CaPO.sub.4, liposome-mediated and
electroporation. Depending on the host cell used, transformation is
performed using standard techniques appropriate to such cells. The
calcium treatment employing calcium chloride, as described in
Sambrook et al., supra, or electroporation is generally used for
prokaryotes. Infection with Agrobacteriun tumefaciens is used for
transformation of certain plant cells, as described by Shaw et al.,
Gene, 23:315 (1983) and WO 89/05859 published Jun. 29, 1989. For
mammalian cells without such cell walls, the calcium phosphate
precipitation method of Graham and van der Eb, Virology, 52:456-457
(1978) can be employed. General aspects of mammalian cell host
system transfections have been described in U.S. Pat. No.
4,399,216. Transformations into yeast are typically carried out
according to the method of Van Solingen et al., J. Bact., 130:946
(1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829
(1979). However, other methods for introducing DNA into cells, such
as by nuclear microinjection, electroporation, bacterial protoplast
fusion with intact cells, or polycations, e.g., polybrene,
polyornithine, may also be used. For various techniques for
transforming mammalian cells, see Keown et al., Methods in
Enzymology, 185:527-537 (1990) and Mansour et al., Nature,
336:348-352 (1988).
[0390] Suitable host cells for cloning or expressing the DNA in the
vectors herein include prokaryote, yeast, or higher eukaryote
cells. Suitable prokaryotes include but are not limited to
eubacteria, such as Gram-negative or Gram-positive organisms, for
example, Enterobacteriaceae such as E. coli. Various E. coli
strains are publicly available, such as E. coli K12 strain MM294
(ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W3110
(ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic
host cells include Enterobacteriaceae such as Escherichia, e.g., E.
coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g.,
Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and
Shigella, as well as Bacilli such as B. subtilis and B.
licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710
published Apr. 12 1989), Pseudomonas such as P. aeruginosa, and
Streptomyces. These examples are illustrative rather than limiting.
Strain W3110 is one particularly preferred host or parent host
because it is a common host strain for recombinant DNA product
fermentations. Preferably, the host cell secretes minimal amounts
of proteolytic enzymes. For example, strain W3110 may be modified
to effect a genetic mutation in the genes encoding proteins
endogenous to the host, with examples of such hosts including E.
coli W3110 strain 1A2, which has the complete genotype tonA ; E.
coli W3110 strain 9E4, which has the complete genotype tonA ptr3;
E. coli W3110 strain 27C7 (ATCC 55,244), which has the complete
genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan.sup.r; E.
coli W3110 strain 37D6, which has the complete genotype tonA ptr3
phoA E15 (argF-lac)169 degP ompT rbs7ilvG kan.sup.r; E. coli W3110
strain 40B4, which is strain 37D6 with a non-kanamycin resistant
degP deletion mutation; and an E. coli strain having mutant
periplasmic protease disclosed in U.S. Pat. No. 4,946,783 issued
Aug. 7, 1990. Alternatively, in vitro methods of cloning, e.g., PCR
or other nucleic acid polymerase reactions, are suitable.
[0391] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for PRO-encoding vectors. Saccharomyces cerevisiae is a commonly
used lower eukaryotic host microorganism. Others include
Schizosaccharomyces pombe (Beach and Nurse, Nature, 290: 140
[1981]; EP 139,383 published May 2, 1985); Kluyveromyces hosts
(U.S. Pat. No. 4,943,529; Fleer et al., Bio/Technology, 9:968-975
(1991)) such as, e.g., K. lactis (MW98-8C, CBS683, CBS4574;
Louvencour et al., J. Bacteriol., 154(2):737-742 [1983]), K.
fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii
(ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC
36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), K.
thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia
pastoris (EP 183,070; Sreekrishna et al., J. Basic Microbiol.,
28:265-278 [1988]); Candida; Trichoderma reesia (EP 244,234);
Neurospora crassa (Case et al., Proc. Natl. Acad. Sci. USA,
76:5259-5263 [1979]); Schwanniomyces such as Schwanniomyces
occidentalis (EP 394,538 published Oct. 31, 1990); and filamentous
fungi such as, e.g., Neurospora, Penicillium, Tolypocladium
(WO91/00357 published Jan. 10, 1991), and Aspergillus hosts such as
A. nidulans (Ballance et al., Biochem. Biophys. Res. Commun.,
112:284-289 [1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yelton
et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and A.
niger (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylotropic
yeasts are suitable herein and include, but are not limited to,
yeast capable of growth on methanol selected from the genera
consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces,
Torulopsis, and Rhodotorula. A list of specific species that are
exemplary of this class of yeasts may be found in C. Anthony, The
Biochemistry of Methylotroplis, 269 (1982).
[0392] Suitable host cells for the expression of glycosylated PRO
are derived from multicellular organisms. Examples of invertebrate
cells include insect cells such as Drosophila S2 and Spodoptera
Sf9, as well as plant cells. Examples of useful mammalian host cell
lines include Chinese hamster ovary (CHO) and COS cells. More
specific examples include monkey kidney CV1 line transformed by
SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or
293 cells subcloned for growth in suspension culture, Graham et
al., J. Gen Virol., 36:59 (1977)); Chinese hamster ovary
cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA,
77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod.,
23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human
liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562,
ATCC CCL5 1). The selection of the appropriate host cell is deemed
to be within the skill in the art.
[0393] 3. Selection and Use of a Replicable Vector
[0394] The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO
may be inserted into a replicable vector for cloning (amplification
of the DNA) or for expression. Various vectors are publicly
available. The vector may, for example, be in the form of a
plasmid, cosmid, viral particle, or pliage. The appropriate nucleic
acid sequence may be inserted into the vector by a variety of
procedures. In general, DNA is inserted into an appropriate
restriction endonuclease site(s) using techniques known in the art.
Vector components generally include, but are not limited to, one or
more of a signal sequence, an origin of replication, one or more
marker genes, an enhancer element, a promoter, and a transcription
termination sequence. Construction of suitable vectors containing
one or more of these components employs standard ligation
techniques which are known to the skilled artisan.
[0395] The PRO may be produced recombinantly not only directly, but
also as a fusion polypeptide with a heterologous polypeptide, which
may be a signal sequence or other polypeptide having a specific
cleavage site at the N-terminus of the mature protein or
polypeptide. In general, the signal sequence may be a component of
the vector, or it may be a part of the PRO-encoding DNA that is
inserted into the vector. The signal sequence may be a prokaryotic
signal sequence selected, for example, from the group of the
alkaline phosphatase, penicillinase, lpp, or heat-stable
enterotoxin II leaders. For yeast secretion the signal sequence may
be, e.g., the yeast invertase leader, alpha factor leader
(including Saccharomyces and Kluyveromyces .alpha.-factor leaders,
the latter described in U.S. Pat. No. 5,010,182), or acid
phosphatase leader, the C. albicans glucoamylase leader (EP 362,179
published Apr. 4, 1990), or the signal described in WO 90/13646
published Nov. 15, 1990. In mammalian cell expression, mammalian
signal sequences may be used to direct secretion of the protein,
such as signal sequences from secreted polypeptides of the same or
related species, as well as viral secretory leaders.
[0396] Both expression and cloning vectors contain a nucleic acid
sequence that enables the vector to replicate in one or more
selected host cells. Such sequences are well known for a variety of
bacteria, yeast, and viruses. The origin of replication from the
plasmid pBR322 is suitable for most Gram-negative bacteria, the 2
.mu. plasmid origin is suitable for yeast, and various viral
origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for
cloning vectors in mammalian cells.
[0397] Expression and cloning vectors will typically contain a
selection gene, also termed a selectable marker. Typical selection
genes encode proteins that (a) confer resistance to antibiotics or
other toxins, e.g., ampicillin, neomycin, methotrexate, or
tetracycline, (b) complement auxotrophic deficiencies, or (c)
supply critical nutrients not available from complex media, e.g.,
the gene encoding D-alanine racemase for Bacilli.
[0398] An example of suitable selectable markers for mammalian
cells are those that enable the identification of cells competent
to take up the PRO-encoding nucleic acid, such as DHFR or thymidine
kinase. An appropriate host cell when wild-type DHFR is employed is
the CHO cell line deficient in DHFR activity, prepared and
propagated as described by Urlaub et al., Proc. Natl. Acad. Sci.
USA, 77:4216 (1980). A suitable selection gene for use in yeast is
the trp1 gene present in the yeast plasmid YRp7 [Stinchcomb et al.,
Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979);
Tschemper et al., Gene, 10:157 (1980)]. The trp1 gene provides a
selection marker for a mutant strain of yeast lacking the ability
to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1
[Jones, Genetics, 85:12 (1977)].
[0399] Expression and cloning vectors usually contain a promoter
operably linked to the PRO-encoding nucleic acid sequence to direct
mRNA synthesis. Promoters recognized by a variety of potential host
cells are well known. Promoters suitable for use with prokaryotic
hosts include the .beta.-lactamase and lactose promoter systems
[Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature,
281:544 (1979)], alkaline phosphatase, a tryptophan (trp) promoter
system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and
hybrid promoters such as the tac promoter [deBoer et al., Proc.
Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in
bacterial systems also will contain a Shine-Dalgarno (S.D.)
sequence operably linked to the DNA encoding PRO.
[0400] Examples of suitable promoting sequences for use with yeast
hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman
et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic
enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland,
Biochemistry, 17:4900 (1978)], such as enolase,
glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase,
3-phosphoglycerate mutase, pyruvate kinase, triosephosphate
isomerase, phosphoglucose isomerase, and glucokinase.
[0401] Other yeast promoters, which are inducible promoters having
the additional advantage of transcription controlled by growth
conditions, are the promoter regions for alcohol dehydrogenase 2,
isocytochrome C, acid phosphatase, degradative enzymes associated
with nitrogen metabolism, metallothioncin,
glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible
for maltose and galactose utilization. Suitable vectors and
promoters for use in yeast expression are further described in EP
73,657.
[0402] PRO transcription from vectors in mammalian host cells is
controlled, for example, by promoters obtained from the genomes of
viruses such as polyoma virus, fowlpox virus (UK 2,211,504
published July 5, 1989), adenovirus (such as Adenovirus 2), bovine
papilloma virus, avian sarcoma virus, cytomegalovirus, a
retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from
heterologous mammalian promoters, e.g., the actin promoter or an
imununoglobulin promoter, and from heat-shock promoters, provided
such promoters are compatible with the host cell systems.
[0403] Transcription of a DNA encoding the PRO by higher eukaryotes
may be increased by inserting an enhancer sequence into the vector.
Enhancers are cis-acting elements of DNA, usually about from 10 to
300 bp, that act on a promoter to increase its transcription. Many
enhancer sequences are now known from mammalian genes (globin,
elastase, albumin, .alpha.-fetoprotein, and insulin). Typically,
however, one will use an enhancer from a eukaryotic cell virus.
Examples include the SV40 enhancer on the late side of the
replication origin (bp 100-270), the cytomegalovirus early promoter
enhancer, the polyoma enhancer on the late side of the replication
origin, and adenovirus enhancers. The enhancer may be spliced into
the vector at a position 5'or 3'to the PRO coding sequence, but is
preferably located at a site 5'from the promoter.
[0404] Expression vectors used in eukaryotic host cells (yeast,
fungi, insect, plant, animal, human, or nucleated cells from other
multicellular organisms) will also contain sequences necessary for
the termination of transcription and for stabilizing the mRNA. Such
sequences are commonly available from the 5'and, occasionally 3',
untranslated regions of eukaryotic or viral DNAs or cDNAs. These
regions contain nucleotide segments transcribed as polyadenylated
fragments in the untranslated portion of the mRNA encoding PRO.
[0405] Still other methods, vectors, and host cells suitable for
adaptation to the synthesis of PRO in recombinant vertebrate cell
culture are described inGething et al., Nature, 293:620-625 (1981);
Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP
117,058.
[0406] 4. Detecting Gene Amplification/Expression
[0407] Gene amplification and/or expression may be measured in a
sample directly, for example, by conventional Southern blotting,
Northern blotting to quantitate the transcription of mRNA [Thomas,
Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA
analysis), or in situ hybridization, using an appropriately labeled
probe, based on the sequences provided herein. Alternatively,
antibodies may be employed that can recognize specific duplexes,
including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes
or DNA-protein duplexes. The antibodies in turn may be labeled and
the assay may be carried out where the duplex is bound to a
surface, so that upon the formation of duplex on the surface, the
presence of antibody bound to the duplex can be detected.
[0408] Gene expression, alternatively, may be measured by
immunological methods, such as immunohistochemical staining of
cells or tissue sections and assay of cell culture or body fluids,
to quantitate directly the expression of gene product. Antibodies
useful for immunohistochemical staining and/or assay of sample
fluids may be either monoclonal or polyclonal, and may be prepared
in any mammal. Conveniently, the antibodies may be prepared against
a native sequence PRO polypeptide or against a synthetic peptide
based on the DNA sequences provided herein or against exogenous
sequence fused to PRO DNA and encoding a specific antibody
epitope.
[0409] 5. Purification of Polypeptide
[0410] Forms of PRO may be recovered from culture medium or from
host cell lysates. If membrane-bound, it can be released from the
membrane using a suitable detergent solution (e.g. Triton-X 100) or
by enzymatic cleavage. Cells employed in expression of PRO can be
disrupted by various physical or chemical means, such as
freeze-thaw cycling, sonication, mechanical disruption, or cell
lysing agents.
[0411] It may be desired to purify PRO from recombinant cell
proteins or polypeptides. The following procedures are exemplary of
suitable purification procedures: by fractionation on an
ion-exchange column; ethanol precipitation; reverse phase HPLC;
chromatography on silica or on a cation-exchange resin such as
DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation;
gel filtration using, for example, Sephadex G-75; protein A
Sepharose columns to remove contaminants such as IgG; and metal
chelating columns to bind epitope-tagged forms of the PRO. Various
methods of protein purification may be employed and such methods
are known in the art and described for example in Deutscher,
Methods in Enzymology, 182 (1990); Scopes, Protein Purification:
Principles and Practice, Springer-Verlag, New York (1982). The
purification step(s) selected will depend, for example, on the
nature of the production process used and the particular PRO
produced.
[0412] E. Uses for PRO
[0413] Nucleotide sequences (or their complement) encoding PRO have
various applications in the art of molecular biology, including
uses as hybridization probes, in chromosome and gene mapping and in
the generation of anti-sense RNA and DNA. PRO nucleic acid will
also be useful for the preparation of PRO polypeptides by the
recombinant techniques described herein.
[0414] The full-lengtih native sequence PRO gene, or portions
thereof, may be used as hybridization probes for a cDNA library to
isolate the full-length PRO cDNA or to isolate still other cDNAs
(for instance, those encoding naturally-occurring variants of PRO
or PRO from other species) which have a desired sequence identity
to the native PRO sequence disclosed herein. Optionally, the length
of the probes will be about 20 to about 50 bases. The hybridization
probes may be derived from at least partially novel regions of the
full length native nuclcotide sequence wherein those regions may be
determined without undue experimentation or from genomic sequences
including promoters, enhancer elements and introns of native
sequence PRO. By way of example, a screening method will comprise
isolating the coding region of the PRO gene using the known DNA
sequence to synthesize a selected probe of about 40 bases.
Hybridization probes may be labeled by a variety of labels,
including radionucleotides such as .sup.32P or .sup.35S, or
enzymatic labels such as alkaline phosphatase coupled to the probe
via avidin/biotin coupling systems. Labeled probes having a
sequence complementary to that of the PRO gene of the present
invention can be used to screen libraries of human cDNA, genomic
DNA or mRNA to determine which members of such libraries the probe
hybridizes to. Hybridization techniques are described in further
detail in the Examples below.
[0415] Any EST sequences disclosed in the present application may
similarly be employed as probes, using the methods disclosed
herein.
[0416] Other useful fragments of the PRO nucleic acids include
antisense or sense oligonucleotides comprising a singe-stranded
nucleic acid sequence (either RNA or DNA) capable of binding to
target PRO mRNA (sense) or PRO DNA (antisense) sequences. Antisense
or sense oligonucleotides, according to the present invention,
comprise a fragment of the coding region of PRO DNA. Such a
fragment generally comprises at least about 14 nucleotides,
preferably from about 14 to 30 nucleotides. The ability to derive
an antisense or a sense oligonucleotide, based upon a cDNA sequence
encoding a given protein is described in, for example, Stein and
Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al.
(BioTechniqucs 6:958, 1988).
[0417] Binding of antisense or sense oligonucleotides to target
nucleic acid sequences results in the formation of duplexes that
block transcription or translation of the target sequence by one of
several means, including enhanced degradation of the duplexes,
premature termination of transcription or translation, or by other
means. The antisense oligonucleotides thus may be used to block
expression of PRO proteins. Antisense or sense oligonucleotides
further comprise oligonucleotides having modified
sugar-phosphodiester backbones (or other sugar linkages, such as
those described in WO 91/06629) and wherein such sugar linkages are
resistant to endogenous nucleases. Such oligonucleotides with
resistant sugar linkages are stable in vivo (i.e., capable of
resisting enzymatic degradation) but retain sequence specificity to
be able to bind to target nucleotide sequences.
[0418] Other examples of sense or antisense oligonucleotides
include those oligonucleotides which are covalently linked to
organic moieties, such as those described in WO 90/10048, and other
moieties that increases affinity of the oligonucleotide for a
target nucleic acid sequence, such as poly-(L-lysine). Further
still, intercalating agents, such as ellipticine, and alkylating
agents or metal complexes may be attached to sense or antisense
oligonucleotides to modify binding specificities of the antisense
or sense oligonucleotide for the target nucleotide sequence.
[0419] Antisense or sense oligonucleotides may be introduced into a
cell containing the target nucleic acid sequence by any gene
transfer method, including, for example, CaPO.sub.4-mediated DNA
transfection, electroporation, or by using gene transfer vectors
such as Epstein-Barr virus. In a preferred procedure, an antisense
or sense oligonucleotide is inserted into a suitable retroviral
vector. A cell containing the target nucleic acid sequence is
contacted with the recombinant retroviral vector, either in vivo or
ex vivo. Suitable retroviral vectors include, but are not limited
to, those derived from the murine retrovirus M-MuLV , N2 (a
retrovirus derived from M-MuLV), or the double copy vectors
designated DCT5A, DCT5B and DCT5C (see WO 90/13641).
[0420] Sense or antisense oligonucleotides also may be introduced
into a cell containing the target nucleotide sequence by formation
of a conjugate with a ligand binding molecule, as described in WO
91/04753. Suitable ligand binding molecules include, but are not
limited to, cell surface receptors, growth factors, other
cytokines, or other ligands that bind to cell surface receptors.
Preferably, conjugation of the ligand binding molecule does not
substantially interfere with the ability of the ligand binding
molecule to bind to its corresponding molecule or receptor, or
block entry of the sense or antisense oligonucleotide or its
conjugated version into the cell.
[0421] Alternatively, a sense or an antisense oligonucleotide may
be introduced into a cell containing the target nucleic acid
sequence by formation of an oligonucleotide-lipid complex, as
described in WO 90/10448. The sense or antisense
oligonucleotide-lipid complex is preferably dissociated within the
cell by an endogenous lipase.
[0422] Antisense or sense RNA or DNA molecules are generally at
least about 5 bases in length, about 10 bases in length, about 15
bases in length, about 20 bases in length, about 25 bases in
length, about 30 bases in length, about 35 bases in length, about
40 bases in length, about 45 bases in length, about 50 bases in
length, about 55 bases in length, about 60 bases in length, about
65 bases in length, about 70 bases in length, about 75 bases in
length, about 80 bases in length, about 85 bases in length, about
90 bases in length, about 95 bases in length, about 100 bases in
length, or more.
[0423] The probes may also be employed in PCR techniques to
generate a pool of sequences for identification of closely related
PRO coding sequences.
[0424] Nucleotide sequences encoding a PRO can also be used to
construct hybridization probes for mapping the gene which encodes
that PRO and for the genetic analysis of individuals with genetic
disorders. The nucleotide sequences provided herein may be mapped
to a chromosome and specific regions of a chromosome using known
techniques, such as in situ hybridization, linkage analysis against
known chromosomal markers, and hybridization screening with
libraries.
[0425] When the coding sequences for PRO encode a protein which
binds to another protein (example, where the PRO is a receptor),
the PRO can be used in assays to identify the other proteins or
molecules involved in the binding interaction. By such methods,
inhibitors of the receptor/ligand binding interaction can be
identified. Proteins involved in such binding interactions can also
be used to screen for peptide or small molecule inhibitors or
agonists of the binding interaction. Also, the receptor PRO can be
used to isolate correlative ligand(s). Screening assays can be
designed to find lead compounds that mimic the biological activity
of a native PRO or a receptor for PRO. Such screening assays will
include assays amenable to high-throughput screening of chemical
libraries, making them particularly suitable for identifying small
molecule drug candidates. Small molecules contemplated include
synthetic organic or inorganic compounds. The assays can be
performed in a variety of formats, including protein-protein
binding assays, biochemical screening assays, immunoassays and cell
based assays, which are well characterized in the art.
[0426] Nucleic acids which encode PRO or its modified forms can
also be used to generate either transgenic animals or "knock out"
animals which, in turn, are useful in the development and screening
of therapeutically useful reagents. A transgenic animal (e.g., a
mouse or rat) is an animal having cells that contain a transgene,
which transgene was introduced into the animal or an ancestor of
the animal at a prenatal, e.g., an embryonic stage. A transgene is
a DNA which is integrated into the genome of a cell from which a
transgenic animal develops. In one embodiment, cDNA encoding PRO
can be used to clone genomiiic DNA encoding PRO in accordance with
established techniques and the genoinic sequences used to generate
transgenic animals that contain cells which express DNA encoding
PRO. Methods for generating transgenic animals, particularly
animals such as mice or rats, have become conventional in the art
and are described, for example, in U.S. Pat. Nos. 4,736,866 and
4,870,009. Typically, particular cells would be targeted for PRO
transgene incorporation with tissue-specific enhancers. Transgenic
animals that include a copy of a transgene encoding PRO introduced
into the germ line of the animal at an embryonic stage can be used
to examine the effect of increased expression of DNA encoding PRO.
Such animals can be used as tester animals for reagents thought to
confer protection from, for example, pathological conditions
associated with its overexpression. In accordance with this facet
of the invention, an animal is treated with the reagent and a
reduced incidence of the pathological condition, compared to
untreated animals bearing the transgene, would indicate a potential
therapeutic intervention for the pathological condition.
[0427] Alternatively, non-human homologues of PRO can be used to
construct a PRO "knock out" animal which has a defective or altered
gene encoding PRO as a result of homologous recombination between
the endogenous gene encoding PRO and altered genomic DNA encoding
PRO introduced into an embryonic stem cell of the animal. For
example, cDNA encoding PRO can be used to clone genomic DNA
encoding PRO in accordance with established techniques. A portion
of the genomic DNA encoding PRO can be deleted or replaced with
another gene, such as a gene encoding a selectable marker which can
be used to monitor integration. Typically, several kilobases of
unaltered flanking DNA (both at the 5'and 3'ends) are included in
the vector [see e.g., Thomas and Capecchi, Cell, 51:503 (1987) for
a description of homologous recombination vectors]. The vector is
introduced into an embryonic stem cell line (e.g., by
electroporation) and cells in which the introduced DNA has
homologously recombined with the endogenous DNA are selected [see
e.g., Li et al., Cell, 69:915 (1992)]. The selected cells are then
injected into a blastocyst of an animal (e.g., a mouse or rat) to
form aggregation chimeras [see e.g., Bradley, in Teratocarcinonias
and Embryonic Stem Cells: A Practical Approach, E. J. Robertson,
ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then
be implanted into a suitable pseudopregnant female foster animal
and the embryo brought to term to create a "knock out" animal.
Progeny harboring the homologously recombined DNA in their germ
cells can be identified by standard techniques and used to breed
animals in which all cells of the animal contain the homologously
recombined DNA. Knockout animals can be characterized for instance,
for their ability to defend against certain pathological conditions
and for their development of pathological conditions due to absence
of the PRO polypeptide.
[0428] Nucleic acid encoding the PRO polypeptides may also be used
in gene therapy. In gene therapy applications, genes are introduced
into cells in order to achieve in vivo synthesis of a
therapeutically effective genetic product, for example for
replacement of a defective gene. "Gene therapy" includes both
conventional gene therapy where a lasting effect is achieved by a
single treatment, and the administration of gene therapeutic
agents, which involves the one time or repeated administration of a
therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can
be used as therapeutic agents for blocking the expression of
certain genes in vivo. It has already been shown that short
antisense oligonucleotides can be imported into cells where they
act as inhibitors, despite their low intracellular concentrations
caused by their restricted uptake by the cell membrane. (Zamecnik
et al., Proc. Natl. Acad. Sci. USA 83:4143-4146 [1986]). The
oligonucleotides can be modified to enhance their uptake, e.g. by
substituting their negatively charged phosphodiester groups by
uncharged groups.
[0429] There are a variety of techniques available for introducing
nucleic acids into viable cells. The techniques vary depending upon
whether the nucleic acid is transferred into cultured cells in
vitro, or in vivo in the cells of the intended host. Techniques
suitable for the transfer of nucleic acid into mammalian cells in
vitro include the use of liposomes, electroporation,
microinjection, cell fusion, DEAE-dextran, the calcium phosphate
precipitation method, etc. The currently preferred in vivo gene
transfer techniques include transfection with viral (typically
retroviral) vectors and viral coat protein-liposome mediated
transfection (Dzau et al., Trends in Biotechnology 11, 205-210
[1993]). In some situations it is desirable to provide the nucleic
acid source with an agent that targets the target cells, such as an
antibody specific for a cell surface membrane protein or the target
cell, a ligand for a receptor on the target cell, etc. Where
liposomes are employed, proteins which bind to a cell surface
membrane protein associated with endocytosis may be used for
targeting and/or to facilitate uptake, e.g. capsid proteins or
fragments thereof tropic for a particular cell type, antibodies for
proteins which undergo internalization in cycling, proteins that
target intracellular localization and enhance intracellular
half-life. The technique of receptor-mediated endocytosis is
described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432
(1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414
(1990). For review of gene marking and gene therapy protocols see
Anderson et al., Science 256, 808-813 (1992).
[0430] The PRO polypeptides described herein may also be employed
as molecular weight markers for protein electrophoresis purposes
and the isolated nucleic acid sequences may be used for
recombinantly expressing those markers.
[0431] The nucleic acid molecules encoding the PRO polypeptides or
fragments thereof described herein are useful for chromosome
identification. In this regard, there exists an ongoing need to
identify new chromosome markers, since relatively few chromosome
marking reagents, based upon actual sequence data are presently
available. Each PRO nucleic acid molecule of the present invention
can be used as a chromosome marker.
[0432] The PRO polypeptides and nucleic acid molecules of the
present invention may also be used for tissue typing, wherein the
PRO polypeptides of the present invention may be differentially
expressed in one tissue as compared to another. PRO nucleic acid
molecules will find use for generating probes for PCR, Northern
analysis, Southern analysis and Western analysis.
[0433] The PRO polypeptides described herein may also be employed
as therapeutic agents. The PRO polypeptides of the present
invention can be formulated according to known methods to prepare
pharmaceutically useful compositions, whereby the PRO product
hereof is combined in admixture with a pharmaceutically acceptable
carrier vehicle. Therapeutic formulations are prepared for storage
by mixing the active ingredient having the desired degree of purity
with optional physiologically acceptable carriers, excipients or
stabilizers (Remington's Pharmaceutical Sciences 16th edition,
Osol, A. Ed. (1980)), in the form of lyophilized formulations or
aqueous solutions. Acceptable carriers, excipients or stabilizers
are nontoxic to recipients at the dosages and concentrations
employed, and include buffers such as phosphate, citrate and other
organic acids; antioxidants including ascorbic acid; low molecular
weight (less than about 10 residues) polypeptides; proteins, such
as serum albumin, gelatin or immunoglobulins; hydrophilic polymers
such as polyvinylpyrrolidone, amino acids such as glycine,
glutamine, asparagine, arginine or lysine; monosaccharides,
disaccharides and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugar alcohols such as
mannitol or sorbitol; salt-forming counterions such as sodium;
and/or nonionic surfactants such as TWEEN.RTM., PLURONICS.RTM. or
PEG.
[0434] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished by filtration through
sterile filtration membranes, prior to or following lyophilization
and reconstitution.
[0435] Therapeutic compositions herein generally are placed into a
container having a sterile access port, for example, an intravenous
solution bag or vial having a stopper pierceable by a hypodermic
injection needle.
[0436] The route of administration is in accord with known methods,
e.g. injection or infusion by intravenous, intraperitoneal,
intracerebral, intramuscular, intraocular, intraarterial or
intralesional routes, topical administration, or by sustained
release systems.
[0437] Dosages and desired drug concentrations of pharmaceutical
compositions of the present invention may vary depending on the
particular use envisioned. The determination of the appropriate
dosage or route of administration is well within the skill of an
ordinary physician. Animal experiments provide reliable guidance
for the determination of effective doses for human therapy.
Interspecies scaling of effective doses can be performed following
the principles laid down by Mordenti, J. and Chappell, W. "The use
of interspecies scaling in toxicokinetics" In Toxicokinetics and
New Drug Development, Yacobi et al., Eds., Pergamon Press, New York
1989, pp. 42-96.
[0438] When in vivo administration of a PRO polypeptide or agonist
or antagonist thereof is employed, normal dosage amounts may vary
from about 10 ng/kg to up to 100 mg/kg of mammal body weight or
more per day, preferably about 1 .mu.g/kg/day to 10 mg/kg/day,
depending upon the route of administration. Guidance as to
particular dosages and methods of delivery is provided in the
literature; see, for example, U.S. Pat. Nos. 4,657,160; 5,206,344;
or 5,225,212. It is anticipated that different formulations will be
effective for different treatment compounds and different
disorders, that administration targeting one organ or tissue, for
example, may necessitate delivery in a manner different from that
to another organ or tissue.
[0439] Where sustained-release administration of a PRO polypeptide
is desired in a formulation with release characteristics suitable
for the treatment of any disease or disorder requiring
administration of the PRO polypeptide, microencapsulation of the
PRO polypeptide is contemplated. Microencapsulation of recombinant
proteins for sustained release has been successfully performed with
human growth hormone (rhGH), interferon- (rhIFN- ), interleukin-2,
and MN rp120. Johnson et al., Nat. Med., 2:795-799 (1996); Yasuda,
Biomed. Ther., 27:1221-1223 (1993); Hora et al., Bio/Technology,
8:755-758 (1990); Cleland, "Design and Production of Single
Immunization Vaccines Using Polylactide Polyglycolide Microsphere
Systems," in Vaccine Design: The Subunit and Adjuvant Approach,
Powell and Newman, eds, (Plenum Press: New York, 1995), pp.
439-462; WO 97/03692, WO 96/40072, WO 96/07399; and U.S. Pat. No.
5,654,010.
[0440] The sustained-release formulations of these proteins were
developed using poly-lactic-coglycolic acid (PLGA) polymer due to
its biocompatibility and wide range of biodegradable properties.
The degradation products of PLGA, lactic and glycolic acids, can be
cleared quickly within the human body. Moreover, the degradability
of this polymer can be adjusted from months to years depending on
its molecular weight and composition. Lewis, "Controlled release of
bioactive agents from lactide/glycolide polymer," in: M. Chasin and
R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems
(Marcel Dekker: New York, 1990), pp. 1-41.
[0441] This invention encompasses methods of screening compounds to
identify those that mimic the PRO polypeptide (agonists) or prevent
the effect of the PRO polypeptide (antagonists). Screening assays
for antagonist drug candidates are designed to identify compounds
that bind or complex with the PRO polypeptides encoded by the genes
identified herein, or otherwise interfere with the interaction of
the encoded polypeptides with other cellular proteins. Such
screening assays will include assays amenable to high-throughput
screening of chemical libraries, making them particularly suitable
for identifying small molecule drug candidates.
[0442] The assays can be performed in a variety of formats,
including protein-protein binding assays, biochemical screening
assays, immunoassays, and cell-based assays, which are well
characterized in the art.
[0443] All assays for antagonists are common in that they call for
contacting the drug candidate with a PRO polypeptide encoded by a
nucleic acid identified herein under conditions and for a time
sufficient to allow these two components to interact.
[0444] In binding assays, the interaction is binding and the
complex formed can be isolated or detected in the reaction mixture.
In a particular embodiment, the PR polypeptide encoded by the gene
identified herein or the drug candidate is immobilized on a solid
phase, e.g., on a microtiter plate, by covalent or non-covalent
attachments. Non-covalent attachment generally is accomplished by
coating the solid surface with a solution of the PRO polypeptide
and drying. Alternatively, an immobilized antibody, e.g., a
monoclonal antibody, specific for the PRO polypeptide to be
immobilized can be used to anchor it to a solid surface. The assay
is performed by adding the non-immobilized component, which may be
labeled by a detectable label, to the immobilized component, e.g.,
the coated surface containing the anchored component. When the
reaction is complete, the non-reacted components are removed, e.g.,
by washing, and complexes anchored on the solid surface are
detected. When the originally non-immobilized component carries a
detectable label, the detection of label immobilized on the surface
indicates that complexing occurred. Where the originally
non-immobilized component does not carry a label, complexing can be
detected, for example, by using a labeled antibody specifically
binding the immobilized complex.
[0445] If the candidate compound interacts with but does not bind
to a particular PRO polypeptide encoded by a gene identified
herein, its interaction with that polypeptide can be assayed by
methods well known for detecting protein-protein interactions. Such
assays include traditional approaches, such as, e.g.,
cross-linking, co-immunoprecipitation, and co-purification through
gradients or chromatographic columns. In addition, protein-protein
interactions can be monitored by using a yeast-based genetic system
described by Fields and co-workers (Fields and Song, Nature
(London), 340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci.
USA, 88:9578-9582 (1991)) as disclosed by Chevray and Nathans,
Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many
transcriptional activators, such as yeast GAL4, consist of two
physically discrete modular domains, one acting as the DNA-binding
domain, the other one functioning as the transcription-activation
domain. The yeast expression system described in the foregoing
publications (generally referred to as the "two-hybrid system")
takes advantage of this property, and employs two hybrid proteins,
one in which the target protein is fused to the DNA-binding domain
of GAL4, and another, in which candidate activating proteins are
fused to the activation domain. The expression of a GAL1-lacZ
reporter gene under control of a GAL4-activated promoter depends on
reconstitution of GAL4 activity via protein-protein interaction.
Colonies containing interacting polypeptides are detected with a
chromogenic substrate for .beta.-galactosidase. A complete kit
(MATCHMAKER.TM.) for identifying protein-protein interactions
between two specific proteins using the two-hybrid technique is
commercially available from Clontech. This system can also be
extended to map protein domains involved in specific protein
interactions as well as to pinpoint amino acid residues that are
crucial for these interactions.
[0446] Compounds that interfere with the interaction of a gene
encoding a PRO polypeptide identified herein and other intra- or
extracellular components can be tested as follows: usually a
reaction mixture is prepared containing the product of the gene and
the intra- or extracellular component under conditions and for a
time allowing for the interaction and binding of the two products.
To test the ability of a candidate compound to inhibit binding, the
reaction is run in the absence and in the presence of the test
compound. In addition, a placebo may be added to a third reaction
mixture, to serve as positive control. The binding (complex
formation) between the test compound and the intra or extracellular
component present in the mixture is monitored as described
hereinabove. The formation of a complex in the control reaction(s)
but not in the reaction mixture containing the test compound
indicates that the test compound interferes with the interaction of
the test compound and its reaction partner.
[0447] To assay for antagonists, the PRO polypeptide may be added
to a cell along with the compound to be screened for a particular
activity and the ability of the compound to inhibit the activity of
interest in the presence of the PRO polypeptide indicates that the
compound is an antagonist to the PRO polypeptide. Alternatively,
antagonists may be detected by combining the PRO polypeptide and a
potential antagonist with membrane-bound PRO polypeptide receptors
or recombinant receptors under appropriate conditions for a
competitive inhibition assay. The PRO polypeptide can be labeled,
such as by radioactivity, such that the number of PRO polypeptide
molecules bound to the receptor can be used to determine the
effectiveness of the potential antagonist. The gene encoding the
receptor can be identified by numerous methods known to those of
skill in the art, for example, ligand panning and FACS sorting.
Coligan et al., Current Protocols in Immun., 1(2): Chapter 5
(1991). Preferably, expression cloning is employed wherein
polyadenylated RNA is prepared from a cell responsive to the PRO
polypeptide and a cDNA library created from this RNA is divided
into pools and used to transfect COS cells or other cells that are
not responsive to the PRO polypeptide. Transfected cells that are
grown on glass slides are exposed to labeled PRO polypeptide. The
PRO polypeptide can be labeled by a variety of means including
iodination or inclusion of a recognition site for a site-specific
protein kinase. Following fixation and incubation, the slides are
subjected to autoradiographic analysis. Positive pools are
identified and sub-pools are prepared and re-transfected using an
interactive sub-pooling and re-screening process, eventually
yielding a single clone that encodes the putative receptor.
[0448] As an alternative approach for receptor identification,
labeled PRO polypeptide can be photoaffinity-linked with cell
membrane or extract preparations that express the receptor
molecule. Cross-linked material is resolved by PAGE and exposed to
X-ray film. The labeled complex containing the receptor can be
excised, resolved into peptide fragments, and subjected to protein
micro-sequencing. The amino acid sequence obtained from
micro-sequencing would be used to design a set of degenerate
oligonucleotide probes to screen a cDNA library to identify the
gene encoding the putative receptor.
[0449] In another assay for antagonists, mammalian cells or a
membrane preparation expressing the receptor would be incubated
with labeled PRO polypeptide in the presence of the candidate
compound. The ability of the compound to enhance or block this
interaction could then be measured.
[0450] More specific examples of potential antagonists include an
oligonucleotide that binds to the fusions of immunoglobulin with
PRO polypeptide, and, in particular, antibodies including, without
limitation, poly- and monoclonal antibodies and antibody fragments,
single-chain antibodies, anti-idiotypic antibodies, and chimeric or
humanized versions of such antibodies or fragments, as well as
human antibodies and antibody fragments. Alternatively, a potential
antagonist may be a closely related protein, for example, a mutated
form of the PRO polypeptide that recognizes the receptor but
imparts no effect, thereby competitively inhibiting the action of
the PRO polypeptide.
[0451] Another potential PRO polypeptide antagonist is an antisense
RNA or DNA construct prepared using antisense technology, where,
e.g., an antisense RNA or DNA molecule acts to block directly the
translation of mRNA by hybridizing to targeted mRNA and preventing
protein translation. Antisense technology can be used to control
gene expression through triple-helix formation or antisense DNA or
RNA, both of which methods are based on binding of a polynucleotide
to DNA or RNA. For example, the 5' coding portion of the
polynucleotide sequence, which encodes the mature PRO polypeptides
herein, is used to design an antisense RNA oligonucleotide of from
about 10 to 40 base pairs in length. A DNA oligonucleotide is
designed to be complementary to a region of the gene involved in
transcription (triple helix--see Lee et al., Nucl. Acids Res.,
6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et
al., Science, 251:1360 (1991)), thereby preventing transcription
and the production of the PRO polypeptide. The antisense RNA
oligonucleotide hybridizes to the mRNA in vivo and blocks
translation of the mRNA molecule into the PRO polypeptide
(antisense--Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides
as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton,
Fla., 1988). The oligonucleotides described above can also be
delivered to cells such that the antisense RNA or DNA may be
expressed in vivo to inhibit production of the PRO polypeptide.
When antisense DNA is used, oligodeoxyribonucleotides derived from
the translation-initiation site, e.g., between about -10 and +10
positions of the target gene nucleotide sequence, are
preferred.
[0452] Potential antagonists include small molecules that bind to
the active site, the receptor binding site, or growth factor or
other relevant binding site of the PRO polypeptide, thereby
blocking the normal biological activity of the PRO polypeptide.
Examples of small molecules include, but are not limited to, small
peptides or peptide-like molecules, preferably soluble peptides,
and synthetic non-peptidyl organic or inorganic compounds.
[0453] Ribozymes are enzymatic RNA molecules capable of catalyzing
the specific cleavage of RNA. Ribozymes act by sequence-specific
hybridization to the complementary target RNA, followed by
endonucleolytic cleavage. Specific ribozyme cleavage sites within a
potential RNA target can be identified by known techniques. For
further details see, e.g., Rossi, Current Biology, 4:469-471
(1994), and PCT publication No. WO 97/33551 (published Sep. 18,
1997).
[0454] Nucleic acid molecules in triple-helix formation used to
inhibit transcription should be single-stranded and composed of
deoxynucleotides. The base composition of these oligonucleotides is
designed such that it promotes triple-helix formation via Hoogsteen
base-pairing rules, which generally require sizeable stretches of
purines or pyrimidines on one strand of a duplex. For further
details see, e.g., PCT publication No. WO 97/33551, supra.
[0455] These small molecules can be identified by any one or more
of the screening assays discussed hereinabove and/or by any other
screening techniques well known for those skilled in the art.
[0456] Uses of the herein disclosed molecules may also be based
upon the positive functional assay hits disclosed and described
below. Methods based upon those assay hits are also encompassed by
the present invention.
[0457] F. Anti-PRO Antibodies
[0458] The present invention further provides anti-PRO antibodies.
Exemplary antibodies include polyclonal, monoclonal, humanized,
bispecific, and heteroconjugate antibodies.
[0459] 1. Polyclonal Antibodies
[0460] The anti-PRO antibodies may comprise polyclonal antibodies.
Methods of preparing polyclonal antibodies are known to the skilled
artisan. Polyclonal antibodies can be raised in a mammal, for
example, by one or more injections of an immunizing agent and, if
desired, an adjuvant. Typically, the immunizing agent and/or
adjuvant will be injected in the mammal by multiple subcutaneous or
intraperitoneal injections. The immunizing agent may include the
PRO polypeptide or a fusion protein thereof. It may be useful to
conjugate the immunizing agent to a protein known to be immunogenic
in the mammal being immunized. Examples of such immunogenic
proteins include but are not limited to keyhole limpet hemocyanin,
serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor.
Examples of adjuvants which may be employed include Freund's
complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A,
synthetic trehalose dicorynomycolate). The immunization protocol
may be selected by one skilled in the art without undue
experimentation.
[0461] 3. Monoclonal Antibodies
[0462] The anti-PRO antibodies may, alternatively, be monoclonal
antibodies. Monoclonal antibodies may be prepared using hybridoma
methods, such as those described by Kohler and Milstein, Nature,
256:495 (1975). In a hybridoma method, a mouse, hamster, or other
appropriate host animal, is typically immunized with an immunizing
agent to elicit lymphocytes that produce or are capable of
producing antibodies that will specifically bind to the immunizing
agent. Alternatively, the lymphocytes may be immunized in
vitro.
[0463] The immunizing agent will typically include the PRO
polypeptide or a fusion protein thereof. Generally, either
peripheral blood lymphocytes ("PBLs") are used if cells of human
origin are desired, or spleen cells or lymph node cells are used if
non-human mammalian sources are desired. The lymphocytes are then
fused with an immortalized cell line using a suitable fusing agent,
such as polyethylene glycol, to form a hybridoma cell [Goding,
Monoclonal Antibodies: Principles and Practice, Academic Press,
(1986) pp. 59-103]. Immortalized cell lines are usually transformed
mammalian cells, particularly myeloma cells of rodent, bovine and
human origin. Usually, rat or mouse myeloma cell lines are
employed. The hybridoma cells may be cultured in a suitable culture
medium that preferably contains one or more substances that inhibit
the growth or survival of the unfused, immortalized cells. For
example, if the parental cells lack the enzyme hypoxanthine guanine
phosphoribosyl transferase (HGPRT or HPRT), the culture medium for
the hybridomas typically will include hypoxanthine, aminopterin,
and thymidine ("HAT medium"), which substances prevent the growth
of HGPRT-deficient cells.
[0464] Preferred immortalized cell lines are those that fuse
efficiently, support stable high level expression of antibody by
the selected antibody-producing cells, and are sensitive to a
medium such as HAT medium. More preferred immortalized cell lines
are murine myeloma lines, which can be obtained, for instance, from
the Salk Institute Cell Distribution Center, San Diego, Calif. and
the American Type Culture Collection, Manassas, Va. Human myeloma
and mouse-human heteromyeloma cell lines also have been described
for the production of human monoclonal antibodies [Kozbor, J.
Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody
Production Techniques and Applications, Marcel Dekker, Inc., New
York, (1987) pp. 59-63].
[0465] The culture medium in which the hybridoma cells are cultured
can then be assayed for the presence of monoclonal antibodies
directed against PRO. Preferably, the binding specificity of
monoclonal antibodies produced by the hybridoma cells is determined
by immunoprecipitation or by an in vitro binding assay, such as
radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay
(ELISA). Such techniques and assays are known in the art. The
binding affinity of the monoclonal antibody can, for example, be
determined by the Scatchard analysis of Munson and Pollard, Anal.
Biochem., 107:220 (1980).
[0466] After the desired hybridoma cells are identified, the clones
may be subcloned by limiting dilution procedures and grown by
standard methods [Goding, supra]. Suitable culture media for this
purpose include, for example, Dulbecco's Modified Eagle's Medium
and RPMI-1640 medium. Alternatively, the hybridoma cells may be
grown in vivo as ascites in a mammal.
[0467] The monoclonal antibodies secreted by the subclones may be
isolated or purified from the culture medium or ascites fluid by
conventional immunoglobulin purification procedures such as, for
example, protein A-Sepharose, hydroxylapatite chromatography, gel
electrophoresis, dialysis, or affinity chromatography.
[0468] The monoclonal antibodies may also be made by recombinant
DNA methods, such as those described in U.S. Pat. No. 4,816,567.
DNA encoding the monoclonal antibodies of the invention can be
readily isolated and sequenced using conventional procedures (e.g.,
by using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of murine
antibodies). The hybridoma cells of the invention serve as a
preferred source of such DNA. Once isolated, the DNA may be placed
into expression vectors, which are then transfected into host cells
such as simian COS cells, Chinese hamster ovary (CHO) cells, or
myeloma cells that do not otherwise produce immunoglobulin protein,
to obtain the synthesis of monoclonal antibodies in the recombinant
host cells. The DNA also may be modified, for example, by
substituting the coding sequence for human heavy and light chain
constant domains in place of the homologous murine sequences [U.S.
Pat. No. 4,816,567; Morrison et al., supra] or by covalently
joining to the immunoglobulin coding sequence all or part of the
coding sequence for a non-immunoglobulin polypeptide. Such a
non-immunoglobulin polypeptide can be substituted for the constant
domains of an antibody of the invention, or can be substituted for
the variable domains of one antigen-combining site of an antibody
of the invention to create a chimeric bivalent antibody.
[0469] The antibodies may be monovalent antibodies. Methods for
preparing nonovalent antibodies are well known in the art. For
example, one method involves recombinant expression of
immunoglobulin light chain and modified heavy chain. The heavy
chain is truncated generally at any point in the Fc region so as to
prevent heavy chain crosslinking. Alternatively, the relevant
cysteine residues are substituted with another amino acid residue
or are deleted so as to prevent crosslinking.
[0470] In vitro methods are also suitable for preparing monovalent
antibodies. Digestion of antibodies to produce fragments thereof,
particularly, Fab fragments, can be accomplished using routine
techniques known in the art.
[0471] 3. Human and Humanized Antibodies
[0472] The anti-PRO antibodies of the invention may further
comprise humanized antibodies or human antibodies. Humanized forms
of non-human (e.g., murine) antibodies are chimeric
immunoglobulins, immunoglobulin chains or fragments thereof (such
as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding
subsequences of antibodies) which contain minimal sequence derived
from non-human immunoglobulin. Humanized antibodies include human
immunoglobulins (recipient antibody) in which residues from a
complementary determining region (CDR) of the recipient are
replaced by residues from a CDR of a non-human species (donor
antibody) such as mouse, rat or rabbit having the desired
specificity, affinity and capacity. In some instances, Fv framework
residues of the human immunoglobulin are replaced by corresponding
non-human residues. Humanized antibodies may also comprise residues
which are found neither in the recipient antibody nor in the
imported CDR or framework sequences. In general, the humanized
antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all
of the CDR regions correspond to those of a non-human
immunoglobulin and all or substantially all of the FR regions are
those of a human immunoglobulin consensus sequence. The humanized
antibody optimally also will comprise at least a portion of an
immunoglobulin constant region (Fc), typically that of a human
immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann
et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct.
Biol., 2:593-596 (1992)].
[0473] Methods for humanizing non-human antibodies are well known
in the art. Generally, a humanized antibody has one or more amino
acid residues introduced into it from a source which is non-human.
These non-human amino acid residues are often referred to as
"import" residues, which are typically taken from an "import"
variable domain. Humanization can be essentially performed
following the method of Winter and co-workers [Jones et al.,
Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327
(1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by
substituting rodent CDRs or CDR sequences for the corresponding
sequences of a human antibody. Accordingly, such "humanized"
antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567),
wherein substantially less than an intact human variable domain has
been substituted by the corresponding sequence from a non-human
species. In practice, humanized antibodies are typically human
antibodies in which some CDR residues and possibly some FR residues
are substituted by residues from analogous sites in rodent
antibodies.
[0474] Human antibodies can also be produced using various
techniques known in the art, including phage display libraries
[Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et
al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al.
and Boerner et al. are also available for the preparation of human
monoclonal antibodies (Cole et al., Monoclonal Antibodies and
Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J.
Immunol., 147(1):86-95 (1991). Similarly, human antibodies can be
made by introducing of human immunoglobulin loci into transgenic
animals, e.g., mice in which the endogenous immunoglobulin genes
have been partially or completely inactivated. Upon challenge,
human antibody production is observed, which closely resembles that
seen in humans in all respects, including gene rearrangement,
assembly, and antibody repertoire. This approach is described, for
example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825;
5,625,126; 5,633,425; 5,661,016, and in the following scientific
publications: Marks et al., Bio/Technology 10, 779-783 (1992);
Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368,
812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51
(1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and
Huszar, Intern. Rev. Immunol. 13 65-93 (1995).
[0475] The antibodies may also be affinity matured using known
selection and/or mutagenesis methods as described above. Preferred
affinity matured antibodies have an affinity which is five times,
more preferably 10 times, even more preferably 20 or 30 times
greater than the starting antibody (generally murine, humanized or
human) from which the matured antibody is prepared.
[0476] 4. Bispecific Antibodies
[0477] Bispecific antibodies are monoclonal, preferably human or
humanized, antibodies that have binding specificities for at least
two different antigens. In the present case, one of the binding
specificities is for the PRO, the other one is for any other
antigen, and preferably for a cell-surface protein or receptor or
receptor subunit.
[0478] Methods for making bispecific antibodies are known in the
art. Traditionally, the recombinant production of bispecific
antibodies is based on the co-expression of two immunoglobulin
heavy-chain/light-chain pairs, where the two heavy chains have
different specificities [Milstein and Cuello, Nature, 305:537-539
(1983)]. Because of the random assortment of immunoglobulin heavy
and light chains, these hybridomas (quadromas) produce a potential
mixture of ten different antibody molecules, of which only one has
the correct bispecific structure. The purification of the correct
molecule is usually accomplished by affinity chromatography steps.
Similar procedures are disclosed in WO 93/08829, published May 13,
1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).
[0479] Antibody variable domains with the desired binding
specificities (antibody-antigen combining sites) can be fused to
immunoglobulin constant domain sequences. The fusion preferably is
with an immunoglobulin heavy-chain constant domain, comprising at
least part of the hinge, CH2, and CH3 regions. It is preferred to
have the first heavy-chain constant region (CH1) containing the
site necessary for light-chain binding present in at least one of
the fusions. DNAs encoding the immunoglobulin heavy-chain fusions
and, if desired, the immunoglobulin light chain, are inserted into
separate expression vectors, and are co-transfected into a suitable
host organism. For further details of generating bispecific
antibodies see, for example, Suresh et al., Methods in Enzymology,
121:210 (1986).
[0480] According to another approach described in WO96/27011, the
interface between a pair of antibody molecules can be engineered to
maximize the percentage of heterodimers which are recovered from
recombinant cell culture. The preferred interface comprises at
least a part of the CH3 region of an antibody constant domain. In
this method, one or more small amino acid side chains from the
interface of the first antibody molecule are replaced with larger
side chains (e.g. tyrosine or tryptophan). Compensatory "cavities"
of identical or similar size to the large side chain(s) are created
on the interface of the second antibody molecule by replacing large
amino acid side chains with smaller ones (e.g. alanine or
threonine). This provides a mechanism for increasing the yield of
the heterodimer over other unwanted end-products such as
homodimers.
[0481] Bispecific antibodies can be prepared as full length
antibodies or antibody fragments (e.g. F(ab').sub.2 bispecific
antibodies). Techniques for generating bispecific antibodies from
antibody fragments have been described in the literature. For
example, bispecific antibodies can be prepared can be prepared
using chemical linkage. Brennan et al., Science 229:81 (1985)
describe a procedure wherein intact antibodies are proteolytically
cleaved to generate F(ab').sub.2 fragments. These fragments are
reduced in the presence of the dithiol complexing agent sodium
arsenite to stabilize vicinal dithiols and prevent intermolecular
disulfide formation. The Fab' fragments generated are then
converted to thionitrobenzoate (TNB) derivatives. One of the
Fab'-TNB derivatives is then reconverted to the Fab'-thiol by
reduction with mercaptoethylamine and is mixed with an equimolar
amount of the other Fab'-TNB derivative to form the bispecific
antibody. The bispecific antibodies produced can be used as agents
for the selective immobilization of enzymes.
[0482] Fab' fragments may be directly recovered from E. coli and
chemically coupled to form bispecific antibodies. Shalaby et al.,
J. Exp. Med. 175:217-225 (1992) describe the production of a fully
humanized bispecific antibody F(ab').sub.2 molecule. Each Fab'
fragment was separately secreted from E. coli and subjected to
directed chemical coupling in vitro to form the bispecific
antibody. The bispecific antibody thus formed was able to bind to
cells overexpressing the ErbB2 receptor and normal human T cells,
as well as trigger the lytic activity of human cytotoxic
lymphocytes against human breast tumor targets.
[0483] Various technique for making and isolating bispecific
antibody fragments directly from recombinant cell culture have also
been described. For example, bispecific antibodies have been
produced using leucine zippers. Kostelny et al., J. Immunol.
148(5): 1547-1553 (1992). The leucine zipper peptides from the Fos
and Jun proteins were linked to the Fab' portions of two different
antibodies by gene fusion. The antibody homodimers were reduced at
the hinge region to form monomers and then re-oxidized to form the
antibody heterodimers. This method can also be utilized for the
production of antibody homodimers. The "diabody" technology
described by Hollinger et al., Proc. Natl. Acad. Sci. USA
90:6444-6448 (1993) has provided an alternative mechanism for
making bispecifie antibody fragments. The fragments comprise a
heavy-chain variable domain (V.sub.H) connected to a light-chain
variable domain (V.sub.L) by a linker which is too short to allow
pairing between the two domains on the same chain. Accordingly, the
V.sub.H and V.sub.L domains of one fragment are forced to pair with
the complementary V.sub.L and V.sub.H domains of another fragment,
thereby forming two antigen-binding sites. Another strategy for
making bispecific antibody fragments by the use of single-chain Fv
(sFv) dimers has also been reported. See, Gruber et al., J.
Immunol. 152:5368 (1994). Antibodies with more than two valencies
are contemplated. For example, trispecific antibodies can be
prepared. Tutt et al., J. Immunol. 147:60 (1991).
[0484] Exemplary bispecific antibodies may bind to two different
epitopes on a given PRO polypeptide herein. Alternatively, an
anti-PRO polypeptide arm may be combined with an arm which binds to
a triggering molecule on a leukocyte such as a T-cell receptor
molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG
(Fc.gamma.R), such as Fc.gamma.RI (CD64), Fc.gamma.RII (CD32) and
Fc.gamma.RIII (CD16) so as to focus cellular defense mechanisms to
the cell expressing the particular PRO polypeptide. Bispecific
antibodies may also be used to localize cytotoxic agents to cells
which express a particular PRO polypeptide. These antibodies
possess a PRO-binding arm and an arm which binds a cytotoxic agent
or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA.
Another bispecific antibody of interest binds the PRO polypeptide
and further binds tissue factor (TF).
[0485] 5. Heteroconjugate Antibodies
[0486] Heteroconjugate antibodies are also within the scope of the
present invention. Heteroconjugate antibodies are composed of two
covalently joined antibodies. Such antibodies have, for example,
been proposed to target immune system cells to unwanted cells [U.S.
Pat. No. 4,676,980], and for treatment of HIV infection [WO
91/00360; WO 92/200373; EP 03089]. It is contemplated that the
antibodies may be prepared in vitro using known methods in
synthetic protein chemistry, including those involving crosslinking
agents. For example, immunotoxins may be constructed using a
disulfide exchange reaction or by forming a thioether bond.
Examples of suitable reagents for this purpose include
iminothiolate and methyl-4-mercaptobutyrimidate and those
disclosed, for example, in U.S. Pat. No. 4,676,980.
[0487] 6. Effector Function Engineering
[0488] It may be desirable to modify the antibody of the invention
with respect to effector function, so as to enhance, e.g., the
effectiveness of the antibody in treating cancer. For example,
cysteine residue(s) may be introduced into the Fe region, thereby
allowing interchain disulfide bond formation in this region. The
homodimeric antibody thus generated may have improved
internalization capability and/or increased complement-mediated
cell killing and antibody-dependent cellular cytotoxicity (ADCC).
See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J.
Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with
enhanced anti-tumor activity may also be prepared using
heterobifunctional cross-linkers as described in Wolff et al.
Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody
can be engineered that has dual Fc regions and may thereby have
enhanced complement lysis and ADCC capabilities. See Stevenson et
al., Anti-Cancer Drug Design, 3: 219-230 (1989).
[0489] 7. Immunoconjugates
[0490] The invention also pertains to immunoconjugates comprising
an antibody conjugated to a cytotoxic agent such as a
chemotherapeutic agent, toxin (e.g., an enzymatically active toxin
of bacterial, fungal, plant, or animal origin, or fragments
thereof), or a radioactive isotope (i.e., a radioconjugate).
[0491] Chemotherapeutic agents useful in the generation of such
immunoconjugates have been described above. Enzymatically active
toxins and fragments thereof that can be used include diphtheria A
chain, nonbinding active fragments of diphtheria toxin, exotoxin A
chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain,
modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin
proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S),
momordica charantia inhibitor, curcin, crotin, sapaonaria
officinalis inhibitor, gelonin, mitogellin, restrictocin,
phenomycin, enomycin, and the tricothecenes. A variety of
radionuclides are available for the production of radioconjugated
antibodies. Examples include .sup.212Bi, .sup.131I, .sup.131In,
.sup.90Y, and .sup.186Re. Conjugates of the antibody and cytotoxic
agent are made using a variety of bifunctional protein-coupling
agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate
(SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters
(such as dimethyl adipimidate HCL), active esters (such as
disuccinimidyl suberate), aldehydes (such as glutareldehyde),
bis-azido compounds (such as bis (p-azidobenzoyl)hexanediamine),
bis-diazonium derivatives (such as
bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as
tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such
as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin
immunotoxin can be prepared as described in Vitetta et al.,
Science, 238: 1098 (1987). Carbon-14-labeled
1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid
(MX-DTPA) is an exemplary chelating agent for conjugation of
radionucleotide to the antibody. See WO94/11026.
[0492] In another embodiment, the antibody may be conjugated to a
"receptor" (such streptavidin) for utilization in tumor
pretargeting wherein the antibody-receptor conjugate is
administered to the patient, followed by removal of unbound
conjugate from the circulation using a clearing agent and then
administration of a "ligand" (e.g., avidin) that is conjugated to a
cytotoxic agent (e.g., a radionucleotide).
[0493] 8. Immunoliposomes
[0494] The antibodies disclosed herein may also be formulated as
immunoliposomes. Liposomes containing the antibody are prepared by
methods known in the art, such as described in Epstein et al.,
Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc.
Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045
and 4,544,545. Liposomes with enhanced circulation time are
disclosed in U.S. Pat. No. 5,013,556.
[0495] Particularly useful liposomes can be generated by the
reverse-phase evaporation method with a lipid composition
comprising phosphatidylcholine, cholesterol, and PEG-derivatized
phosphatidylethanolaminc (PEG-PE). Liposomes are extruded through
filters of defined pore size to yield liposomes with the desired
diameter. Fab' fragments of the antibody of the present invention
can be conjugated to the liposomes as described in Martin et al .,
J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange
reaction. A chemotherapeutic agent (such as Doxorubicin) is
optionally contained within the liposome. See Gabizon et al., J.
National Cancer Inst., 81(19): 1484 (1989).
[0496] 9. Pharmaceutical Compositions of Antibodies
[0497] Antibodies specifically binding a PRO polypeptide identified
herein, as well as other molecules identified by the screening
assays disclosed hereinbefore, can be administered for the
treatment of various disorders in the form of pharmaceutical
compositions.
[0498] If the PRO polypeptide is intracellular and whole antibodies
are used as inhibitors, internalizing antibodies are preferred.
However, lipofections or liposomes can also be used to deliver the
antibody, or an antibody fragment, into cells. Where antibody
fragments are used, the smallest inhibitory fragment that
specifically binds to the binding domain of the target protein is
preferred. For example, based upon the variable-region sequences of
an antibody, peptide molecules can be designed that retain the
ability to bind the target protein sequence. Such peptides can be
synthesized chemically and/or produced by recombinant DNA
technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA,
90: 7889-7893 (1993). The formulation herein may also contain more
than one active compound as necessary for the particular indication
being treated, preferably those with complementary activities that
do not adversely affect each other. Alternatively, or in addition,
the composition may comprise an agent that enhances its function,
such as, for example, a cytotoxic agent, cytokine, chemotherapeutic
agent, or growth-inhibitory agent. Such molecules are suitably
present in combination in amounts that are effective for the
purpose intended.
[0499] The active ingredients may also be entrapped in
microcapsules prepared, for example, by coacervation techniques or
by interfacial polymerization, for example, hydroxymethylcellulose
or gelatin-microcapsules and poly-(methylmethacylate)
microcapsules, respectively, in colloidal drug delivery systems
(for example, liposomes, albumin microspheres, microemulsions,
nano-particles, and nanocapsules) or in macroemulsions. Such
techniques are disclosed in Remington's Pharmaceutical Sciences,
supra.
[0500] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished by filtration through
sterile filtration membranes.
[0501] Sustained-release preparations may be prepared. Suitable
examples of sustained-release preparations include semipermeable
matrices of solid hydrophobic polymers containing the antibody,
which matrices are in the form of shaped articles, e.g., films, or
microcapsules. Examples of sustained-release matrices include
polyesters, hydrogels (for example,
poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic
acid and .gamma. ethyl-L-glutamate, non-degradable ethylene-vinyl
acetate, degradable lactic acid-glycolic acid copolymers such as
the LUPRON DEPOT.TM. (injectable microspheres composed of lactic
acid-glycolic acid copolymer and leuprolide acetate), and
poly-D-(-)-3-hydroxybutyric acid. While polymers such as
ethylene-vinyl acetate and lactic acid-glycolic acid enable release
of molecules for over 100 days, certain hydrogels release proteins
for shorter time periods. When encapsulated antibodies remain in
the body for a long time, they may denature or aggregate as a
result of exposure to moisture at 37.degree. C., resulting in a
loss of biological activity and possible changes in immunogenicity.
Rational strategies can be devised for stabilization depending on
the mechanism involved. For example, if the aggregation mechanism
is discovered to be intermolecular S--S bond formation through
thio-disulfide interchange, stabilization may be achieved by
modifying sulfhydryl residues, lyophilizing from acidic solutions,
controlling moisture content, using appropriate additives, and
developing specific polymer matrix compositions.
[0502] G. Uses for anti-PRO Antibodies
[0503] The anti-PRO antibodies of the invention have various
utilities. For example, anti-PRO antibodies may be used in
diagnostic assays for PRO, e.g., detecting its expression in
specific cells, tissues, or serum. Various diagnostic assay
techniques known in the art may be used, such as competitive
binding assays, direct or indirect sandwich assays and
immunoprecipitation assays conducted in either heterogeneous or
homogeneous phases [Zola, Monoclonal Antibodies: A Manual of
Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies
used in the diagnostic assays can be labeled with a detectable
moiety. The detectable moiety should be capable of producing,
either directly or indirectly, a detectable signal. For example,
the detectable moiety may be a radioisotope, such as .sup.3H,
.sup.14C, .sup.32P, .sup.35S, or .sup.125I, a fluorescent or
chemiluminescent compound, such as fluorescein isothiocyanate,
rhodamine, or luciferin, or an enzyme, such as alkaline
phosphatase, beta-galaetosidase or horseradish peroxidase. Any
method known in the art for conjugating the antibody to the
detectable moiety may be employed, including those methods
described by Hunter et al., Nature, 144:945 (1962); David et al.,
Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth.,
40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407
(1982).
[0504] Anti-PRO antibodies also are useful for the affinity
purification of PRO from recombinant cell culture or natural
sources. In this process, the antibodies against PRO are
immobilized on a suitable support, such a Sephadex resin or filter
paper, using methods well known in the art. The immobilized
antibody then is contacted with a sample containing the PRO to be
purified, and thereafter the support is washed with a suitable
solvent that will remove substantially all the material in the
sample except the PRO, which is bound to the immobilized antibody.
Finally, the support is washed with another suitable solvent that
will release the PRO from the antibody.
[0505] The following examples are offered for illustrative purposes
only, and are not intended to limit the scope of the present
invention in any way.
[0506] All patent and literature references cited in the present
specification are hereby incorporated by reference in their
entirety.
EXAMPLES
[0507] Commercially available reagents referred to in the examples
were used according to manufacturer's instructions unless otherwise
indicated. The source of those cells identified in the following
examples, and throughout the specification, by ATCC accession
numbers is the American Type Culture Collection, Manassas, Va.
Example 1
[0508] Extracellular Domain Homology Screening to Identify Novel
Polypeptides and cDNA Encoding Therefor
[0509] The extracellular domain (ECD) sequences (including the
secretion signal sequence, if any) from about 950 known secreted
proteins from the Swiss-Prot public database were used to search
EST databases. The EST databases included public databases (e.g.,
Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQ.TM.,
Incyte Pharmaceuticals, Palo Alto, Calif.). The search was
performed using the computer program BLAST or BLAST-2 (Altschul et
al., Methods in Enzymology 266:460-480 (1996)) as a comparison of
the ECD protein sequences to a 6 frame translation of the EST
sequences. Those comparisons with a BLAST score of 70 (or in some
cases 90) or greater that did not encode known proteins were
clustered and assembled into consensus DNA sequences with the
program "phrap" (Phil Green, University of Washington, Seattle,
Wash.).
[0510] Using this extracellular domain homology screen, consensus
DNA sequences were assembled relative to the other identified EST
sequences using phrap. In addition, the consensus DNA sequences
obtained were often (but not always) extended using repeated cycles
of BLAST or BLAST-2 and phrap to extend the consensus sequence as
far as possible using the sources of EST sequences discussed
above.
[0511] Based upon the consensus sequences obtained as described
above, oligonucleotides were then synthesized and used to identify
by PCR a cDNA library that contained the sequence of interest and
for use as probes to isolate a clone of the full-length coding
sequence for a PRO polypeptide. Forward and reverse PCR primers
generally range from 20 to 30 nucleotides and are often designed to
give a PCR product of about 100-1000 bp in length. The probe
sequences are typically 40-55 bp in length. In some cases,
additional oligonucleotides are synthesized when the consensus
sequence is greater than about 1-1.5 kbp. In order to screen
several libraries for a full-length clone, DNA from the libraries
was screened by PCR amplification, as per Ausubel et al., Current
Protocols in Molecular Biology, with the PCR primer pair. A
positive library was then used to isolate clones encoding the gene
of interest using the probe oligonucleotide and one of the primer
pairs.
[0512] The cDNA libraries used to isolate the cDNA clones were
constructed by standard methods using commercially available
reagents such as those from Invitrogen, San Diego, Calif. The cDNA
was primed with oligo dT containing a NotI site, linked with blunt
to SalI hemikinased adaptors, cleaved with NotI, sized
appropriately by gel electrophoresis, and cloned in a defined
orientation into a suitable cloning vector (such as pRKB or pRKD;
pRK5B is a precursor of pRK5D that does not contain the SfiI site;
see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique
XhoI and NotI sites.
Example 2
[0513] Isolation of cDNA Clones by Amylase Screening
[0514] 1. Preparation of Oligo dT Primed cDNA Library
[0515] mRNA was isolated from a human tissue of interest using
reagents and protocols from Invitrogen, San Diego, Calif. (Fast
Track 2). This RNA was used to generate an oligo dT primed cDNA
library in the vector pRK5D using reagents and protocols from Life
Technologies, Gaithersburg, Md. (Super Script Plasmid System). In
this procedure, the double stranded cDNA was sized to greater than
1000 bp and the SalI/NotI inkered cDNA was cloned into XhoI/NotI
cleaved vector. pRK5D is a cloning vector that has an sp6
transcription initiation site followed by an SfiI restriction
enzyme site preceding the XhoI/NotI cDNA cloning sites.
[0516] 2. Preparation of Random Primed cDNA Library
[0517] A secondary cDNA library was generated in order to
preferentially represent the 5' ends of the primary cDNA clones.
Sp6 RNA was generated from the primary library (described above),
and this RNA was used to generate a random primed cDNA library in
the vector pSST-AMY.0 using reagents and protocols from Life
Technologies (Super Script Plasmid System, referenced above). In
this procedure the double stranded cDNA was sized to 500-1000 bp,
Tinkered with blunt to NotI adaptors, cleaved with SfiI, and cloned
into SfiI/NotI cleaved vector. pSST-AMY.0 is a cloning vector that
has a yeast alcohol dehydrogenase promoter preceding the cDNA
cloning sites and the mouse amylase sequence (the mature sequence
without the secretion signal) followed by the yeast alcohol
dehydrogenase terminator, after the cloning sites. Thus, cDNAs
cloned into this vector that are fused in frame with amylase
sequence will lead to the secretion of amylase from appropriately
transfected yeast colonies.
[0518] 3. Transformation and Detection
[0519] DNA from the library described in paragraph 2 above was
chilled on ice to which was added electrocompetent DH10B bacteria
(Life Technologies, 20 ml). The bacteria and vector mixture was
then electroporated as recommended by the manufacturer.
Subsequently, SOC media (Life Technologies, 1 ml) was added and the
mixture was incubated at 37.degree. C. for 30 minutes. The
transformants were then plated onto 20 standard 150 mm LB plates
containing ampicillin and incubated for 16 hours (37.degree. C.).
Positive colonies were scraped off the plates and the DNA was
isolated from the bacterial pellet using standard protocols, e.g.
CsCl-gradient. The purified DNA was then carried on to the yeast
protocols below.
[0520] The yeast methods were divided into three categories: (1)
Transformation of yeast with the plasmid/cDNA combined vector; (2)
Detection and isolation of yeast clones secreting amylase; and (3)
PCR amplification of the insert directly from the yeast colony and
purification of the DNA for sequencing and further analysis.
[0521] The yeast strain used was HD56-5A (ATCC-90785). This strain
has the following genotype: MAT alpha, ura3-52, leu2-3, leu2-112,
his3-11, his3-15, MAL.sup.+, SUC.sup.+, GAL.sup.+. Preferably,
yeast mutants can be employed that have deficient
post-translational pathways. Such mutants may have translocation
deficient alleles in sec71, sec72, sec62, with truncated sec71
being most preferred. Alternatively, antagonists (including
antisense nucleotides and/or ligands) which interfere with the
normal operation of these genes, other proteins implicated in this
post translation pathway (e.g., SEC61p, SEC72p, SEC62p, SEC63p,
TDJ1p or SSA1p-4p) or the complex formation of these proteins may
also be preferably employed in combination with the
amylase-expressing yeast.
[0522] Transformation was performed based on the protocol outlined
by Gietz et al., Nucl. Acid. Res., 20:1425 (1992). Transforned
cells were then inoculated from agar into YEPD complex media broth
(100 ml) and grown overnight at 30.degree. C. The YEPD broth was
prepared as described in Kaiser et al., Methods in Yeast Genetics,
Cold Spring Harbor Press, Cold Spring Harbor, N.Y., p. 207 (1994).
The overnight culture was then diluted to about 2.times.10.sup.6
cells/ml (approx. OD.sub.600=0.1) into fresh YEPD broth (500 ml)
and regrown to 1.times.10.sup.7 cells/ml (approx.
OD.sub.600=0.4-0.5).
[0523] The cells were then harvested and prepared for
transformation by transfer into GS3 rotor bottles in a Sorval GS3
rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and
then resuspended into sterile water, and centrifuged again in 50 ml
falcon tubes at 3,500 rpm in a Beckman GS-6KR centrifuge. The
supernatant was discarded and the cells were subsequently washed
with LiAc/TE (10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM
Li.sub.2OOCCH.sub.3), and resuspended into LiAc/TE (2.5 ml).
[0524] Transformation tookplace by mixing the prepared cells
(100.mu.l) with freshly denatured single stranded salmon testes DNA
(Lofstrand Labs, Gaithersburg, Md.) and transforming DNA (1 .mu.g,
vol. <10 .mu.l) in microfuge tubes. The mixture was mixed
briefly by vortexing, then 40% PEG/TE (600 .mu.l, 40% polyethylene
glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li.sub.2OOCCH.sub.3,
pH 7.5) was added. This mixture was gently mixed and incubated at
30.degree. C. while agitating for 30 minutes. The cells were then
heat shocked at 42.degree. C. for 15 minutes, and the reaction
vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds,
decanted and resuspended into TE (500 .mu.l, 10 mM Tris-HCl, 1 mM
EDTA pH 7.5) followed by recentrifugation. The cells were then
diluted into TE (1 ml) and aliquots (200 .mu.l) were spread onto
the selective media previously prepared in 150 mm growth plates
(VWR).
[0525] Alternatively, instead of multiple small reactions, the
transformation was performed using a single, large scale reaction,
wherein reagent amounts were scaled up accordingly.
[0526] The selective media used was a synthetic complete dextrose
agar lacking uracil (SCD-Ura) prepared as described in Kaiser et
al., Methods in Yeast Genetics, Cold Spring Harbor Press, Cold
Spring Harbor, N.Y., p. 208-210 (1994). Transformants were grown at
30.degree. C. for 2-3 days.
[0527] The detection of colonies secreting amylase was performed by
including red starch in the selective growth media. Starch was
coupled to the red dye (Reactive Red-120, Sigma) as per the
procedure described by Biely et al., Anal. Biochem., 172:176-179
(1988). The coupled starch was incorporated into the SCD-Ura agar
plates at a final concentration of 0.15 % (w/v), and was buffered
with potassium phosphate to a pH of 7.0 (50-100 mM final
concentration).
[0528] The positive colonies were picked and streaked across fresh
selective media (onto 150 mm plates) in order to obtain well
isolated and identifiable single colonies. Well isolated single
colonies positive for amylase secretion were detected by direct
incorporation of red starch into buffered SCD-Ura agar. Positive
colonies were determined by their ability to break down starch
resulting in a clear halo around the positive colony visualized
directly.
[0529] 4. Isolation of DNA by PCR Amplification
[0530] When a positive colony was isolated, a portion of it was
picked by a toothpick and diluted into sterile water (30 .mu.l) in
a 96 well plate. At this time, the positive colonies were either
frozen and stored for subsequent analysis or immediately amplified.
An aliquot of cells (5 .mu.l) was used as a template for the PCR
reaction in a 25 .mu.l volume containing: 0.5 .mu.l Klentaq
(Clontech, Palo Alto, Calif.); 4.0 .mu.l 10 mM dNTP's (Perkin
Elmer-Cetus); 2.5 .mu.l Kentaq buffer (Clontech); 0.25 .mu.l
forward oligo 1; 0.25 .mu.l reverse oligo 2; 12.5 .mu.l distilled
water. The sequence of the forward oligonucleotide 1 was:
[0531] 5'-TGTAAAACGACGGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID
NO:1)
[0532] The sequence of reverse oligonucleotide 2 was:
[0533] 5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID
NO:2)
[0534] PCR was then performed as follows:
7 a. Denature 92.degree. C., 5 minutes b. 3 cycles of: Denature
92.degree. C., 30 seconds Anneal 59.degree. C., 30 seconds Extend
72.degree. C., 60 seconds c. 3 cycles of: Denature 92.degree. C.,
30 seconds Anneal 57.degree. C., 30 sceonds Extend 72.degree. C.,
60 seconds d. 25 cycles of: Denature 92.degree. C., 30 seconds
Anneal 55.degree. C., 30 seconds Extend 72.degree. C., 60 seconds
e. Hold 4.degree. C.,
[0535] The underlined regions of the oligonucleotides annealed to
the ADH promoter region and the amylase region, respectively, and
amplified a 307 bp region from vector pSST-AMY.0 when no insert was
present. Typically, the first 18 nucleotides of the 5' end of these
oligonucleotides contained annealing sites for the sequencing
primers. Thus, the total product of the PCR reaction from an empty
vector was 343 bp. However, signal sequence-fused cDNA resulted in
considerably longer nucleotide sequences.
[0536] Following the PCR, an aliquot of the reaction (5 .mu.l) was
examined by agarose gel electrophoresis in a 1% agarose gel using a
Tris-Borate-EDTA (TBE) buffering system as described by Sambrook et
al., supra. Clones resulting in a single strong PCR product larger
than 400 bp were further analyzed by DNA sequencing after
purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc.,
Chatsworth, Calif.).
Example 3
[0537] Isolation of cDNA Clones Using Signal Algorithm Analysis
[0538] Various polypeptide-encoding nucleic acid sequences were
identified by applying a proprietary signal sequence finding
algorithm developed by Genentech, Inc. (South San Francisco,
Calif.) upon ESTs as well as clustered and assembled EST fragments
from public (e.g., GenBank) and/or private (LIFESEQ.RTM., Incyte
Pharmaceuticals, Inc., Palo Alto, Calif.) databases. The signal
sequence algorithm computes a secretion signal score based on the
character of the DNA nucleotides surrounding the first and
optionally the second methionine codon(s) (ATG) at the 5'-end of
the sequence or sequence fragment under consideration. The
nucleotides following the first ATG must code for at least 35
unambiguous amino acids without any stop codons. If the first ATG
has the required amino acids, the second is not examined. If
neither meets the requirement, the candidate sequence is not
scored. In order to determine whether the EST sequence contains an
authentic signal sequence, the DNA and corresponding amino acid
sequences surrounding the ATG codon are scored using a set of seven
sensors (evaluation parameters) known to be associated with
secretion signals. Use of this algorithm resulted in the
identification of numerous polypeptide-encoding nucleic acid
sequences.
Example 4
[0539] Isolation of cDNA Clones Encoding Human PRO196
[0540] PRO196 was identified by screening the GenBank database
using the computer program BLAST (Altshul et al., Methods in
Enzymology 266:460-480 (1996). The PRO196 sequence shows homology
with known expressed sequence tag (EST) sequences T35448, T11442,
and W77823. None of the known EST sequences have been identified as
full length sequences, or described as ligands associated with the
TIE receptors.
[0541] Following its identification, NL1 was cloned from a human
fetal lung library prepared from mRNA purchased from Clontech, Inc.
(Palo Alto, Calif., USA), catalog # 6528-1, following the
manufacturer's instructions. The library was screened by
hybridization with synthetic oligonucleotide probes:
[0542] (a) 5'-GCTGACGAACCAAGGCAACTACAAACTCCTGGT-3' (SEQ ID
NO:5);
[0543] (b) 5'-TGCGGCCGGACCAGTCCTCCATGGTCACCAGGAGTTTGTAG-3' (SEQ ID
NO:6);
[0544] (c) 5'-GGTGGTGAACTGCTTGCCGTTGTGCCATGTAAA-3' (SEQ ID
NO:7).
[0545] based on the ESTs found in the GenBank database. cDNA
sequences were sequenced in their entireties.
[0546] The nucleotide and amino acid sequences of PRO196 are shown
in FIG. 1 (SEQ ID NO:3) and FIG. 2 (SEQ ID NO:4), respectively.
PRO196 shows significant sequence identity with both the TIE1 and
the TIE2 ligand.
[0547] A clone of PRO196 was deposited with the American Type
Culture Collection, 10801 University Blvd., Manassas, Va.
20110-2209, USA (ATCC) on Sep. 18, 1997 under the terms of the
Budapest Treaty, and has been assigned the deposit number
209280.
Example 5
[0548] Isolation of cDNA Clones Encoding Human PRO444
[0549] A cDNA sequence isolated in the amylase screen described in
Example 2 above was designated DNA13121. Oligonucleotide probes
were generated to this sequence and used to screen a human fetal
lung library (LIB25) prepared as described in paragraph 1 of
Example 2 above. The cloning vector was pRK5B (pRK5B is a precursor
of pRK5D that does not contain the SfiI site; see, Holmes et al.,
Science, 253:1278-1280 (1991)), and the cDNA size cut was less than
2800 bp.
[0550] A full length clone was identilied that contained a single
open reading frame with an apparent translational initiation site
at nucleotide positions 608-610 and ending at the stop codon found
at nucleotide positions 959-961 (FIG. 3, SEQ ID NO:8). The
predicted polypeptide precursor is 117 amino acids long, has a
calculated molecular weight of approximately 12,692 daltons and an
estimated pI of approximately 7.50. Analysis of the full-length
PRO444 sequence shown in FIG. 4 (SEQ ID NO:9) evidences the
presence of a signal peptide at amino acid 1 to about amino acid
16. An analysis of the Dayhoff database (version 35.45 SwissProt
35) evidenced homology between the PRO444 amino acid sequence and
the following Dayhoff sequences: CEF44D12.sub.--8, P_R88452,
YNE1_CAEEL, A47312, AF009957.sub.--1, and A06133.sub.--1.
[0551] Clone DNA26846-1397 was deposited with the ATCC on Oct. 27,
1998 and is assigned ATCC deposit no. 203406.
Example 6
[0552] Isolation of cDNA Clones Encoding Human PRO183, PRO185,
PRO9940, PRO2630 and PRO6309
[0553] DNA molecules encoding the PRO183, PRO185, PRO9940, PRO2630
and PRO6309 polypeptides shown in the accompanying figures were
obtained through GenBank.
Example 7
[0554] Isolation of cDNA clones Encoding Human PRO210 and
PRO217
[0555] A consensus DNA sequence was assembled using phrap as
described in Example 1 above. In some cases, the consensus DNA
sequence as extended using repeated cycles of blast and phrap to
extend the consensus sequence as far as possible using the sources
of EST sequences listed above. Based on this consensus sequence,
oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of interest, and 2) for use as
probes to isolate a clone of the full-length coding sequence. The
library used to isolate DNA32279-1131 was fetal kidney.
[0556] cDNA clones were sequenced in their entirety. The entire
nucleotide sequence of DNA32279-1131 is shown in FIG. 9 (SEQ ID
NO:14) and amino acid sequence of PRO210 is shown in FIG. 10 (SEQ
ID NO:15). The entire nucleotide sequence of DNA33094-1131 is shown
in FIG. 13 (SEQ ID NO:21) and amino acid sequence of PRO217 is
shown in FIG. 14 (SEQ ID NO:22).
Example 8
[0557] Isolation of cDNA Clones Encoding Human PRO215
[0558] A consensus DNA sequence was assembled relative to the other
identified EST sequences as described in Example 1 above, wherein
the consensus sequence was designated herein as DNA28748. Based on
the DNA28748 consensus sequence, oligonucleotides were synthesized
to identify by PCR a cDNA library that contained the sequence of
interest and for use as probes to isolate a clone of the
full-length coding sequence for PRO215.
[0559] A pair of PCR primers (forward and reverse) were
synthesized:
[0560] forward PCR primer 5'-GTGGCTGGCACACAATGAGATC-3' (SEQ ID
NO:18)
[0561] reverse PCR primer 5'-CCAATGTGTGCAAGCGGTTGTG-3' (SEQ ID
NO:19)
[0562] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA28748 sequence which
had the following nucleotide sequence: hybridization probe
[0563] 5'-TCAAGAGCCTGGACCTCAGCCACAATCTCATCTCTGACTTTGCCTGGAGC-3'
(SEQ ID NO:20).
[0564] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO215 gene
using the probe oligonucleotide and one of the PCR primers.
[0565] RNA for construction of the cDNA libraries was isolated from
human fetal lung tissue. The cDNA libraries used to isolate the
cDNA clones were constructed by standard methods using commercially
available reagents such as those from Invitrogen, San Diego, Calif.
The cDNA was primed with oligo dT containing a NotI site, linked
with blunt to SalI hemikinased adaptors, cleaved with NotI, sized
appropriately by gel electrophoresis, and cloned in a defined
orientation into a suitable cloning vector (such as pRKB or pRKD;
pRK5B is a precursor of pRK5D that does not contain the SfiI site;
see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique
XhoI and NotI sites.
[0566] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO215 wherein designated as
DNA32288-1132 and the derived protein sequence for PRO215.
[0567] The entire nucleotide sequence of DNA32288-1132 is shown in
FIG. 11 (SEQ ID NO:16). Clone DNA32288-1132 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 308-310 and ending at the stop codon at
nucleotide positions 1591-1593 (FIG. 11, the initiation and stop
codons are circled). The predicted polypeptide precursor is 428
amino acids long (FIG. 12). Clone DNA32288-1132 has been deposited
with ATCC and is assigned ATCC deposit no. 209261.
[0568] Analysis of the amino acid sequence of the full-length
PRO215 shows it has homology to member of the leucine rich repeat
protein superfamily, including the leucine rich repeat protein and
the SLIT protein.
Example 9
[0569] Isolation of cDNA Clones Encoding Human PRO242
[0570] An expressed sequence tag (EST) DNA database (LIFESEQ.TM.,
Incyte Pharmaceuticals, Palo Alto, Calif.) was searched and an EST
was identified which showed homology to a chemokine. Based on this
sequence, oligonucleotides were synthesized to identify by PCR a
cDNA library that contained the sequence of interest and for use as
probes to isolate a clone of the full-length coding sequence for
PRO242.
[0571] A pair of PCR primer (forward and reverse) were
synthesized:
[0572] forward PCR primer 5'-GGATCAGGCAGGAGGAGTTTGGG-3' (SEQ ID
NO:25)
[0573] reverse PCR primer 5'-GGATGGGTACAGACTTTCTTGCC-3' (SEQ ID
NO:26)
[0574] Additionaly, a synthetic oligonucleotide hybridization probe
was constructed from the consensus DNA28709 sequence which had the
following nucleotide sequence:
[0575] hybridization probe
[0576] 5' -ATGATGGGCCTCTCCTTGGCCTCTGCTGTGCTCCTGGCCTCCCTCCTGAG-3"
(SEQ ID NO:27)
[0577] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO242 gene
using the probe oligonucleotide and one of the PCR primers.
[0578] RNA for construction of the cDNA libraries was isolated from
human fetal lung tissue. A cDNA clone was sequenced in entirety.
The entire nucleotide sequence of DNA33785-1143 is shown in FIG. 15
(SEQ ID NO:23). Clone DNA33785-1143 contains a single open reading
frame with an apparent translational initiation site at nucleotide
positions 333-335 and ending at the stop codon at nucleotide
positions 615-617 (FIG. 16; SEQ ID NO:24). The predicted
polypeptide precursor is 94 amino acids long (FIG. 16).
[0579] Based on a BLAST and FastA sequence alignment analysis
(using the ALIGN computer program) of the full-length sequence,
PRO242 shows amino acid sequence identity to human macrophage
inflammatory protein 1-alpha, rabbitt macrophage inflammatory
protein 1-beta, human LD78 and rabbit immune activation gene 2.
Example 10
[0580] Isolation of cDNA Clones Encoding Human PRO288
[0581] A synthetic probe based on the sequence encoding the DCR1
ECD [Sheridan et al., supra] and having the following sequence:
[0582] 5'-CATAAAAGTTCCTGCACCATGACCAGAGACACAGTGTGTCAGTGTAAAGA-3'
(SEQ ID NO:30)
[0583] was used to screen a human fetal lung cDNA library. To
prepare the DNA library, mRNA was isolated from human fetal lung
tissue using reagents and protocols from Invitrogen, San Diego,
Calif. (Fast Track 2). This RNA was used to generate an oligo dT
primed cDNA library in the vector pRK5D using reagents and
protocols from Life Technologies, Gaithersburg, Md. (Super Script
Plasmid System). In this procedure, the double stranded cDNA was
sized to greater than 1000 bp and the SalI/NotI Tinkered cDNA was
cloned into XhoI/NotI cleaved vector. pRK5D is a cloning vector
that has an sp6 transcription initiation site followed by an SfiI
restriction enzyme site preceding the XhoI/NotI cDNA cloning
sites.
[0584] A full length clone was identified (DNA35663-1129) that
contained a single open reading frame with an apparent
translational initiation site at nucleotide positions 157-159 and
ending at the stop codon found at nucleotide positions 1315-1317
(FIG. 17; SEQ ID NO:28). The clone is referred to as pRK5-35663 and
is deposited as ATCC No. 209201.
[0585] The predicted polypeptide precursor is 386 amino acids long
and has a calculated molecular weight of approximately 41.8 kDa.
Sequence analysis indicated a N-terminal signal peptide (amino
acids 1-55), followed by an ECD (amino acids 56-212), transmembrane
domain (amino acids 213-232) and intracellular region (amino acids
233-386). (FIG. 18). The signal peptide cleavage site was confirmed
by N-terminal protein sequencing of a PRO288 ECD immunoadhesin (not
shown). This structure suggests that PRO288 is a type I
transmembrane protein. PRO288 contains 3 potential N-linked
glycosylation sites, at amino acid positions 127, 171 and 182.
(FIG. 18)
[0586] TNF receptor family proteins are typically characterized by
the presence of multiple (usually four) cysteine-rich domains in
their extracellular regions--each cysteine-rich domain being
approximately 45 amino acids long and containing approximately 6,
regularly spaced, cysteine residues. Based on the crystal structure
of the type 1 TNF receptor, the cysteines in each domain typically
form three disulfide bonds in which usually cysteines 1 and 2, 3
and 5, and 4 and 6 are paired together. Like DR4, DR5, and DcR1,
PRO288 contains two extracellular cysteine-rich pseudorepeats,
whereas other identified mammalian TNFR family members contain
three or more such domains [Smith et al., Cell, 76:959 (1994)].
[0587] Based on an alignment analysis of the PRO288 sequence shown
in FIG. 18 (SEQ ID NO:29), PRO288 shows more sequence identity to
the ECD of DR4, DR5, or DcR1 than to other apoptosis-linked
receptors, such as TNFR1, Fas/Apo-1 or DR3. The predicted
intracellular sequence of PRO288 also shows more homology to the
corresponding region of DR4 or DR5 as compared to TNFR1, Fas or
DR3. The intracellular region of PRO288 is about 50 residues
shorter than the intracellular regions identified for DR4 or DR5.
It is presently believed that PRO288 may contain an truncated death
domain (amino acids 340-364), which corresponds to the
carboxy-terminal portion of the death domain sequences of DR4 and
DR5. Five out of six amino acids that are essential for signaling
by TNFR1 [Tartaglia et al., supra] and that are conserved or
semi-conserved in DR4 and DR5, are absent in PRO288.
Example 11
[0588] Isolation of cDNA Clones Encoding Human PRO365
[0589] A consensus DNA sequence was assembled relative to other EST
sequences using phrap as described in Example 1 above. This
consensus sequence is herein designated DNA35613. Based on the
DNA35613 consensus sequence, oligonucleotides were synthesized: 1)
to identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO365.
[0590] Forward and reverse PCR primers were synthesized:
[0591] forward PCR primer 5'-GGCTGGCCTGCAGAGATC-3' (SEQ ID
NO:33)
[0592] forward PCR primer 5'-AATGTGACCACTGGACTCCC-3' (SEQ ID
NO:34)
[0593] forward PCR primer 5'-AGGCTTGGAACTCCCTTC-3' (SEQ ID
NO:35)
[0594] reverse PCR primer 5'-AAGATTCTTGAGCGATTCCAGCTG-3' (SEQ ID
NO:36)
[0595] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA35613 sequence which
had the following nucleotide sequence
[0596] hybridization probe
[0597] 5'-AATCCCTGCTCTTCATGGTGACCTATGACGACGGAAGCACAAGACTG-3' (SEQ
ID NO:37)
[0598] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate clones encoding the
PRO365 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of the cDNA libraries was isolated
from human fetal kidney tissue.
[0599] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO365 [herein designated as
DNA46777-1253] (SEQ ID NO:31) and the derived protein sequence for
PRO365.
[0600] The entire nucleotide sequence of DNA46777-1253 is shown in
FIG. 19 (SEQ ID NO:3 1). Clone DNA46777-1253 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 15-17 and ending at the stop codon at
nucleotide positions 720-722 (FIG. 19). The predicted polypeptide
precursor is 235 amino acids long (FIG. 20). Important regions of
the polypeptide sequence encoded by clone DNA46777-1253 have been
identified and include the following: a signal peptide
corresponding to amino acids 1-20 and multiple potential
N-glycosylation sites. Clone DNA46777-1253 has been deposited with
ATCC and is assigned ATCC deposit no. 209619.
[0601] Analysis of the amino acid sequence of the full-length
PRO365 polypeptide suggests that portions of it possess significant
homology to the human 2-19 protein, thereby indicating that PRO365
may be a novel human 2-19 protein homolog.
Example 12
[0602] Isolation of cDNA clones Encoding Human PRO1361
[0603] Use of the signal sequence algorithm described in Example 3
above allowed identification of an EST cluster sequence from the
Incyte database, designated Incyte cluster sequence 10685. This EST
cluster sequence was then compared to a variety of expressed
sequence tag (EST) databases which included public EST databases
(e.g., GenBank) and a proprietary EST DNA database (Lifeseq.RTM.,
Incyte Pharmaceuticals, Palo Alto, Calif.) to identify existing
homologies. The homology search was performed using the computer
program BLAST or BLAST2 (Altshul et al., Methods in Enzymology
266:460-480 (1996)). Those comparisons resulting in a BLAST score
of 70 (or in some cases 90) or greater that did not encode known
proteins were clustered and assembled into a consensus DNA sequence
with the program "phrap" (Phil Green, University of Washington,
Seattle, Wash.). The consensus sequence obtained therefrom is
herein designated DNA58839.
[0604] In light of an observed sequence homology between the
DNA58839 sequence and an EST sequence contained within the Incyte
EST clone no. 2967927, the Incyte EST clone no. 2967927 was
purchased and the cDNA insert was obtained and sequenced. The
sequence of this cDNA insert is shown in FIG. 21 and is herein
designated as DNA60783-1611.
[0605] Clone DNA60783-1611 contains a single open reading frame
with an apparent translational initiation site at nucleotide
positions 142-144 and ending at the stop codon at nucleotide
positions 1132-1134 (FIG. 21). The predicted polypeptide precursor
is 330 amino acids long (FIG. 22). The full-length PRO1361 protein
shown in FIG. 22 has an estimated molecular weight of about 36,840
daltons and a pI of about 4.84. Analysis of the full-length PRO1361
sequence shown in FIG. 22 (SEQ ID NO:39) evidences the presence of
the following: a signal peptide from about amino acid 1 to about
amino acid 23, a transmembrane domain from about amino acid 266 to
about amino acid 284, a leucine zipper pattern sequence from about
amino acid 155 to about amino acid 176 and potential
N-glycosylation sites from about amino acid 46 to about amino acid
49, from about amino acid 64 to about amino acid 67, from about
amino acid 166 to about amino acid 169 and from about amino acid
191 to about amino acid 194. Clone DNA60783-1611 has been deposited
with ATCC on Aug. 18, 1998 and is assigned ATCC deposit no.
203130.
[0606] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST2 sequence alignment analysis of the
full-length sequence shown in FIG. 22 (SEQ ID NO:39), evidenced
significant homology between the PRO1361 amino acid sequence and
the following Dayhoff sequences: 150620, G64876,
PMCMSG102B.sub.--2MSG104, HUMIGLVXY.sub.--1 and PH1370.
Example 13
[0607] Isolation of cDNA Clones Encoding Human PRO1308
[0608] A consensus DNA sequence was assembled relative to other EST
sequences using phrap as described in Example 1 above. The
consensus sequence was extended then using repeated cycles of BLAST
and phrap to extend the consensus sequence as far as possible using
the sources of EST sequences discussed above. The extended
consensus sequence is designated herein as "DNA35726". Based on the
DNA35726 consensus sequence, oligonucleotides were synthesized: 1)
to identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO 1308.
[0609] The following PCR primers (forward and reverse) were
synthesized:
[0610] forward PCR primers
[0611] 5'-TCCTGTGAGCACGTGGTGTG-3' (SEQ ID NO:42);
[0612] 5'-GGGTGGGATAGACCTGCG-3' (SEQ ID NO:43);
[0613] 5'-AAGGCCAAGAAGGCTGCC-3' (SEQ ID NO:44); and
[0614] 5'-CCAGGCCTGCAGACCCAG-3' (SEQ ID NO:45).
[0615] reverse PCR primers
[0616] 5'-CTTCCTCAGTCCTTCCAGGATATC-3' (SEQ ID NO:46);
[0617] 5'-AAGCTGGATATCCTCCGTGTTGTC-3' (SEQ ID NO:47);
[0618] 5'-CCTGAAGAGGCATGACTGCTTTTCTCA-3' (SEQ ID NO:48); and
[0619] 5'-GGGGATAAACCTATTAATTATTGCTAC-3' (SEQ ID NO:49).
[0620] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA35726 sequence which
had the following nucleotide sequence:
[0621] hybridization probe:
5'-AACGTCACCTACATCTCCTCGTGCCACATGCGCCAGGCCACCT- G-3' (SEQ ID
NO:50).
[0622] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO1308 gene
using the probe oligonucleotide and one of the PCR primers. RNA for
construction of the cDNA libraries was isolated from a human
SK-Lu-1 adenocarcinoma cell line.
[0623] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO1308 (designated herein as
DNA62306-1570 [FIG. 23, SEQ ID NO:40]; and the derived protein
sequence for PRO1308.
[0624] The entire coding sequence of PRO1308 is shown in FIG. 23
(SEQ ID NO:40). Clone DNA62306-1570 contains a single open reading
frame with an apparent translational initiation site at nucleotide
positions 17-19 and an apparent stop codon at nucleotide positions
806-808. The predicted polypeptide precursor is 263 amino acids
long. The full-length PRO1308 protein shown in FIG. 24 has an
estimated molecular weight of about 27,663 daltons and a pI of
about 6.77. Additional features include a signal peptide at about
amino acids 1-20, potential N-glycosylation sites at about amino
acids 73-76 and 215-218, and regions of homology with osteonectin
domains at about amino acids 97-129 and 169-201.
[0625] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST2 sequence alignment analysis of the
full-length sequence shown in FIG. 24 (SEQ ID NO:41), revealed
significant homology between the PRO1308 amino acid sequence and
Dayhoff sequence S55369. Homology was also revealed between the
PRO1308 amino acid sequence and the following Dayhoff sequences:
FSA_HUMAN, P_R20063, CELT13C2.sub.--1, AGR1_RAT, p_W09406, G01639,
SC1_RAT, S60062, S51362, and IOV7_CHICK.
[0626] Clone DNA62306-1570 has been deposited with ATCC and is
assigned ATCC deposit no. 203254.
Example 14
[0627] Isolation of cDNA Clones Encoding Human PRO1183
[0628] Use of the signal sequence algorithm described in Example 3
above allowed identification of an EST cluster sequence from the
Incyte database. This EST cluster sequence was then compared to a
variety of expressed sequence tag (EST) databases which included
public EST databases (e.g., GenBank) and a proprietary EST DNA
database (LIFESEQ.RTM., Incyte Pharmaceuticals, Palo Alto, Calif.)
to identify existing homologies. The homology search was performed
using the computer program BLAST or BLAST2 (Altshul et al., Methods
in Enzymology 266:460-480 (1996)). Those comparisons resulting in a
BLAST score of 70 (or in some cases 90) or greater that did not
encode known proteins were clustered and assembled into a consensus
DNA sequence with the program "phrap" (Phil Green, University of
Washington, Seattle, Wash.). The consensus sequence obtained
therefrom is herein designated DNA56037.
[0629] In light of an observed sequence homology between the
DNA56037 sequence and an EST sequence contained within the Incyte
EST 1645856 (from a library constructed from prostate tumor
tissue), the clone which includes EST 1645856 was purchased and the
cDNA insert was obtained and sequenced. The sequence of this cDNA
insert is shown in FIG. 25 and is herein designated as
DNA62880-1513.
[0630] The full length clone shown in FIG. 25 contained a single
open reading frame with an apparent translational initiation site
at nucleotide positions 20-22 and ending at the stop codon found at
nucleotide positions 1535-1537 (FIG. 25; SEQ ID NO:51). The
predicted polypeptide precursor (FIG. 26, SEQ ID NO:52) is 505
amino acids long. The signal peptide is approximately at amino
acids 1-23 of SEQ ID NO:52. PRO1183 has a calculated molecular
weight of approximately 56,640 daltons and an estimated pI of
approximately 6.1. Clone DNA62880-1513 was deposited with the ATCC
on August 4, 1998 and is assigned ATCC deposit no. 203097.
[0631] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST2 sequence alignment analysis of the
full-length sequence shown in FIG. 26 (SEQ ID NO: 52), revealed
sequence identity between the PRO1183 amino acid sequence and the
following Dayhoff sequences: MTV010.sub.--1, P_W41604, S54021,
AOFB_HUMAN, NPAJ4683.sub.--1, S74689, GEN13608, ACHC_ACHFU,
AB011173.sub.--1 and PUO_MICRU. It is believed that administration
of PRO1183 or regulators thereof may treat certain oxidase
disorders such as variegate porphyria.
Example 15
[0632] Isolation of cDNA Clones Encoding Human PR01272
[0633] Use of the signal sequence algorithm described in Example 3
above allowed identification of an EST cluster sequence from the
Incyte database. This EST cluster sequence was then compared to a
variety of expressed sequence tag (EST) databases which included
public EST databases (e.g., GenBank) and a proprietary EST DNA
database (LIFESEQ.RTM., Incyte Pharmaceuticals, Palo Alto, Calif.)
to identify existing homologies. The homology search was performed
using the computer program BLAST or BLAST2 (Altshul et al., Methods
in Enzymology 266:460-480 (1996)). Those comparisons resulting in a
BLAST score of 70 (or in some cases 90) or greater that did not
encode known proteins were clustered and assembled into a consensus
DNA sequence with the program "phrap" (Phil Green, University of
Washington, Seattle, Wash.). The consensus sequence obtained
therefrom is herein designated DNA58753.
[0634] In light of an observed sequence homology between the
DNA58753 sequence and an EST sequence contained witin the EST clone
3049165, the Incyte clone (from a lung library) including EST
3049165 was purchased and the cDNA insert was obtained and
sequenced. The sequence of this cDNA insert is shown in FIG. 27 and
is herein designated as DNA64896-1539.
[0635] The full length clone shown in FIG. 27 contained a single
open reading frame with an apparent translational initiation site
at nucleotide positions 58-60 and ending at the stop codon found at
nucleotide positions 556-558 (FIG. 27; SEQ ID NO:53). The predicted
polypeptide precursor (FIG. 28, SEQ ID NO:54) is 166 amino acids
long. The signal peptide is at about amino acids 1-23 of SEQ ID
NO:54. PRO1272 has a calculated molecular weight of approximately
19,171 daltons and an estimated pI of approximately 8.26. Clone
DNA64896-1539 was deposited with the ATCC on September 9, 1998 and
is assigned ATCC deposit no. 203238.
[0636] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST2 sequence alignment analysis of the
full-length sequence shown in FIG. 28 (SEQ ID NO:54), revealed
sequence identity between the PRO1272 amino acid sequence and the
following Dayhoff sequences (information from database incorporated
herein): AF025474.sub.--1, D69100, AE000757.sub.--10, H69466,
CELC50E3.sub.--12, XLRANBP1.sub.--1, YD67_SCHPO, B69459, H36856,
and FRU40755.sub.--1.
Example 16
[0637] Isolation of cDNA Clones Encoding Human PRO1419
[0638] Use of the signal sequence algorithm described in Example 3
above allowed identification of an EST cluster sequence from the
Incyte database. This EST cluster sequence was then compared to a
variety of expressed sequence tag (EST) databases which included
public EST databases (e.g., GenBank) and a proprietary EST DNA
database (LIFESEQ.RTM., Incyte Pharmaceuticals, Palo Alto, Calif.)
to identify existing homologies. One or more of the ESTs was
derived from a diseased tonsil tissue library. The homology search
was performed using the computer program BLAST or BLAST2 (Altshul
et al., Methods in Enzymology 266:460-480 (1996)). Those
comparisons resulting in a BLAST score of 70 (or in some cases 90)
or greater that did not encode known proteins were clustered and
assembled into a consensus DNA sequence with the program "phrap"
(Phil Green, University of Washington, Seattle, Wash.). The
consensus sequence obtained therefrom is herein designated
DNA59761.
[0639] In light of an observed sequence homology between the
DNA59761 sequence and an EST sequence contained within the Incyte
EST 3815008, the clone including this EST was purchased and the
cDNA insert was obtained and sequenced. The sequence of this cDNA
insert is shown in FIG. 29 and is herein designated as
DNA71290-1630.
[0640] The full length clone shown in FIG. 29 contained a single
open reading frame with an apparent translational initiation site
at nucleotide positions 86-88 and ending at the stop codon found at
nucleotide positions 341-343 (FIG. 29; SEQ ID NO:55). The predicted
polypeptide precursor (FIG. 30, SEQ ID NO:56) is 85 amino acids
long with the signal peptide at about amino acids 1-17 of SEQ ID
NO:56. PRO1419 has a calculated molecular weight of approximately
9,700 daltons and an estimated pI of approximately 9.55. Clone
DNA71290-1630 was deposited with the ATCC on Sep. 22, 1998 and is
assigned ATCC deposit no. 203275.
[0641] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST2 sequence alignment analysis of the
full-length sequence shown in FIG. 30 (SEQ ID NO:56), revealed
sequence identity between the PRO1419 amino acid sequence and the
following Dayhoff sequences (data incorporated herein): S07975
(B3-hordein), C48232, HOR7_HORVU, GEN11764, S14970,
AF020312.sub.--1, STAJ3220.sub.--1, CER07E3.sub.--1,
CEY37A1B.sub.--4, and ATAC00423810.
Example 17
[0642] Isolation of cDNA Clones Encoding Human PRO4999
[0643] A consensus DNA sequence was assembled relative to other EST
sequences using phrap as described in Example 1 above. This
consensus sequence is herein designated DNA86634. Based on the
DNA86634 consensus sequence, oligonucleotides were synthesized: 1)
to identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO4999.
[0644] PCR primers (forward and reverse) were synthesized:
[0645] forward PCR primer 5'-CCACTTGCCATGAACATGCCAC-3' (SEQ ID
NO:59)
[0646] reverse PCR primer 5'-CCTCTTGACAGACATAGCGAGCCAC-3' (SEQ ID
NO:60)
[0647] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA86634 sequence which
had the following nucleotide sequence
[0648] hybridization probe
[0649] 5'-CACTCTTGTCTGTGGGAACCACACATCTTGCCACAACTGTGGC-3' (SEQ ID
NO:61)
[0650] RNA for construction of the cDNA libraries was isolated from
human testis tissue. DNA sequencing of the clones isolated as
described above gave the full-length DNA sequence for a full-length
PRO4999 polypeptide (designated herein as DNA96031-2664 [FIG. 31,
SEQ ID NO:57]) and the derived protein sequence for that PRO4999
polypeptide.
[0651] The full length clone identified above contained a single
open reading frame with an apparent translational initiation site
at nucleotide positions 42-44 and a stop signal at nucleotide
positions 2283-2285 (FIG. 31, SEQ ID NO:57). The predicted
polypeptide precursor is 747 amino acids long, has a calculated
molecular weight of approximately 82,710 daltons and an estimated
pI of approximately 6.36. Analysis of the full-length PRO4999
sequence shown in FIG. 32 (SEQ ID NO:58) evidences the presence of
a variety of important polypeptide domains as shown in FIG. 32,
wherein the locations given for those important polypeptide domains
are approximate as described above. Clone DNA96031-2664 has been
deposited with ATCC on Jun. 15, 1999 and is assigned ATCC deposit
no. 237-PTA.
[0652] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using the ALIGN-2 sequence alignment analysis of the
full-length sequence shown in FIG. 32 (SEQ ID NO:58), evidenced
sequence identity between the PRO4999 amino acid sequence and the
following Dayhoff sequences: UROM_HUMAN; FBN1_HUMAN;
GGU88872.sub.--1; S52111; GEN12408; P_R79478; P_W48756;
P.sub.R53087; P_R14584; and S78549.
Example 18
[0653] Isolation of cDNA Clones Encoding Human PRO7170
[0654] Use of the signal sequence algorithm described in Example 3
above allowed identification of an EST cluster sequence from the
LIFESEQ.RTM. database, Incyte Pharmaceuticals, Palo Alto,
designated herein as CLU57836. This EST cluster sequence was then
compared to a variety of expressed sequence tag (EST) databases
which included public EST databases (e.g., Genbank) and a
proprietary EST DNA database (LIFESEQ.RTM., Incyte Pharmaceuticals,
Palo Alto, Calif.) to identify existing homologies. The homology
search was performed using the computer program BLAST or BLAST2
(Altshul et al., Methods in Enzymology 266:460-480 (1996)). Those
comparisons resulting in a BLAST score of 70 (or in some cases 90)
or greater that did not encode known proteins were clustered and
assembled into a consensus DNA sequence with the program "phrap"
(Phil Green, University of Washington, Seattle, Wash.). The
consensus sequence obtained therefrom is herein designated
DNA58756.
[0655] In light of an observed sequence homology between the
DNA58756 sequence and an EST sequence encompassed within clone no.
2251462 from the LIFESEQ.RTM. database, Incyte Pharmaceuticals,
Palo Alto, Calif., clone no. 2251462 was purchased and the cDNA
insert was obtained and sequenced. It was found herein that that
cDNA insert encoded a full-length protein. The sequence of this
cDNA insert is shown in FIG. 33 and is herein designated as
DNA108722-2743.
[0656] Clone DNA 108722-2743 contains a single open reading frame
with an apparent translational initiation site at nucleotide
positions 60-62 and ending at the stop codon at nucleotide
positions 1506-1508 (FIG. 33). The predicted polypeptide precursor
is 482 amino acids long (FIG. 34). The full-length PRO7170 protein
shown in FIG. 34 has an estimated molecular weight of about 49,060
daltons and a pI of about 4.74. Analysis of the full-length PRO7170
sequence shown in FIG. 34 (SEQ ID NO:63) evidences the presence of
a variety of important polypeptide domains as shown in FIG. 34,
wherein the locations given for those important polypeptide domains
are approximate as described above. Clone DNA108722-2743 has been
deposited with ATCC on Aug. 17, 1999 and is assigned ATCC Deposit
No. 552-PTA.
[0657] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using the ALIGN-2 sequence alignment analysis of the
full-length sequence shown in FIG. 34 (SEQ ID NO:63), evidenced
sequence identity between the PRO7170 amino acid sequence and the
following Dayhoff sequences: P_Y12291, I47141, D88733.sub.--1,
DMC56G7.sub.--1, P_Y11606, HWP1_CANAL, HSMUC5BEX.sub.--1,
HSU78550.sub.--1, HSU70136.sub.--1, and SGS3_DROME.
Example 19
[0658] Isolation of cDNA Clones Encoding Human PRO248
[0659] A consensus DNA sequence was assembled relative to the other
identified EST sequences as described in Example 1 above, wherein
the consensus sequence is designated herein as DNA33481. Based on
the DNA33481 consensus sequence, oligonucleotides were synthesized
to identify by PCR a cDNA library that contained the sequence of
interest and for use as probes to isolate a clone of the
full-length coding sequence for PRO248. Specifically, the following
primers were used:
[0660] Forward primer 1 (SEQ ID NO:66):
5'-GTCTGACAGCCACTCCAGAG-3'
[0661] Hybridization probe (SEQ ID NO:67):
[0662] 5'-TCTCCAATTTCTGGGCTTAGATAAGGCGCCTTCACCCCAGAAGTTCC-3'
[0663] Reverse primer 1 (SEQ ID NO:68):
5'-GTCCCAGGTTATAGTAAGAATTGG-3'
[0664] Forward primer 2 (SEQ ID NO:69):
5'-GTGTTGCGGTCAGTCCCATG-3'
[0665] Forward primer 3 (SEO ID NO:70):
5'-GCTGTCTCCCATTTCCATGC-3'
[0666] Reverse primer 2 (SEQ ID NO:71):
5'-CGACTACCATGTCTTCATAATGTC-3'
[0667] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO248 gene
using the probe oligonucleotide and one of the PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal
kidney tissue.
[0668] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO248 [herein designated as
DNA35674-1142] and the derived protein sequence for PRO248.
[0669] The entire nucleotide sequence of DNA35674-1142 is shown in
FIG. 35 (SEQ ID NO:64). Clone DNA35674-1142 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 66-68 and ending at the stop codon at
nucleotide positions 1217-1219 (FIG. 35; SEQ ID NO:64). The
predicted polypeptide precursor is 364 amino acids long (FIG. 36).
Clone DNA35674-1142 has been deposited on Oct. 28, 1997 with ATCC
and is assigned ATCC deposit no. 209416.
[0670] Analysis of the amino acid sequence of the full-length
PRO248 suggests that it has certain amino acid sequence identity
with growth differentiation factor 3 from human and mouse.
Example 20
[0671] Isolation of cDNA Clones Encoding Human PRO353
[0672] A consensus DNA sequence was assembled relative to other EST
sequences using phrap as described in Example 1 above. This
consensus sequences is herein designated DNA36363. The consensus
DNA sequence was extended using repeated cycles of BLAST and phrap
to extend the consensus sequence as far as possible using the
sources of EST sequences discussed above. Based on the DNA36363
consensus sequence, oligonucleotides were synthesized: 1) to
identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO353.
[0673] Based on the DNA36363 consensus sequence, forward and
reverse PCR primers were synthesized as follows:
[0674] forward PCR primer 5'-TACAGGCCCAGTCAGGACCAGGGG-3' (SEQ ID
NO:74)
[0675] reverse PCR primer 5'-CTGAAGAAGTAGAGGCCGGGCACG-3' (SEQ ID
NO:75).
[0676] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the DNA36363 consensus sequence which
had the following nucleotide sequence:
[0677] hybridization probe
[0678] 5'-CCCGGTGCTTGCGCTGCTGTGACCCCGGTACCTCCATGTACCCGG-3' (SEQ ID
NO:76)
[0679] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate clones encoding the
PRO353 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of the cDNA libraries was isolated
from human fetal kidney tissue.
[0680] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO353 [herein designated as
DNA41234-1242] (SEQ ID NO:72) and the derived protein sequence for
PRO353.
[0681] The entire nucleotide sequence of DNA41234-1242 is shown in
FIG. 37 (SEQ ID NO:72). Clone DNA41234-1242 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 305-307 and ending at the stop codon at
nucleotide positions 1148-1150 (FIG. 37). The predicted polypeptide
precursor is 281 amino acids long (FIG. 38). Important regions of
the amino acid sequence encoded by PRO353 include the signal
peptide, corresponding to amino acids 1-26, the start of the mature
protein at amino acid position 27, a potential N-glycosylation
site, corresponding to amino acids 93-98 and a region which has
homology to a 30 kd adipocyte complement-related protein precursor,
corresponding to amino acids 99-281. Clone DNA41234-1242 has been
deposited with the ATCC and is assigned ATCC deposit no.
209618.
[0682] Analysis of the amino acid sequence of the full-length
PRO353 polypeptides suggests that portions of them possess
significant homology to portions of human and murine complement
proteins, thereby indicating that PRO353 may be a novel complement
protein.
Example 21
[0683] Isolation of cDNA Clones Encoding Human PRO1318
[0684] The cDNA molecule corresponding to DNA73838-1674 as shown in
FIG. 39 (SEQ ID NO:77) was obtained from Curagen, Inc.
Example 22
[0685] Isolation of cDNA Clones Encoding Human PRO1600
[0686] A consensus DNA sequence was assembled relative to other EST
sequences using phrap as described in Example 1 above. This
consensus sequences is herein designated DNA75516. The consensus
DNA sequence was extended using repeated cycles of BLAST and phrap
to extend the consensus sequence as far as possible using the
sources of EST sequences discussed above. Based on the DNA75516
consensus sequence, oligonucleotides were synthesized: 1) to
identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO1600.
[0687] Based on the DNA75516 consensus sequence, oligonucleotide
probes were synthesized as follows:
[0688] 5'-AGACATGGCTCAGTCACTGG-3' (SEQ ID NO:81)
[0689] 5'-GACCCCTAAAGGGCCATAG-3' (SEQ ID NO:82).
[0690] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened with the
probes identified above. RNA for construction of the cDNA libraries
was isolated from human fetal heart tissue.
[0691] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO1600 [herein designated as
DNA77503-1686] (SEQ ID NO:79) and the derived protein sequence for
PRO 1600.
[0692] The entire nucleotide sequence of DNA77503-1686 is shown in
FIG. 41 (SEQ ID NO:79). Clone DNA77503-1686 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 6-8 and ending at the stop codon at nucleotide
positions 408-410 (FIG. 41). The predicted polypeptide precursor is
134 amino acids long (FIG. 42). Important regions of the amino acid
sequence of PRO1600 are shown in FIG. 42. Clone DNA77503-1686 has
been deposited with the ATCC and is assigned ATCC deposit no.
203362.
Example 23
[0693] Isolation of cDNA Clones Encoding Human PRO533
[0694] The EST sequence accession number AF007268, a murine
fibroblast growth factor (FGF-15) was used to search various public
EST databases (e.g., GenBank, Dayhoff, etc.). The search was
performed using the computer program BLAST or BLAST2 [Altschul et
al., Methods in Enzymology, 266:460-480 (1996)] as a comparison of
the ECD protein sequences to a 6 frame translation of the EST
sequences. The search resulted in a hit with GenBank EST AA220994,
which has been identified as stratagene NT2 neuronal precursor
937230.
[0695] Based on the Genbank EST AA220994 sequence, oligonucleotides
were synthesized: 1) to identify by PCR a cDNA library that
contained the sequence of interest, and 2) for use as probes to
isolate a clone of the full-length coding sequence. Forward and
reverse PCR primers may range from 20 to 30 nucleotides (typically
about 24), and are designed to give a PCR product of 100-1000 bp in
length. The probe sequences are typically 40-55 bp (typically about
50) in length. In order to screen several libraries for a source of
a full-length clone, DNA from the libraries was screened by PCR
amplification, as per Ausubel et al., Current Protocols in
Molecular Biology, with the PCR primer pair. A positive library was
then used to isolate clones encoding the gene of interest using the
probe oligonucleotide and one of the PCR primers.
[0696] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified below. A positive
library was then used to isolate clones encoding the PRO533 gene
using the probe oligonucleotide and one of the PCR primers.
[0697] RNA for construction of the cDNA libraries was isolated from
human fetal retina. The cDNA libraries used to isolated the cDNA
clones were constructed by standard methods using commercially
available reagents (e.g., Invitrogen, San Diego, Calif.; Clontech,
etc.) The cDNA was primed with oligo dT containing a NotI site,
linked with blunt to SalI hemikinased adaptors, cleaved with NotI,
sized appropriately by gel electrophoresis, and cloned in a defined
orientation into a suitable cloning vector (such as pRKB or pRKD;
pRK5B is a precursor of pRK5D that does not contain the SfiI site;
see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique
XhoI and NotI sites.
[0698] A cDNA clone was sequenced in its entirety. The full length
nucleotide sequence of PRO533 is shown in FIG. 45 (SEQ ID NO:85).
Clone DNA49435-1219 contains a single open reading frame with an
apparent translational initiation site at nucleotide positions
459-461 (FIG. 45; SEQ ID NO:85). The predicted polypeptide
precursor is 216 amino acids long. Clone DNA47412-1219 has been
deposited with ATCC and is assigned ATCC deposit no. ATCC
209480.
[0699] Based on a BLAST-2 and FastA sequence alignment analysis of
the full-length sequence, PRO533 shows amino acid sequence identity
to fibroblast growth factor (53%).
[0700] The oligonucleotide sequences used in the above procedure
were the following:
[0701] FGF15.forward: 5'-ATCCGCCCAGATGGCTACAATGTGTA-3' (SEQ ID
NO:87);
[0702] FGF15.probe:
5'-GCCTCCCGGTCTCCCTGAGCAGTGCCAAACAGCGGCAGTGTA-3' (SEQ ID
NO:88);
[0703] FGF15.reverse: 5'-CCAGTCCGGTGACAAGCCCAAA-3' (SEQ ID
NO:89).
Example 24
[0704] Isolation of cDNA Clones Encoding Human PRO301
[0705] A consensus DNA sequence designated herein as DNA35936 was
assembled using phrap as described in Example 1 above. Based on
this consensus sequence, oligonucleotides were synthesized: 1) to
identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence.
[0706] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified below. A positive
library was then used to isolate clones encoding the PRO301 gene
using the probe oligonucleotide and one of the PCR primers.
[0707] RNA for construction of the cDNA libraries was isolated from
human fetal kidney.
[0708] A cDNA clone was sequenced in its entirety. The full length
nucleotide sequence of native sequence PRO301 is shown in FIG. 47
(SEQ ID NO:90). Clone DNA40628-1216 contains a single open reading
frame with an apparent translational initiation site at nucleotide
positions 52-54 (FIG. 47; SEQ ID NO:90). The predicted polypeptide
precursor is 299 amino acids long with a predicted molecular weight
of 32,583 daltons and pI of 8.29. Clone DNA40628-1216 has been
deposited with ATCC and is assigned ATCC deposit No. ATCC
209432.
[0709] Based on a BLAST and FastA sequence alignment analysis of
the full-length sequence, PRO301 shows amino acid sequence identity
to A33 antigen precursor (30%) and coxsackie and adenovirus
receptor protein (29%).
[0710] The oligonucleotide sequences used in the above procedure
were the following:
[0711] OLI2162 (35936.f1) 5'-TCGCGGAGCTGTGTTCTGTTTCCC-3' (SEQ ID
NO:92)
[0712] OLI2163 (35936.p1)
[0713] 5' -TGATCGCGATGGGGACAAAGGCGCAAGCTCGAGAGGAAACTGTTGTGCCT-3'
(SEQ ID NO:93)
[0714] OLI2164 (35936.f2)
[0715] 5'-ACACCTGGTTCAAAGATGGG-3' (SEQ ID NO:94)
[0716] OLI2165 (35936.r1)
[0717] 5'-TAGGAAGAGTTGCTGAAGGCACGG-3' (SEQ ID NO:95)
[0718] OLI2166 (35936.f3)
[0719] 5'-TTGCCTTACTCAGGTGCTAC-3' (SEQ ID NO:96)
[0720] OLI2167 (35936.r2)
[0721] 5'-ACTCAGCAGTGGTAGGAAAG-3' (SEQ ID NO:97)
Example 25
[0722] Isolation of cDNA Clones Encoding Human PRO187
[0723] A proprietary expressed sequence tag (EST) DNA database
(LIFESEQ.TM., Incyte Pharmaceuticals, Palo Alto, Calif.) was
searched and an EST (#843193) was identified which showed homology
to fibroblast growth factor (FGF-8) also known as androgen-induced
growth factor. mRNA was isolated from human fetal lung tissue using
reagents and protocols from Invitrogen, San Diego, Calif. (Fast
Track 2). The cDNA libraries used to isolate the cDNA clones were
constructed by standard methods using commercially available
reagents (e.g., Invitrogen, San Diego, Calif., Life Technologies,
Gaithersburg, Md.). The cDNA was primed with oligo dT containing a
NotI site, linked with blunt to SalI hemikinased adaptors, cleaved
with NotI, sized appropriately by gel electrophoresis, and cloned
in a defined orientation into the cloning vector pRK5D using
reagents and protocols from Life Technologies, Gaithersburg, Md.
(Super Script Plasmid System). The double-stranded cDNA was sized
to greater than 1000 bp and the SalI/NotI linkered cDNA was cloned
into XhoI/NotI cleaved vector. pRK5D is a cloning vector that has
an sp6 transcription initiation site followed by an SfiI
restriction enzyme site preceding the XhoI/NotI cDNA cloning
sites.
[0724] Several libraries from various tissue sources were screened
by PCR amplification with the following oligonucleotide probes:
[0725] IN843193.f (OLI315) (SEQ ID NO:100)
[0726] 5' -CAGTACGTGAGGGACCAGGGCGCCATGA-3'
[0727] IN843193.r (OLI 317) (SEQ ID NO:101)
[0728] 25. 5'-CCGGTGACCTGCACGTGCTTGCCA-3'
[0729] A positive library was then used to isolate clones encoding
the PRO187 gene using one of the above oligonucleotides and the
following oligonucleotide probe:
[0730] IN843193.p (OLI 316) (SEQ ID NO:102)
[0731] 5 '-GCGGATCTGCCGCCTGCTCANCTGGTCGGTCATGGCGCCCT-3'
[0732] A cDNA clone was sequenced in entirety. The entire
nucleotide sequence of PRO187 (DNA27864-1155) is shown in FIG. 49
(SEQ ID NO:98). Clone DNA27864-1155 contains a single open reading
frame with an apparent translational initiation site at nucleotide
position 1 (FIG. 49; SEQ ID NO:98). The predicted polypeptide
precursor is 205 amino acids long. Clone DNA27864-1155 has been
deposited with the ATCC (designation: DNA27864-1155) and is
assigned ATCC deposit no. ATCC 209375.
[0733] Based on a BLAST and FastA sequence alignment analysis
(using the ALIGN computer program) of the full-length sequence, the
PRO 187 polypeptide shows 74% amino acid sequence identity (Blast
score 310) to human fibroblast growth factor-8 (androgen-induced
growth factor).
Example 26
[0734] Isolation of cDNA Clones Encoding Human PRO337
[0735] A cDNA sequence identified in the amylase screen described
in Example 2 above is herein designated DNA42301. The DNA42301
sequence was then compared to other EST sequences using phrap as
described in Example 1 above and a consensus sequence designated
herein as DNA28761 was identified. Based on this consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR
a cDNA library that contained the sequence of interest, and 2) for
use as probes to isolate a clone of the full-length coding
sequence. In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO337 gene
using the probe oligonucleotide and one of the PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal
brain.
[0736] A cDNA clone was sequenced in its entirety. The full length
nucleotide sequence of DNA43316-1237 is shown in FIG. 51 (SEQ ID
NO: 103). Clone DNA43316-1237 contains a single open reading frame
with an apparent translational initiation site at nucleotide
positions 134-136 (FIG. 51; SEQ ID NO:103). The predicted
polypeptide precursor is 344 amino acids long. Clone DNA43316-1237
has been deposited with ATCC and is assigned ATCC deposit no.
209487.
[0737] Based on a BLAST-2 and FastA sequence alignment analysis of
the full-length sequence, PRO337 shows amino acid sequence identity
to rat neurotrimin (97%).
Example 27
[0738] Isolation of cDNA Clones Encoding Human PRO1411
[0739] Use of the signal sequence algorithm described in Example 3
above allowed identification of an EST cluster sequence from an
Incyte database. This EST cluster sequence was then compared to a
variety of expressed sequence tag (EST) databases which included
public EST databases (e.g., GenBank) and a proprietary EST DNA
database (LIFESEQ.RTM., Incyte Pharmaceuticals, Palo Alto, Calif.)
to identify existing homologies. One or more of the ESTs were
derived from a thryroid tissue library. The homology search was
performed using the computer program BLAST or BLAST2 (Altshul et
al., Methods in Enzymology 266:460-480 (1996)). Those comparisons
resulting in a BLAST score of 70 (or in some cases 90) or greater
that did not encode known proteins were clustered and assembled
into a consensus DNA sequence with the program "phrap" (Phil Green,
University of Washington, Seattle, Wash.). The consensus sequence
obtained therefrom is herein designated DNA56013.
[0740] In light of the sequence homology between the DNA56013
sequence and an EST sequence contained within the Incyte EST
1444225, the clone including this EST was purchased and the cDNA
insert was obtained and sequenced. The sequence of this cDNA insert
is shown in FIG. 53 and is herein designated as DNA59212-1627.
[0741] The full length clone shown in FIG. 53 contained a single
open reading frame with an apparent translational initiation site
at nucleotide positions 184-186 and ending at the stop codon found
at nucleotide positions 1504-1506 (FIG. 53; SEQ ID NO:105). The
predicted polypeptide precursor (FIG. 54, SEQ ID NO:106) is 440
amino acids long. The signal peptide is at about amino acids 1-21,
and the cell attachment site is at about amino acids 301-303 of SEQ
ID NO:106. PRO1411 has a calculated molecular weight of
approximately 42,208 daltons and an estimated pI of approximately
6.36. Clone DNA59212-1627 was deposited with the ATCC on Sep. 9,
1998 and is assigned ATCC deposit no. 203245.
[0742] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST2 sequence alignment analysis of the
full-length sequence shown in FIG. 54 (SEQ ID NO:106), revealed
sequence identity between the PRO1411 amino acid sequence and the
following Dayhoff sequences (data from database incorporated
herein): MTV023.sub.--19, P_R05307, P_W26348, P_P82962,
AF000949.sub.--1, EBN1_EBV, P_R95107, GRP2_PHAVU, P_R81318, and
S74439.sub.--1.
Example 28
[0743] Isolation of cDNA Clones Encoding Human PRO4356
[0744] A consensus DNA sequence was assembled relative to other EST
sequences using phrap asdescribed in Example 1 above. This
consensus sequence is designated herein "DNA80200". Based upon an
observed homology between the DNA80200 consensus sequence and an
EST sequence contained within Merck EST clone 248287, Merck EST
clone 248287 was purchased and its insert obtained and sequenced,
thereby providing DNA86576-2595.
[0745] The entire coding sequence of PRO4356 is shown in FIG. 55
(SEQ ID NO:107). Clone DNA86576-2595 contains a single open reading
frame with an apparent translational initiation site at nucleotide
positions 55-57, and an apparent stop codon at nucleotide positions
808-810. The predicted polypeptide precursor is 251 amino acids
long. Clone DNA86576-2595 has been deposited with ATCC and is
assigned ATCC deposit no. 203868. The full-length PRO4356 protein
shown in FIG. 56 has an estimated molecular weight of about 26,935
daltons and a pI of about 7.42.
[0746] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using a WU-BLAST2 sequence alignment analysis of the
full-length sequence shown in FIG. 56 (SEQ ID NO:108), revealed
homology between the PRO4356 amino acid sequence and the following
Dayhoff sequences incorporated herein: RNMAGPIAN.sub.--1,
UPAR_BOVIN, S42152, AF007789.sub.--1, UPAR_RAT, UPAR_MOUSE,
P_W31165, P_W31168, P_R44423 and P_W26359.
Example 29
[0747] Isolation of cDNA Clones Encoding Human PRO246
[0748] A consensus DNA sequence was assembled relative to other EST
sequences using phrap as described in Example 1 above. This
consensus sequence is herein designated DNA30955. Based on the
DNA30955 consensus sequence, oligonucleotides were synthesized: 1)
to identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO246.
[0749] A pair of PCR primers (forward and reverse) were
synthesized:
[0750] forward PCR primer 5'-AGGGTCTCCAGGAGAAAGACTC-3' (SEQ ID
NO:111)
[0751] reverse PCR primer 5'-ATTGTGGGCCTTGCAGACATAGAC-3' (SEQ ID
NO:112)
[0752] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA30955 sequence which
had the following nucleotide sequence
[0753] hybridization probe
[0754] 5'-GGCCACAGCATCAAAACCTTAGAACTCAATGTACTGGTTCCTCCAGCTCC-3'
(SEQ ID NO:113)
[0755] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO246 gene
using the probe oligonucleotide and one of the PCR primers.
[0756] RNA for construction of the cDNA libraries was isolated from
human fetal liver tissue. DNA sequencing of the clones isolated as
described above gave the full-length DNA sequence for PRO246
[herein designated as DNA35639-1172] (SEQ ID NO:109) and the
derived protein sequence for PRO246.
[0757] The entire nucleotide sequence of DNA35639-1172 is shown in
FIG. 57 (SEQ ID NO:109). Clone DNA35639-1172 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 126-128 and ending at the stop codon at
nucleotide positions 1296-1298 (FIG. 57). The predicted polypeptide
precursor is 390 amino acids long (FIG. 58). Clone DNA35639-1172
has been deposited with ATCC and is assigned ATCC deposit no. ATCC
209396.
[0758] Analysis of the amino acid sequence of the full-length
PRO246 polypeptide suggests that it possess significant homology to
the human cell surface protein HCAR, thereby indicating that PRO246
may be a novel cell surface virus receptor.
Example 30
[0759] Isolation of cDNA Clones Encoding Human PRO265
[0760] A consensus DNA sequence was assembled relative to other EST
sequences as described in Example 1 above using phrap. This
consensus sequence is herein designated DNA33679. Based on the
DNA33679 consensus sequence, oligonucleotides were synthesized: 1)
to identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO265.
[0761] PCR primers (two forward and one reverse) were
synthesized:
[0762] forward PCR primer A: 5'-CGGTCTACCTGTATGGCAACC-3' (SEQ ID
NO:116);
[0763] forward PCR primer B: 5'-GCAGGACAACCAGATAAACCAC-3' (SEQ ID
NO:117);
[0764] reverse PCR primer 5'-ACGCAGATTTGAGAAGGCTGTC-3' (SEQ ID
NO:118)
[0765] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA33679 sequence which
had the following nucleotide sequence
[0766] hybridization probe
[0767] 5'-TTCACGGGCTGCTCTTGCCCAGCTCTTGAAGCTTGAAGAGCTGCAC-3' (SEQ ID
NO:119)
[0768] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with PCR primer pairs identified above. A positive
library was then used to, isolate clones encoding the PRO265 gene
using the probe oligonucleotide and one of the PCR primers.
[0769] RNA for construction of the cDNA libraries was isolated from
human a fetal brain library.
[0770] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO265 [herein designated as
DNA36350-1158] (SEQ ID NO:114) and the derived protein sequence for
PRO265.
[0771] The entire nucleotide sequence of DNA36350-1158 is shown in
FIG. 59 (SEQ ID NO:114). Clone DNA36350-1158 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 352-354 and ending at the stop codon at
positions 2332-2334 (FIG. 59). The predicted polypeptide precursor
is 660 amino acids long (FIG. 60). Clone DNA36350-1158 has been
deposited with ATCC and is assigned ATCC deposit no. ATCC
209378.
[0772] Analysis of the amino acid sequence of the full-length
PRO265 polypeptide suggests that portions of it possess significant
homology to the fibromodulin and the fibromodulin precursor,
thereby indicating that PRO265 may be a novel member of the leucine
rich repeat family, particularly related to fibromodulin.
Example 31
[0773] Isolation of cDNA Clones Encoding Human PRO941
[0774] A consensus sequence was obtained relative to a variety of
EST sequences as described in Example 1 above, wherein the
consensus sequence obtained is herein designated DNA35941. Based on
the DNA35941 consensus sequence, oligonucleotides were synthesized:
1) to identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO941.
[0775] A pair of PCR primers (forward and reverse) were
synthesized:
[0776] forward PCR primer 5'-CTTGACTGTCTCTGAATCTGCACCC-3' (SEQ ID
NO:122)
[0777] reverse PCR primer 5'-AAGTGGTGGAAGCCTCCAGTGTGG-3' (SEQ ID
NO:123)
[0778] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA35941 sequence which
had the following nucleotide sequence
[0779] hybridization probe
[0780] 5'-CCACTACGGTATTAGAGCAAAAGTTAAAAACCATCATGGTTCCTGGAGCAGC-3'
(SEQ ID NO:124)
[0781] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO941 gene
using the probe oligonucleotide and one of the PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal
kidney tissue (LIB227).
[0782] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO941 [herein designated as
DNA53906-1368] (SEQ ID NO:120) and the derived protein sequence for
PRO941.
[0783] The entire nucleotide sequence of DNA53906-1368 is shown in
FIG. 61 (SEQ ID NO:120). Clone DNA53906-1368 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 37-39 and ending at the stop codon at
nucleotide positions 2353-2355 (FIG. 61). The predicted polypeptide
precursor is 772 amino acids long (FIG. 62). The full-length PRO941
protein shown in FIG. 62 has an estimated molecular weight of about
87,002 daltons and a pI of about 4.64. Analysis of the full-length
PRO941 sequence shown in FIG. 62 (SEQ ID NO:121) evidences the
presence of the following: a signal peptide from about amino acid 1
to about amino acid 21, potential N-glycosylation sites from about
amino acid 57 to about amino acid 60, from about amino acid 74 to
about amino acid 77, from about amino acid 419 to about amino acid
422, from about amino acid 437 to about amino acid 440, from about
amino acid 508 to about amino acid 511, from about amino acid 515
to about amino acid 518, from about amino acid 516 to about amino
acid 519 and from about amino acid 534 to about amino acid 537, and
cadherin extracellular repeated domain signature sequences from
about amino acid 136 to about amino acid 146 and from about amino
acid 244 to about amino acid 254. Clone DNA53906-1368 has been
deposited with ATCC on Apr. 7, 1998 and is assigned ATCC deposit
no. 209747.
[0784] Analysis of the amino acid sequence of the full-length
PRO941 polypeptide suggests that it possesses significant sequence
similarity to a cadherin protein, thereby indicating that PRO941
may be a novel cadherin protein family member. More specifically,
an analysis of the Dayhoff database (version 35.45 SwissProt 35)
evidenced significant homology between the PRO941 amino acid
sequence and the following Dayhoff sequences, I50180, CADA_CHICK,
I50178, GEN12782, CADC_HUMAN, P_W25637, A38992, P_R49731, D38992
and G02678.
Example 32
[0785] Isolation of cDNA Clones Encoding Human PRO10096
[0786] Use of the signal sequence algorithm described in Example 3
above allowed identification of an EST cluster sequence from the
Incyte database, designated herein as 5086173H1. This EST cluster
sequence was then compared to a variety of expressed sequence tag
(EST) databases which included public EST databases (e.g., GenBank)
and a proprietary EST DNA database (LIFESEQ.RTM., Incyte
Pharmaceuticals, Palo Alto, Calif.) to identify existing
homologies. The homology search was performed using the computer
program BLAST or BLAST2 (Altshul et al., Methods in Enzymology
266:460-480 (1996)). Those comparisons resulting in a BLAST score
of 70 (or in some cases 90) or greater that did not encode known
proteins were clustered and assembled into a consensus DNA sequence
with the program "phrap" (Phil Green, University of Washington,
Seattle, Wash.). The consensus sequence obtained therefrom is
herein designated DNA110880.
[0787] In light of an observed sequence homology between the
DNA110880 sequence and an EST sequence encompassed within clone no.
5088384 from the Incyte database, clone no. 5088384 was purchased
and the cDNA insert was obtained and sequenced. It was found herein
that that cDNA insert encoded a full-length protein. The sequence
of this cDNA insert is shown in FIG. 63 and is herein designated as
DNA125185-2506.
[0788] Clone DNA125185-2506 contains a single open reading frame
with an apparent translational initiation site at nucleotide
positions 58-60 and ending at the stop codon at nucleotide
positions 595-597 (FIG. 63). The predicted polypeptide precursor is
179 amino acids long (FIG. 64). The full-length PRO10096 protein
shown in FIG. 64 has an estimated molecular weight of about 20,011
daltons and a pI of about 8.10. Analysis of the full-length
PRO10096 sequence shown in FIG. 64 (SEQ ID NO:126) evidences the
presence of a variety of important polypeptide domains as shown in
FIG. 64, wherein the locations given for those important
polypeptide domains are approximate as described above. Clone
DNA125185-2506 has been deposited with ATCC on Dec. 7, 1999 and is
assigned ATCC deposit no. 1031-PTA.
Example 33
[0789] Isolation of cDNA Clones Encoding Human PRO6003
[0790] A cDNA clone (DNA83568-2692) encoding a native human PRO6003
polypeptide was identified using a yeast screen, in a human fetal
kidney cDNA library that preferentially represents the 5' ends of
the primary cDNA clones.
[0791] Clone DNA83568-2692 contains a single open reading frame
with an apparent translational initiation site at nucleotide
positions 638-640 and ending at the stop codon at nucleotide
positions 2225-2227 (FIG. 65). The predicted polypeptide precursor
is 529 amino acids long (FIG. 66). The full-length PRO6003 protein
shown in FIG. 66 has an estimated molecular weight of about 59,583
daltons and a pI of about 6.36. Analysis of the full-length PRO6003
sequence shown in FIG. 66 (SEQ ID NO:128) evidences the presence of
a variety of important polypeptide domains as shown in FIG. 66,
wherein the locations given for those important polypeptide domains
are approximate as described above. Clone DNA83568-2692 has been
deposited with ATCC on Jul. 20, 1999 and is assigned ATCC Deposit
No. 386-PTA.
[0792] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using the ALIGN-2 sequence alignment analysis of the
full-length sequence shown in FIG. 66 (SEQ ID NO:128), evidenced
sequence identity between the PRO6003 amino acid sequence and the
following Dayhoff sequences: P_W58986, PTND7.sub.--1, YKZ3_YEAST,
CEK04B12.sub.--1, AB014464.sub.--1, PCU07059.sub.--1, S31213,
CELF25E2.sub.--2, AF036408.sub.--1, and AB007932.sub.--1.
Example 34
[0793] Isolation of cDNA Clones Encoding Human PRO6004
[0794] A consensus sequence was obtained relative to a variety of
EST sequences as described in Example 1 above, wherein the
consensus sequence obtained is herein designated DNA85042. Based
upon an observed homology between the DNA85402 consensus sequence
and an EST sequence contained within Incyte EST clone no. 3078492,
that clone was purchased and its insert obtained and sequenced. The
sequence of that insert is herein designated as DNA92259 and is
shown in FIGS. 67A-B (SEQ ID NO:129).
[0795] Clone DNA92259 contains a single open reading frame with an
apparent translational initiation site at nucleotide positions
16-18 and ending at the stop codon at nucleotide positions
1078-1080 (FIGS. 67A-B). The predicted polypeptide precursor is 354
amino acids long (FIG. 68). The full-length PRO6004 protein shown
in FIG. 68 has an estimated molecular weight of about 38,719
daltons and a pI of about 6.12. Analysis of the full-length PRO6004
sequence shown in FIG. 68 (SEQ ID NO:130) evidences the presence of
a variety of important polypeptide domains as shown in FIG. 68,
wherein the locations given for those important polypeptide domains
are approximate as described above.
[0796] An analysis of the Dayhoff database (version 35.45 SwissProt
35), using the ALIGN-2 sequence alignment analysis of the
full-length sequence shown in FIG. 68 (SEQ ID NO:130), evidenced
sequence identity between the PRO6004 amino acid sequence and the
following Dayhoff sequences: P_W05152, LAMP_HUMAN, P_W05157,
P_W05155,156551, OPCM_RAT, AMAL_DROME, DMU78177.sub.--1, I37246 and
NCA1_HUMAN.
Example 35
[0797] Isolation of cDNA Clones Encoding Human PRO350
[0798] A consensus sequence was obtained relative to a variety of
EST sequences as described in Example 1 above, wherein the
consensus sequence obtained is herein designated DNA39493. Based on
the DNA39493 consensus sequence, oligonucleotides were synthesized:
1) to identify by PCR a cDNA library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PRO350.
[0799] A pair of PCR primers (forward and reverse) were
synthesized:
[0800] forward PCR primer 5'-TCAGGGCTGCCAGGAAGGAAGAGC-3' (SEQ ID
NO:133)
[0801] reverse PCR primer 5'-GCAGGAGGAGAAGGTCTTCCAGAAGAAG-3' (SEQ
ID NO:134)
[0802] Additionally, a synthetic oligonucleotide hybridization
probe was constructed from the consensus DNA39493 sequence which
had the following nucleotide sequence
[0803] hybridization probe
[0804] 5'-AGAAGTTCCAGTCAGCCCACAAGATGCCATTGTCCCCCGGCCTCC-3' (SEQ ID
NO:135)
[0805] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO350 gene
using the probe oligonucleotide and one of the PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal
kidney tissue.
[0806] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO350 [herein designated as
DNA44175-1314] (SEQ ID NO:131) and the derived protein sequence for
PRO350.
[0807] The entire nucleotide sequence of DNA44175-1314 is shown in
FIG. 69 (SEQ ID NO:131). Clone DNA44175-1314 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 356-358 and ending at the stop codon at
nucleotide positions 821-823 (FIG. 69). The predicted polypeptide
precursor is 155 amino acids long (FIG. 70). The full-length PRO350
protein shown in FIG. 70 has an estimated molecular weight of about
17,194 daltons and a pI of about 10.44. Analysis of the full-length
PRO350 sequence shown in FIG. 70 (SEQ ID NO:132) evidences the
presence of a variety of important polypeptide domains as shown in
FIG. 70.
Example 36
[0808] Use of PRO as a Hybridization Probe
[0809] The following method describes use of a nucleotide sequence
encoding PRO as a hybridization probe.
[0810] DNA comprising the coding sequence of full-length or mature
PRO as disclosed herein is employed as a probe to screen for
homologous DNAs (such as those encoding naturally-occurring
variants of PRO) in human tissue cDNA libraries or human tissue
genomic libraries.
[0811] Hybridization and washing of filters containing either
library DNAs is performed under the following high stringency
conditions. Hybridization of radiolabeled PRO-derived probe to the
filters is performed in a solution of 50% formamide, 5.times.SSC,
0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH
6.8, 2.times.Denhardt's solution, and 10% dextran sulfate at
42.degree. C. for 20 hours. Washing of the filters is performed in
an aqueous solution of 0.1.times.SSC and 0.1% SDS at 42.degree.
C.
[0812] DNAs having a desired sequence identity with the DNA
encoding full-length native sequence PRO can then be identified
using standard techniques known in the art.
Example 37
[0813] Expression of PRO in E. coli
[0814] This example illustrates preparation of an unglycosylated
form of PRO by recombinant expression in E. coli.
[0815] The DNA sequence encoding PRO is initially amplified using
selected PCR primers. The primers should contain restriction enzyme
sites which correspond to the restriction enzyme sites on the
selected expression vector. A variety of expression vectors may be
employed. An example of a suitable vector is pBR322 (derived from
E. coli; see Bolivar et al., Gene, 2:95 (1977)) which contains
genes for ampicillin and tetracycline resistance. The vector is
digested with restriction enzyme and dephosphorylated. The PCR
amplified sequences are then ligated into the vector. The vector
will preferably include sequences which encode for an antibiotic
resistance gene, a trp promoter, a polyhis leader (including the
first six STII codons, polyhis sequence, and enterokinase cleavage
site), the PRO coding region, lambda transcriptional terminator,
and an argU gene.
[0816] The ligation mixture is then used to transform a selected E.
coli strain using the methods described in Sambrook et al., supra.
Transformants are identified by their ability to grow on LB plates
and antibiotic resistant colonies are then selected. Plasmid DNA
can be isolated and confirmed by restriction analysis and DNA
sequencing.
[0817] Selected clones can be grown overnight in liquid culture
medium such as LB broth supplemented with antibiotics. The
overnight culture may subsequently be used to inoculate a larger
scale culture. The cells are then grown to a desired optical
density, during which the expression promoter is turned on.
[0818] After culturing the cells for several more hours, the cells
can be harvested by centrifugation. The cell pellet obtained by the
centrifugation can be solubilized using various agents known in the
art, and the solubilized PRO protein can then be purified using a
metal chelating column under conditions that allow tight binding of
the protein.
[0819] PRO may be expressed in E. coli in a poly-His tagged form,
using the following procedure. The DNA encoding PRO is initially
amplified using selected PCR primers. The primers will contain
restriction enzyme sites which correspond to the restriction enzyme
sites on the selected expression vector, and other useful sequences
providing for efficient and reliable translation initiation, rapid
purification on a metal chelation column, and proteolytic removal
with enterokinase. The PCR-amplified, poly-His tagged sequences are
then ligated into an expression vector, which is used to transform
an E. coli host based on strain 52 (W3110 fuhA(ton-A) Ion galE
rpoHts(htpRts) clpP(laclq). Transformants are first grown in LB
containing 50 mg/ml carbenicillin at 30.degree. C. with shaking
until an O.D.600 of 3-5 is reached. Cultures are then diluted
50-100 fold into CRAP media (prepared by mixing 3.57 g
(NH.sub.4).sub.2SO.sub.4, 0.71 g sodium citrate.2H2O, 1.07 g KCl,
5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL
water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM
MgSO.sub.4) and grown for approximately 20-30 hours at 30.degree.
C. with shaking. Samples are removed to verify expression by
SDS-PAGE analysis, and the bulk culture is centrifuged to pellet
the cells. Cell pellets are frozen until purification and
refolding.
[0820] E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets)
is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH
8 buffer. Solid sodium sulfite and sodium tetrathionate is added to
make final concentrations of 0.1M and 0.02 M, respectively, and the
solution is stirred overnight at 4.degree. C. This step results in
a denatured protein with all cysteine residues blocked by
sulfitolization. The solution is centrifuged at 40,000 rpm in a
Beckman Ultracentifuge for 30 min. The supernatant is diluted with
3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM
Tris, pH 7.4) and filtered through 0.22 micron filters to clarify.
The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal
chelate column equilibrated in the metal chelate column buffer. The
column is washed with additional buffer containing 50 mM imidazole
(Calbiochem, Utrol grade), pH 7.4. The protein is eluted with
buffer containing 250 mM imidazole. Fractions containing the
desired protein are pooled and stored at 4.degree. C. Protein
concentration is estimated by its absorbance at 280 nm using the
calculated extinction coefficient based on its amino acid
sequence.
[0821] The proteins are refolded by diluting the sample slowly into
freshly prepared refolding buffer consisting of: 20 mM Tris, pH
8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM
EDTA. Refolding volumes are chosen so that the final protein
concentration is between 50 to 100 micrograms/ml. The refolding
solution is stirred gently at 4.degree. C. for 12-36 hours. The
refolding reaction is quenched by the addition of TFA to a final
concentration of 0.4% (pH of approximately 3). Before further
purification of the protein, the solution is filtered through a
0.22 micron filter and acetonitrile is added to 2-10% final
concentration. The refolded protein is chromatographed on a Poros
R1/H reversed phase column using a mobile buffer of 0.1% TFA with
elution with a gradient of acetonitrile from 10 to 80%. Aliquots of
fractions with A280 absorbance are analyzed on SDS polyacrylamide
gels and fractions containing homogeneous refolded protein are
pooled. Generally, the properly refolded species of most proteins
are eluted at the lowest concentrations of acetonitrile since those
species are the most compact with their hydrophobic interiors
shielded from interaction with the reversed phase resin. Aggregated
species are usually eluted at higher acetonitrile concentrations.
In addition to resolving misfolded forms of proteins from the
desired form, the reversed phase step also removes endotoxin from
the samples.
[0822] Fractions containing the desired folded PRO polypeptide are
pooled and the acetonitrile removed using a gentle stream of
nitrogen directed at the solution. Proteins are formulated into 20
mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by
dialysis or by gel filtration using G25 Superfine (Pharmacia)
resins equilibrated in the formulation buffer and sterile
filtered.
[0823] Many of the PRO polypeptides disclosed herein were
successfully expressed as described above.
Example 38
[0824] Expression of PRO in Mammalian Cells
[0825] This example illustrates preparation of a potentially
glycosylated form of PRO by recombinant expression in mammalian
cells.
[0826] The vector, pRK5 (see EP 307,247, published Mar. 15, 1989),
is employed as the expression vector. Optionally, the PRO DNA is
ligated into pRK5 with selected restriction enzymes to allow
insertion of the PRO DNA using ligation methods such as described
in Sambrook et al., supra. The resulting vector is called
pRK5-PRO.
[0827] In one embodiment, the selected host cells may be 293 cells.
Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue
culture plates in medium such as DMEM supplemented with fetal calf
serum and optionally, nutrient components and/or antibiotics. About
10 .mu.g pRK5-PRO DNA is mixed with about 1 .mu.g DNA encoding the
VA RNA gene [Thimmappaya et al., Cell, 31:543 (1982)] and dissolved
in 500 .mu.l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl.sub.2. To
this mixture is added, dropwise, 500 .mu.l of 50 mM HEPES (pH
7.35), 280 mM NaCl, 1.5 mM NaPO.sub.4, and a precipitate is allowed
to form for 10 minutes at 25.degree. C. The precipitate is
suspended and added to the 293 cells and allowed to settle for
about four hours at 37.degree. C. The culture medium is aspirated
off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The
293 cells are then washed with serum free medium, fresh medium is
added and the cells are incubated for about 5 days.
[0828] Approximately 24 hours after the transfections, the culture
medium is removed and replaced with culture medium (alone) or
culture medium containing 200 .mu.Ci/ml .sup.35S-cysteine and 200
.mu.Ci/ml .sup.35S-methionine. After a 12 hour incubation, the
conditioned medium is collected, concentrated on a spin filter, and
loaded onto a 15% SDS gel. The processed gel may be dried and
exposed to film for a selected period of time to reveal the
presence of PRO polypeptide. The cultures containing transfected
cells may undergo further incubation (in serum free medium) and the
medium is tested in selected bioassays.
[0829] In an alternative technique, PRO may be introduced into 293
cells transiently using the dextran sulfate method described by
Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293
cells are grown to maximal density in a spinner flask and 700 .mu.g
pRK5-PRO DNA is added. The cells are first concentrated from the
spinner flask by centrifugation and washed with PBS. The
DNA-dextran precipitate is incubated on the cell pellet for four
hours. The cells are treated with 20% glycerol for 90 seconds,
washed with tissue culture medium, and re-introduced into the
spinner flask containing tissue culture medium, 5 .mu.g/ml bovine
insulin and 0.1 .mu.g/ml bovine transferrin. After about four days,
the conditioned media is centrifuged and filtered to remove cells
and debris. The sample containing expressed PRO can then be
concentrated and purified by any selected method, such as dialysis
and/or column chromatography.
[0830] In another embodiment, PRO can be expressed in CHO cells.
The pRK5-PRO can be transfected into CHO cells using known reagents
such as CaPO.sub.4 or DEAE-dextran. As described above, the cell
cultures can be incubated, and the medium replaced with culture
medium (alone) or medium containing a radiolabel such as
.sup.35S-methionine. After determining the presence of PRO
polypeptide, the culture medium may be replaced with serum free
medium. Preferably, the cultures are incubated for about 6 days,
and then the conditioned medium is harvested. The medium containing
the expressed PRO can then be concentrated and purified by any
selected method.
[0831] Epitope-tagged PRO may also be expressed in host CHO cells.
The PRO may be subcloned out of the pRK5 vector. The subclone
insert can undergo PCR to fuse in frame with a selected epitope tag
such as a poly-his tag into a Baculovirus expression vector. The
poly-his tagged PRO insert can then be subcloned into a SV40 driven
vector containing a selection marker such as DHFR for selection of
stable clones. Finally, the CHO cells can be transfected (as
described above) with the SV40 driven vector. Labeling may be
performed, as described above, to verify expression. The culture
medium containing the expressed poly-His tagged PRO can then be
concentrated and purified by any selected method, such as by
Ni.sup.2+-chelate affinity chromatography.
[0832] PRO may also be expressed in CHO and/or COS cells by a
transient expression procedure or in CHO cells by another stable
expression procedure.
[0833] Stable expression in CHO cells is performed using the
following procedure. The proteins are expressed as an IgG construct
(immunoadhesin), in which the coding sequences for the soluble
forms (e.g. extracellular domains) of the respective proteins are
fused to an IgG I constant region sequence containing the hinge,
CH2 and CH2 domains and/or is a poly-His tagged form.
[0834] Following PCR amplification, the respective DNAs are
subcloned in a CHO expression vector using standard techniques as
described in Ausubel et al., Current Protocols of Molecular
Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression
vectors are constructed to have compatible restriction sites 5' and
3' of the DNA of interest to allow the convenient shuttling of
cDNA's. The vector used expression in CHO cells is as described in
Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the
SV40 early promoter/enhancer to drive expression of the cDNA of
interest and dihydrofolate reductase (DHFR). DHFR expression
permits selection for stable maintenance of the plasmid following
transfection.
[0835] Twelve micrograms of the desired plasmid DNA is introduced
into approximately 10 million CHO cells using commercially
available transfection reagents Superfect.RTM. (Quiagen),
Dosper.RTM. or Fugene.RTM. (Boehringer Mannheim). The cells are
grown as described in Lucas et al., supra. Approximately
3.times.10.sup.-7 cells are frozen in an ampule for further growth
and production as described below.
[0836] The ampules containing the plasmid DNA are thawed by
placement into water bath and mixed by vortexing. The contents are
pipetted into a centrifuge tube containing 10 mLs of media and
centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated
and the cells are resuspended in 10 mL of selective media (0.2
.mu.m filtered PS20 with 5% 0.2 .mu.m diafiltered fetal bovine
serum). The cells are then aliquoted into a 100 mL spinner
containing 90 mL of selective media. After 1-2 days, the cells are
transferred into a 250 mL spinner filled with 150 mL selective
growth medium and incubated at 37.degree. C. After another 2-3
days, 250 mL, 500 mL and 2000 mL spinners are seeded with
3.times.10.sup.5 cells/mL. The cell media is exchanged with fresh
media by centrifugation and resuspension in production medium.
Although any suitable CHO media may be employed, a production
medium described in U.S. Pat. No. 5,122,469, issued Jun. 16, 1992
may actually be used. A 3L production spinner is seeded at
1.2.times.10.sup.6 cells/mL. On day 0, the cell number pH ie
determined. On day 1, the spinner is sampled and sparging with
filtered air is commenced. On day 2, the spinner is sampled, the
temperature shifted to 33.degree. C., and 30 mL of 500 g/L glucose
and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane
emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout
the production, the pH is adjusted as necessary to keep it at
around 7.2. After 10 days, or until the viability dropped below
70%, the cell culture is harvested by centrifugation and filtering
through a 0.22 .mu.m filter. The filtrate was either stored at
4.degree. C. or immediately loaded onto columns for
purification.
[0837] For the poly-His tagged constructs, the proteins are
purified using a Ni-NTA column (Qiagen). Before purification,
imidazole is added to the conditioned media to a concentration of 5
mM. The conditioned media is pumped onto a 6 ml Ni-NTA column
equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl
and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4.degree. C.
After loading, the column is washed with additional equilibration
buffer and the protein eluted with equilibration buffer containing
0.25 M imidazole. The highly purified protein is subsequently
desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl
and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia)
column and stored at -80.degree. C.
[0838] Immunoadhesin (Fc-containing) constructs are purified from
the conditioned media as follows. The conditioned medium is pumped
onto a 5 ml Protein A column (Pharmacia) which had been
equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading,
the column is washed extensively with equilibration buffer before
elution with 100 mM citric acid, pH 3.5. The eluted protein is
immediately neutralized by collecting 1 ml fractions into tubes
containing 275 .mu.L of 1 M Tris buffer, pH 9. The highly purified
protein is subsequently desalted into storage buffer as described
above for the poly-His tagged proteins. The homogeneity is assessed
by SDS polyacrylamide gels and by N-terminal amino acid sequencing
by Edman degradation.
[0839] Many of the PRO polypeptides disclosed herein were
successfully expressed as described above.
Example 39
[0840] Expression of PRO in Yeast
[0841] The following method describes recombinant expression of PRO
in yeast.
[0842] First, yeast expression vectors are constructed for
intracellular production or secretion of PRO from the ADH2/GAPDH
promoter. DNA encoding PRO and the promoter is inserted into
suitable restriction enzyme sites in the selected plasmid to direct
intracellular expression of PRO. For secretion, DNA encoding PRO
can be cloned into the selected plasmid, together with DNA encoding
the ADH2/GAPDH promoter, a native PRO signal peptide or other
mammalian signal peptide, or, for example, a yeast alpha-factor or
invertase secretory signal/leader sequence, and linker sequences
(if needed) for expression of PRO.
[0843] Yeast cells, such as yeast strain AB110, can then be
transformed with the expression plasmids described above and
cultured in selected fermentation media. The transformed yeast
supernatants can be analyzed by precipitation with 10%
trichloroacetic acid and separation by SDS-PAGE, followed by
staining of the gels with Coomassie Blue stain.
[0844] Recombinant PRO can subsequently be isolated and purified by
removing the yeast cells from the fermentation medium by
centrifugation and then concentrating the medium using selected
cartridge filters. The concentrate containing PRO may further be
purified using selected column chromatography resins.
[0845] Many of the PRO polypeptides disclosed herein were
successfully expressed as described above.
Example 40
[0846] Expression of PRO in Baculovirus-Infected Insect Cells
[0847] The following method describes recombinant expression of PRO
in Baculovirus-infected insect cells.
[0848] The sequence coding for PRO is fused upstream of an epitope
tag contained within a baculovirus expression vector. Such epitope
tags include poly-his tags and immunoglobulin tags (like Fe regions
of IgG). A variety of plasmids may be employed, including plasmids
derived from commercially available plasmids such as pVL1393
(Novagen). Briefly, the sequence encoding PRO or the desired
portion of the coding sequence of PRO such as the sequence encoding
the extracellular domain of a transmembrane protein or the sequence
encoding the mature protein if the protein is extracellular is
amplified by PCR with primers complementary to the 5' and 3'
regions. The 5' primer may incorporate flanking (selected)
restriction enzyme sites. The product is then digested with those
selected restriction enzymes and subcloned into the expression
vector.
[0849] Recombinant baculovirus is generated by co-transfecting the
above plasmid and BaculoGold.TM. virus DNA (Pharmingen) into
Spodoplera frugiperda ("Sf9") cells (ATCC CRL 1711) using
lipofectin (commercially available from GIBCO-BRL). After 4-5 days
of incubation at 28.degree. C., the released viruses are harvested
and used for further amplifications. Viral infection and protein
expression are performed as described by O'Reilley et al.,
Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford
University Press (1994).
[0850] Expressed poly-his tagged PRO can then be purified, for
example, by Ni.sup.2+-chelate affinity chromatography as follows.
Extracts are prepared from recombinant virus-infected Sf9 cells as
described by Rupert et al., Nature, 362:175-179 (1993). Briefly,
Sf9 cells are washed, resuspended in sonication buffer (25 mL
Hepes, pH 7.9; 12.5 mM MgCl.sub.2; 0.1 mM EDTA; 10% glycerol; 0.1%
NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The
sonicates are cleared by centrifugation, and the supernatant is
diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl,
10% glycerol, pH 7.8) and filtered through a 0.45 .mu.m filter. A
Ni.sup.2+-NTA agarose column (commercially available from Qiagen)
is prepared with a bed volume of 5 mL, washed with 25 mL of water
and equilibrated with 25 mL of loading buffer. The filtered cell
extract is loaded onto the column at 0.5 mL per minute. The column
is washed to baseline A.sub.280 with loading buffer, at which point
fraction collection is started. Next, the column is washed with a
secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol,
pH 6.0), which elutes nonspecifically bound protein. After reaching
A.sub.280 baseline again, the column is developed with a 0 to 500
mM Imidazole gradient in the secondary wash buffer. One mL
fractions are collected and analyzed by SDS-PAGE and silver
staining or Western blot with Ni.sup.2+-NTA-conjugated to alkaline
phosphatase (Qiagen). Fractions containing the eluted
His.sub.10-tagged PRO are pooled and dialyzed against loading
buffer.
[0851] Alternatively, purification of the IgG tagged (or Fe tagged)
PRO can be performed using known chromatography techniques,
including for instance, Protein A or protein G column
chromatography.
[0852] Many of the PRO polypeptides disclosed herein were
successfully expressed as described above.
Example 41
[0853] Preparation of Antibodies that Bind PRO
[0854] This example illustrates preparation of monoclonal
antibodies which can specifically bind PRO.
[0855] Techniques for producing the monoclonal antibodies are known
in the art and are described, for instance, in Goding, supra.
Immunogens that may be employed include purified PRO, fusion
proteins containing PRO, and cells expressing recombinant PRO on
the cell surface. Selection of the immunogen can be made by the
skilled artisan without undue experimentation.
[0856] Mice, such as Balb/c, are immunized with the PRO immunogen
emulsified in complete Freund's adjuvant and injected
subcutaneously or intraperitoneally in an amount from 1-100
micrograms. Alternatively, the immunogen is emulsified in MPL-TDM
adjuvant (Ribi Immunochemical Research, Hamilton, Mont.) and
injected into the animal's hind foot pads. The immunized mice are
then boosted 10 to 12 days later with additional immunogen
emulsified in the selected adjuvant. Thereafter, for several weeks,
the mice may also be boosted with additional immunization
injections. Serum samples may be periodically obtained from the
mice by retro-orbital bleeding for testing in ELISA assays to
detect anti-PRO antibodies.
[0857] After a suitable antibody titer has been detected, the
animals "positive" for antibodies can be injected with a final
intravenous injection of PRO. Three to four days later, the mice
are sacrificed and the spleen cells are harvested. The spleen cells
are then fused (using 35% polyethylene glycol) to a selected murine
myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL
1597. The fusions generate hybridoma cells which can then be plated
in 96 well tissue culture plates containing HAT (hypoxanthine,
aminopterin, and thymidine) medium to inhibit proliferation of
non-fused cells, mycloma hybrids, and spleen cell hybrids.
[0858] The hybridoma cells will be screened in an ELISA for
reactivity against PRO. Determination of "positive" hybridoma cells
secreting the desired monoclonal antibodies against PRO is within
the skill in the art.
[0859] The positive hybridoma cells can be injected
intraperitoneally into syngeneic Balb/c mice to produce ascites
containing the anti-PRO monoclonal antibodies. Alternatively, the
hybridoma cells can be grown in tissue culture flasks or roller
bottles. Purification of the monoclonal antibodies produced in the
ascites can be accomplished using ammonium sulfate precipitation,
followed by gel exclusion chromatography. Alternatively, affinity
chromatography based upon binding of antibody to protein A or
protein G can be employed.
Example 43
[0860] Purification of PRO Polypeptides Using Specific
Antibodies
[0861] Native or recombinant PRO polypeptides may be purified by a
variety of standard techniques in the art of protein purification.
For example, pro-PRO polypeptide, mature PRO polypeptide, or
pre-PRO polypeptide is purified by immunoaffinity chromatography
using antibodies specific for the PRO polypeptide of interest. In
general, an immunoaffinity column is constructed by covalently
coupling the anti-PRO polypeptide antibody to an activated
chromatographic resin.
[0862] Polyclonal immunoglobulins are prepared from immune sera
either by precipitation with ammonium sulfate or by purification on
immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway,
N.J.). Likewise, monoclonal antibodies are prepared from mouse
ascites fluid by ammonium sulfate precipitation or chromatography
on immobilized Protein A. Partially purified immunoglobulin is
covalently attached to a chromatographic resin such as
CnBr-activated SEPHAROSE.TM. (Pharmacia LKB Biotechnology). The
antibody is coupled to the resin, the resin is blocked, and the
derivative resin is washed according to the manufacturer's
instructions.
[0863] Such an immunoaffinity column is utilized in the
purification of PRO polypeptide by preparing a fraction from cells
containing PRO polypeptide in a soluble form. This preparation is
derived by solubilization of the whole cell or of a subcellular
fraction obtained via differential centrifugation by the addition
of detergent or by other methods well known in the art.
Alternatively, soluble PRO polypeptide containing a signal sequence
may be secreted in useful quantity into the medium in which the
cells are grown.
[0864] A soluble PRO polypeptide-containing preparation is passed
over the immunoaffinity column, and the column is washed under
conditions that allow the preferential absorbance of PRO
polypeptide (e.g., high ionic strength buffers in the presence of
detergent). Then, the column is eluted under conditions that
disrupt antibody/PRO polypeptide binding (e.g., a low pH buffer
such as approximately pH 2-3, or a high concentration of a
chaotrope such as urea or thiocyanate ion), and PRO polypeptide is
collected.
Example 44
[0865] Drug Screening
[0866] This invention is particularly useful for screening
compounds by using PRO polypeptides or binding fragment thereof in
any of a variety of drug screening techniques. The PRO polypeptide
or fragment employed in such a test may either be free in solution,
affixed to a solid support, borne on a cell surface, or located
intracellularly. One method of drug screening utilizes eukaryotic
or prokaryotic host cells which are stably transformed with
recombinant nucleic acids expressing the PRO polypeptide or
fragment. Drugs are screened against such transformed cells in
competitive binding assays. Such cells, either in viable or fixed
form, can be used for standard binding assays. One may measure, for
example, the formation of complexes between PRO polypeptide or a
fragment and the agent being tested. Alternatively, one can examine
the diminution in complex formation between the PRO polypeptide and
its target cell or target receptors caused by the agent being
tested.
[0867] Thus, the present invention provides methods of screening
for drugs or any other agents which can affect a PRO
polypeptide-associated disease or disorder. These methods comprise
contacting such an agent with an PRO polypeptide or fragment
thereof and assaying (I) for the presence of a complex between the
agent and the PRO polypeptide or fragment, or (ii) for the presence
of a complex between the PRO polypeptide or fragment and the cell,
by methods well known in the art. In such competitive binding
assays, the PRO polypeptide or fragment is typically labeled. After
suitable incubation, free PRO polypeptide or fragment is separated
from that present in bound form, and the amount of free or
uncomplexed label is a measure of the ability of the particular
agent to bind to PRO polypeptide or to interfere with the PRO
polypeptide/cell complex.
[0868] Another technique for drug screening provides high
throughput screening for compounds having suitable binding affinity
to a polypeptide and is described in detail in WO 84/03564,
published on Sep. 13, 1984. Briefly stated, large numbers of
different small peptide test compounds are synthesized on a solid
substrate, such as plastic pins or some other surface. As applied
to a PRO polypeptide, the peptide test compounds are reacted with
PRO polypeptide and washed. Bound PRO polypeptide is detected by
methods well known in the art. Purified PRO polypeptide can also be
coated directly onto plates for use in the aforementioned drug
screening techniques. In addition, non-neutralizing antibodies can
be used to capture the peptide and immobilize it on the solid
support.
[0869] This invention also contemplates the use of competitive drug
screening assays in which neutralizing antibodies capable of
binding PRO polypeptide specifically compete with a test compound
for binding to PRO polypeptide or fragments thereof. In this
manner, the antibodies can be used to detect the presence of any
peptide which shares one or more antigenic determinants with PRO
polypeptide.
Example 45
[0870] Rational Drug Design
[0871] The goal of rational drug design is to produce structural
analogs of biologically active polypeptide of interest (i.e., a PRO
polypeptide) or of small molecules with which they interact, e.g.,
agonists, antagonists, or inhibitors. Any of these examples can be
used to fashion drugs which are more active or stable forms of the
PRO polypeptide or which enhance or interfere with the function of
the PRO polypeptide in vivo (c.f., Hodgson, Bio/Technology, 2:
19-21 (1991)).
[0872] In one approach, the three-dimensional structure of the PRO
polypeptide, or of an PRO polypeptide-inhibitor complex, is
determined by x-ray crystallography, by computer modeling or, most
typically, by a combination of the two approaches. Both the shape
and charges of the PRO polypeptide must be ascertained to elucidate
the structure and to determine active site(s) of the molecule. Less
often, useful information regarding the structure of the PRO
polypeptide may be gained by modeling based on the structure of
homologous proteins. In both cases, relevant structural information
is used to design analogous PRO polypeptide-like molecules or to
identify efficient inhibitors. Useful examples of rational drug
design may include molecules which have improved activity or
stability as shown by Braxton and Wells, Biochemistry. 31:7796-7801
(1992) or which act as inhibitors, agonists, or antagonists of
native peptides as shown by Athauda et al., J. Biochem.,
113:742-746 (1993).
[0873] It is also possible to isolate a target-specific antibody,
selected by functional assay, as described above, and then to solve
its crystal structure. This approach, in principle, yields a
pharmacore upon which subsequent drug design can be based. It is
possible to bypass protein crystallography altogether by generating
anti-idiotypic antibodies (anti-ids) to a functional,
pharmacologically active antibody. As a mirror image of a mirror
image, the binding site of the anti-ids would be expected to be an
analog of the original receptor. The anti-id could then be used to
identify and isolate peptides from banks of chemically or
biologically produced peptides. The isolated peptides would then
act as the pharmacore.
[0874] By virtue of the present invention, sufficient amounts of
the PRO polypeptide may be made available to perform such
analytical studies as X-ray crystallography. In addition, knowledge
of the PRO polypeptide amino acid sequence provided herein will
provide guidance to those employing computer modeling techniques in
place of or in addition to x-ray crystallography.
Example 46
[0875] Mouse Kidney Mesangial Cell Proliferation Assay (Assay
92)
[0876] This assay shows that certain polypeptides of the invention
act to induce proliferation of mammalian kidney mesangial cells
and, therefore, are useful for treating kidney disorders associated
with decreased mesangial cell function such as Berger disease or
other nephropathies associated with Schonlein-Henoch purpura,
celiac disease, dermatitis herpetiformis or Crohn disease. The
assay is performed as follows. On day one, mouse kidney mesangial
cells are plated on a 96 well plate in growth media (3:1 mixture of
Dulbecco's modified Eagle's medium and Ham's F12 medium, 95% fetal
bovine serum, 5% supplemented with 14 mM HEPES) and grown
overnight. On day 2, PRO polypeptides are diluted at 2
concentrations(1% and 0.1%) in serum-free medium and added to the
cells. Control samples are serum-free medium alone. On day 4, 20
.mu.l of the Cell Titer 96 Aqueous one solution reagent (Progema)
was added to each well and the colormetric reaction was allowed to
proceed for 2 hours. The absorbance (OD) is then measured at 490
nm. A positive in the assay is anything that gives an absorbance
reading which is at least 15% above the control reading.
[0877] The following polypeptides tested positive in this assay:
PRO1272.
Example 47
[0878] Detection of PRO Polypeptides that Affect Glucose or FFA
Uptake by Primary Rat Adipocytes (Assay 94)
[0879] This assay is designed to determine whether PRO polypeptides
show the ability to affect glucose or FFA uptake by adipocyte
cells. PRO polypeptides testing positive in this assay would be
expected to be useful for the therapeutic treatment of disorders
where either the stimulation or inhibition of glucose uptake by
adipocytes would be beneficial including, for example, obesity,
diabetes or hyper- or hypo-insulinemia.
[0880] In a 96 well format, PRO polypeptides to be assayed are
added to primary rat adipocytes, and allowed to incubate overnight.
Samples are taken at 4 and 16 hours and assayed for glycerol,
glucose and FFA uptake. After the 16 hour incubation, insulin is
added to the media and allowed to incubate for 4 hours. At this
time, a sample is taken and glycerol, glucose and FFA uptake is
measured. Media containing insulin without the PRO polypeptide is
used as a positive reference control. As the PRO polypeptide being
tested may either stimulate or inhibit glucose and FFA uptake,
results are scored as positive in the assay if greater than 1.5
times or less than 0.5 times the insulin control.
[0881] The following PRO polypeptides tested positive as either
stimulators or inhibitors of glucose and/or FFA uptake in this
assay: PRO196, PRO185, PRO210, PRO215, PRO242, PRO288, PRO1183,
PRO1419, PRO9940, PRO301, PRO337 and PRO265.
Example 48
[0882] Stimulation of Adult Heart Hypertrophy (Assay 2)
[0883] This assay is designed to measure the ability of various PRO
polypeptides to stimulate hypertrophy of adult heart. PRO
polypeptides testing positive in this assay would be expected to be
useful for the therapeutic treatment of various cardiac
insufficiency disorders.
[0884] Ventricular myocytes freshly isolated from adult (250 g)
Sprague Dawley rats are plated at 2000 cell/well in 180 .mu.l
volume. Cells are isolated and plated on day 1, the PRO
polypeptide-containing test samples or growth medium only (negative
control) (20 .mu.l volume) is added on day 2 and the cells are then
fixed and stained on day 5. After staining, cell size is visualized
wherein cells showing no growth enhancement as compared to control
cells are given a value of 0.0, cells showing small to moderate
growth enhancement as compared to control cells are given a value
of 1.0 and cells showing large growth enhancement as compared to
control cells are given a value of 2.0. Any degree of growth
enhancement as compared to the negative control cells is considered
positive for the assay.
[0885] The following PRO polypeptides tested positive in this
assay: PRO301.
Example 49
[0886] Inhibition of Vascular Endothelial Growth Factor (VEGF)
Stimulated Proliferation of Endothelial Cell Growth (Assay 9)
[0887] The ability of various PRO polypeptides to inhibit VEGF
stimulated proliferation of endothelial cells was tested.
Polypeptides testing positive in this assay are useful for
inhibiting endothelial cell growth in mammals where such an effect
would be beneficial, e.g., for inhibiting tumor growth.
[0888] Specifically, bovine adrenal cortical capillary endothelial
cells (ACE) (from primary culture, maximum of 12-14 passages) were
plated in 96-well plates at 500 cells/well per 100 microliter.
Assay media included low glucose DMEM, 10% calf serum, 2 mM
glutamine, and 1.times. penicillin/streptomycin/fungizone. Control
wells included the following: (1) no ACE cells added; (2) ACE cells
alone; (3) ACE cells plus 5 ng/ml FGF; (4) ACE cells plus 3 ng/ml
VEGF; (5) ACE cells plus 3 ng/ml VEGF plus 1 ng/ml TGF-beta; and
(6) ACE cells plus 3 ng/ml VEGF plus 5 ng/ml LIF. The test samples,
poly-his tagged PRO polypeptides (in 100 microliter volumes), were
then added to the wells (at dilutions of 1%, 0.1% and 0.01%,
respectively). The cell cultures were incubated for 6-7 days at
37.degree. C./5% CO.sub.2. After the incubation, the media in the
wells wa aspirated, and the cells were washed 1.times. with PBS. An
acid phosphatase reaction mixture (100 microliter; 0.1M sodium
acetate, pH 5.5, 0.1% Triton X-100, 10 mM p-nitrophenyl phosphate)
was then added to each well. After a 2 hour incubation at
37.degree. C., the reaction was stopped by addition of 10
microliters 1N NaOH. Optical density (OD) was measured on a
microplate reader at 405 nm.
[0889] The activity of PRO polypeptides was calculated as the
percent inhibition of VEGF (3 ng/ml) stimulated proliferation (as
determined by measuring acid phosphatase activity at OD 405 nm)
relative to the cells without stimulation. TGF-beta was employed as
an activity reference at 1 ng/ml, since TGF-beta blocks 70-90% of
VEGF-stimulated ACE cell proliferation. The results are indicative
of the utility of the PRO polypeptides in cancer therapy and
specifically in inhibiting tumor angiogenesis. Numerical values
(relative inhibition) are determined by calculating the percent
inhibition of VEGF stimulated proliferation by the PRO polypeptides
relative to cells without stimulation and then dividing that
percentage into the percent inhibition obtained by TGF-.beta. at 1
ng/ml which is known to block 70-90% of VEGF stimulated cell
proliferation. The results are considered positive if the PRO
polypeptide exhibits 30% or greater inhibition of VEGF stimulation
of endothelial cell growth (relative inhibition 30% or
greater).
[0890] The following polypeptide tested positive in this assay:
PRO301, PRO187 and PRO246.
Example 50
[0891] Stimulatory Activity in Mixed Lymphocyte Reaction (MLR)
Assay (Assay 24)
[0892] This example shows that certain polypeptides of the
invention are active as a stimulator of the proliferation of
stimulated T-lymphocytes. Compounds which stimulate proliferation
of lymphocytes are useful therapeutically where enhancement of an
immune response is beneficial. A therapeutic agent may take the
form of antagonists of the polypeptide of the invention, for
example, murine-human chimeric, humanized or human antibodies
against the polypeptide.
[0893] The basic protocol for this assay is described in Current
Protocols in Immunology, unit 3.12; edited by J E Coligan, A M
Kruisbeek, D H Marglies, E M Shevach, W Strober, National Insitutes
of Health, Published by John Wiley & Sons, Inc.
[0894] More specifically, in one assay variant, peripheral blood
mononuclear cells (PBMC) are isolated from mammalian individuals,
for example a human volunteer, by leukopheresis (one donor will
supply stimulator PBMCs, the other donor will supply responder
PBMCs). If desired, the cells are frozen in fetal bovine serum and
DMSO after isolation. Frozen cells may be thawed overnight in assay
media (37.degree. C., 5% CO.sub.2) and then washed and resuspended
to 3.times.10.sup.6 cells/ml of assay media (RPMI; 10% fetal bovine
serum, 1% penicillin/streptomycin, 1% glutamine, 1% HEPES, 1%
non-essential amino acids, 1% pyruvate). The stimulator PBMCs are
prepared by irradiating the cells (about 3000 Rads).
[0895] The assay is prepared by plating in triplicate wells a
mixture of:
[0896] 100:1 of test sample diluted to 1% or to 0.1%,
[0897] 50:1 of irradiated stimulator cells, and
[0898] 50:1 of responder PBMC cells.
[0899] 100 microliters of cell culture media or 100 microliter of
CD4-IgG is used as the control. The wells are then incubated at
37.degree. C., 5% CO.sub.2 for 4 days. On day 5, each well is
pulsed with tritiated thymidine (1.0 mC/well; Amersham). After 6
hours the cells are washed 3 times and then the uptake of the label
is evaluated.
[0900] In another variant of this assay, PBMCs are isolated from
the spleens of Balb/c mice and C57B6 mice. The cells are teased
from freshly harvested spleens in assay media (RPMI; 10% fetal
bovine serum, 1% penicillin/streptomycin, 1% glutamine, 1% HEPES,
1% non-essential amino acids, 1% pyruvate) and the PBMCs are
isolated by overlaying these cells over Lympholyte M (Organon
Teknika), centrifuging at 2000 rpm for 20 minutes, collecting and
washing the mononuclear cell layer in assay media and resuspending
the cells to 1.times.10.sup.7 cells/ml of assay media. The assay is
then conducted as described above.
[0901] Positive increases over control are considered positive with
increases of greater than or equal to 180% being preferred.
However, any value greater than control indicates a stimulatory
effect for the test protein.
[0902] The following PRO polypeptides tested positive in this
assay: PRO533 and PRO301.
Example 51
[0903] PDB12 Cell Proliferation (Assay 29)
[0904] This example demonstrates that various PRO polypeptides have
efficacy in inducing proliferation of PDB12 pancreatic ductal cells
and are, therefore, useful in the therapeutic treatment of
disorders which involve protein secretion by the pancreas,
including diabetes, and the like.
[0905] PDB12 pancreatic ductal cells are plated on fibronectin
coated 96 well plates at 1.5.times.10.sup.3 cells per well in 100
.mu.L/180 .mu.L of growth media. 100 .mu.L of growth media with the
PRO polypeptide test sample or negative control lacking the PRO
polypeptide is then added to well, for a final volume of 200 .mu.L.
Controls contain growth medium containing a protein shown to be
inactive in this assay. Cells are incubated for 4 days at
37.degree. C. 20 .mu.L of Alamar Blue Dye (AB) is then added to
each well and the flourescent reading is measured at 4 hours post
addition of AB, on a microtiter plate reader at 530 nm excitation
and 590 nm emission. The standard employed is cells without Bovine
Pituitary Extract (BPE) and with various concentrations of BPE.
Buffer or growth medium only controls from unknowns are run 2 times
on each 96 well plate.
[0906] Percent increase in protein production is calculated by
comparing the Alamar Blue Dye calculated protein concentration
produced by the PRO polypeptide-treated cells with the Alamar Blue
Dye calculated protein concentration produced by the negative
control cells. A percent increase in protein production of greater
than or equal to 25% as compared to the negative control cells is
considered positive.
[0907] The following PRO polypeptides tested positive in this
assay: PRO301.
Example 52
[0908] Guinea Pig Vascular Leak (Assay 32)
[0909] This assay is designed to determine whether PRO polypeptides
of the present invention show the ability to induce vascular
permeability. Polypeptides testing positive in this assay are
expected to be useful for the therapeutic treatment of conditions
which would benefit from enhanced vascular permeability including,
for example, conditions which may benefit from enhanced local
immune system cell infiltration.
[0910] Hairless guinea pigs weighing 350 grams or more were
anesthetized with Ketamine (75-80 mg/kg) and 5 mg/kg Xylazine
intramuscularly. Test samples containing the PRO polypeptide or a
physiological buffer without the test polypeptide are injected into
skin on the back of the test animals with 100 .mu.l per injection
site intradermally. There were approximately 16-24 injection sites
per animal. One ml of Evans blue dye (1% in PBS) is then injected
intracardially. Skin vascular permeability responses to the
compounds (i.e., blemishes at the injection sites of injection) are
visually scored by measuring the diameter (in mm) of blue-colored
leaks from the site of injection at 1, 6 and 24 hours post
administration of the test materials. The mm diameter of blueness
at the site of injection is observed and recorded as well as the
severity of the vascular leakage. Blemishes of at least 5 mm in
diameter are considered positive for the assay when testing
purified proteins, being indicative of the ability to induce
vascular leakage or permeability. A response greater than 7 mm
diameter is considered positive for conditioned media samples.
Human VEGF at 0.1 .mu.g/100 .mu.l is used as a positive control,
inducing a response of 4-8 mm diameter.
[0911] The following PRO polypeptides tested positive in this
assay: PRO533.
Example 53
[0912] Retinal Neuron Survival (Assay 52)
[0913] This example demonstrates that certain PRO polypeptides have
efficacy in enhancing the survival of retinal neuron cells and,
therefore, are useful for the therapeutic treatment of retinal
disorders or injuries including, for example, treating sight loss
in mammals due to retinitis pigmentosum, AMD, etc.
[0914] Sprague Dawley rat pups at postnatal day 7 (mixed
population: glia and retinal neuronal types) are killed by
decapitation following CO.sub.2 anesthesia and the eyes are removed
under sterile conditions. The neural retina is dissected away from
the pigment epithelium and other ocular tissue and then dissociated
into a single cell suspension using 0.25% trypsin in Ca.sup.2+,
Mg.sup.2+-free PBS. The retinas are incubated at 37.degree. C. for
7-10 minutes after which the trypsin is inactivated by adding 1 ml
soybean trypsin inhibitor. The cells are plated at 100,000 cells
per well in 96 well plates in DMEM/F12 supplemented with N2 and
with or without the specific test PRO polypeptide. Cells for all
experiments are grown at 37.degree. C. in a water saturated
atmosphere of 5% CO.sub.2. After 2-3 days in culture, cells are
stained with calcein AM then fixed using 4% paraformaldehyde and
stained with DAPI for determination of total cell count. The total
cells (fluorescent) are quantified at 20.times. objective
magnification using CCD camera and NIH image software for McIntosh.
Fields in the well are chosen at random.
[0915] The effect of various concentration of PRO polypeptides are
reported herein where percent survival is calculated by dividing
the total number of calcein AM positive cells at 2-3 days in
culture by the total number of DAPI-labeled cells at 2-3 days in
culture. Anything above 30% survival is considered positive.
[0916] The following PRO polypeptides tested positive in this assay
using polypeptide concentrations within the range of 0.01 % to 1.0%
in the assay: PRO350.
Example 54
[0917] Proliferation of Rat Utricular Supporting Cells (Assay
54)
[0918] This assay shows that certain polypeptides of the invention
act as potent mitogens for inner ear supporting cells which are
auditory hair cell progenitors and, therefore, are useful for
inducing the regeneration of auditory hair cells and treating
hearing loss in mammals. The assay is performed as follows. Rat
UEC-4 utricular epithelial cells are aliquoted into 96 well plates
with a density of 3000 cells/well in 200 .mu.l of serum-containing
medium at 33.degree. C. The cells are cultured overnight and are
then switched to serum-free medium at 37.degree. C. Various
dilutions of PRO polypeptides (or nothing for a control) are then
added to the cultures and the cells are incubated for 24 hours.
After the 24 hour incubation, .sup.3H-thymidine (1 .mu.Ci/well) is
added and the cells are then cultured for an additional 24 hours.
The cultures are then washed to remove unincorporated radiolabel,
the cells harvested and Cpm per well determined. Cpm of at least
30% or greater in the PRO polypeptide treated cultures as compared
to the control cultures is considered a positive in the assay.
[0919] The following polypeptides tested positive in this assay:
PRO337.
Example 55
[0920] Rod Photoreceptor Cell Survival (Assay 56)
[0921] This assay shows that certain polypeptides of the invention
act to enhance the survival/proliferation of rod photoreceptor
cells and, therefore, are useful for the therapeutic treatment of
retinal disorders or injuries including, for example, treating
sight loss in mammals due to retinitis pigmentosum, AMD, etc.
[0922] Sprague Dawley rat pups at 7 day postnatal (mixed
population: glia and retinal neuronal cell types) are killed by
decapitation following CO.sub.2 anesthesis and the eyes are removed
under sterile conditions. The neural retina is dissected away form
the pigment epithelium and other ocular tissue and then dissociated
into a single cell suspension using 0.25% trypsin in Ca.sup.2+,
Mg.sup.2+-free PBS. The retinas are incubated at 37.degree. C. for
7-10 minutes after which the trypsin is inactivated by adding 1 ml
soybean trypsin inhibitor. The cells are plated at 100,000 cells
per well in 96 well plates in DMEM/F12 supplemented with N.sub.2.
Cells for all experiments are grown at 37.degree. C. in a water
saturated atmosphere of 5 % CO.sub.2. After 2-3 days in culture,
cell are fixed using 4% paraformaldehyde, and then stained using
CellTracker Green CMFDA. Rho 4D2 (ascites or IgG 1:100), a
monoclonal antibody directed towards the visual pigment rhodopsin
is used to detect rod photoreceptor cells by indirect
immunofluorescence. The results are calculated as % survival: total
number of calcein--rhodopsin positive cells at 2-3 days in culture,
divided by the total number of rhodopsin positive cells at time 2-3
days in culture. The total cells (fluorescent) arc quantified at
20.times. objective magnification using a CCD camera and NIH image
software for MacIntosh. Fields in the well are chosen at
random.
[0923] The following polypeptides tested positive in this assay:
PRO350.
Example 56
[0924] Skin Vascular Permeability Assay (Assay 64)
[0925] This assay shows that certain polypeptides of the invention
stimulate an immune response and induce inflammation by inducing
mononuclear cell, eosinophil and PMN infiltration at the site of
injection of the animal. Compounds which stimulate an immune
response are useful therapeutically where stimulation of an immune
response is beneficial. This skin vascular permeability assay is
conducted as follows. Hairless guinea pigs weighing 350 grams or
more are anesthetized with ketamine (75-80 mg/Kg) and 5 mg/Kg
xylazine intramuscularly (1M). A sample of purified polypeptide of
the invention or a conditioned media test sample is injected
intradermally onto the backs of the test animals with 100 .mu.l per
injection site. It is possible to have about 10-30, preferably
about 16-24, injection sites per animal. One .mu.l of Evans blue
dye (1% in physiologic buffered saline) is injected intracardially.
Blemishes at the injection sites are then measured (mm diameter) at
1 hr and 6 hr post injection. Animals were sacrificed at 6 hrs
after injection. Each skin injection site is biopsied and fixed in
formalin. The skins are then prepared for histopathologic
evaluation. Each site is evaluated for inflammatory cell
infiltration into the skin. Sites with visible inflammatory cell
inflammation are scored as positive. Inflammatory cells may be
neufrophilic, eosinophilic, monocytic or lymphocytic. At least a
minimal perivascular infiltrate at the injection site is scored as
positve, no infiltrate at the site of injection is scored as
negative.
[0926] The following polypeptide tested positive in this assay:
PRO301.
Example 57
[0927] Induction of Endothelial Cell Apoptosis (Assay 73)
[0928] The ability of PRO polypeptides to induce apoptosis in
endothelial cells was tested in human venous umbilical vein
endothelial cells (HUVEC, Cell Systems). A positive test in the
assay is indicative of the usefulness of the polypeptide in
therapeutically treating tumors as well as vascular disorders where
inducing apoptosis of endothielial cells would be beneficial.
[0929] The cells were plated on 96-well microtiter plates (Amersham
Life Science, cytostar-T scintillating microplate, RPNQ160,
sterile, tissue-culture treated, individually wrapped), in 10%
serum (CSG-medium, Cell Systems), at a density of 2.times.10.sup.4
cells per well in a total volume of 100 .mu.l. On day 2, test
samples containing the PRO polypeptide were added in triplicate at
dilutions of 1%, 0.33% and 0.11%. Wells without cells were used as
a blank and wells with cells only were used as a negative control.
As a positive control 1:3 serial dilutions of 50 .mu.l of a
3.times. stock of staurosporine were used. The ability of the PRO
polypeptide to induce apoptosis was determined by processing of the
96 well plates for detection of Annexin V, a member of the calcium
and phospholipid binding proteins, to detect apoptosis.
[0930] 0.2 ml Annexin V--Biotin stock solution (100 .mu.g/ml) was
diluted in 4.6 ml 2.times.Ca.sup.2+ binding buffer and 2.5 % BSA
(1:25 dilution). 50 .mu.l of the diluted Annexin V - Biotin
solution was added to each well (except controls) to a final
concentration of 1.0 .mu.g/ml. The samples were incubated for 10-15
minutes with Annexin-Biotin prior to direct addition of
.sup.3S-Streptavidin. .sup.35S-Streptavidin was diluted in
2.times.Ca.sup.2+ Binding buffer, 2.5% BSA and was added to all
wells at a final concentration of 3.times.10.sup.4 cpm/well. The
plates were then sealed, centrifuged at 1000 rpm for 15 minutes and
placed on orbital shaker for 2 hours. The analysis was performed on
a 1450 Microbeta Trilux (Wallac). Percent above background
represents the percentage amount of counts per minute above the
negative controls. Percents greater than or equal to 30% above
background are considered positive.
[0931] The following PRO polypeptides tested positive in this
assay: PRO301.
Example 58
[0932] Induction of c-fos in Cortical Neurons (Assay 83)
[0933] This assay is designed to determine whether PRO polypeptides
show the ability to induce c-fos in cortical neurons. PRO
polypeptides testing positive in this assay would be expected to be
useful for the therapeutic treatment of nervous system disorders
and injuries where neuronal proliferation would be beneficial.
[0934] Cortical neurons are dissociated and plated in growth medium
at 10,000 cells per well in 96 well plates. After aproximately 2
cellular divisions, the cells are treated for 30 minutes with the
PRO polypeptide or nothing (negative control). The cells are then
fixed for 5 minutes with cold methanol and stained with an antibody
directed against phosphorylated CREB. mRNA levels are then
calculated using chemiluminiescence. A positive in the assay is any
factor that results in at least a 2-fold increase in c-fos message
as compared to the negative controls.
[0935] The following PRO polypeptides tested positive in this
assay: PRO288.
Example 59
[0936] Induction of Pancreatic .beta.-Cell Precursor
Differentiation (Assay 89)
[0937] This assay shows that certain polypeptides of the invention
act to induce differentiation of pancreatic .beta.-cell precursor
cells into mature pancreatic .beta.-cells and, therefore, are
useful for treating various insulin deficient states in mammals,
including diabetes mellitus. The assay is performed as follows. The
assay uses a primary culture of mouse fetal pancreatic cells and
the primary readout is an alteration in the expression of markers
that represent either .beta.-cell precursors or mature
.beta.-cells. Marker expression is measured by real time
quantitative PCR (RTQ-PCR); wherein the marker being evaluated is
insulin.
[0938] The pancreata are dissected from E14 embryos (CD1 mice). The
pancreata arc then digested with collagenase/dispase in F12/DMEM at
37.degree. C. for 40 to 60 minutes (collagenase/dispase, 1.37
mg/ml, Boehringer Mannheim, #1097113). The digestion is then
neutralized with an equal volume of 5% BSA and the cells are washed
once with RPM 1640. At day 1, the cells are seeded into 12-well
tissue culture plates (pre-coated with laminin, 20 .mu.g/ml in PBS,
Boehringer Mannheim, #124317). Cells from pancreata from 1-2
embryos are distributed per well. The culture medium for this
primary culture is 14F/1640. At day 2, the media is removed and the
attached cells washed with RPMI/1640. Two mls of minimal media are
added in addition to the protein to be tested. At day 4, the media
is removed and RNA prepared from the cells and marker expression
analyzed by real time quantitative RT-PCR. A protein is considered
to be active in the assay if it increases the expression of the
relevant P-cell marker as compared to untreated controls.
[0939] 14F/1640 is RPM11640 (Gibco) plus the following:
[0940] group A 1:1000
[0941] group B 1:1000
[0942] recombinant human insulin 10 .mu.g/ml
[0943] Aprotinin (50 .mu.g/ml) 1:2000 (Boehringer manheim
#981532)
[0944] Bovine pituitary extract (BPE) 60 .mu.g/ml
[0945] Gentamycin 100 ng/ml
[0946] Group A: (in 10 ml PBS)
[0947] Transferrin, 100 mg (Sigma T2252)
[0948] Epidermal Growth Factor, 100 .mu.g (BRL 100004)
[0949] Triiodothyronine, 10 .mu.l of 5.times.10.sup.4 M (Sigma
T5516)
[0950] Ethanolamine, 100 .mu.l of 10.sup.-1 M (Sigma E0135)
[0951] Phosphoethalamine, 100 .mu.l of 10.sup.-1 M (Sigma
P0503)
[0952] Selenium, 4 .mu.l of 10.sup.-1 M (Aesar #12574)
[0953] Group C : (in 10 ml 100% ethanol)
[0954] Hydrocortisone, 2 .mu.l of 5.times.10.sup.-3 M (Sigma
#H0135)
[0955] Progesterone, 100 .mu.l of 1.times.10.sup.-3 M (Sigma
#P6149)
[0956] Forskolin, 500 .mu.l of 20 mM (Calbiochem #344270)
[0957] Minimal media:
[0958] RPMI 1640 plus transferrin (10 .mu.g/ml), insulin (1
.mu.g/ml), gentamycin (100 ng/ml), aprotinin (50 .mu.g/ml) and BPE
(15 .mu.g/ml).
[0959] Defined media:
[0960] RPMI 1640 plus transferrin (10 .mu.g/ml), insulin (1
.mu.g/ml), gentamycin (100 ng/ml) and aprotinin (50 .mu.g/ml).
[0961] The following polypeptides were positive in this assay:
PRO1361, PRO1308, PRO1600 and PRO4356.
Example 60
[0962] Pericyte c-Fos Induction (Assay 93)
[0963] This assay shows that certain polypeptides of the invention
act to induce the expression of c-fos in pericyte cells and,
therefore, are useful not only as diagnostic markers for particular
types of pericyte-associated tumors but also for giving rise to
antagonists which would be expected to be useful for the
therapeutic treatment of pericyte-associated tumors. Induction of
c-fos expression in pericytes is also indicative of the induction
of angiogenesis and, as such, PRO polypeptides capable of inducing
the expression of c-fos would be expected to be useful for the
treatment of conditions where induced angiogenesis would be
beneficial including, for example, wound healing, and the like.
Specifically, on day 1, pericytes are received from VEC
Technologies and all but 5 ml of media is removed from flask. On
day 2, the pericytes are trypsinized, washed, spun and then plated
onto 96 well plates. On day 7, the media is removed and the
pericytes are treated with 100 .mu.l of PRO polypeptide test
samples and controls (positive control=DME+5% serum +/-PDGF at 500
ng/ml; negative control=protein 32). Replicates are averaged and
SD/CV are determined. Fold increase over Protein 32 (buffer
control) value indicated by chemiluminescence units (RLU)
luminometer reading verses frequency is plotted on a histogram.
Two-fold above Protein 32 value is considered positive for the
assay. ASY Matrix: Growth media=low glucose DMEM=20%
FBS+1.times.pen strep+1.times.fungizone. Assay Media=low glucose
DMEM+5% FBS.
[0964] The following polypeptides tested positive in this assay:
PRO444 and PRO217.
Example 61
[0965] Detection of Polypeptides that Affect Glucose or FFA Uptake
in Skeletal Muscle (Assay 106)
[0966] This assay is designed to determine whether PRO polypeptides
show the ability to affect glucose or FFA uptake by skeletal muscle
cells. PRO polypeptides testing positive in this assay would be
expected to be useful for the therapeutic treatment of disorders
where either the stimulation or inhibition of glucose uptake by
skeletal muscle would be beneficial including, for example,
diabetes or hyper- or hypo-insulinemia.
[0967] In a 96 well format, PRO polypeptides to be assayed are
added to primary rat differentiated skeletal muscle, and allowed to
incubate overnight. Then fresh media with the PRO polypeptide and
+/- insulin are added to the wells. The sample media is then
monitored to determine glucose and FFA uptake by the skeletal
muscle cells. The insulin will stimulate glucose and FFA uptake by
the skeletal muscle, and insulin in media without the PRO
polypeptide is used as a positive control, and a limit for scoring.
As the PRO polypeptide being tested may either stimulate or inhibit
glucose and FFA uptake, results are scored as positive in the assay
if greater than 1.5 times or less than 0.5 times the insulin
control.
[0968] The following PRO polypeptides tested positive as either
stimulators or inhibitors of glucose and/or FFA uptake in this
assay: PRO196, PRO183, PRO185, PRO215, PRO288, PRO1361, PRO1600,
PRO4999, PRO7170, PRO533 and PRO187.
Example 62
[0969] Fetal Hemoglobin Induction in an Erythroblastic Cell Line
(Assay 107)
[0970] This assay is useful for screening PRO polypeptides for the
ability to induce the switch from adult hemoglobin to fetal
hemoglobin in an erythroblastic cell line. Molecules testing
positive in this assay are expected to be useful for
therapeutically treating various mammalian hemoglobin-associated
disorders such as the various thalassemias. The assay is performed
as follows. Erythroblastic cells are plated in standard growth
medium at 1000 cells/well in a 96 well format. PRO polypeptides are
added to the growth medium at a concentration of 0.2% or 2% and the
cells are incubated for 5 days at 37.degree. C. As a positive
control, cells are treated with 100 .mu.M hemin and as a negative
control, the cells are untreated. After 5 days, cell lysates are
prepared and analyzed for the expression of gamma globin (a fetal
marker). A positive in the assay is a gamma globin level at least
2-fold above the negative control.
[0971] The following polypeptides tested positive in this assay:
PRO1419.
Example 63
[0972] Chondrocyte Re-differentiation Assay (Assay 110)
[0973] This assay shows that certain polypeptides of the invention
act to induce redifferentiation of chondrocytes, therefore, are
expected to be useful for the treatment of various bone and/or
cartilage disorders such as, for example, sports injuries and
arthritis. The assay is performed as follows. Porcine chondrocytes
are isolated by overnight collagenase digestion of articulary
cartilage of metacarpophalangeal joints of 4-6 month old female
pigs. The isolated cells are then seeded at 25,000 cells/cm.sup.2
in Ham F-12 containing 10% FBS and 4 .mu.g/ml gentamycin. The
culture media is changed every third day and the cells are then
seeded in 96 well plates at 5,000 cells/well in 100 .mu.l of the
same media without serum and 100 .mu.l of the test PRO polypeptide,
5 nM staurosporin (positive control) or medium alone (negative
control) is added to give a final volume of 200 .mu.l/well. After 5
days of incubation at 37.degree. C., a picture of each well is
taken and the differentiation state of the chondrocytes is
determined. A positive result in the assay occurs when the
redifferentiation of the chondrocytes is determined to be more
similar to the positive control than the negative control.
[0974] The following polypeptide tested positive in this assay:
PRO215, PRO353, PRO365, PRO1272, PRO301 and PRO337.
Example 64
[0975] Chondrocyte Proliferation Assay (Assay 111)
[0976] This assay is designed to determine whether PRO polypeptides
of the present invention show the ability to induce the
proliferation and/or redifferentiation of chondrocytes in culture.
PRO polypeptides testing positive in this assay would be expected
to be useful for the therapeutic treatment of various bone and/or
cartilage disorders such as, for example, sports injuries and
arthritis.
[0977] Porcine chondrocytes are isolated by overnight collagenase
digestion of articular cartilage of the metacarpophalangeal joint
of 4-6 month old female pigs. The isolated cells are then seeded at
25,000 cells/cm.sup.2 in Ham F-12 containing 10% FBS and 4 .mu.g/ml
gentamycin. The culture media is changed every third day and the
cells are reseeded to 25,000 cells/cm.sup.2 every five days. On day
12, the cells are seeded in 96 well plates at 5,000 cells/well in
100 .mu.l of the same media without serum and 100 .mu.l of either
serum-free medium (negative control), staurosporin (final
concentration of 5 nM; positive control) or the test PRO
polypeptide are added to give a final volume of 200 .mu.l/well.
After 5 days at 37.degree. C., 20 .mu.l of Alamar blue is added to
each well and the plates are incubated for an additional 3 hours at
37.degree. C. The fluorescence is then measured in each well
(Ex:530 nm; Em: 590 nm). The fluorescence of a plate containing 200
.mu.l of the serum-free medium is measured to obtain the
background. A positive result in the assay is obtained when the
fluorescence of the PRO polypeptide treated sample is more like
that of the positive control than the negative control.
[0978] The following PRO polypeptides tested positive in this
assay: PRO215, PRO217, PRO248, PRO 1361, PRO1419, PRO533 and
PRO265.
Example 65
[0979] Mouse Mesengial Cell Inhibition Assay (Assay 114)
[0980] This assay is designed to determine whether PRO polypeptides
of the present invention show the ability to inhibit the
proliferation of mouse mesengial cells in culture. PRO polypeptides
testing positive in this assay would be expected to be useful for
the therapeutic treatment of such diseases or conditions where
inhibition of mesengial cell proliferation would be beneficial such
as, for example, cystic renal dysplasia, polycystic kidney disease,
or other kidney disease assoiciated with abnormal mesengial cell
proliferation, renal tumors, and the like.
[0981] On day 1, mouse mesengial cells are plated on a 96 well
plate in growth medium (a 3:1 mixture of Dulbecco's modified
Eagle's medium and Ham's F12 medium, 95%; fetal bovine serum, 5%;
supplemented with 14 mM HEPES) and then are allowed to grow
overnight. On day 2, the PRO polypeptide is diluted at 2 different
concentrations (1%, 0.1%) in serum-free medium and is added to the
cells. The negative control is growth medium without added PRO
polypeptide. After the cells are allowed to incubate for 48 hours,
20 .mu.l of the Cell Titer 96 Aqueous one solution reagent
(Promega) is added to each well and the colormetric reaction is
allowed to proceed for 2 hours. The absorbance (OD) is then
measured at 490 nm. A positive in the assay is an absorbance
reading which is at least 10% above the negative control.
[0982] The following PRO polypeptides tested positive in this
assay: PRO1318.
Example 66
[0983] Induction of Pancreatic .beta.-Cell Precursor Proliferation
(Assay 117)
[0984] This assay shows that certain polypeptides of the invention
act to induce an increase in the number of pancreatic .beta.-cell
precursor cells and, therefore, are useful for treating various
insulin deficient states in mammals, including diabetes mellitus.
The assay is performed as follows. The assay uses a primary culture
of mouse fetal pancreatic cells and the primary readout is an
alteration in the expression of markers that represent either
.beta.-cell precursors or mature .beta.-cells. Marker expression is
measured by real time quantitative PCR (RTQ-PCR); wherein the
marker being evaluated is a transcription factor called Pdx1.
[0985] The pancreata are dissected from E14 embryos (CDI mice). The
pancreata are then digested with collagenase/dispase in F12/DMEM at
37.degree. C. for 40 to 60 minutes (collagenase/dispase, 1.37
mg/ml, Boehringer Mannheim, #1097113). The digestion is then
neutralized with an equal volume of 5% BSA and the cells are washed
once with RPMI 1640. At day 1, the cells are seeded into 12-well
tissue culture plates (pre-coated with laminin, 20 .mu.g/ml in PBS,
Boehringer Mannheim, #124317). Cells from pancreata from 1-2
embryos are distributed per well. The culture medium for this
primary culture is 14F/1640. At day 2, the media is removed and the
attached cells washed with RPMI/1640. Two mis of minimal media are
added in addition to the protein to be tested. At day 4, the media
is removed and RNA prepared from the cells and marker expression
analyzed by real time quantitative RT-PCR. A protein is considered
to be active in the assay if it increases the expression of the
relevant .beta.-cell marker as compared to untreated controls.
[0986] 14F/1640 is RPMI1640 (Gibco) plus the following:
[0987] group A 1:1000
[0988] group B 1:1000
[0989] recombinant human insulin 10 .mu.g/ml
[0990] Aprotinin (50 .mu.g/ml) 1:2000 (Boehringer manheim
#981532)
[0991] Bovine pituitary extract (BPE) 60 .mu.g/ml
[0992] Gentamycin 100 ng/ml
[0993] Group A: (in 10 ml PBS)
[0994] Transferrin, 100 mg (Sigma T2252)
[0995] Epidermal Growth Factor, 100 .mu.g (BRL 100004)
[0996] Triiodothyronine, 10 .mu.l of 5.times.10.sup.-6 M (Sigma
T5516)
[0997] Ethanolamine, 100 .mu.l of 10.sup.-1 M (Sigma E0135)
[0998] Phosphoethalamine, 100 .mu.l of 10.sup.-1 M (Sigma
P0503)
[0999] Selenium, 4 .mu.l of 10.sup.-1 M (Aesar #12574)
[1000] Group C: (in 10 ml 100% ethanol)
[1001] Hydrocortisone, 2 .mu.l of 5.times.10.sup.-3 M (Sigma
#H0135)
[1002] Progesterone, 100 .mu.l of 1.times.10.sup.-3 M (Sigma
#P6149)
[1003] Forskolin, 500 .mu.l of 20 mM (Calbiochem #344270)
[1004] Minimal media:
[1005] RPMI 1640 plus transferrin (10 .mu.g/ml), insulin (1
.mu.g/ml), gentamycin (100 ng/ml), aprotinin (50 .mu.g/ml) and BPE
(15 .mu.g/ml).
[1006] Defined media:
[1007] RPMI 1640 plus transferrin (10 .mu.g/ml), insulin (1
.mu.g/ml), gentamycin (100 ng/ml) and aprotinin (50 .mu.g/ml).
[1008] The following polypeptides tested positive in this assay:
PRO183, PRO185, PRO288.
Example 67
[1009] In Vitro Antitumor Assay (Assay 161)
[1010] The antiproliferative activity of various PRO polypeptides
was determined in the investigational, disease-oriented in vitro
anti-cancer drug discovery assay of the National Cancer Institute
(NCI), using a sulforhodamine B (SRB) dye binding assay essentially
as described by Skehan et al., J. Natl. Cancer Inst. 82:1107-1112
(1990). The 60 tumor cell lines employed in this study ("the NCI
panel"), as well as conditions for their maintenance and culture in
vitro have been described by Monks et al., J. Natl. Cancer Inst.
83:757-766 (1991). The purpose of this screen is to initially
evaluate the cytotoxic and/or cytostatic activity of the test
compounds against different types of tumors (Monks et al., supra;
Boyd, Cancer: Princ. Pract. Oncol. Update 3(10):1-12 [1989]).
[1011] Cells from approximately 60 human tumor cell lines were
harvested with trypsin/EDTA (Gibco), washed once, resuspended in
IMEM and their viability was determined. The cell suspensions were
added by pipet (100 .mu.L volume) into separate 96-well microtiter
plates. The cell density for the 6-day incubation was less than for
the 2-day incubation to prevent overgrowth. Inoculates were allowed
a preincubation period of 24 hours at 37.degree. C. for
stabilization. Dilutions at twice the intended test concentration
were added at time zero in 100 .mu.L aliquots to the microtiter
plate wells (1:2 dilution). Test compounds were evaluated at five
half-log dilutions (1000 to 100,000-fold). Incubations took place
for two days and six days in a 5% CO.sub.2 atmosphere and 100%
humidity.
[1012] After incubation, the medium was removed and the cells were
fixed in 0.1 ml of 10% trichloroacetic acid at 40.degree. C. The
plates were rinsed five times with deionized water, dried, stained
for 30 minutes with 0.1 ml of 0.4% sulforhodamine B dye (Sigma)
dissolved in 1% acetic acid, rinsed four times with 1% acetic acid
to remove unbound dye, dried, and the stain was extracted for five
minutes with 0.1 ml of 10 mM Tris base
[tris(hydroxymethyl)aminomethane], pH 10.5. The absorbance (OD) of
sulforhodamine B at 492 nm was measured using a
computer-interfaced, 96-well microtiter plate reader.
[1013] A test sample is considered positive if it shows at least
50% growth inhibitory effect at one or more concentrations. The
positive results are shown in the following Table 7.
8TABLE 7 Compound Tumor Type Designation PRO301 NSCL NCI-H322M
PRO301 Leukemia MOLT-4; SR PRO301 NSCL A549/ATCC; EKVX; PRO301 NSCL
NCI-H23; NCI-460; NCI-H226 PRO301 Colon COLO 205; HCC-2998; PRO301
Colon HCT-15; KM12; HT29; PRO301 Colon HCT-116 PRO301 CNS SF-268;
SF-295; SNB-19 PRO301 Melanoma MALME-3M; SK-MEL-2; PRO301 Melanoma
SK-MEL-5;UACC-257 PRO301 Melanoma UACC-62 PRO301 Ovarian IGROV1;
OVCAR-4 PRO301 Ovarian OVCAR-5 PRO301 Ovarian OVCAR-8; SK0OV-3
PRO301 Renal ACHN; CAKI-1; TK-10; UO-31 PRO301 Prostate PC-3;
DU-145 PRO301 Breast NCI/ADR-RES; HS 578T PRO301 Breast MDA-MB-435;
MDA-N; T-47D PRO301 Melanoma M14 PRO301 Leukemia CCRF-CEM ;
HL-60(TB); K-562 PRO301 Leukemia RPMI-8226 PRO301 Melanoma LOX IMVI
PRO301 Renal 786-0; SN12C PRO301 Breast MCF7; MDA-MB-231/ATCC
PRO301 Breast BT-549 PRO301 NSCL HOP-62 PRO301 CNS SF-539 PRO301
Ovarian OVCAR-3
[1014] The results of these assays demonstrate that the positive
testing PRO polypeptides are useful for inhibiting neoplastic
growth in a number of different tumor cell types and may be used
therapeutically therefor. Antibodies against these PRO polypeptides
are useful for affinity purification of these useful polypeptides.
Nucleic acids encoding these PRO polypeptides are useful for the
recombinant preparation of these polypeptides.
Example 68
[1015] Gene Amplification in Tumors
[1016] This example shows that certain PRO polypeptide-encoding
genes are amplified in the genome of certain human lung, colon
and/or breast cancers and/or cell lines. Amplification is
associated with overexpression of the gene product, indicating that
the polypeptides are useful targets for therapeutic intervention in
certain cancers such as colon, lung, breast and other cancers and
diagnostic determination of the presence of those cancers.
Therapeutic agents may take the form of antagonists of the PRO
polypeptide, for example, murine-human chimeric, humanized or human
antibodies against a PRO polypeptide.
[1017] The starting material for the screen was genomic DNA
isolated from a variety cancers. The DNA is quantitated precisely,
e.g., fluorometrically. As a negative control, DNA was isolated
from the cells of ten normal healthy individuals which was pooled
and used as assay controls for the gene copy in healthy individuals
(not shown). The 5' nuclease assay (for example, TaqMan.TM.) and
real-time quantitative PCR (for example, ABI Prizm 7700 Sequence
Detection System.TM. (Perkin Elmer, Applied Biosystems Division,
Foster City, Calif.)), were used to find genes potentially
amplified in certain cancers. The results were used to determine
whether the DNA encoding the PRO polypeptide is over-represented in
any of the primary lung or colon cancers or cancer cell lines or
breast cancer cell lines that were screened. The primary lung
cancers were obtained from individuals with tumors of the type and
stage as indicated in Table 8. An explanation of the abbreviations
used for the designation of the primary tumors listed in Table 8
and the primary tumors and cell lines referred to throughout this
example are given below.
[1018] The results of the TaqMan.TM. are reported in delta
(.DELTA.) Ct units. One unit corresponds to 1 PCR cycle or
approximately a 2-fold amplification relative to normal, two units
corresponds to 4-fold, 3 units to 8-fold amplification and so on.
Quantitation was obtained using primers and a TaqMan.TM.
fluorescent probe derived from the PRO polypeptide-encoding gene.
Regions of the PRO polypeptide-encoding gene which are most likely
to contain unique nucleic acid sequences and which are least likely
to have spliced out introns are preferred for the primer and probe
derivation, e.g., 3'-untranslated regions. The sequences for the
primers and probes (forward, reverse and probe) used for the PRO
polypeptide gene amplification analysis were as follows:
[1019] PRO533 (DNA49435-1219)
[1020] forward: 5'-GGGACGTGCTTCTACAAGAACAG-3' (SEQ ID NO:140)
[1021] reverse: 5'-CAGGCTTACAATGTTATGATCAGACA-3' (SEQ ID
NO:141)
[1022] probe: 5'-TATTCAGAGTTTTCCATTGGCAGTGCCAGTT-3' (SEQ ID
NO:142)
[1023] PRO187 (DNA27864-1155)
[1024] forward: 5'-GGCCTTGCAGACAACCGT-3' (SEQ ID NO:143)
[1025] reverse: 5'-CAGACTGAGGGAGATCCGAGA-3' (SEQ ID NO:144)
[1026] probe: 5'-GCAGATTTTGAGGACAGCCACCTCCA-3' (SEQ ID NO:145)
[1027] forward2: 5'-CATCAAGCGCCTCTACCA-3' (SEQ ID NO:146)
[1028] reverse2: 5'-CACAAACTCGAACTGCTTCTG-3' (SEQ ID NO:147)
[1029] probe2: 5'-CAGCTGCCCTTCCCCAACCA-3' (SEQ ID NO:148)
[1030] PRO246 (DNA35639-1172)
[1031] forward: 5'-GGCAGAGACTTCCAGTCACTGA-3' (SEQ ID NO:149)
[1032] reverse: 5'-GCCAAGGGTGGTGTTAGATAGG-3' (SEQ ID NO:150)
[1033] probe: 5'-CAGGCCCCCTTGATCTGTACCCCA-3' (SEQ ID NO:151)
[1034] The 5' nuclease assay reaction is a fluorescent PCR-based
technique which makes use of the 5' exonuclease activity of Taq DNA
polymerase enzyme to monitor amplification in real time. Two
oligonucleotide primers (forward [.f] and reverse [.r]) are used to
generate an amplicon typical of a PCR reaction. A third
oligonucleotide, or probe (.p), is designed to detect nucleotide
sequence located between the two PCR primers. The probe is
non-extendible by Taq DNA polymerase enzyme, and is labeled with a
reporter fluorescent dye and a quencher fluorescent dye. Any
laser-induced emission from the reporter dye is quenched by the
quenching dye when the two dyes are located close together as they
are on the probe. During the amplification reaction, the Taq DNA
polymerase enzyme cleaves the probe in a template-dependent manner.
The resultant probe fragments disassociate in solution, and signal
from the released reporter dye is free from the quenching effect of
the second fluorophore. One molecule of reporter dye is liberated
for each new molecule synthesized, and detection of the unquenched
reporter dye provides the basis for quantitative interpretation of
the data.
[1035] The 5' nuclease procedure is run on a real-time quantitative
PCR device such as the ABI Prism 7700TM Sequence Detection. The
system consists of a thermocycler, laser, charge-coupled device
(CCD) camera and computer. The system amplifies samples in a
96-well format on a thermocycler. During amplification,
laser-induced fluorescent signal is collected in real-time through
fiber optics cables for all 96 wells, and detected at the CCD. The
system includes software for running the instrument and for
analyzing the data.
[1036] 5' Nuclease assay data are initially expressed as Ct, or the
threshold cycle. This is defined as the cycle at which the reporter
signal accumulates above the background level of fluorescence. The
.DELTA.Ct values are used as quantitative measurement of the
relative number of starting copies of a particular target sequence
in a nucleic acid sample when comparing cancer DNA results to
normal human DNA results.
[1037] Table 8 describes the stage, T stage and N stage of various
primary tumors which were used to screen the PRO polypeptide
compounds of the invention.
9TABLE 8 Primary Lung and Colon Tumor Profiles Primary Tumor Stage
Stage Other Stage Dukes Stage T Stage N Stage Human lung tumor
AdenoCa (SRCC724) [LT1] IIA T1 N1 Human lung tumor SqCCa (SRCC725)
[LT1a] IIB T3 N0 Human lung tumor AdenoCa (SRCC726) [LT2] IB T2 N0
Human lung tumor AdenoCa (SRCC727) [LT3] IIIA T1 N2 Human lung
tumor AdenoCa (SRCC728) [LT4] IB T2 N0 Human lung tumor SqCCa
(SRCC729) [LT6] IB T2 N0 Human lung tumor Aden/SqCCa (SRCC730)
[LT7] IA T1 N0 Human lung tumor AdenoCa (SRCC731) [LT9] IB T2 N0
Human lung tumor SqCCa (SRCC732) [LT10] IIB T2 N1 Human lung tumor
SqCCa (SRCC733) [LT11] IIA T1 N1 Human lung tumor AdenoCa (SRCC734)
[LT12] IV T2 N0 Human lung tumor AdenoSqCCa (SRCC735) [LT13] IB T2
N0 Human lung tumor SqCCa (SRCC736) [LT15] IB T2 N0 Human iung
tumor SqCCa (SRCC737) [LT16] IB T2 N0 Human lung tumor SqCCa
(SRCC738) [LT17] IIB T2 N1 Human lung tumor SqCCa (SRCC739) [LT18]
IB T2 N0 Human lung tumor SqCCa (SRCC740) [LT19] IB T2 N0 Human
lung tumor LCCa (SRCC741) [LT21] IIB T3 N1 Human lung AdenoCa
(SRCC811) [LT22] 1A T1 N0 Human colon AdenoCa (SRCC742) [CT2] M1 D
pT4 N0 Human colon AdenoCa (SRCC743) [CT3] B pT3 N0 Human colon
AdenoCa (SRCC744) [CT8] B T3 N0 Human colon AdenoCa (SRCC745)
[CT10] A pT2 N0 Human colon AdenoCa (SRCC746) [CT12] MO, R1 B T3 N0
Human colon AdenoCa (SRCC747) [CT14] pMO, RO B pT3 pN0 Human colon
AdenoCa (SRCC748) [CT15] M1, R2 D T4 N2 Human colon AdenoCa
(SRCC749) [CT16] pMO B pT3 pN0 Human colon AdenoCa (SRCC750) [CT17]
C1 pT3 pN1 Human colon AdenoCa (SRCC751) [CT1] MO, R1 B pT3 N0
Human colon AdenoCa (SRCC752) [CT4] B pT3 M0 Human colon AdenoCa
(SRCC753) [CT5] G2 C1 pT3 pN0 Human colon AdenoCa (SRCC754) [CT6]
pMO, RO B pT3 pN0 Human colon AdenoCa (SRCC755) [CT7] G1 A pT2 pN0
Human colon AdenoCa (SRCC756) [CT9] G3 D pT4 pN2 Human colon
AdenoCa (SRCC757) [CT11] B T3 N0 Human colon AdenoCa (SRCC758)
[CT18] MO, RO B pT3 pN0
[1038] DNA Preparation:
[1039] DNA was prepared from cultured cell lines, primary tumors,
normal human blood. The isolation was performed using purification
kit, buffer set and protease and all from Quiagen, according to the
manufacturer's instructions and the description below.
[1040] Cell culture lysis:
[1041] Cells were washed and trypsinized at a concentration of
7.5.times.10.sup.8 per tip and pelleted by centrifuging at 1000 rpm
for 5 minutes at 4.degree. C., followed by washing again with 1/2
volume of PBS recentrifugation. The pellets were washed a third
time, the suspended cells collected and washed 2.times. with PBS.
The cells were then suspended into 10 ml PBS. Buffer C1 was
equilibrated at 4.degree. C. Qiagen protease #19155 was diluted
into 6.25 ml cold ddH.sub.2O to a final concentration of 20 mg/ml
and equilibrated at 4.degree. C. 10 ml of G2 Buffer was pre by
diluting Qiagen RNAse A stock (100 mg/ml) to a final concentration
of 200 .mu.g/nl.
[1042] Buffer C1 (10 ml, 4.degree. C.) and ddH2O (40 ml, 4.degree.
C.) were then added to the 10 ml of cell suspension, mixed by
inverting and incubated on ice for 10 minutes. The cell nuclei were
pelleted by centrifuging in a Beckman swinging bucket rotor at 2500
rpm at 4.degree. C. for 15 minutes. The supernatant was discarded
and the nuclei were suspended with a vortex into 2 ml Buffer C1 (at
4.degree. C.) and 6 ml ddH.sub.2O, followed by a second 4.degree.
C. centrifugation at 2500 rpm for 15 minutes. The nuclei were then
resuspended into the residual buffer using 200 .mu.l per tip. G2
buffer (10 ml) was added to the suspended nuclei while gentle
vortexing was applied. Upon completion of buffer addition, vigorous
vortexing was applied for 30 seconds. Quiagen protease (200 .mu.l,
prepared as indicated above) was added and incubated at 50.degree.
C. for 60 minutes. The incubation and centrifugation was repeated
until the lysates were clear (e.g., incubating additional 30-60
minutes, pelleting at 3000.times.g for 10 min., 4.degree. C.).
[1043] Solid human tumor sample preparation and lysis:
[1044] Tumor samples were weighed and placed into 50 ml conical
tubes and held on ice. Processing was limited to no more than 250
mg tissue per preparation (1 tip/preparation). The protease
solution was freshly prepared by diluting into 6.25 ml cold
ddH.sub.2O to a final concentration of 20 mg/ml and stored at
4.degree. C. G2 buffer (20 ml) was prepared by diluting DNAse A to
a final concentration of 200 mg/ml (from 100 mg/ml stock). The
tumor tissue was homogenated in 19 ml G2 buffer for 60 seconds
using the large tip of the polytron in a laminar-flow TC hood in
order to avoid inhalation of aerosols, and held at room
temperature. Between samples, the polytron was cleaned by spinning
at 2.times.30 seconds each in 2L ddH.sub.2O, followed by G2 buffer
(50 ml). If tissue was still present on the generator tip, the
apparatus was disassembled and cleaned.
[1045] Quiagen protease (prepared as indicated above, 1.0 ml) was
added, followed by vortexing and incubation at 50.degree. C. for 3
hours. The incubation and centrifugation was repeated until the
lysates were clear (e.g., incubating additional 30-60 minutes,
pelleting at 3000.times.g for 10 min., 4.degree. C.).
[1046] Human blood preparation and lysis:
[1047] Blood was drawn from healthy volunteers using standard
infectious agent protocols and citrated into 10 ml samples per tip.
Quiagen protease was freshly prepared by dilution into 6.25 ml cold
ddH.sub.2O to a final concentration of 20 mg/ml and stored at
4.degree. C. G2 buffer was prepared by diluting RNAse A to a final
concentration of 200 .mu.g/ml from 100 mg/ml stock. The blood (10
ml) was placed into a 50 ml conical tube and 10 ml C1 buffer and 30
ml ddH.sub.2O (both previously equilibrated to 4.degree. C.) were
added, and the components mixed by inverting and held on ice for 10
minutes. The nuclei were pelleted with a Beckman swinging bucket
rotor at 2500 rpm, 4.degree. C. for 15 minutes and the supernatant
discarded. With a vortex, the nuclei were suspended into 2 ml C1
buffer (4.degree. C.) and 6 ml ddH.sub.2O (4.degree. C.). Vortexing
was repeated until the pellet was white. The nuclei were then
suspended into the residual buffer using a 200 .mu.l tip. G2 buffer
(10 ml) were added to the suspended nuclei while gently vortexing,
followed by vigorous vortexing for 30 seconds. Quiagen protease was
added (200 .mu.l) and incubated at 50.degree. C. for 60 minutes.
The incubation and centrifugation was repeated until the lysates
were clear (e.g., incubating additional 30-60 minutes, pelleting at
3000.times.g for 10 min., 4.degree. C.).
[1048] Purification of cleared lysates:
[1049] (1) Isolation of genomic DNA:
[1050] Genomic DNA was equilibrated (1 sample per maxi tip
preparation) with 10 ml QBT buffer. QF elution buffer was
equilibrated at 50.degree. C. The samples were vortexed for 30
seconds, then loaded onto equilibrated tips and drained by gravity.
The tips were washed with 2.times.15 ml QC buffer. The DNA was
eluted into 30 ml silanized, autoclaved 30 ml Corex tubes with 15
ml QF buffer (50.degree. C.). Isopropanol (10.5 ml) was added to
each sample, the tubes covered with parafin and mixed by repeated
inversion until the DNA precipitated. Samples were pelleted by
centrifugation in the SS-34 rotor at 15,000 rpm for 10 minutes at
4.degree. C. The pellet location was marked, the supernatant
discarded, and 10 ml 70% ethanol (4.degree. C.) was added. Samples
were pelleted again by centrifugation on the SS-34 rotor at 10,000
rpm for 10 minutes at 4.degree. C. The pellet location was marked
and the supernatant discarded. The tubes were then placed on their
side in a drying rack and dried 10 minutes at 37.degree. C., taking
care not to overdry the samples.
[1051] After drying, the pellets were dissolved into 1.0 ml TE (pH
8.5) and placed at 50.degree. C. for 1-2 hours. Samples were held
overnight at 4.degree. C. as dissolution continued. The DNA
solution was then transferred to 1.5 ml tubes with a 26 gauge
needle on a tuberculin syringe. The transfer was repeated 5.times.
in order to shear the DNA. Samples were then placed at 50.degree.
C. for 1-2 hours.
[1052] (2) Quantitation of genomic DNA and preparation for gene
amplification assay:
[1053] The DNA levels in each tube were quantified by standard
A.sub.260, A.sub.280 spectrophotometry on a 1:20 dilution (5 .mu.l
DNA+95 .mu.l ddH.sub.2O) using the 0.1 ml quartz cuvetts in the
Beckman DU640 spectrophotometer. A.sub.260/A.sub.280 ratios were in
the range of 1.8-1.9. Each DNA samples was then diluted further to
approximately 200 ng/ml in TE (pH 8.5). If the original material
was highly concentrated (about 700 ng/.mu.l), the material was
placed at 50.degree. C. for several hours until resuspended.
[1054] Fluorometric DNA quantitation was then performed on the
diluted material (20-600 ng/ml) using the manufacturer's guidelines
as modified below. This was accomplished by allowing a Hoeffer DyNA
Quant 200 fluorometer to warm-up for about 15 minutes. The Hoechst
dye working solution (#H33258, 10 .mu.l, prepared within 12 hours
of use) was diluted into 100 ml 1.times.TNE buffer. A 2 ml cuvette
was filled with the fluorometer solution, placed into the machine,
and the machine was zeroed. pGEM 3Zf(+) (2 .mu.l, lot #360851026)
was added to 2 ml of fluorometer solution and calibrated at 200
units. An additional 2 .mu.l of pGEM 3Zf(+) DNA was then tested and
the reading confirmed at 400+/-10 units. Each sample was then read
at least in triplicate. When 3 samples were found to be within 10%
of each other, their average was taken and this value was used as
the quantification value.
[1055] The fluorometrically determined concentration was then used
to dilute each sample to 10 ng/.mu.l in ddH.sub.2O. This was done
simultaneously on all template samples for a single TaqMan plate
assay, and with enough material to run 500-1000 assays. The samples
were tested in triplicate with Taqman.TM. primers and probe both
B-actin and GAPDH on a single plate with normal human DNA and
no-template controls. The diluted samples were used provided that
the CT value of normal human DNA subtracted from test DNA was +/-1
Ct. The diluted, lot-qualified genomic DNA was stored in 1.0 ml
aliquots at -80.degree. C. Aliquots which were subsequently to be
used in the gene amplification assay were stored at 4.degree. C.
Each 1 ml aliquot is enough for 8-9 plates or 64 tests.
[1056] Gene amplification assay:
[1057] The PRO polypeptide compounds of the invention were screened
in the following primary tumors and the resulting .DELTA.Ct values
greater than or equal to 1.0 are reported in Table 9 below.
10TABLE 9 .DELTA.Ct values in lung and colon primary tumors and
cell line models Primary Tumors or Cell Lines PRO187 PRO533 PRO246
LT7 1.04 LT13 2.74 1.63 2.98 1.68 2.44 LT3 1.06 LT12 2.70 2.47 2.90
1.74 2.27 LT30 1.67 LT21 1.50 LT-1a 1.02 LT10 1.07 LT11 1.09 3.43
1.41 LT15 3.75 2.11 3.92 1.56 3.49 LT16 2.10 1.66 LT17 1.32 2.68
1.69 LT19 4.05 1.67 1.91 3.99 1.68 1.16 CT2 3.56 CT8 1.01 CT10 1.81
CT14 1.82 CT1 1.24 1.34 CT5 2.96 1.33 2.99 2.39 CT6 1.10 CT7 1.40
CT9 1.39 1.09 CT11 2.22 1.48 2.26 1.12
[1058] Because amplification of the various DNAs described above
occurs in various cancerous tumors and tumor cell lines derived
from various human tissues, these molecules likely play a
significant role in tumor formation and/or growth. As a result,
amplification and/or enhanced expression of these molecules can
serve as a diagnostic for detecting the presence of tumor in an
individual and antagonists (e.g., antibodies) directed against the
proteins encoded by the above described DNA molecules would be
expected to have utility in cancer therapy.
Example 69
[1059] Gene Expression in Bovine Pericytes (Assay 105)
[1060] This assay is designed to identify gene expression patterns
in pericytes induced by the hits in assay 93 described above.
Bovine pericytes are plated on 60 mm culture dishes in growth media
for 1 week. On day 1, various PRO polypeptides are diluted (1%) and
incubated with the pericytes for 1, 4 and 24 hr. timepoints. The
cells are harvested and the RNA isolated using TRI-Reagent
following the included instructions. The RNA is then quantified by
reading the 260/280 OD using a spectrophotometer. The gene
expression analysis is done by TaqMan reactions using Perkin Elmer
reagents and specially designed bovine probes and primers.
Expression of the following genes is analyzed: GAPDH,
beta-integrin, connective tissue growth factor (CTGF), ICAM-1,
monocyte chemoattractant protein-1 (MCP-1), osteopontin,
transforming growth factor-beta (TGF-beta), TGF-beta receptor,
tissue inhibitor of metalloproteinase (TIMP), tissue factor (TF),
VEGF-.alpha., thrombospondin, VEGF-.beta., angiopoeitin-2, and
collagenase. Replicates are then averaged and the SD determined.
The gene expression levels are then normalized to GAPDH. These are
then normalized to the expression levels obtained with a protein
(PIN32) which does not significantly induce gene expression in
bovine pericytes when compared to untreated controls. Any PRO
polypeptide that gives a gene expression level 2-fold or higher
over the PIN32 control is considered a positive hit.
[1061] The following PRO polypeptides tested positive in this
assay: PRO217.
Example 70
[1062] Cytokine Release Assay (Assay 120)
[1063] This assay is designed to determine whether PRO polypeptides
of the present invention are capable of inducing the release of
cytokines from peripheral blood mononuclear cells (PBMCs). PRO
polypeptides capable of inducing the release of cytokines from
PBMCs are useful from the treatment of conditions which would
benefit from enhanced cytokine release and will be readily evident
to those of ordinary skill in the art. Specifically,
1.times.10.sup.6 cells/ml of peripheral blood mononuclear cells
(PBMC) are cultured with 1% of a PRO polypeptide for 3 days in
complete RPMI media. The supernatant is then harvested and tested
for increased concentrations of various cytokines by ELISA as
compared to a human IgG treated control. A positive in the assay is
a 10-fold or greater increase in cytokine concentration in the PRO
polypeptide treated sample as compared to the human IgG treated
control.
[1064] The following polypeptides tested positive in this assay:
PRO9940.
Example 71
[1065] Identification of PRO Polypeptides that Activate Pericytes
(Assay 125)
[1066] This assay shows that certain polypeptides of the invention
act to activate proliferation of pericyte cells and, therefore, are
useful not only as diagnostic markers for particular types of
pericyte-associated tumors but also for giving rise to antagonists
which would be expected to be useful for the therapeutic treatment
of pericyte-associated tumors. Activation of pericyte proliferation
also correlates with the induction of angiogenesis and, as such,
PRO polypeptides capable of inducing pericyte proliferation would
be expected to be useful for the treatment of conditions where
induced angiogenesis would be beneficial including, for example,
wound healing, and the like. Specifically, on day 1, pericytes are
received from VEC Technologies, and all but 5 ml media is removed
from the flask. On day 2, the pericytes are trypsinized, washed,
spun and plated on 96 well plates. On day 7, the media is removed
and the pericytes are treated with 100 .mu.l of either the specific
PRO polypeptide or control treatments (positive control=DME+5% +/-
PDGF @ 500 ng/.mu.l; negative control=PIN32, a polypeptide
determined to have no significant effect on pericyte
proliferation). C-fos and GAPDH gene expression levels are then
determined and the replicates are averaged and the SD is
determined. The c-fos values are normalized to GAPDH and the
results are expressed as fold increase over PIN2. Anything
providing at least a 2-fold or higher response as compared to the
negative control is considered positive for the assay.
[1067] The following polypeptides tested positive in this assay:
PRO217.
Example 72
[1068] Identification of Receptor/Ligand Interactions
[1069] In this assay, various PRO polypeptides are tested for
ability to bind to a panel of potential receptor or ligand
molecules for the purpose of identifying receptor/ligand
interactions. The identification of a ligand for a known receptor,
a receptor for a known ligand or a novel receptor/ligand pair is
useful for a variety of indications including, for example,
targeting bioactive molecules (linked to the ligand or receptor) to
a cell known to express the receptor or ligand, use of the receptor
or ligand as a reagent to detect the presence of the ligand or
receptor in a composition suspected of containing the same, wherein
the composition may comprise cells suspected of expressing the
ligand or receptor, modulating the growth of or another biological
or immunological activity of a cell known to express or respond to
the receptor or ligand, modulating the immune response of cells or
toward cells that express the receptor or ligand, allowing the
preparaion of agonists, antagonists and/or antibodies directed
against the receptor or ligand which will modulate the growth of or
a biological or immunological activity of a cell expressing the
receptor or ligand, and various other indications which will be
readily apparent to the ordinarily skilled artisan.
[1070] The assay is performed as follows. A PRO polypeptide of the
present invention suspected of being a ligand for a receptor is
expressed as a fusion protein containing the Fe domain of human IgG
(an immunoadhesin). Receptor-ligand binding is detected by allowing
interaction of the immunoadhesin polypeptide with cells (e.g. Cos
cells) expressing candidate PRO polypeptide receptors and
visualization of bound immunoadhesin with fluorescent reagents
directed toward the Fe fusion domain and examination by microscope.
Cells expressing candidate receptors are produced by transient
transfection, in parallel, of defined subsets of a library of cDNA
expression vectors encoding PRO polypeptides that may function as
receptor molecules. Cells are then incubated for 1 hour in the
presence of the PRO polypeptide immunoadhesin being tested for
possible receptor binding. The cells are then washed and fixed with
paraformaldehyde. The cells are then incubated with fluorescent
conjugated antibody directed against the Fe portion of the PRO
polypeptide immunoadhesin (e.g. FITC conjugated goat anti-human-Fe
antibody). The cells are then washed again and examined by
microscope. A positive interaction is judged by the presence of
fluorescent labeling of cells transfected with cDNA encoding a
particular PRO polypeptide receptor or pool of receptors and an
absence of similar fluorescent labeling of similarly prepared cells
that have been transfected with other cDNA or pools of cDNA. If a
defined pool of cDNA expression vectors is judged to be positive
for interaction with a PRO polypeptide immunoadhesin, the
individual cDNA species that comprise the pool are tested
individually (the pool is "broken down") to determine the specific
cDNA that encodes a receptor able to interact with the PRO
polypeptide immunoadhesin.
[1071] In another embodiment of this assay, an epitope-tagged
potential ligand PRO polypeptide (e.g. 8 histidine "His" tag) is
allowed to interact with a panel of potential receptor PRO
polypeptide molecules that have been expressed as fusions with the
Fe domain of human IgG (immunoadhesins). Following a 1 hour
co-incubation with the epitope tagged PRO polypeptide, the
candidate receptors are each immunoprecipitated with protein A
beads and the beads are washed. Potential ligand interaction is
determined by western blot analysis of the immunoprecipitated
complexes with antibody directed towards the epitope tag. An
interaction is judged to occur if a band of the anticipated
molecular weight of the epitope tagged protein is observed in the
western blot analysis with a candidate receptor, but is not
observed to occur with the other members of the panel of potential
receptors.
[1072] Using these assays, the following receptor/ligand
interactions have been herein identified:
[1073] (1) PRO533 binds to the fibroblast growth factor receptor-4
(FGFR-4; see Partanen et al., EMBO J. 10(6):1347-1354 (1991)).
[1074] (2) PRO301 binds to itself and, therefore, functions as an
adhesion molecule.
[1075] (3) PRO187 binds to the fibroblast growth factor receptor-3
(FGFR-3; see Keegan et al., Proc. Natl. Acad. Sci. USA 88:1095-1099
(1991)) with high affinity and with lower affinity to to FGFR-1, 2
and 4 (see Isacchi et al., Nuc. Acids Res. 18(7):1906 (1990),
Dionne et al., EMBO J. 9(9):2685-2692 (1990) and Partanen et al.,
EMBO J. 10(6):1347-1354 (1991), respectively).
[1076] (4) PRO337 binds to PRO6004.
[1077] (5) PRO1411 binds to PRO4356.
[1078] (6) PRO 10096 binds to PRO2630.
[1079] (7) PRO246 binds to itself and, therefore, functions as an
adhesion molecule.
[1080] (8) PRO6307 binds to PRO265.
[1081] (9) PRO6003 binds to PRO941.
[1082] Deposit of Material
[1083] The following materials have been deposited with the
American Type Culture Collection, 10801 University Blvd., Manassas,
Va. 20110-2209, USA (ATCC):
11 TABLE 10 Material ATCC Dep. No. Deposit Date DNA22779-1130
209280 Sept. 18, 1997 DNA26846-1397 203406 Oct. 27, 1998
DNA32279-1131 209259 Sept. 16, 1997 DNA32288-1132 209261 Sept. 16,
1997 DNA33094-1131 209256 Sept. 16, 1997 DNA33785-1143 209417 Oct.
28, 1997 DNA35663-1129 209201 June 18, 1997 DNA46777-1253 209619
Feb. 5, 1998 DNA60783-1611 203130 Aug. 18, 1998 DNA62306-1570
203254 Sept. 9, 1998 DNA62880-1513 203097 Aug. 4, 1998
DNA64896-1539 203238 Sept. 9, 1998 DNA71290-1630 203275 Sept. 22,
1998 DNA96031-2664 PTA-237 June 15, 1999 DNA108722-2743 PTA-552
Aug. 17, 1999 DNA35674-1142 209416 Oct. 28, 1997 DNA41234 209618
Feb. 5, 1998 DNA77503-1686 203362 Oct. 20, 1998 DNA49435-1219
209480 Nov. 21, 1997 DNA40628-1216 209432 Nov. 7, 1997
DNA27864-1155 209375 Oct. 16, 1997 DNA43316-1237 209487 Nov. 21,
1997 DNA59212-1627 203245 Sept. 9, 1998 DNA86576-2595 203868 March
23, 1999 DNA35639-1172 209396 Oct. 17, 1997 DNA36350-1158 209378
Oct. 16, 1997 DNA53906-1368 209747 April 7, 1998 DNA125185-2806
PTA-1031 Dec. 7, 1999 DNA83568-2692 PTA-386 July 20, 1999
[1084] These deposits were made under the provisions of the
Budapest Treaty on the International Recognition of the Deposit of
Microorganisms for the Purpose of Patent Procedure and the
Regulations thereunder (Budapest Treaty). This assures maintenance
of a viable culture of the deposit for 30 years from the date of
deposit. The deposits will be made available by ATCC under the
terms of the Budapest Treaty, and subject to an agreement between
Genentech, Inc. and ATCC, which assures permanent and unrestricted
availability of the progeny of the culture of the deposit to the
public upon issuance of the pertinent U.S. patent or upon laying
open to the public of any U.S. or foreign patent application,
whichever comes first, and assures availability of the progeny to
one determined by the U.S. Commissioner of Patents and Trademarks
to be entitled thereto according to 35 USC .sctn.122 and the
Commissioner's rules pursuant thereto (including 37 CFR .sctn.1.14
with particular reference to 886 OG 638).
[1085] The assignee of the present application has agreed that if a
culture of the materials on deposit should die or be lost or
destroyed when cultivated under suitable conditions, the materials
will be promptly replaced on notification with another of the same.
Availability of the deposited material is not to be construed as a
license to practice the invention in contravention of the rights
granted under the authority of any government in accordance with
its patent laws.
[1086] The foregoing written specification is considered to be
sufficient to enable one skilled in the art to practice the
invention. The present invention is not to be limited in scope by
the construct deposited, since the deposited embodiment is intended
as a single illustration of certain aspects of the invention and
any constructs that are functionally equivalent are within the
scope of this invention. The deposit of material herein does not
constitute an admission that the written description herein
contained is inadequate to enable the practice of any aspect of the
invention, including the best mode thereof, nor is it to be
construed as limiting the scope of the claims to the specific
illustrations that it represents. Indeed. various modifications of
the invention in addition to those shown and described herein will
become apparent to those skilled in the art from the foregoing
description and fall within the scope of the appended claims.
Sequence CWU 1
1
151 1 43 DNA Artificial Sequence Synthetic oligonucleotide probe 1
tgtaaaacga cggccagtta aatagacctg caattattaa tct 43 2 41 DNA
Artificial Sequence Synthetic oligonucleotide probe 2 caggaaacag
ctatgaccac ctgcacacct gcaaatccat t 41 3 2290 DNA Homo Sapien 3
ggctgagggg aggcccggag cctttctggg gcctggggga tcctcttgca 50
ctggtgggtg gagagaagcg cctgcagcca accagggtca ggctgtgctc 100
acagtttcct ctggcggcat gtaaaggctc cacaaaggag ttgggagttc 150
aaatgaggct gctgcggacg gcctgaggat ggaccccaag ccctggacct 200
gccgagcgtg gcactgaggc agcggctgac gctactgtga gggaaagaag 250
gttgtgagca gccccgcagg acccctggcc agccctggcc ccagcctctg 300
ccggagccct ctgtggaggc agagccagtg gagcccagtg aggcagggct 350
gcttggcagc caccggcctg caactcagga acccctccag aggccatgga 400
caggctgccc cgctgacggc cagggtgaag catgtgagga gccgccccgg 450
agccaagcag gagggaagag gctttcatag attctattca caaagaataa 500
ccaccatttt gcaaggacca tgaggccact gtgcgtgaca tgctggtggc 550
tcggactgct ggctgccatg ggagctgttg caggccagga ggacggtttt 600
gagggcactg aggagggctc gccaagagag ttcatttacc taaacaggta 650
caagcgggcg ggcgagtccc aggacaagtg cacctacacc ttcattgtgc 700
cccagcagcg ggtcacgggt gccatctgcg tcaactccaa ggagcctgag 750
gtgcttctgg agaaccgagt gcataagcag gagctagagc tgctcaacaa 800
tgagctgctc aagcagaagc ggcagatcga gacgctgcag cagctggtgg 850
aggtggacgg cggcattgtg agcgaggtga agctgctgcg caaggagagc 900
cgcaacatga actcgcgggt cacgcagctc tacatgcagc tcctgcacga 950
gatcatccgc aagcgggaca acgcgttgga gctctcccag ctggagaaca 1000
ggatcctgaa ccagacagcc gacatgctgc agctggccag caagtacaag 1050
gacctggagc acaagtacca gcacctggcc acactggccc acaaccaatc 1100
agagatcatc gcgcagcttg aggagcactg ccagagggtg ccctcggcca 1150
ggcccgtccc ccagccaccc cccgctgccc cgccccgggt ctaccaacca 1200
cccacctaca accgcatcat caaccagatc tctaccaacg agatccagag 1250
tgaccagaac ctgaaggtgc tgccaccccc tctgcccact atgcccactc 1300
tcaccagcct cccatcttcc accgacaagc cgtcgggccc atggagagac 1350
tgcctgcagg ccctggagga tggccacgac accagctcca tctacctggt 1400
gaagccggag aacaccaacc gcctcatgca ggtgtggtgc gaccagagac 1450
acgaccccgg gggctggacc gtcatccaga gacgcctgga tggctctgtt 1500
aacttcttca ggaactggga gacgtacaag caagggtttg ggaacattga 1550
cggcgaatac tggctgggcc tggagaacat ttactggctg acgaaccaag 1600
gcaactacaa actcctggtg accatggagg actggtccgg ccgcaaagtc 1650
tttgcagaat acgccagttt ccgcctggaa cctgagagcg agtattataa 1700
gctgcggctg gggcgctacc atggcaatgc gggtgactcc tttacatggc 1750
acaacggcaa gcagttcacc accctggaca gagatcatga tgtctacaca 1800
ggaaactgtg cccactacca gaagggaggc tggtggtata acgcctgtgc 1850
ccactccaac ctcaacgggg tctggtaccg cgggggccat taccggagcc 1900
gctaccagga cggagtctac tgggctgagt tccgaggagg ctcttactca 1950
ctcaagaaag tggtgatgat gatccgaccg aaccccaaca ccttccacta 2000
agccagctcc ccctcctgac ctctcgtggc cattgccagg agcccaccct 2050
ggtcacgctg gccacagcac aaagaacaac tcctcaccag ttcatcctga 2100
ggctgggagg accgggatgc tggattctgt tttccgaagt cactgcagcg 2150
gatgatggaa ctgaatcgat acggtgtttt ctgtccctcc tactttcctt 2200
cacaccagac agcccctcat gtctccagga caggacagga ctacagacaa 2250
ctctttcttt aaataaatta agtctctaca ataaaaaaaa 2290 4 493 PRT Homo
Sapien 4 Met Arg Pro Leu Cys Val Thr Cys Trp Trp Leu Gly Leu Leu
Ala 1 5 10 15 Ala Met Gly Ala Val Ala Gly Gln Glu Asp Gly Phe Glu
Gly Thr 20 25 30 Glu Glu Gly Ser Pro Arg Glu Phe Ile Tyr Leu Asn
Arg Tyr Lys 35 40 45 Arg Ala Gly Glu Ser Gln Asp Lys Cys Thr Tyr
Thr Phe Ile Val 50 55 60 Pro Gln Gln Arg Val Thr Gly Ala Ile Cys
Val Asn Ser Lys Glu 65 70 75 Pro Glu Val Leu Leu Glu Asn Arg Val
His Lys Gln Glu Leu Glu 80 85 90 Leu Leu Asn Asn Glu Leu Leu Lys
Gln Lys Arg Gln Ile Glu Thr 95 100 105 Leu Gln Gln Leu Val Glu Val
Asp Gly Gly Ile Val Ser Glu Val 110 115 120 Lys Leu Leu Arg Lys Glu
Ser Arg Asn Met Asn Ser Arg Val Thr 125 130 135 Gln Leu Tyr Met Gln
Leu Leu His Glu Ile Ile Arg Lys Arg Asp 140 145 150 Asn Ala Leu Glu
Leu Ser Gln Leu Glu Asn Arg Ile Leu Asn Gln 155 160 165 Thr Ala Asp
Met Leu Gln Leu Ala Ser Lys Tyr Lys Asp Leu Glu 170 175 180 His Lys
Tyr Gln His Leu Ala Thr Leu Ala His Asn Gln Ser Glu 185 190 195 Ile
Ile Ala Gln Leu Glu Glu His Cys Gln Arg Val Pro Ser Ala 200 205 210
Arg Pro Val Pro Gln Pro Pro Pro Ala Ala Pro Pro Arg Val Tyr 215 220
225 Gln Pro Pro Thr Tyr Asn Arg Ile Ile Asn Gln Ile Ser Thr Asn 230
235 240 Glu Ile Gln Ser Asp Gln Asn Leu Lys Val Leu Pro Pro Pro Leu
245 250 255 Pro Thr Met Pro Thr Leu Thr Ser Leu Pro Ser Ser Thr Asp
Lys 260 265 270 Pro Ser Gly Pro Trp Arg Asp Cys Leu Gln Ala Leu Glu
Asp Gly 275 280 285 His Asp Thr Ser Ser Ile Tyr Leu Val Lys Pro Glu
Asn Thr Asn 290 295 300 Arg Leu Met Gln Val Trp Cys Asp Gln Arg His
Asp Pro Gly Gly 305 310 315 Trp Thr Val Ile Gln Arg Arg Leu Asp Gly
Ser Val Asn Phe Phe 320 325 330 Arg Asn Trp Glu Thr Tyr Lys Gln Gly
Phe Gly Asn Ile Asp Gly 335 340 345 Glu Tyr Trp Leu Gly Leu Glu Asn
Ile Tyr Trp Leu Thr Asn Gln 350 355 360 Gly Asn Tyr Lys Leu Leu Val
Thr Met Glu Asp Trp Ser Gly Arg 365 370 375 Lys Val Phe Ala Glu Tyr
Ala Ser Phe Arg Leu Glu Pro Glu Ser 380 385 390 Glu Tyr Tyr Lys Leu
Arg Leu Gly Arg Tyr His Gly Asn Ala Gly 395 400 405 Asp Ser Phe Thr
Trp His Asn Gly Lys Gln Phe Thr Thr Leu Asp 410 415 420 Arg Asp His
Asp Val Tyr Thr Gly Asn Cys Ala His Tyr Gln Lys 425 430 435 Gly Gly
Trp Trp Tyr Asn Ala Cys Ala His Ser Asn Leu Asn Gly 440 445 450 Val
Trp Tyr Arg Gly Gly His Tyr Arg Ser Arg Tyr Gln Asp Gly 455 460 465
Val Tyr Trp Ala Glu Phe Arg Gly Gly Ser Tyr Ser Leu Lys Lys 470 475
480 Val Val Met Met Ile Arg Pro Asn Pro Asn Thr Phe His 485 490 5
33 DNA Artificial Sequence Synthetic oligonucleotide probe 5
gctgacgaac caaggcaact acaaactcct ggt 33 6 41 DNA Artificial
Sequence Synthetic oligonucleotide probe 6 tgcggccgga ccagtcctcc
atggtcacca ggagtttgta g 41 7 33 DNA Artificial Sequence Synthetic
oligonucleotide probe 7 ggtggtgaac tgcttgccgt tgtgccatgt aaa 33 8
1218 DNA Homo Sapien 8 cccacgcgtc cggcgccgtg gcctcgcgtc catctttgcc
gttctctcgg 50 acctgtcaca aaggagtcgc gccgccgccg ccgccccctc
cctccggtgg 100 gcccgggagg tagagaaagt cagtgccaca gcccgaccgc
gctgctctga 150 gccctgggca cgcggaacgg gagggagtct gagggttggg
gacgtctgtg 200 agggagggga acagccgctc gagcctgggg cgggcggacc
ggactggggc 250 cggggtaggc tctggaaagg gcccgggaga gaggtggcgt
tggtcagaac 300 ctgagaaaca gccgagaggt tttccaccga ggcccgcgct
tgagggatct 350 gaagaggttc ctagaagagg gtgttccctc tttcgggggt
cctcaccaga 400 agaggttctt gggggtcgcc cttctgagga ggctgcggct
aacagggccc 450 agaactgcca ttggatgtcc agaatcccct gtagttgata
atgttgggaa 500 taagctctgc aactttcttt ggcattcagt tgttaaaaac
aaataggatg 550 caaattcctc aactccaggt tatgaaaaca gtacttggaa
aactgaaaac 600 tacctaaatg atcgtctttg gttgggccgt gttcttagcg
agcagaagcc 650 ttggccaggg tctgttgttg actctcgaag agcacatagc
ccacttccta 700 gggactggag gtgccgctac taccatgggt aattcctgta
tctgccgaga 750 tgacagtgga acagatgaca gtgttgacac ccaacagcaa
caggccgaga 800 acagtgcagt acccactgct gacacaagga gccaaccacg
ggaccctgtt 850 cggccaccaa ggaggggccg aggacctcat gagccaagga
gaaagaaaca 900 aaatgtggat gggctagtgt tggacacact ggcagtaata
cggactcttg 950 tagataagta agtatctgac tcacggtcac ctccagtgga
atgaaaagtg 1000 ttctgcccgg aaccatgact ttaggactcc ttcagttcct
ttaggacata 1050 ctcgccaagc cttgtgctca cagggcaaag gagaatattt
taatgctccg 1100 ctgatggcag agtaaatgat aagatttgat gtttttgctt
gctgtcatct 1150 actttgtctg gaaatgtcta aatgtttctg tagcagaaaa
cacgataaag 1200 ctatgatctt tattagag 1218 9 117 PRT Homo Sapien 9
Met Ile Val Phe Gly Trp Ala Val Phe Leu Ala Ser Arg Ser Leu 1 5 10
15 Gly Gln Gly Leu Leu Leu Thr Leu Glu Glu His Ile Ala His Phe 20
25 30 Leu Gly Thr Gly Gly Ala Ala Thr Thr Met Gly Asn Ser Cys Ile
35 40 45 Cys Arg Asp Asp Ser Gly Thr Asp Asp Ser Val Asp Thr Gln
Gln 50 55 60 Gln Gln Ala Glu Asn Ser Ala Val Pro Thr Ala Asp Thr
Arg Ser 65 70 75 Gln Pro Arg Asp Pro Val Arg Pro Pro Arg Arg Gly
Arg Gly Pro 80 85 90 His Glu Pro Arg Arg Lys Lys Gln Asn Val Asp
Gly Leu Val Leu 95 100 105 Asp Thr Leu Ala Val Ile Arg Thr Leu Val
Asp Lys 110 115 10 1231 DNA Homo Sapien 10 cccacgcgtc cgcgcagtcg
cgcagttctg cctccgcctg ccagtctcgc 50 ccgcgatccc ggcccggggc
tgtggcgtcg actccgaccc aggcagccag 100 cagcccgcgc gggagccgga
ccgccgccgg aggagctcgg acggcatgct 150 gagccccctc ctttgctgaa
gcccgagtgc ggagaagccc gggcaaacgc 200 aggctaagga gaccaaagcg
gcgaagtcgc gagacagcgg acaagcagcg 250 gaggagaagg aggaggaggc
gaacccagag aggggcagca aaagaagcgg 300 tggtggtggg cgtcgtggcc
atggcggcgg ctatcgccag ctcgctcatc 350 cgtcagaaga ggcaagcccg
cgagcgcgag aaatccaacg cctgcaagtg 400 tgtcagcagc cccagcaaag
gcaagaccag ctgcgacaaa aacaagttaa 450 atgtcttttc ccgggtcaaa
ctcttcggct ccaagaagag gcgcagaaga 500 agaccagagc ctcagcttaa
gggtatagtt accaagctat acagccgaca 550 aggctaccac ttgcagctgc
aggcggatgg aaccattgat ggcaccaaag 600 atgaggacag cacttacact
ctgtttaacc tcatccctgt gggtctgcga 650 gtggtggcta tccaaggagt
tcaaaccaag ctgtacttgg caatgaacag 700 tgagggatac ttgtacacct
cggaactttt cacacctgag tgcaaattca 750 aagaatcagt gtttgaaaat
tattatgtga catattcatc aatgatatac 800 cgtcagcagc agtcaggccg
agggtggtat ctgggtctga acaaagaagg 850 agagatcatg aaaggcaacc
atgtgaagaa gaacaagcct gcagctcatt 900 ttctgcctaa accactgaaa
gtggccatgt acaaggagcc atcactgcac 950 gatctcacgg agttctcccg
atctggaagc gggaccccaa ccaagagcag 1000 aagtgtctct ggcgtgctga
acggaggcaa atccatgagc cacaatgaat 1050 caacgtagcc agtgagggca
aaagaagggc tctgtaacag aaccttacct 1100 ccaggtgctg ttgaattctt
ctagcagtcc ttcacccaaa agttcaaatt 1150 tgtcagtgac atttaccaaa
caaacaggca gagttcacta ttctatctgc 1200 cattagacct tcttatcatc
catactaaag c 1231 11 245 PRT Homo Sapien 11 Met Ala Ala Ala Ile Ala
Ser Ser Leu Ile Arg Gln Lys Arg Gln 1 5 10 15 Ala Arg Glu Arg Glu
Lys Ser Asn Ala Cys Lys Cys Val Ser Ser 20 25 30 Pro Ser Lys Gly
Lys Thr Ser Cys Asp Lys Asn Lys Leu Asn Val 35 40 45 Phe Ser Arg
Val Lys Leu Phe Gly Ser Lys Lys Arg Arg Arg Arg 50 55 60 Arg Pro
Glu Pro Gln Leu Lys Gly Ile Val Thr Lys Leu Tyr Ser 65 70 75 Arg
Gln Gly Tyr His Leu Gln Leu Gln Ala Asp Gly Thr Ile Asp 80 85 90
Gly Thr Lys Asp Glu Asp Ser Thr Tyr Thr Leu Phe Asn Leu Ile 95 100
105 Pro Val Gly Leu Arg Val Val Ala Ile Gln Gly Val Gln Thr Lys 110
115 120 Leu Tyr Leu Ala Met Asn Ser Glu Gly Tyr Leu Tyr Thr Ser Glu
125 130 135 Leu Phe Thr Pro Glu Cys Lys Phe Lys Glu Ser Val Phe Glu
Asn 140 145 150 Tyr Tyr Val Thr Tyr Ser Ser Met Ile Tyr Arg Gln Gln
Gln Ser 155 160 165 Gly Arg Gly Trp Tyr Leu Gly Leu Asn Lys Glu Gly
Glu Ile Met 170 175 180 Lys Gly Asn His Val Lys Lys Asn Lys Pro Ala
Ala His Phe Leu 185 190 195 Pro Lys Pro Leu Lys Val Ala Met Tyr Lys
Glu Pro Ser Leu His 200 205 210 Asp Leu Thr Glu Phe Ser Arg Ser Gly
Ser Gly Thr Pro Thr Lys 215 220 225 Ser Arg Ser Val Ser Gly Val Leu
Asn Gly Gly Lys Ser Met Ser 230 235 240 His Asn Glu Ser Thr 245 12
744 DNA Homo Sapien 12 atggccgcgg ccatcgctag cggcttgatc cgccagaagc
ggcaggcgcg 50 ggagcagcac tgggaccggc cgtctgccag caggaggcgg
agcagcccca 100 gcaagaaccg cgggctctgc aacggcaacc tggtggatat
cttctccaaa 150 gtgcgcatct tcggcctcaa gaagcgcagg ttgcggcgcc
aagatcccca 200 gctcaagggt atagtgacca ggttatattg caggcaaggc
tactacttgc 250 aaatgcaccc cgatggagct ctcgatggaa ccaaggatga
cagcactaat 300 tctacactct tcaacctcat accagtggga ctacgtgttg
ttgccatcca 350 gggagtgaaa acagggttgt atatagccat gaatggagaa
ggttacctct 400 acccatcaga actttttacc cctgaatgca agtttaaaga
atctgttttt 450 gaaaattatt atgtaatcta ctcatccatg ttgtacagac
aacaggaatc 500 tggtagagcc tggtttttgg gattaaataa ggaagggcaa
gctatgaaag 550 ggaacagagt aaagaaaacc aaaccagcag ctcattttct
acccaagcca 600 ttggaagttg ccatgtaccg agaaccatct ttgcatgatg
ttggggaaac 650 ggtcccgaag cctggggtga cgccaagtaa aagcacaagt
gcgtctgcaa 700 taatgaatgg aggcaaacca gtcaacaaga gtaagacaac atag 744
13 247 PRT Homo Sapien 13 Met Ala Ala Ala Ile Ala Ser Gly Leu Ile
Arg Gln Lys Arg Gln 1 5 10 15 Ala Arg Glu Gln His Trp Asp Arg Pro
Ser Ala Ser Arg Arg Arg 20 25 30 Ser Ser Pro Ser Lys Asn Arg Gly
Leu Cys Asn Gly Asn Leu Val 35 40 45 Asp Ile Phe Ser Lys Val Arg
Ile Phe Gly Leu Lys Lys Arg Arg 50 55 60 Leu Arg Arg Gln Asp Pro
Gln Leu Lys Gly Ile Val Thr Arg Leu 65 70 75 Tyr Cys Arg Gln Gly
Tyr Tyr Leu Gln Met His Pro Asp Gly Ala 80 85 90 Leu Asp Gly Thr
Lys Asp Asp Ser Thr Asn Ser Thr Leu Phe Asn 95 100 105 Leu Ile Pro
Val Gly Leu Arg Val Val Ala Ile Gln Gly Val Lys 110 115 120 Thr Gly
Leu Tyr Ile Ala Met Asn Gly Glu Gly Tyr Leu Tyr Pro 125 130 135 Ser
Glu Leu Phe Thr Pro Glu Cys Lys Phe Lys Glu Ser Val Phe 140 145 150
Glu Asn Tyr Tyr Val Ile Tyr Ser Ser Met Leu Tyr Arg Gln Gln 155 160
165 Glu Ser Gly Arg Ala Trp Phe Leu Gly Leu Asn Lys Glu Gly Gln 170
175 180 Ala Met Lys Gly Asn Arg Val Lys Lys Thr Lys Pro Ala Ala His
185 190 195 Phe Leu Pro Lys Pro Leu Glu Val Ala Met Tyr Arg Glu Pro
Ser 200 205 210 Leu His Asp Val Gly Glu Thr Val Pro Lys Pro Gly Val
Thr Pro 215 220 225 Ser Lys Ser Thr Ser Ala Ser Ala Ile Met Asn Gly
Gly Lys Pro 230 235 240 Val Asn Lys Ser Lys Thr Thr 245 14 2609 DNA
Homo Sapien 14 ctcgcagccg agcgcggccg gggaagggct ctccttccag
cgccgagcac 50 tgggccctgg cagacgcccc aagattgttg tgaggagtct
agccagttgg 100 tgagcgctgt aatctgaacc agctgtgtcc agactgaggc
cccatttgca 150 ttgtttaaca tacttagaaa atgaagtgtt catttttaac
attcctcctc 200 caattggttt aatgctgaat tactgaagag ggctaagcaa
aaccaggtgc 250 ttgcgctgag ggctctgcag tggctgggag gaccccggcg
ctctccccgt 300 gtcctctcca cgactcgctc ggcccctctg gaataaaaca
cccgcgagcc
350 ccgagggccc agaggaggcc gacgtgcccg agctcctccg ggggtcccgc 400
ccgcgagctt tcttctcgcc ttcgcatctc ctcctcgcgc gtcttggaca 450
tgccaggaat aaaaaggata ctcactgtta ccattctggc tctctgtctt 500
ccaagccctg ggaatgcaca ggcacagtgc acgaatggct ttgacctgga 550
tcgccagtca ggacagtgtt tagatattga tgaatgccga accatccccg 600
aggcctgccg aggagacatg atgtgtgtta accaaaatgg cgggtattta 650
tgcattcccc ggacaaaccc tgtgtatcga gggccctact cgaaccccta 700
ctcgaccccc tactcaggtc cgtacccagc agctgcccca ccactctcag 750
ctccaaacta tcccacgatc tccaggcctc ttatatgccg ctttggatac 800
cagatggatg aaagcaacca atgtgtggat gtggacgagt gtgcaacaga 850
ttcccaccag tgcaacccca cccagatctg catcaatact gaaggcgggt 900
acacctgctc ctgcaccgac ggatattggc ttctggaagg ccagtgctta 950
gacattgatg aatgtcgcta tggttactgc cagcagctct gtgcgaatgt 1000
tcctggatcc tattcttgta catgcaaccc tggttttacc ctcaatgagg 1050
atggaaggtc ttgccaagat gtgaacgagt gtgccaccga gaacccctgc 1100
gtgcaaacct gcgtcaacac ctacggctct ctcatctgcc gctgtgaccc 1150
aggatatgaa cttgaggaag atggcgttca ttgcagtgat atggacgagt 1200
gcagcttctc tgagttcctc tgccaacatg agtgtgtgaa ccagcccggc 1250
acatacttct gctcctgccc tccaggctac atcctgctgg atgacaaccg 1300
aagctgccaa gacatcaacg aatgtgagca caggaaccac acgtgcaacc 1350
tgcagcagac gtgctacaat ttacaagggg gcttcaaatg catcgacccc 1400
atccgctgtg aggagcctta tctgaggatc agtgataacc gctgtatgtg 1450
tcctgctgag aaccctggct gcagagacca gccctttacc atcttgtacc 1500
gggacatgga cgtggtgtca ggacgctccg ttcccgctga catcttccaa 1550
atgcaagcca cgacccgcta ccctggggcc tattacattt tccagatcaa 1600
atctgggaat gagggcagag aattttacat gcggcaaacg ggccccatca 1650
gtgccaccct ggtgatgaca cgccccatca aagggccccg ggaaatccag 1700
ctggacttgg aaatgatcac tgtcaacact gtcatcaact tcagaggcag 1750
ctccgtgatc cgactgcgga tatatgtgtc gcagtaccca ttctgagcct 1800
cgggctggag cctccgacgc tgcctctcat tggcaccaag ggacaggaga 1850
agagaggaaa taacagagag aatgagagcg acacagacgt taggcatttc 1900
ctgctgaacg tttccccgaa gagtcagccc cgacttcctg actctcacct 1950
gtactattgc agacctgtca ccctgcagga cttgccaccc ccagttccta 2000
tgacacagtt atcaaaaagt attatcattg ctcccctgat agaagattgt 2050
tggtgaattt tcaaggcctt cagtttattt ccactatttt caaagaaaat 2100
agattaggtt tgcgggggtc tgagtctatg ttcaaagact gtgaacagct 2150
tgctgtcact tcttcacctc ttccactcct tctctcactg tgttactgct 2200
ttgcaaagac ccgggagctg gcggggaacc ctgggagtag ctagtttgct 2250
ttttgcgtac acagagaagg ctatgtaaac aaaccacagc aggatcgaag 2300
ggtttttaga gaatgtgttt caaaaccatg cctggtattt tcaaccataa 2350
aagaagtttc agttgtcctt aaatttgtat aacggtttaa ttctgtcttg 2400
ttcattttga gtatttttaa aaaatatgtc gtagaattcc ttcgaaaggc 2450
cttcagacac atgctatgtt ctgtcttccc aaacccagtc tcctctccat 2500
tttagcccag tgttttcttt gaggacccct taatcttgct ttctttagaa 2550
tttttaccca attggattgg aatgcagagg tctccaaact gattaaatat 2600
ttgaagaga 2609 15 448 PRT Homo Sapien 15 Met Pro Gly Ile Lys Arg
Ile Leu Thr Val Thr Ile Leu Ala Leu 1 5 10 15 Cys Leu Pro Ser Pro
Gly Asn Ala Gln Ala Gln Cys Thr Asn Gly 20 25 30 Phe Asp Leu Asp
Arg Gln Ser Gly Gln Cys Leu Asp Ile Asp Glu 35 40 45 Cys Arg Thr
Ile Pro Glu Ala Cys Arg Gly Asp Met Met Cys Val 50 55 60 Asn Gln
Asn Gly Gly Tyr Leu Cys Ile Pro Arg Thr Asn Pro Val 65 70 75 Tyr
Arg Gly Pro Tyr Ser Asn Pro Tyr Ser Thr Pro Tyr Ser Gly 80 85 90
Pro Tyr Pro Ala Ala Ala Pro Pro Leu Ser Ala Pro Asn Tyr Pro 95 100
105 Thr Ile Ser Arg Pro Leu Ile Cys Arg Phe Gly Tyr Gln Met Asp 110
115 120 Glu Ser Asn Gln Cys Val Asp Val Asp Glu Cys Ala Thr Asp Ser
125 130 135 His Gln Cys Asn Pro Thr Gln Ile Cys Ile Asn Thr Glu Gly
Gly 140 145 150 Tyr Thr Cys Ser Cys Thr Asp Gly Tyr Trp Leu Leu Glu
Gly Gln 155 160 165 Cys Leu Asp Ile Asp Glu Cys Arg Tyr Gly Tyr Cys
Gln Gln Leu 170 175 180 Cys Ala Asn Val Pro Gly Ser Tyr Ser Cys Thr
Cys Asn Pro Gly 185 190 195 Phe Thr Leu Asn Glu Asp Gly Arg Ser Cys
Gln Asp Val Asn Glu 200 205 210 Cys Ala Thr Glu Asn Pro Cys Val Gln
Thr Cys Val Asn Thr Tyr 215 220 225 Gly Ser Leu Ile Cys Arg Cys Asp
Pro Gly Tyr Glu Leu Glu Glu 230 235 240 Asp Gly Val His Cys Ser Asp
Met Asp Glu Cys Ser Phe Ser Glu 245 250 255 Phe Leu Cys Gln His Glu
Cys Val Asn Gln Pro Gly Thr Tyr Phe 260 265 270 Cys Ser Cys Pro Pro
Gly Tyr Ile Leu Leu Asp Asp Asn Arg Ser 275 280 285 Cys Gln Asp Ile
Asn Glu Cys Glu His Arg Asn His Thr Cys Asn 290 295 300 Leu Gln Gln
Thr Cys Tyr Asn Leu Gln Gly Gly Phe Lys Cys Ile 305 310 315 Asp Pro
Ile Arg Cys Glu Glu Pro Tyr Leu Arg Ile Ser Asp Asn 320 325 330 Arg
Cys Met Cys Pro Ala Glu Asn Pro Gly Cys Arg Asp Gln Pro 335 340 345
Phe Thr Ile Leu Tyr Arg Asp Met Asp Val Val Ser Gly Arg Ser 350 355
360 Val Pro Ala Asp Ile Phe Gln Met Gln Ala Thr Thr Arg Tyr Pro 365
370 375 Gly Ala Tyr Tyr Ile Phe Gln Ile Lys Ser Gly Asn Glu Gly Arg
380 385 390 Glu Phe Tyr Met Arg Gln Thr Gly Pro Ile Ser Ala Thr Leu
Val 395 400 405 Met Thr Arg Pro Ile Lys Gly Pro Arg Glu Ile Gln Leu
Asp Leu 410 415 420 Glu Met Ile Thr Val Asn Thr Val Ile Asn Phe Arg
Gly Ser Ser 425 430 435 Val Ile Arg Leu Arg Ile Tyr Val Ser Gln Tyr
Pro Phe 440 445 16 2447 DNA Homo Sapien 16 caggtccaac tgcacctcgg
ttctatcgat tgaattcccc ggggatcctc 50 tagagatccc tcgacctcga
cccacgcgtc cgaacacagg tccttgttgc 100 tgcagagaag cagttgtttt
gctggaagga gggagtgcgc gggctgcccc 150 gggctcctcc ctgccgcctc
ctctcagtgg atggttccag gcaccctgtc 200 tggggcaggg agggcacagg
cctgcacatc gaaggtgggg tgggaccagg 250 ctgcccctcg ccccagcatc
caagtcctcc cttgggcgcc cgtggccctg 300 cagactctca gggctaaggt
cctctgttgc tttttggttc caccttagaa 350 gaggctccgc ttgactaaga
gtagcttgaa ggaggcacca tgcaggagct 400 gcatctgctc tggtgggcgc
ttctcctggg cctggctcag gcctgccctg 450 agccctgcga ctgtggggaa
aagtatggct tccagatcgc cgactgtgcc 500 taccgcgacc tagaatccgt
gccgcctggc ttcccggcca atgtgactac 550 actgagcctg tcagccaacc
ggctgccagg cttgccggag ggtgccttca 600 gggaggtgcc cctgctgcag
tcgctgtggc tggcacacaa tgagatccgc 650 acggtggccg ccggagccct
ggcctctctg agccatctca agagcctgga 700 cctcagccac aatctcatct
ctgactttgc ctggagcgac ctgcacaacc 750 tcagtgccct ccaattgctc
aagatggaca gcaacgagct gaccttcatc 800 ccccgcgacg ccttccgcag
cctccgtgct ctgcgctcgc tgcaactcaa 850 ccacaaccgc ttgcacacat
tggccgaggg caccttcacc ccgctcaccg 900 cgctgtccca cctgcagatc
aacgagaacc ccttcgactg cacctgcggc 950 atcgtgtggc tcaagacatg
ggccctgacc acggccgtgt ccatcccgga 1000 gcaggacaac atcgcctgca
cctcacccca tgtgctcaag ggtacaccgc 1050 tgagccgcct gccgccactg
ccatgctcgg cgccctcagt gcagctcagc 1100 taccaaccca gccaggatgg
tgccgagctg cggcctggtt ttgtgctggc 1150 actgcactgt gatgtggacg
ggcagccggc ccctcagctt cactggcaca 1200 tccagatacc cagtggcatt
gtggagatca ccagccccaa cgtgggcact 1250 gatgggcgtg ccctgcctgg
cacccctgtg gccagctccc agccgcgctt 1300 ccaggccttt gccaatggca
gcctgcttat ccccgacttt ggcaagctgg 1350 aggaaggcac ctacagctgc
ctggccacca atgagctggg cagtgctgag 1400 agctcagtgg acgtggcact
ggccacgccc ggtgagggtg gtgaggacac 1450 actggggcgc aggttccatg
gcaaagcggt tgagggaaag ggctgctata 1500 cggttgacaa cgaggtgcag
ccatcagggc cggaggacaa tgtggtcatc 1550 atctacctca gccgtgctgg
gaaccctgag gctgcagtcg cagaaggggt 1600 ccctgggcag ctgcccccag
gcctgctcct gctgggccaa agcctcctcc 1650 tcttcttctt cctcacctcc
ttctagcccc acccagggct tccctaactc 1700 ctccccttgc ccctaccaat
gcccctttaa gtgctgcagg ggtctggggt 1750 tggcaactcc tgaggcctgc
atgggtgact tcacattttc ctacctctcc 1800 ttctaatctc ttctagagca
cctgctatcc ccaacttcta gacctgctcc 1850 aaactagtga ctaggataga
atttgatccc ctaactcact gtctgcggtg 1900 ctcattgctg ctaacagcat
tgcctgtgct ctcctctcag gggcagcatg 1950 ctaacggggc gacgtcctaa
tccaactggg agaagcctca gtggtggaat 2000 tccaggcact gtgactgtca
agctggcaag ggccaggatt gggggaatgg 2050 agctggggct tagctgggag
gtggtctgaa gcagacaggg aatgggagag 2100 gaggatggga agtagacagt
ggctggtatg gctctgaggc tccctggggc 2150 ctgctcaagc tcctcctgct
ccttgctgtt ttctgatgat ttgggggctt 2200 gggagtccct ttgtcctcat
ctgagactga aatgtgggga tccaggatgg 2250 ccttccttcc tcttaccctt
cctccctcag cctgcaacct ctatcctgga 2300 acctgtcctc cctttctccc
caactatgca tctgttgtct gctcctctgc 2350 aaaggccagc cagcttggga
gcagcagaga aataaacagc atttctgatg 2400 ccaaaaaaaa aaaaaaaaaa
gggcggccgc gactctagag tcgacct 2447 17 428 PRT Homo Sapien 17 Met
Gln Glu Leu His Leu Leu Trp Trp Ala Leu Leu Leu Gly Leu 1 5 10 15
Ala Gln Ala Cys Pro Glu Pro Cys Asp Cys Gly Glu Lys Tyr Gly 20 25
30 Phe Gln Ile Ala Asp Cys Ala Tyr Arg Asp Leu Glu Ser Val Pro 35
40 45 Pro Gly Phe Pro Ala Asn Val Thr Thr Leu Ser Leu Ser Ala Asn
50 55 60 Arg Leu Pro Gly Leu Pro Glu Gly Ala Phe Arg Glu Val Pro
Leu 65 70 75 Leu Gln Ser Leu Trp Leu Ala His Asn Glu Ile Arg Thr
Val Ala 80 85 90 Ala Gly Ala Leu Ala Ser Leu Ser His Leu Lys Ser
Leu Asp Leu 95 100 105 Ser His Asn Leu Ile Ser Asp Phe Ala Trp Ser
Asp Leu His Asn 110 115 120 Leu Ser Ala Leu Gln Leu Leu Lys Met Asp
Ser Asn Glu Leu Thr 125 130 135 Phe Ile Pro Arg Asp Ala Phe Arg Ser
Leu Arg Ala Leu Arg Ser 140 145 150 Leu Gln Leu Asn His Asn Arg Leu
His Thr Leu Ala Glu Gly Thr 155 160 165 Phe Thr Pro Leu Thr Ala Leu
Ser His Leu Gln Ile Asn Glu Asn 170 175 180 Pro Phe Asp Cys Thr Cys
Gly Ile Val Trp Leu Lys Thr Trp Ala 185 190 195 Leu Thr Thr Ala Val
Ser Ile Pro Glu Gln Asp Asn Ile Ala Cys 200 205 210 Thr Ser Pro His
Val Leu Lys Gly Thr Pro Leu Ser Arg Leu Pro 215 220 225 Pro Leu Pro
Cys Ser Ala Pro Ser Val Gln Leu Ser Tyr Gln Pro 230 235 240 Ser Gln
Asp Gly Ala Glu Leu Arg Pro Gly Phe Val Leu Ala Leu 245 250 255 His
Cys Asp Val Asp Gly Gln Pro Ala Pro Gln Leu His Trp His 260 265 270
Ile Gln Ile Pro Ser Gly Ile Val Glu Ile Thr Ser Pro Asn Val 275 280
285 Gly Thr Asp Gly Arg Ala Leu Pro Gly Thr Pro Val Ala Ser Ser 290
295 300 Gln Pro Arg Phe Gln Ala Phe Ala Asn Gly Ser Leu Leu Ile Pro
305 310 315 Asp Phe Gly Lys Leu Glu Glu Gly Thr Tyr Ser Cys Leu Ala
Thr 320 325 330 Asn Glu Leu Gly Ser Ala Glu Ser Ser Val Asp Val Ala
Leu Ala 335 340 345 Thr Pro Gly Glu Gly Gly Glu Asp Thr Leu Gly Arg
Arg Phe His 350 355 360 Gly Lys Ala Val Glu Gly Lys Gly Cys Tyr Thr
Val Asp Asn Glu 365 370 375 Val Gln Pro Ser Gly Pro Glu Asp Asn Val
Val Ile Ile Tyr Leu 380 385 390 Ser Arg Ala Gly Asn Pro Glu Ala Ala
Val Ala Glu Gly Val Pro 395 400 405 Gly Gln Leu Pro Pro Gly Leu Leu
Leu Leu Gly Gln Ser Leu Leu 410 415 420 Leu Phe Phe Phe Leu Thr Ser
Phe 425 18 22 DNA Artificial Sequence Synthetic oligonucleotide
probe 18 gtggctggca cacaatgaga tc 22 19 22 DNA Artificial Sequence
Synthetic oligonucleotide probe 19 ccaatgtgtg caagcggttg tg 22 20
50 DNA Artificial Sequence Synthetic oligonucleotide probe 20
tcaagagcct ggacctcagc cacaatctca tctctgactt tgcctggagc 50 21 2033
DNA Homo Sapien 21 ccaggccggg aggcgacgcg cccagccgtc taaacgggaa
cagccctggc 50 tgagggagct gcagcgcagc agagtatctg acggcgccag
gttgcgtagg 100 tgcggcacga ggagttttcc cggcagcgag gaggtcctga
gcagcatggc 150 ccggaggagc gccttccctg ccgccgcgct ctggctctgg
agcatcctcc 200 tgtgcctgct ggcactgcgg gcggaggccg ggccgccgca
ggaggagagc 250 ctgtacctat ggatcgatgc tcaccaggca agagtactca
taggatttga 300 agaagatatc ctgattgttt cagaggggaa aatggcacct
tttacacatg 350 atttcagaaa agcgcaacag agaatgccag ctattcctgt
caatatccat 400 tccatgaatt ttacctggca agctgcaggg caggcagaat
acttctatga 450 attcctgtcc ttgcgctccc tggataaagg catcatggca
gatccaaccg 500 tcaatgtccc tctgctggga acagtgcctc acaaggcatc
agttgttcaa 550 gttggtttcc catgtcttgg aaaacaggat ggggtggcag
catttgaagt 600 ggatgtgatt gttatgaatt ctgaaggcaa caccattctc
caaacacctc 650 aaaatgctat cttctttaaa acatgtcaac aagctgagtg
cccaggcggg 700 tgccgaaatg gaggcttttg taatgaaaga cgcatctgcg
agtgtcctga 750 tgggttccac ggacctcact gtgagaaagc cctttgtacc
ccacgatgta 800 tgaatggtgg actttgtgtg actcctggtt tctgcatctg
cccacctgga 850 ttctatggag tgaactgtga caaagcaaac tgctcaacca
cctgctttaa 900 tggagggacc tgtttctacc ctggaaaatg tatttgccct
ccaggactag 950 agggagagca gtgtgaaatc agcaaatgcc cacaaccctg
tcgaaatgga 1000 ggtaaatgca ttggtaaaag caaatgtaag tgttccaaag
gttaccaggg 1050 agacctctgt tcaaagcctg tctgcgagcc tggctgtggt
gcacatggaa 1100 cctgccatga acccaacaaa tgccaatgtc aagaaggttg
gcatggaaga 1150 cactgcaata aaaggtacga agccagcctc atacatgccc
tgaggccagc 1200 aggcgcccag ctcaggcagc acacgccttc acttaaaaag
gccgaggagc 1250 ggcgggatcc acctgaatcc aattacatct ggtgaactcc
gacatctgaa 1300 acgttttaag ttacaccaag ttcatagcct ttgttaacct
ttcatgtgtt 1350 gaatgttcaa ataatgttca ttacacttaa gaatactggc
ctgaatttta 1400 ttagcttcat tataaatcac tgagctgata tttactcttc
cttttaagtt 1450 ttctaagtac gtctgtagca tgatggtata gattttcttg
tttcagtgct 1500 ttgggacaga ttttatatta tgtcaattga tcaggttaaa
attttcagtg 1550 tgtagttggc agatattttc aaaattacaa tgcatttatg
gtgtctgggg 1600 gcaggggaac atcagaaagg ttaaattggg caaaaatgcg
taagtcacaa 1650 gaatttggat ggtgcagtta atgttgaagt tacagcattt
cagattttat 1700 tgtcagatat ttagatgttt gttacatttt taaaaattgc
tcttaatttt 1750 taaactctca atacaatata ttttgacctt accattattc
cagagattca 1800 gtattaaaaa aaaaaaaatt acactgtggt agtggcattt
aaacaatata 1850 atatattcta aacacaatga aatagggaat ataatgtatg
aactttttgc 1900 attggcttga agcaatataa tatattgtaa acaaaacaca
gctcttacct 1950 aataaacatt ttatactgtt tgtatgtata aaataaaggt
gctgctttag 2000 ttttttggaa aaaaaaaaaa aaaaaaaaaa aaa 2033 22 379
PRT Homo Sapien 22 Met Ala Arg Arg Ser Ala Phe Pro Ala Ala Ala Leu
Trp Leu Trp 1 5 10 15 Ser Ile Leu Leu Cys Leu Leu Ala Leu Arg Ala
Glu Ala Gly Pro 20 25 30 Pro Gln Glu Glu Ser Leu Tyr Leu Trp Ile
Asp Ala His Gln Ala 35 40 45 Arg Val Leu Ile Gly Phe Glu Glu Asp
Ile Leu Ile Val Ser Glu 50 55 60 Gly Lys Met Ala Pro Phe Thr His
Asp Phe Arg Lys Ala Gln Gln 65 70 75 Arg Met Pro Ala Ile Pro Val
Asn Ile His Ser Met Asn Phe Thr 80 85 90 Trp Gln Ala Ala Gly Gln
Ala Glu Tyr Phe Tyr Glu Phe Leu Ser 95 100 105 Leu Arg Ser Leu Asp
Lys
Gly Ile Met Ala Asp Pro Thr Val Asn 110 115 120 Val Pro Leu Leu Gly
Thr Val Pro His Lys Ala Ser Val Val Gln 125 130 135 Val Gly Phe Pro
Cys Leu Gly Lys Gln Asp Gly Val Ala Ala Phe 140 145 150 Glu Val Asp
Val Ile Val Met Asn Ser Glu Gly Asn Thr Ile Leu 155 160 165 Gln Thr
Pro Gln Asn Ala Ile Phe Phe Lys Thr Cys Gln Gln Ala 170 175 180 Glu
Cys Pro Gly Gly Cys Arg Asn Gly Gly Phe Cys Asn Glu Arg 185 190 195
Arg Ile Cys Glu Cys Pro Asp Gly Phe His Gly Pro His Cys Glu 200 205
210 Lys Ala Leu Cys Thr Pro Arg Cys Met Asn Gly Gly Leu Cys Val 215
220 225 Thr Pro Gly Phe Cys Ile Cys Pro Pro Gly Phe Tyr Gly Val Asn
230 235 240 Cys Asp Lys Ala Asn Cys Ser Thr Thr Cys Phe Asn Gly Gly
Thr 245 250 255 Cys Phe Tyr Pro Gly Lys Cys Ile Cys Pro Pro Gly Leu
Glu Gly 260 265 270 Glu Gln Cys Glu Ile Ser Lys Cys Pro Gln Pro Cys
Arg Asn Gly 275 280 285 Gly Lys Cys Ile Gly Lys Ser Lys Cys Lys Cys
Ser Lys Gly Tyr 290 295 300 Gln Gly Asp Leu Cys Ser Lys Pro Val Cys
Glu Pro Gly Cys Gly 305 310 315 Ala His Gly Thr Cys His Glu Pro Asn
Lys Cys Gln Cys Gln Glu 320 325 330 Gly Trp His Gly Arg His Cys Asn
Lys Arg Tyr Glu Ala Ser Leu 335 340 345 Ile His Ala Leu Arg Pro Ala
Gly Ala Gln Leu Arg Gln His Thr 350 355 360 Pro Ser Leu Lys Lys Ala
Glu Glu Arg Arg Asp Pro Pro Glu Ser 365 370 375 Asn Tyr Ile Trp 23
783 DNA Homo Sapien 23 agaacctcag aaatgtgagt tatttgggaa tggctgtttg
taaatgtcct 50 tacgtaagcc aagaggaggt cttgacttgg ggtcccaggg
gtaccgcaga 100 tcccagggac tggagcagca ctagcaagct ctggaggatg
agccaggagt 150 ctggaattga ggctgagcca aagaccccag ggccgtctca
gtctcataaa 200 aggggatcag gcaggaggag tttgggagaa acctgagaag
ggcctgattt 250 gcagcatcat gatgggcctc tccttggcct ctgctgtgct
cctggcctcc 300 ctcctgagtc tccaccttgg aactgccaca cgtgggagtg
acatatccaa 350 gacctgctgc ttccaataca gccacaagcc ccttccctgg
acctgggtgc 400 gaagctatga attcaccagt aacagctgct cccagcgggc
tgtgatattc 450 actaccaaaa gaggcaagaa agtctgtacc catccaagga
aaaaatgggt 500 gcaaaaatac atttctttac tgaaaactcc gaaacaattg
tgactcagct 550 gaattttcat ccgaggacgc ttggaccccg ctcttggctc
tgcagccctc 600 tggggagcct gcggaatctt ttctgaaggc tacatggacc
cgctggggag 650 gagagggtgt ttcctcccag agttacttta ataaaggttg
ttcatagagt 700 tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa 750 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 783 24 94 PRT
Homo Sapien 24 Met Met Gly Leu Ser Leu Ala Ser Ala Val Leu Leu Ala
Ser Leu 1 5 10 15 Leu Ser Leu His Leu Gly Thr Ala Thr Arg Gly Ser
Asp Ile Ser 20 25 30 Lys Thr Cys Cys Phe Gln Tyr Ser His Lys Pro
Leu Pro Trp Thr 35 40 45 Trp Val Arg Ser Tyr Glu Phe Thr Ser Asn
Ser Cys Ser Gln Arg 50 55 60 Ala Val Ile Phe Thr Thr Lys Arg Gly
Lys Lys Val Cys Thr His 65 70 75 Pro Arg Lys Lys Trp Val Gln Lys
Tyr Ile Ser Leu Leu Lys Thr 80 85 90 Pro Lys Gln Leu 25 23 DNA
Artificial Sequence Synthetic oligonucleotide probe 25 ggatcaggca
ggaggagttt ggg 23 26 23 DNA Artificial Sequence Synthetic
oligonucleotide probe 26 ggatgggtac agactttctt gcc 23 27 50 DNA
Artificial Sequence Synthetic oligonucleotide probe 27 atgatgggcc
tctccttggc ctctgctgtg ctcctggcct ccctcctgag 50 28 3552 DNA Homo
Sapien 28 gcgagaacct ttgcacgcgc acaaactacg gggacgattt ctgattgatt 50
tttggcgctt tcgatccacc ctcctccctt ctcatgggac tttggggaca 100
aagcgtcccg accgcctcga gcgctcgagc agggcgctat ccaggagcca 150
ggacagcgtc gggaaccaga ccatggctcc tggaccccaa gatccttaag 200
ttcgtcgtct tcatcgtcgc ggttctgctg ccggtccggg ttgactctgc 250
caccatcccc cggcaggacg aagttcccca gcagacagtg gccccacagc 300
aacagaggcg cagcctcaag gaggaggagt gtccagcagg atctcataga 350
tcagaatata ctggagcctg taacccgtgc acagagggtg tggattacac 400
cattgcttcc aacaatttgc cttcttgcct gctatgtaca gtttgtaaat 450
caggtcaaac aaataaaagt tcctgtacca cgaccagaga caccgtgtgt 500
cagtgtgaaa aaggaagctt ccaggataaa aactcccctg agatgtgccg 550
gacgtgtaga acagggtgtc ccagagggat ggtcaaggtc agtaattgta 600
cgccccggag tgacatcaag tgcaaaaatg aatcagctgc cagttccact 650
gggaaaaccc cagcagcgga ggagacagtg accaccatcc tggggatgct 700
tgcctctccc tatcactacc ttatcatcat agtggtttta gtcatcattt 750
tagctgtggt tgtggttggc ttttcatgtc ggaagaaatt catttcttac 800
ctcaaaggca tctgctcagg tggtggagga ggtcccgaac gtgtgcacag 850
agtccttttc cggcggcgtt catgtccttc acgagttcct ggggcggagg 900
acaatgcccg caacgagacc ctgagtaaca gatacttgca gcccacccag 950
gtctctgagc aggaaatcca aggtcaggag ctggcagagc taacaggtgt 1000
gactgtagag tcgccagagg agccacagcg tctgctggaa caggcagaag 1050
ctgaagggtg tcagaggagg aggctgctgg ttccagtgaa tgacgctgac 1100
tccgctgaca tcagcacctt gctggatgcc tcggcaacac tggaagaagg 1150
acatgcaaag gaaacaattc aggaccaact ggtgggctcc gaaaagctct 1200
tttatgaaga agatgaggca ggctctgcta cgtcctgcct gtgaaagaat 1250
ctcttcagga aaccagagct tccctcattt accttttctc ctacaaaggg 1300
aagcagcctg gaagaaacag tccagtactt gacccatgcc ccaacaaact 1350
ctactatcca atatggggca gcttaccaat ggtcctagaa ctttgttaac 1400
gcacttggag taatttttat gaaatactgc gtgtgataag caaacgggag 1450
aaatttatat cagattcttg gctgcatagt tatacgattg tgtattaagg 1500
gtcgttttag gccacatgcg gtggctcatg cctgtaatcc cagcactttg 1550
ataggctgag gcaggtggat tgcttgagct cgggagtttg agaccagcct 1600
catcaacaca gtgaaactcc atctcaattt aaaaagaaaa aaagtggttt 1650
taggatgtca ttctttgcag ttcttcatca tgagacaagt ctttttttct 1700
gcttcttata ttgcaagctc catctctact ggtgtgtgca tttaatgaca 1750
tctaactaca gatgccgcac agccacaatg ctttgcctta tagtttttta 1800
actttagaac gggattatct tgttattacc tgtattttca gtttcggata 1850
tttttgactt aatgatgaga ttatcaagac gtagccctat gctaagtcat 1900
gagcatatgg acttacgagg gttcgactta gagttttgag ctttaagata 1950
ggattattgg ggcttacccc caccttaatt agagaaacat ttatattgct 2000
tactactgta ggctgtacat ctcttttccg atttttgtat aatgatgtaa 2050
acatggaaaa actttaggaa atgcacttat taggctgttt acatgggttg 2100
cctggataca aatcagcagt caaaaatgac taaaaatata actagtgacg 2150
gagggagaaa tcctccctct gtgggaggca cttactgcat tccagttctc 2200
cctcctgcgc cctgagactg gaccagggtt tgatggctgg cagcttctca 2250
aggggcagct tgtcttactt gttaatttta gaggtatata gccatattta 2300
tttataaata aatatttatt tatttattta taagtagatg tttacatatg 2350
cccaggattt tgaagagcct ggtatctttg ggaagccatg tgtctggttt 2400
gtcgtgctgg gacagtcatg ggactgcatc ttccgacttg tccacagcag 2450
atgaggacag tgagaattaa gttagatccg agactgcgaa gagcttctct 2500
ttcaagcgcc attacagttg aacgttagtg aatcttgagc ctcatttggg 2550
ctcagggcag agcaggtgtt tatctgcccc ggcatctgcc atggcatcaa 2600
gagggaagag tggacggtgc ttgggaatgg tgtgaaatgg ttgccgactc 2650
aggcatggat gggcccctct cgcttctggt ggtctgtgaa ctgagtccct 2700
gggatgcctt ttagggcaga gattcctgag ctgcgtttta gggtacagat 2750
tccctgtttg aggagcttgg cccctctgta agcatctgac tcatctcaga 2800
gatatcaatt cttaaacact gtgacaacgg gatctaaaat ggctgacaca 2850
tttgtccttg tgtcacgttc cattatttta tttaaaaacc tcagtaatcg 2900
ttttagcttc tttccagcaa actcttctcc acagtagccc agtcgtggta 2950
ggataaatta cggatatagt cattctaggg gtttcagtct tttccatctc 3000
aaggcattgt gtgttttgtt ccgggactgg tttggctggg acaaagttag 3050
aactgcctga agttcgcaca ttcagattgt tgtgtccatg gagttttagg 3100
aggggatggc ctttccggtc ttcgcacttc catcctctcc cacttccatc 3150
tggcgtccca caccttgtcc cctgcacttc tggatgacac agggtgctgc 3200
tgcctcctag tctttgcctt tgctgggcct tctgtgcagg agacttggtc 3250
tcaaagctca gagagagcca gtccggtccc agctcctttg tcccttcctc 3300
agaggccttc cttgaagatg catctagact accagcctta tcagtgttta 3350
agcttattcc tttaacataa gcttcctgac aacatgaaat tgttggggtt 3400
ttttggcgtt ggttgatttg tttaggtttt gctttatacc cgggccaaat 3450
agcacataac acctggttat atatgaaata ctcatatgtt tatgaccaaa 3500
ataaatatga aacctcatrt taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3550 aa 3552
29 386 PRT Homo Sapien 29 Met Gly Leu Trp Gly Gln Ser Val Pro Thr
Ala Ser Ser Ala Arg 1 5 10 15 Ala Gly Arg Tyr Pro Gly Ala Arg Thr
Ala Ser Gly Thr Arg Pro 20 25 30 Trp Leu Leu Asp Pro Lys Ile Leu
Lys Phe Val Val Phe Ile Val 35 40 45 Ala Val Leu Leu Pro Val Arg
Val Asp Ser Ala Thr Ile Pro Arg 50 55 60 Gln Asp Glu Val Pro Gln
Gln Thr Val Ala Pro Gln Gln Gln Arg 65 70 75 Arg Ser Leu Lys Glu
Glu Glu Cys Pro Ala Gly Ser His Arg Ser 80 85 90 Glu Tyr Thr Gly
Ala Cys Asn Pro Cys Thr Glu Gly Val Asp Tyr 95 100 105 Thr Ile Ala
Ser Asn Asn Leu Pro Ser Cys Leu Leu Cys Thr Val 110 115 120 Cys Lys
Ser Gly Gln Thr Asn Lys Ser Ser Cys Thr Thr Thr Arg 125 130 135 Asp
Thr Val Cys Gln Cys Glu Lys Gly Ser Phe Gln Asp Lys Asn 140 145 150
Ser Pro Glu Met Cys Arg Thr Cys Arg Thr Gly Cys Pro Arg Gly 155 160
165 Met Val Lys Val Ser Asn Cys Thr Pro Arg Ser Asp Ile Lys Cys 170
175 180 Lys Asn Glu Ser Ala Ala Ser Ser Thr Gly Lys Thr Pro Ala Ala
185 190 195 Glu Glu Thr Val Thr Thr Ile Leu Gly Met Leu Ala Ser Pro
Tyr 200 205 210 His Tyr Leu Ile Ile Ile Val Val Leu Val Ile Ile Leu
Ala Val 215 220 225 Val Val Val Gly Phe Ser Cys Arg Lys Lys Phe Ile
Ser Tyr Leu 230 235 240 Lys Gly Ile Cys Ser Gly Gly Gly Gly Gly Pro
Glu Arg Val His 245 250 255 Arg Val Leu Phe Arg Arg Arg Ser Cys Pro
Ser Arg Val Pro Gly 260 265 270 Ala Glu Asp Asn Ala Arg Asn Glu Thr
Leu Ser Asn Arg Tyr Leu 275 280 285 Gln Pro Thr Gln Val Ser Glu Gln
Glu Ile Gln Gly Gln Glu Leu 290 295 300 Ala Glu Leu Thr Gly Val Thr
Val Glu Ser Pro Glu Glu Pro Gln 305 310 315 Arg Leu Leu Glu Gln Ala
Glu Ala Glu Gly Cys Gln Arg Arg Arg 320 325 330 Leu Leu Val Pro Val
Asn Asp Ala Asp Ser Ala Asp Ile Ser Thr 335 340 345 Leu Leu Asp Ala
Ser Ala Thr Leu Glu Glu Gly His Ala Lys Glu 350 355 360 Thr Ile Gln
Asp Gln Leu Val Gly Ser Glu Lys Leu Phe Tyr Glu 365 370 375 Glu Asp
Glu Ala Gly Ser Ala Thr Ser Cys Leu 380 385 30 50 DNA Artificial
Sequence Synthetic oligonucleotide probe 30 cataaaagtt cctgcaccat
gaccagagac acagtgtgtc agtgtaaaga 50 31 963 DNA Homo Sapien 31
gcggcacctg gaagatgcgc ccattggctg gtggcctgct caaggtggtg 50
ttcgtggtct tcgcctcctt gtgtgcctgg tattcggggt acctgctcgc 100
agagctcatt ccagatgcac ccctgtccag tgctgcctat agcatccgca 150
gcatcgggga gaggcctgtc ctcaaagctc cagtccccaa aaggcaaaaa 200
tgtgaccact ggactccctg cccatctgac acctatgcct acaggttact 250
cagcggaggt ggcagaagca agtacgccaa aatctgcttt gaggataacc 300
tacttatggg agaacagctg ggaaatgttg ccagaggaat aaacattgcc 350
attgtcaact atgtaactgg gaatgtgaca gcaacacgat gttttgatat 400
gtatgaaggc gataactctg gaccgatgac aaagtttatt cagagtgctg 450
ctccaaaatc cctgctcttc atggtgacct atgacgacgg aagcacaaga 500
ctgaataacg atgccaagaa tgccatagaa gcacttggaa gtaaagaaat 550
caggaacatg aaattcaggt ctagctgggt atttattgca gcaaaaggct 600
tggaactccc ttccgaaatt cagagagaaa agatcaacca ctctgatgct 650
aagaacaaca gatattctgg ctggcctgca gagatccaga tagaaggctg 700
catacccaaa gaacgaagct gacactgcag ggtcctgagt aaatgtgttc 750
tgtataaaca aatgcagctg gaatcgctca agaatcttat ttttctaaat 800
ccaacagccc atatttgatg agtattttgg gtttgttgta aaccaatgaa 850
catttgctag ttgtatcaaa tcttggtacg cagtattttt ataccagtat 900
tttatgtagt gaagatgtca attagcagga aactaaaatg aatggaaatt 950
cttaaaaaaa aaa 963 32 235 PRT Homo Sapien 32 Met Arg Pro Leu Ala
Gly Gly Leu Leu Lys Val Val Phe Val Val 1 5 10 15 Phe Ala Ser Leu
Cys Ala Trp Tyr Ser Gly Tyr Leu Leu Ala Glu 20 25 30 Leu Ile Pro
Asp Ala Pro Leu Ser Ser Ala Ala Tyr Ser Ile Arg 35 40 45 Ser Ile
Gly Glu Arg Pro Val Leu Lys Ala Pro Val Pro Lys Arg 50 55 60 Gln
Lys Cys Asp His Trp Thr Pro Cys Pro Ser Asp Thr Tyr Ala 65 70 75
Tyr Arg Leu Leu Ser Gly Gly Gly Arg Ser Lys Tyr Ala Lys Ile 80 85
90 Cys Phe Glu Asp Asn Leu Leu Met Gly Glu Gln Leu Gly Asn Val 95
100 105 Ala Arg Gly Ile Asn Ile Ala Ile Val Asn Tyr Val Thr Gly Asn
110 115 120 Val Thr Ala Thr Arg Cys Phe Asp Met Tyr Glu Gly Asp Asn
Ser 125 130 135 Gly Pro Met Thr Lys Phe Ile Gln Ser Ala Ala Pro Lys
Ser Leu 140 145 150 Leu Phe Met Val Thr Tyr Asp Asp Gly Ser Thr Arg
Leu Asn Asn 155 160 165 Asp Ala Lys Asn Ala Ile Glu Ala Leu Gly Ser
Lys Glu Ile Arg 170 175 180 Asn Met Lys Phe Arg Ser Ser Trp Val Phe
Ile Ala Ala Lys Gly 185 190 195 Leu Glu Leu Pro Ser Glu Ile Gln Arg
Glu Lys Ile Asn His Ser 200 205 210 Asp Ala Lys Asn Asn Arg Tyr Ser
Gly Trp Pro Ala Glu Ile Gln 215 220 225 Ile Glu Gly Cys Ile Pro Lys
Glu Arg Ser 230 235 33 18 DNA Artificial Sequence Synthetic
oligonucleotide probe 33 ggctggcctg cagagatc 18 34 20 DNA
Artificial Sequence Synthetic oligonucleotide probe 34 aatgtgacca
ctggactccc 20 35 18 DNA Artificial Sequence Synthetic
oligonucleotide probe 35 aggcttggaa ctcccttc 18 36 24 DNA
Artificial Sequence Synthetic oligonucleotide probe 36 aagattcttg
agcgattcca gctg 24 37 47 DNA Artificial Sequence Synthetic
oligonucleotide probe 37 aatccctgct cttcatggtg acctatgacg
acggaagcac aagactg 47 38 1215 DNA Homo Sapien 38 ccggggaggg
gagggcccgt cccgcccctc cccgtctctc cccgcccctc 50 cccgtccctc
ccgccgaagc tccgtcccgc ccgcgggccg gctccgccct 100 cacctcccgg
ccgcggctgc cctctgcccg ggttgtccaa gatggagggc 150 gctccaccgg
ggtcgctcgc cctccggctc ctgctgttcg tggcgctacc 200 cgcctccggc
tggctgacga cgggcgcccc cgagccgccg ccgctgtccg 250 gagccccaca
ggacggcatc agaattaatg taactacact gaaagatgat 300 ggggacatat
ctaaacagca ggttgttctt aacataacct atgagagtgg 350 acaggtgtat
gtaaatgact tacctgtaaa tagtggtgta acccgaataa 400 gctgtcagac
tttgatagtg aagaatgaaa atcttgaaaa tttggaggaa 450 aaagaatatt
ttggaattgt cagtgtaagg attttagttc atgagtggcc 500 tatgacatct
ggttccagtt tgcaactaat tgtcattcaa gaagaggtag 550 tagagattga
tggaaaacaa gttcagcaaa aggatgtcac tgaaattgat 600 attttagtta
agaaccgggg agtactcaga cattcaaact ataccctccc 650 tttggaagaa
agcatgctct actctatttc tcgagacagt gacattttat 700 ttacccttcc
taacctctcc aaaaaagaaa gtgttagttc actgcaaacc
750 actagccagt atcttatcag gaatgtggaa accactgtag atgaagatgt 800
tttacctggc aagttacctg aaactcctct cagagcagag ccgccatctt 850
catataaggt aatgtgtcag tggatggaaa agtttagaaa agatctgtgt 900
aggttctgga gcaacgtttt cccagtattc tttcagtttt tgaacatcat 950
ggtggttgga attacaggag cagctgtggt aataaccatc ttaaaggtgt 1000
ttttcccagt ttctgaatac aaaggaattc ttcagttgga taaagtggac 1050
gtcatacctg tgacagctat caacttatat ccagatggtc cagagaaaag 1100
agctgaaaac cttgaagata aaacatgtat ttaaaacgcc atctcatatc 1150
atggactccg aagtagcctg ttgcctccaa atttgccact tgaatataat 1200
tttctttaaa tcgtt 1215 39 330 PRT Homo Sapien 39 Met Glu Gly Ala Pro
Pro Gly Ser Leu Ala Leu Arg Leu Leu Leu 1 5 10 15 Phe Val Ala Leu
Pro Ala Ser Gly Trp Leu Thr Thr Gly Ala Pro 20 25 30 Glu Pro Pro
Pro Leu Ser Gly Ala Pro Gln Asp Gly Ile Arg Ile 35 40 45 Asn Val
Thr Thr Leu Lys Asp Asp Gly Asp Ile Ser Lys Gln Gln 50 55 60 Val
Val Leu Asn Ile Thr Tyr Glu Ser Gly Gln Val Tyr Val Asn 65 70 75
Asp Leu Pro Val Asn Ser Gly Val Thr Arg Ile Ser Cys Gln Thr 80 85
90 Leu Ile Val Lys Asn Glu Asn Leu Glu Asn Leu Glu Glu Lys Glu 95
100 105 Tyr Phe Gly Ile Val Ser Val Arg Ile Leu Val His Glu Trp Pro
110 115 120 Met Thr Ser Gly Ser Ser Leu Gln Leu Ile Val Ile Gln Glu
Glu 125 130 135 Val Val Glu Ile Asp Gly Lys Gln Val Gln Gln Lys Asp
Val Thr 140 145 150 Glu Ile Asp Ile Leu Val Lys Asn Arg Gly Val Leu
Arg His Ser 155 160 165 Asn Tyr Thr Leu Pro Leu Glu Glu Ser Met Leu
Tyr Ser Ile Ser 170 175 180 Arg Asp Ser Asp Ile Leu Phe Thr Leu Pro
Asn Leu Ser Lys Lys 185 190 195 Glu Ser Val Ser Ser Leu Gln Thr Thr
Ser Gln Tyr Leu Ile Arg 200 205 210 Asn Val Glu Thr Thr Val Asp Glu
Asp Val Leu Pro Gly Lys Leu 215 220 225 Pro Glu Thr Pro Leu Arg Ala
Glu Pro Pro Ser Ser Tyr Lys Val 230 235 240 Met Cys Gln Trp Met Glu
Lys Phe Arg Lys Asp Leu Cys Arg Phe 245 250 255 Trp Ser Asn Val Phe
Pro Val Phe Phe Gln Phe Leu Asn Ile Met 260 265 270 Val Val Gly Ile
Thr Gly Ala Ala Val Val Ile Thr Ile Leu Lys 275 280 285 Val Phe Phe
Pro Val Ser Glu Tyr Lys Gly Ile Leu Gln Leu Asp 290 295 300 Lys Val
Asp Val Ile Pro Val Thr Ala Ile Asn Leu Tyr Pro Asp 305 310 315 Gly
Pro Glu Lys Arg Ala Glu Asn Leu Glu Asp Lys Thr Cys Ile 320 325 330
40 2498 DNA Homo Sapien 40 cgtctctgcg ttcgccatgc gtcccggggc
gccagggcca ctctggcctc 50 tgccctgggg ggccctggct tgggccgtgg
gcttcgtgag ctccatgggc 100 tcggggaacc ccgcgcccgg tggtgtttgc
tggctccagc agggccagga 150 ggccacctgc agcctggtgc tccagactga
tgtcacccgg gccgagtgct 200 gtgcctccgg caacattgac accgcctggt
ccaacctcac ccacccgggg 250 aacaagatca acctcctcgg cttcttgggc
cttgtccact gccttccctg 300 caaagattcg tgcgacggcg tggagtgcgg
cccgggcaag gcgtgccgca 350 tgctgggggg ccgcccgcgc tgcgagtgcg
cgcccgactg ctcggggctc 400 ccggcgcggc tgcaggtctg cggctcagac
ggcgccacct accgcgacga 450 gtgcgagctg cgcgccgcgc gctgccgcgg
ccacccggac ctgagcgtca 500 tgtaccgggg ccgctgccgc aagtcctgtg
agcacgtggt gtgcccgcgg 550 ccacagtcgt gcgtcgtgga ccagacgggc
agcgcccact gcgtggtgtg 600 tcgagcggcg ccctgccctg tgccctccag
ccccggccag gagctttgcg 650 gcaacaacaa cgtcacctac atctcctcgt
gccacatgcg ccaggccacc 700 tgcttcctgg gccgctccat cggcgtgcgc
cacgcgggca gctgcgcagg 750 cacccctgag gagccgccag gtggtgagtc
tgcagaagag gaagagaact 800 tcgtgtgagc ctgcaggaca ggcctgggcc
tggtgcccga ggccccccat 850 catcccctgt tatttattgc cacagcagag
tctaatttat atgccacgga 900 cactccttag agcccggatt cggaccactt
ggggatccca gaacctccct 950 gacgatatcc tggaaggact gaggaaggga
ggcctggggg ccggctggtg 1000 ggtgggatag acctgcgttc cggacactga
gcgcctgatt tagggccctt 1050 ctctaggatg ccccagcccc taccctaaga
cctattgccg gggaggattc 1100 cacacttccg ctcctttggg gataaaccta
ttaattattg ctactatcaa 1150 gagggctggg cattctctgc tggtaattcc
tgaagaggca tgactgcttt 1200 tctcagcccc aagcctctag tctgggtgtg
tacggagggt ctagcctggg 1250 tgtgtacgga gggtctagcc tgggtgagta
cggagggtct agcctgggtg 1300 agtacggagg gtctagcctg ggtgagtacg
gagggtctag cctgggtgtg 1350 tatggaggat ctagcctggg tgagtatgga
gggtctagcc tgggtgagta 1400 tggagggtct agcctgggtg tgtatggagg
gtctagcctg ggtgagtatg 1450 gagggtctag cctgggtgtg tatggagggt
ctagcctggg tgagtatgga 1500 gggtctagcc tgggtgtgta cggagggtct
agtctgagtg cgtgtgggga 1550 cctcagaaca ctgtgacctt agcccagcaa
gccaggccct tcatgaaggc 1600 caagaaggct gccaccattc cctgccagcc
caagaactcc agcttcccca 1650 ctgcctctgt gtgccccttt gcgtcctgtg
aaggccattg agaaatgccc 1700 agtgtgcccc ctgggaaagg gcacggcctg
tgctcctgac acgggctgtg 1750 cttggccaca gaaccaccca gcgtctcccc
tgctgctgtc cacgtcagtt 1800 catgaggcaa cgtcgcgtgg tctcagacgt
ggagcagcca gcggcagctc 1850 agagcagggc actgtgtccg gcggagccaa
gtccactctg ggggagctct 1900 ggcggggacc acgggccact gctcacccac
tggccccgag gggggtgtag 1950 acgccaagac tcacgcatgt gtgacatccg
gagtcctgga gccgggtgtc 2000 ccagtggcac cactaggtgc ctgctgcctc
cacagtgggg ttcacaccca 2050 gggctccttg gtcccccaca acctgccccg
gccaggcctg cagacccaga 2100 ctccagccag acctgcctca cccaccaatg
cagccggggc tggcgacacc 2150 agccaggtgc tggtcttggg ccagttctcc
cacgacggct caccctcccc 2200 tccatctgcg ttgatgctca gaatcgccta
cctgtgcctg cgtgtaaacc 2250 acagcctcag accagctatg gggagaggac
aacacggagg atatccagct 2300 tccccggtct ggggtgagga atgtggggag
cttgggcatc ctcctccagc 2350 ctcctccagc ccccaggcag tgccttacct
gtggtgccca gaaaagtgcc 2400 cctaggttgg tgggtctaca ggagcctcag
ccaggcagcc caccccaccc 2450 tggggccctg cctcaccaag gaaataaaga
ctcaagccat aaaaaaaa 2498 41 263 PRT Homo Sapien 41 Met Arg Pro Gly
Ala Pro Gly Pro Leu Trp Pro Leu Pro Trp Gly 1 5 10 15 Ala Leu Ala
Trp Ala Val Gly Phe Val Ser Ser Met Gly Ser Gly 20 25 30 Asn Pro
Ala Pro Gly Gly Val Cys Trp Leu Gln Gln Gly Gln Glu 35 40 45 Ala
Thr Cys Ser Leu Val Leu Gln Thr Asp Val Thr Arg Ala Glu 50 55 60
Cys Cys Ala Ser Gly Asn Ile Asp Thr Ala Trp Ser Asn Leu Thr 65 70
75 His Pro Gly Asn Lys Ile Asn Leu Leu Gly Phe Leu Gly Leu Val 80
85 90 His Cys Leu Pro Cys Lys Asp Ser Cys Asp Gly Val Glu Cys Gly
95 100 105 Pro Gly Lys Ala Cys Arg Met Leu Gly Gly Arg Pro Arg Cys
Glu 110 115 120 Cys Ala Pro Asp Cys Ser Gly Leu Pro Ala Arg Leu Gln
Val Cys 125 130 135 Gly Ser Asp Gly Ala Thr Tyr Arg Asp Glu Cys Glu
Leu Arg Ala 140 145 150 Ala Arg Cys Arg Gly His Pro Asp Leu Ser Val
Met Tyr Arg Gly 155 160 165 Arg Cys Arg Lys Ser Cys Glu His Val Val
Cys Pro Arg Pro Gln 170 175 180 Ser Cys Val Val Asp Gln Thr Gly Ser
Ala His Cys Val Val Cys 185 190 195 Arg Ala Ala Pro Cys Pro Val Pro
Ser Ser Pro Gly Gln Glu Leu 200 205 210 Cys Gly Asn Asn Asn Val Thr
Tyr Ile Ser Ser Cys His Met Arg 215 220 225 Gln Ala Thr Cys Phe Leu
Gly Arg Ser Ile Gly Val Arg His Ala 230 235 240 Gly Ser Cys Ala Gly
Thr Pro Glu Glu Pro Pro Gly Gly Glu Ser 245 250 255 Ala Glu Glu Glu
Glu Asn Phe Val 260 42 20 DNA Artificial Sequence Synthetic
oligonucleotide probe 42 tcctgtgagc acgtggtgtg 20 43 18 DNA
Artificial Sequence Synthetic oligonucleotide probe 43 gggtgggata
gacctgcg 18 44 18 DNA Artificial Sequence Synthetic oligonucleotide
probe 44 aaggccaaga aggctgcc 18 45 18 DNA Artificial Sequence
Synthetic oligonucleotide probe 45 ccaggcctgc agacccag 18 46 24 DNA
Artificial Sequence Synthetic oligonucleotide probe 46 cttcctcagt
ccttccagga tatc 24 47 24 DNA Artificial Sequence Synthetic
oligonucleotide probe 47 aagctggata tcctccgtgt tgtc 24 48 27 DNA
Artificial Sequence Synthetic oligonucleotide probe 48 cctgaagagg
catgactgct tttctca 27 49 27 DNA Artificial Sequence Synthetic
oligonucleotide probe 49 ggggataaac ctattaatta ttgctac 27 50 44 DNA
Artificial Sequence Synthetic oligonucleotide probe 50 aacgtcacct
acatctcctc gtgccacatg cgccaggcca cctg 44 51 1690 DNA Homo Sapien 51
tgcagagctt gtggaggcca tggggcgcgt cgtcgcggag ctcgtctcct 50
cgctgctggg gttgtggctg ttgctgtgca gctgcggatg ccccgagggc 100
gccgagctgc gtgctccgcc agataaaatc gcgattattg gagccggaat 150
tggtggcact tcagcagcct attacctgcg gcagaaattt gggaaagatg 200
tgaagataga cctgtttgaa agagaagagg tcgggggccg cctggctacc 250
atgatggtgc aggggcaaga atacgaggca ggaggttctg tcatccatcc 300
tttaaatctg cacatgaaac gttttgtcaa agacctgggt ctctctgctg 350
ttcaggcctc tggtggccta ctggggatat ataatggaga gactctggta 400
tttgaggaga gcaactggtt cataattaac gtgattaaat tagtttggcg 450
ctatggattt caatccctcc gtatgcacat gtgggtagag gacgtgttag 500
acaagttcat gaggatctac cgctaccagt ctcatgacta tgccttcagt 550
agtgtcgaaa aattacttca tgctctagga ggagatgact tccttggaat 600
gcttaatcga acacttcttg aaaccttgca aaaggccggc ttttctgaga 650
agttcctcaa tgaaatgatt gctcctgtta tgagggtcaa ttatggccaa 700
agcacggaca tcaatgcctt tgtgggggcg gtgtcactgt cctgttctga 750
ttctggcctt tgggcagtag aaggtggcaa taaacttgtt tgctcagggc 800
ttctgcaggc atccaaaagc aatcttatat ctggctcagt aatgtacatc 850
gaggagaaaa caaagaccaa gtacacagga aatccaacaa agatgtatga 900
agtggtctac caaattggaa ctgagactcg ttcagacttc tatgacatcg 950
tcttggtggc cactccgttg aatcgaaaaa tgtcgaatat tacttttctc 1000
aactttgatc ctccaattga ggaattccat caatattatc aacatatagt 1050
gacaacttta gttaaggggg aattgaatac atctatcttt agctctagac 1100
ccatagataa atttggcctt aatacagttt taaccactga taattcagat 1150
ttgttcatta acagtattgg gattgtgccc tctgtgagag aaaaggaaga 1200
tcctgagcca tcaacagatg gaacatatgt ttggaagatc ttttcccaag 1250
aaactcttac taaagcacaa attttaaagc tctttctgtc ctatgattat 1300
gctgtgaaga agccatggct tgcatatcct cactataagc ccccggagaa 1350
atgcccctct atcattctcc atgatcgact ttattacctc aatggcatag 1400
agtgtgcagc aagtgccatg gagatgagtg ccattgcagc ccacaacgct 1450
gcactccttg cctatcaccg ctggaacggg cacacagaca tgattgatca 1500
ggatggctta tatgagaaac ttaaaactga actatgaagt gacacactcc 1550
tttttcccct cctagttcca aatgactatc agtggcaaaa aagaacaaaa 1600
tctgagcaga gatgattttg aaccagatat tttgccatta tcattgttta 1650
ataaaagtaa tccctgctgg tcataggaaa aaaaaaaaaa 1690 52 505 PRT Homo
Sapien 52 Met Gly Arg Val Val Ala Glu Leu Val Ser Ser Leu Leu Gly
Leu 1 5 10 15 Trp Leu Leu Leu Cys Ser Cys Gly Cys Pro Glu Gly Ala
Glu Leu 20 25 30 Arg Ala Pro Pro Asp Lys Ile Ala Ile Ile Gly Ala
Gly Ile Gly 35 40 45 Gly Thr Ser Ala Ala Tyr Tyr Leu Arg Gln Lys
Phe Gly Lys Asp 50 55 60 Val Lys Ile Asp Leu Phe Glu Arg Glu Glu
Val Gly Gly Arg Leu 65 70 75 Ala Thr Met Met Val Gln Gly Gln Glu
Tyr Glu Ala Gly Gly Ser 80 85 90 Val Ile His Pro Leu Asn Leu His
Met Lys Arg Phe Val Lys Asp 95 100 105 Leu Gly Leu Ser Ala Val Gln
Ala Ser Gly Gly Leu Leu Gly Ile 110 115 120 Tyr Asn Gly Glu Thr Leu
Val Phe Glu Glu Ser Asn Trp Phe Ile 125 130 135 Ile Asn Val Ile Lys
Leu Val Trp Arg Tyr Gly Phe Gln Ser Leu 140 145 150 Arg Met His Met
Trp Val Glu Asp Val Leu Asp Lys Phe Met Arg 155 160 165 Ile Tyr Arg
Tyr Gln Ser His Asp Tyr Ala Phe Ser Ser Val Glu 170 175 180 Lys Leu
Leu His Ala Leu Gly Gly Asp Asp Phe Leu Gly Met Leu 185 190 195 Asn
Arg Thr Leu Leu Glu Thr Leu Gln Lys Ala Gly Phe Ser Glu 200 205 210
Lys Phe Leu Asn Glu Met Ile Ala Pro Val Met Arg Val Asn Tyr 215 220
225 Gly Gln Ser Thr Asp Ile Asn Ala Phe Val Gly Ala Val Ser Leu 230
235 240 Ser Cys Ser Asp Ser Gly Leu Trp Ala Val Glu Gly Gly Asn Lys
245 250 255 Leu Val Cys Ser Gly Leu Leu Gln Ala Ser Lys Ser Asn Leu
Ile 260 265 270 Ser Gly Ser Val Met Tyr Ile Glu Glu Lys Thr Lys Thr
Lys Tyr 275 280 285 Thr Gly Asn Pro Thr Lys Met Tyr Glu Val Val Tyr
Gln Ile Gly 290 295 300 Thr Glu Thr Arg Ser Asp Phe Tyr Asp Ile Val
Leu Val Ala Thr 305 310 315 Pro Leu Asn Arg Lys Met Ser Asn Ile Thr
Phe Leu Asn Phe Asp 320 325 330 Pro Pro Ile Glu Glu Phe His Gln Tyr
Tyr Gln His Ile Val Thr 335 340 345 Thr Leu Val Lys Gly Glu Leu Asn
Thr Ser Ile Phe Ser Ser Arg 350 355 360 Pro Ile Asp Lys Phe Gly Leu
Asn Thr Val Leu Thr Thr Asp Asn 365 370 375 Ser Asp Leu Phe Ile Asn
Ser Ile Gly Ile Val Pro Ser Val Arg 380 385 390 Glu Lys Glu Asp Pro
Glu Pro Ser Thr Asp Gly Thr Tyr Val Trp 395 400 405 Lys Ile Phe Ser
Gln Glu Thr Leu Thr Lys Ala Gln Ile Leu Lys 410 415 420 Leu Phe Leu
Ser Tyr Asp Tyr Ala Val Lys Lys Pro Trp Leu Ala 425 430 435 Tyr Pro
His Tyr Lys Pro Pro Glu Lys Cys Pro Ser Ile Ile Leu 440 445 450 His
Asp Arg Leu Tyr Tyr Leu Asn Gly Ile Glu Cys Ala Ala Ser 455 460 465
Ala Met Glu Met Ser Ala Ile Ala Ala His Asn Ala Ala Leu Leu 470 475
480 Ala Tyr His Arg Trp Asn Gly His Thr Asp Met Ile Asp Gln Asp 485
490 495 Gly Leu Tyr Glu Lys Leu Lys Thr Glu Leu 500 505 53 728 DNA
Homo Sapien 53 catttccaac aagagcactg gccaagtcag cttcttctga
gagagtctct 50 agaagacatg atgctacact cagctttggg tctctgcctc
ttactcgtca 100 cagtttcttc caaccttgcc attgcaataa aaaaggaaaa
gaggcctcct 150 cagacactct caagaggatg gggagatgac atcacttggg
tacaaactta 200 tgaagaaggt ctcttttatg ctcaaaaaag taagaagcca
ttaatggtta 250 ttcatcacct ggaggattgt caatactctc aagcactaaa
gaaagtattt 300 gcccaaaatg aagaaataca agaaatggct cagaataagt
tcatcatgct 350 aaaccttatg catgaaacca ctgataagaa tttatcacct
gatgggcaat 400 atgtgcctag aatcatgttt gtagaccctt ctttaacagt
tagagctgac 450 atagctggaa gatactctaa cagattgtac acatatgagc
ctcgggattt 500 acccctattg atagaaaaca tgaagaaagc attaagactt
attcagtcag 550 agctataaga gatgatggaa aaaagccttc acttcaaaga
agtcaaattt 600 catgaagaaa acctctggca cattgacaaa tactaaatgt
gcaagtatat 650 agattttgta atattactat ttagtttttt taatgtgttt
gcaatagtct 700 tattaaaata aatgtttttt aaatctga 728 54 166 PRT Homo
Sapien 54 Met Met Leu His Ser Ala Leu Gly Leu Cys Leu Leu Leu Val
Thr 1 5 10 15 Val Ser
Ser Asn Leu Ala Ile Ala Ile Lys Lys Glu Lys Arg Pro 20 25 30 Pro
Gln Thr Leu Ser Arg Gly Trp Gly Asp Asp Ile Thr Trp Val 35 40 45
Gln Thr Tyr Glu Glu Gly Leu Phe Tyr Ala Gln Lys Ser Lys Lys 50 55
60 Pro Leu Met Val Ile His His Leu Glu Asp Cys Gln Tyr Ser Gln 65
70 75 Ala Leu Lys Lys Val Phe Ala Gln Asn Glu Glu Ile Gln Glu Met
80 85 90 Ala Gln Asn Lys Phe Ile Met Leu Asn Leu Met His Glu Thr
Thr 95 100 105 Asp Lys Asn Leu Ser Pro Asp Gly Gln Tyr Val Pro Arg
Ile Met 110 115 120 Phe Val Asp Pro Ser Leu Thr Val Arg Ala Asp Ile
Ala Gly Arg 125 130 135 Tyr Ser Asn Arg Leu Tyr Thr Tyr Glu Pro Arg
Asp Leu Pro Leu 140 145 150 Leu Ile Glu Asn Met Lys Lys Ala Leu Arg
Leu Ile Gln Ser Glu 155 160 165 Leu 55 537 DNA Homo Sapien 55
taaaacagct acaatattcc agggccagtc acttgccatt tctcataaca 50
gcgtcagaga gaaagaactg actgaaacgt ttgagatgaa gaaagttctc 100
ctcctgatca cagccatctt ggcagtggct gttggtttcc cagtctctca 150
agaccaggaa cgagaaaaaa gaagtatcag tgacagcgat gaattagctt 200
cagggttttt tgtgttccct tacccatatc catttcgccc acttccacca 250
attccatttc caagatttcc atggtttaga cgtaattttc ctattccaat 300
acctgaatct gcccctacaa ctccccttcc tagcgaaaag taaacaagaa 350
ggataagtca cgataaacct ggtcacctga aattgaaatt gagccacttc 400
cttgaagaat caaaattcct gttaataaaa gaaaaacaaa tgtaattgaa 450
atagcacaca gcattctcta gtcaatatct ttagtgatct tctttaataa 500
acatgaaagc aaagattttg gtttcttaat ttccaca 537 56 85 PRT Homo Sapien
56 Met Lys Lys Val Leu Leu Leu Ile Thr Ala Ile Leu Ala Val Ala 1 5
10 15 Val Gly Phe Pro Val Ser Gln Asp Gln Glu Arg Glu Lys Arg Ser
20 25 30 Ile Ser Asp Ser Asp Glu Leu Ala Ser Gly Phe Phe Val Phe
Pro 35 40 45 Tyr Pro Tyr Pro Phe Arg Pro Leu Pro Pro Ile Pro Phe
Pro Arg 50 55 60 Phe Pro Trp Phe Arg Arg Asn Phe Pro Ile Pro Ile
Pro Glu Ser 65 70 75 Ala Pro Thr Thr Pro Leu Pro Ser Glu Lys 80 85
57 2997 DNA Homo Sapien 57 cggacgcgtg ggcgggcgcg ccgggaggga
ccggcggcgg catgggccgg 50 gggccctggg atgcgggccc gtctcgccgc
ctgctgccgc tgttgctgct 100 gctcggcctg gcccgcggcg ccgcgggagc
gccgggcccc gacggtttag 150 acgtctgtgc cacttgccat gaacatgcca
catgccagca aagagaaggg 200 aagaagatct gtatttgcaa ctatggattt
gtagggaacg ggaggactca 250 gtgtgttgat aaaaatgagt gccagtttgg
agccactctt gtctgtggga 300 accacacatc ttgccacaac acccccgggg
gcttctattg catttgcctg 350 gaaggatatc gagccacaaa caacaacaag
acattcattc ccaacgatgg 400 caccttttgt acagacatag atgagtgtga
agtttctggc ctgtgcaggc 450 atggagggcg atgcgtgaac actcatggga
gctttgaatg ctactgtatg 500 gatggatact tgccaaggaa tggacctgaa
cctttccacc cgaccaccga 550 tgccacatca tgcacagaaa tagactgtgg
tacccctcct gaggttccag 600 atggctatat cataggaaat tatacgtcta
gtctgggcag ccaggttcgt 650 tatgcttgca gagaaggatt cttcagtgtt
ccagaagata cagtttcaag 700 ctgcacaggc ctgggcacat gggagtcccc
aaaattacat tgccaagaga 750 tcaactgtgg caaccctcca gaaatgcggc
acgccatctt ggtaggaaat 800 cacagctcca ggctgggcgg tgtggctcgc
tatgtctgtc aagagggctt 850 tgagagccct ggaggaaaga tcacttctgt
ttgcacagag aaaggcacct 900 ggagagaaag tactttaaca tgcacagaaa
ttctgacaaa gattaatgat 950 gtatcactgt ttaatgatac ctgtgtgaga
tggcaaataa actcaagaag 1000 aataaacccc aagatctcat atgtgatatc
cataaaagga caacggttgg 1050 accctatgga atcagttcgt gaggagacag
tcaacttgac cacagacagc 1100 aggaccccag aagtgtgcct agccctgtac
ccaggcacca actacaccgt 1150 gaacatctcc acagcacctc ccaggcgctc
gatgccagcc gtcatcggtt 1200 tccagacagc tgaagttgat ctcttagaag
atgatggaag tttcaatatt 1250 tcaatattta atgaaacttg tttgaaattg
aacaggcgtt ctaggaaagt 1300 tggatcagaa cacatgtacc aatttaccgt
tctgggtcag aggtggtatc 1350 tggctaactt ttctcatgca acatcgttta
acttcacaac gagggaacaa 1400 gtgcctgtag tgtgtttgga tctgtaccct
acgactgatt atacggtgaa 1450 tgtgaccctg ctgagatctc ctaagcggca
ctcagtgcaa ataacaatag 1500 caactccccc agcagtaaaa cagaccatca
gtaacatttc aggatttaat 1550 gaaacctgct tgagatggag aagcatcaag
acagctgata tggaggagat 1600 gtatttattc cacatttggg gccagagatg
gtatcagaag gaatttgccc 1650 aggaaatgac ctttaatatc agtagcagca
gccgagatcc cgaggtgtgc 1700 ttggacctac gtccgggtac caactacaat
gtcagtctcc gggctctgtc 1750 ttcggaactt cctgtggtca tctccctgac
aacccagata acagagcctc 1800 ccctcccgga agtagaattt tttacggtgc
acagaggacc tctaccacgc 1850 ctcagactga ggaaagccaa ggagaaaaat
ggaccaatca gttcatatca 1900 ggtgttagtg cttcccctgg ccctccaaag
cacattttct tgtgattctg 1950 aaggcgcttc ctccttcttt agcaacgcct
ctgatgctga tggatacgtg 2000 gctgcagaac tactggccaa agatgttcca
gatgatgcca tggagatacc 2050 tataggagac aggctgtact atggggaata
ttataatgca cccttgaaaa 2100 gagggagtga ttactgcatt atattacgaa
tcacaagtga atggaataag 2150 gtgagaagac actcctgtgc agtttgggct
caggtgaaag attcgtcact 2200 catgctgctg cagatggcgg gtgttggact
gggttccctg gctgttgtga 2250 tcattctcac attcctctcc ttctcagcgg
tgtgatggca gatggacact 2300 gagtggggag gatgcactgc tgctgggcag
gtgttctggc agcttctcag 2350 gtgcccgcac agaggctccg tgtgacttcc
gtccagggag catgtgggcc 2400 tgcaactttc tccattccca gctgggcccc
attcctggat ttaagatggt 2450 ggctatccct gaggagtcac cataaggaga
aaactcagga attctgagtc 2500 ttccctgcta caggaccagt tctgtgcaat
gaacttgaga ctcctgatgt 2550 acactgtgat attgaccgaa ggctacatac
agatctgtga atcttggctg 2600 ggacttcctc tgagtgatgc ctgagggtca
gctcctctag acattgactg 2650 caagagaatc tctgcaacct cctatataaa
agcatttctg ttaattcatt 2700 cagaatccat tctttacaat atgcagtgag
atgggcttaa gtttgggcta 2750 gagtttgact ttatgaagga ggtcattgaa
aaagagaaca gtgacgtagg 2800 caaatgtttc aagcacttta gaaacagtac
ttttcctata attagttgat 2850 atactaatga gaaaatatac tagcctggcc
atgccaataa gtttcctgct 2900 gtgtctgtta ggcagcattg ctttgatgca
atttctattg tcctatatat 2950 tcaaaagtaa tgtctacatt ccagtaaaaa
tatcccgtaa ttaaaaa 2997 58 747 PRT Homo Sapien 58 Met Gly Arg Gly
Pro Trp Asp Ala Gly Pro Ser Arg Arg Leu Leu 1 5 10 15 Pro Leu Leu
Leu Leu Leu Gly Leu Ala Arg Gly Ala Ala Gly Ala 20 25 30 Pro Gly
Pro Asp Gly Leu Asp Val Cys Ala Thr Cys His Glu His 35 40 45 Ala
Thr Cys Gln Gln Arg Glu Gly Lys Lys Ile Cys Ile Cys Asn 50 55 60
Tyr Gly Phe Val Gly Asn Gly Arg Thr Gln Cys Val Asp Lys Asn 65 70
75 Glu Cys Gln Phe Gly Ala Thr Leu Val Cys Gly Asn His Thr Ser 80
85 90 Cys His Asn Thr Pro Gly Gly Phe Tyr Cys Ile Cys Leu Glu Gly
95 100 105 Tyr Arg Ala Thr Asn Asn Asn Lys Thr Phe Ile Pro Asn Asp
Gly 110 115 120 Thr Phe Cys Thr Asp Ile Asp Glu Cys Glu Val Ser Gly
Leu Cys 125 130 135 Arg His Gly Gly Arg Cys Val Asn Thr His Gly Ser
Phe Glu Cys 140 145 150 Tyr Cys Met Asp Gly Tyr Leu Pro Arg Asn Gly
Pro Glu Pro Phe 155 160 165 His Pro Thr Thr Asp Ala Thr Ser Cys Thr
Glu Ile Asp Cys Gly 170 175 180 Thr Pro Pro Glu Val Pro Asp Gly Tyr
Ile Ile Gly Asn Tyr Thr 185 190 195 Ser Ser Leu Gly Ser Gln Val Arg
Tyr Ala Cys Arg Glu Gly Phe 200 205 210 Phe Ser Val Pro Glu Asp Thr
Val Ser Ser Cys Thr Gly Leu Gly 215 220 225 Thr Trp Glu Ser Pro Lys
Leu His Cys Gln Glu Ile Asn Cys Gly 230 235 240 Asn Pro Pro Glu Met
Arg His Ala Ile Leu Val Gly Asn His Ser 245 250 255 Ser Arg Leu Gly
Gly Val Ala Arg Tyr Val Cys Gln Glu Gly Phe 260 265 270 Glu Ser Pro
Gly Gly Lys Ile Thr Ser Val Cys Thr Glu Lys Gly 275 280 285 Thr Trp
Arg Glu Ser Thr Leu Thr Cys Thr Glu Ile Leu Thr Lys 290 295 300 Ile
Asn Asp Val Ser Leu Phe Asn Asp Thr Cys Val Arg Trp Gln 305 310 315
Ile Asn Ser Arg Arg Ile Asn Pro Lys Ile Ser Tyr Val Ile Ser 320 325
330 Ile Lys Gly Gln Arg Leu Asp Pro Met Glu Ser Val Arg Glu Glu 335
340 345 Thr Val Asn Leu Thr Thr Asp Ser Arg Thr Pro Glu Val Cys Leu
350 355 360 Ala Leu Tyr Pro Gly Thr Asn Tyr Thr Val Asn Ile Ser Thr
Ala 365 370 375 Pro Pro Arg Arg Ser Met Pro Ala Val Ile Gly Phe Gln
Thr Ala 380 385 390 Glu Val Asp Leu Leu Glu Asp Asp Gly Ser Phe Asn
Ile Ser Ile 395 400 405 Phe Asn Glu Thr Cys Leu Lys Leu Asn Arg Arg
Ser Arg Lys Val 410 415 420 Gly Ser Glu His Met Tyr Gln Phe Thr Val
Leu Gly Gln Arg Trp 425 430 435 Tyr Leu Ala Asn Phe Ser His Ala Thr
Ser Phe Asn Phe Thr Thr 440 445 450 Arg Glu Gln Val Pro Val Val Cys
Leu Asp Leu Tyr Pro Thr Thr 455 460 465 Asp Tyr Thr Val Asn Val Thr
Leu Leu Arg Ser Pro Lys Arg His 470 475 480 Ser Val Gln Ile Thr Ile
Ala Thr Pro Pro Ala Val Lys Gln Thr 485 490 495 Ile Ser Asn Ile Ser
Gly Phe Asn Glu Thr Cys Leu Arg Trp Arg 500 505 510 Ser Ile Lys Thr
Ala Asp Met Glu Glu Met Tyr Leu Phe His Ile 515 520 525 Trp Gly Gln
Arg Trp Tyr Gln Lys Glu Phe Ala Gln Glu Met Thr 530 535 540 Phe Asn
Ile Ser Ser Ser Ser Arg Asp Pro Glu Val Cys Leu Asp 545 550 555 Leu
Arg Pro Gly Thr Asn Tyr Asn Val Ser Leu Arg Ala Leu Ser 560 565 570
Ser Glu Leu Pro Val Val Ile Ser Leu Thr Thr Gln Ile Thr Glu 575 580
585 Pro Pro Leu Pro Glu Val Glu Phe Phe Thr Val His Arg Gly Pro 590
595 600 Leu Pro Arg Leu Arg Leu Arg Lys Ala Lys Glu Lys Asn Gly Pro
605 610 615 Ile Ser Ser Tyr Gln Val Leu Val Leu Pro Leu Ala Leu Gln
Ser 620 625 630 Thr Phe Ser Cys Asp Ser Glu Gly Ala Ser Ser Phe Phe
Ser Asn 635 640 645 Ala Ser Asp Ala Asp Gly Tyr Val Ala Ala Glu Leu
Leu Ala Lys 650 655 660 Asp Val Pro Asp Asp Ala Met Glu Ile Pro Ile
Gly Asp Arg Leu 665 670 675 Tyr Tyr Gly Glu Tyr Tyr Asn Ala Pro Leu
Lys Arg Gly Ser Asp 680 685 690 Tyr Cys Ile Ile Leu Arg Ile Thr Ser
Glu Trp Asn Lys Val Arg 695 700 705 Arg His Ser Cys Ala Val Trp Ala
Gln Val Lys Asp Ser Ser Leu 710 715 720 Met Leu Leu Gln Met Ala Gly
Val Gly Leu Gly Ser Leu Ala Val 725 730 735 Val Ile Ile Leu Thr Phe
Leu Ser Phe Ser Ala Val 740 745 59 22 DNA Artificial Sequence
Synthetic oligonucleotide probe 59 ccacttgcca tgaacatgcc ac 22 60
25 DNA Artificial Sequence Synthetic oligonucleotide probe 60
cctcttgaca gacatagcga gccac 25 61 43 DNA Artificial Sequence
Synthetic oligonucleotide probe 61 cactcttgtc tgtgggaacc acacatcttg
ccacaactgt ggc 43 62 2015 DNA Homo Sapien 62 ggaaaaggta cccgcgagag
acagccagca gttctgtgga gcagcggtgg 50 ccggctagga tgggctgtct
ctggggtctg gctctgcccc ttttcttctt 100 ctgctgggag gttggggtct
ctgggagctc tgcaggcccc agcacccgca 150 gagcagacac tgcgatgaca
acggacgaca cagaagtgcc cgctatgact 200 ctagcaccgg gccacgccgc
tctggaaact caaacgctga gcgctgagac 250 ctcttctagg gcctcaaccc
cagccggccc cattccagaa gcagagacca 300 ggggagccaa gagaatttcc
cctgcaagag agaccaggag tttcacaaaa 350 acatctccca acttcatggt
gctgatcgcc acctccgtgg agacatcagc 400 cgccagtggc agccccgagg
gagctggaat gaccacagtt cagaccatca 450 caggcagtga tcccgaggaa
gccatctttg acaccctttg caccgatgac 500 agctctgaag aggcaaagac
actcacaatg gacatattga cattggctca 550 cacctccaca gaagctaagg
gcctgtcctc agagagcagt gcctcttccg 600 acggccccca tccagtcatc
accccgtcac gggcctcaga gagcagcgcc 650 tcttccgacg gcccccatcc
agtcatcacc ccgtcacggg cctcagagag 700 cagcgcctct tccgacggcc
cccatccagt catcaccccg tcatggtccc 750 cgggatctga tgtcactctc
ctcgctgaag ccctggtgac tgtcacaaac 800 atcgaggtta ttaattgcag
catcacagaa atagaaacaa caacttccag 850 catccctggg gcctcagaca
tagatctcat ccccacggaa ggggtgaagg 900 cctcgtccac ctccgatcca
ccagctctgc ctgactccac tgaagcaaaa 950 ccacacatca ctgaggtcac
agcctctgcc gagaccctgt ccacagccgg 1000 caccacagag tcagctgcac
ctcatgccac ggttgggacc ccactcccca 1050 ctaacagcgc cacagaaaga
gaagtgacag cacccggggc cacgaccctc 1100 agtggagctc tggtcacagt
tagcaggaat cccctggaag aaacctcagc 1150 cctctctgtt gagacaccaa
gttacgtcaa agtctcagga gcagctccgg 1200 tctccataga ggctgggtca
gcagtgggca aaacaacttc ctttgctggg 1250 agctctgctt cctcctacag
cccctcggaa gccgccctca agaacttcac 1300 cccttcagag acaccgacca
tggacatcgc aaccaagggg cccttcccca 1350 ccagcaggga ccctcttcct
tctgtccctc cgactacaac caacagcagc 1400 cgagggacga acagcacctt
agccaagatc acaacctcag cgaagaccac 1450 gatgaagccc caacagccac
gcccacgact gcccggacga ggccgaccac 1500 agacgtgagt gcaggtgaaa
atggaggttt cctcctcctg cggctgagtg 1550 tggcttcccc ggaagacctc
actgacccca gagtggcaga aaggctgatg 1600 cagcagctcc accgggaact
ccacgcccac gcgcctcact tccaggtctc 1650 cttactgcgt gtcaggagag
gctaacggac atcagctgca gccaggcatg 1700 tcccgtatgc caaaagaggg
tgctgcccct agcctgggcc cccaccgaca 1750 gactgcagct gcgttactgt
gctgagaggt acccagaagg ttcccatgaa 1800 gggcagcatg tccaagcccc
taaccccaga tgtggcaaca ggaccctcgc 1850 tcacatccac cggagtgtat
gtatggggag gggcttcacc tgttcccaga 1900 ggtgtccttg gactcacctt
ggcacatgtt ctgtgtttca gtaaagagag 1950 acctgatcac ccatctgtgt
gcttccatcc tgcattaaaa ttcactcagt 2000 gtggcccaaa aaaaa 2015 63 482
PRT Homo Sapien 63 Met Gly Cys Leu Trp Gly Leu Ala Leu Pro Leu Phe
Phe Phe Cys 1 5 10 15 Trp Glu Val Gly Val Ser Gly Ser Ser Ala Gly
Pro Ser Thr Arg 20 25 30 Arg Ala Asp Thr Ala Met Thr Thr Asp Asp
Thr Glu Val Pro Ala 35 40 45 Met Thr Leu Ala Pro Gly His Ala Ala
Leu Glu Thr Gln Thr Leu 50 55 60 Ser Ala Glu Thr Ser Ser Arg Ala
Ser Thr Pro Ala Gly Pro Ile 65 70 75 Pro Glu Ala Glu Thr Arg Gly
Ala Lys Arg Ile Ser Pro Ala Arg 80 85 90 Glu Thr Arg Ser Phe Thr
Lys Thr Ser Pro Asn Phe Met Val Leu 95 100 105 Ile Ala Thr Ser Val
Glu Thr Ser Ala Ala Ser Gly Ser Pro Glu 110 115 120 Gly Ala Gly Met
Thr Thr Val Gln Thr Ile Thr Gly Ser Asp Pro 125 130 135 Glu Glu Ala
Ile Phe Asp Thr Leu Cys Thr Asp Asp Ser Ser Glu 140 145 150 Glu Ala
Lys Thr Leu Thr Met Asp Ile Leu Thr Leu Ala His Thr 155 160 165 Ser
Thr Glu Ala Lys Gly Leu Ser Ser Glu Ser Ser Ala Ser Ser 170 175 180
Asp Gly Pro His Pro Val Ile Thr Pro Ser Arg Ala Ser Glu Ser 185 190
195 Ser Ala Ser Ser Asp Gly Pro His Pro Val Ile Thr Pro Ser Arg 200
205 210 Ala Ser Glu Ser Ser Ala Ser Ser Asp Gly Pro His Pro Val
Ile
215 220 225 Thr Pro Ser Trp Ser Pro Gly Ser Asp Val Thr Leu Leu Ala
Glu 230 235 240 Ala Leu Val Thr Val Thr Asn Ile Glu Val Ile Asn Cys
Ser Ile 245 250 255 Thr Glu Ile Glu Thr Thr Thr Ser Ser Ile Pro Gly
Ala Ser Asp 260 265 270 Ile Asp Leu Ile Pro Thr Glu Gly Val Lys Ala
Ser Ser Thr Ser 275 280 285 Asp Pro Pro Ala Leu Pro Asp Ser Thr Glu
Ala Lys Pro His Ile 290 295 300 Thr Glu Val Thr Ala Ser Ala Glu Thr
Leu Ser Thr Ala Gly Thr 305 310 315 Thr Glu Ser Ala Ala Pro His Ala
Thr Val Gly Thr Pro Leu Pro 320 325 330 Thr Asn Ser Ala Thr Glu Arg
Glu Val Thr Ala Pro Gly Ala Thr 335 340 345 Thr Leu Ser Gly Ala Leu
Val Thr Val Ser Arg Asn Pro Leu Glu 350 355 360 Glu Thr Ser Ala Leu
Ser Val Glu Thr Pro Ser Tyr Val Lys Val 365 370 375 Ser Gly Ala Ala
Pro Val Ser Ile Glu Ala Gly Ser Ala Val Gly 380 385 390 Lys Thr Thr
Ser Phe Ala Gly Ser Ser Ala Ser Ser Tyr Ser Pro 395 400 405 Ser Glu
Ala Ala Leu Lys Asn Phe Thr Pro Ser Glu Thr Pro Thr 410 415 420 Met
Asp Ile Ala Thr Lys Gly Pro Phe Pro Thr Ser Arg Asp Pro 425 430 435
Leu Pro Ser Val Pro Pro Thr Thr Thr Asn Ser Ser Arg Gly Thr 440 445
450 Asn Ser Thr Leu Ala Lys Ile Thr Thr Ser Ala Lys Thr Thr Met 455
460 465 Lys Pro Gln Gln Pro Arg Pro Arg Leu Pro Gly Arg Gly Arg Pro
470 475 480 Gln Thr 64 1252 DNA Homo Sapien 64 gcctctgaat
tgttgggcag tctggcagtg gagctctccc cggtctgaca 50 gccactccag
aggccatgct tcgtttcttg ccagatttgg ctttcagctt 100 cctgttaatt
ctggctttgg gccaggcagt ccaatttcaa gaatatgtct 150 ttctccaatt
tctgggctta gataaggcgc cttcacccca gaagttccaa 200 cctgtgcctt
atatcttgaa gaaaattttc caggatcgcg aggcagcagc 250 gaccactggg
gtctcccgag acttatgcta cgtaaaggag ctgggcgtcc 300 gcgggaatgt
acttcgcttt ctcccagacc aaggtttctt tctttaccca 350 aagaaaattt
cccaagcttc ctcctgcctg cagaagctcc tctactttaa 400 cctgtctgcc
atcaaagaaa gggaacagtt gacattggcc cagctgggcc 450 tggacttggg
gcccaattct tactataacc tgggaccaga gctggaactg 500 gctctgttcc
tggttcagga gcctcatgtg tggggccaga ccacccctaa 550 gccaggtaaa
atgtttgtgt tgcggtcagt cccatggcca caaggtgctg 600 ttcacttcaa
cctgctggat gtagctaagg attggaatga caacccccgg 650 aaaaatttcg
ggttattcct ggagatactg gtcaaagaag atagagactc 700 aggggtgaat
tttcagcctg aagacacctg tgccagacta agatgctccc 750 ttcatgcttc
cctgctggtg gtgactctca accctgatca gtgccaccct 800 tctcggaaaa
ggagagcagc catccctgtc cccaagcttt cttgtaagaa 850 cctctgccac
cgtcaccagc tattcattaa cttccgggac ctgggttggc 900 acaagtggat
cattgccccc aaggggttca tggcaaatta ctgccatgga 950 gagtgtccct
tctcactgac catctctctc aacagctcca attatgcttt 1000 catgcaagcc
ctgatgcatg ccgttgaccc agagatcccc caggctgtgt 1050 gtatccccac
caagctgtct cccatttcca tgctctacca ggacaataat 1100 gacaatgtca
ttctacgaca ttatgaagac atggtagtcg atgaatgtgg 1150 gtgtgggtag
gatgtcagaa atgggaatag aaggagtgtt cttagggtaa 1200 atcttttaat
aaaactacct atctggttta tgaccactta gatcgaaatg 1250 tc 1252 65 364 PRT
Homo Sapien 65 Met Leu Arg Phe Leu Pro Asp Leu Ala Phe Ser Phe Leu
Leu Ile 1 5 10 15 Leu Ala Leu Gly Gln Ala Val Gln Phe Gln Glu Tyr
Val Phe Leu 20 25 30 Gln Phe Leu Gly Leu Asp Lys Ala Pro Ser Pro
Gln Lys Phe Gln 35 40 45 Pro Val Pro Tyr Ile Leu Lys Lys Ile Phe
Gln Asp Arg Glu Ala 50 55 60 Ala Ala Thr Thr Gly Val Ser Arg Asp
Leu Cys Tyr Val Lys Glu 65 70 75 Leu Gly Val Arg Gly Asn Val Leu
Arg Phe Leu Pro Asp Gln Gly 80 85 90 Phe Phe Leu Tyr Pro Lys Lys
Ile Ser Gln Ala Ser Ser Cys Leu 95 100 105 Gln Lys Leu Leu Tyr Phe
Asn Leu Ser Ala Ile Lys Glu Arg Glu 110 115 120 Gln Leu Thr Leu Ala
Gln Leu Gly Leu Asp Leu Gly Pro Asn Ser 125 130 135 Tyr Tyr Asn Leu
Gly Pro Glu Leu Glu Leu Ala Leu Phe Leu Val 140 145 150 Gln Glu Pro
His Val Trp Gly Gln Thr Thr Pro Lys Pro Gly Lys 155 160 165 Met Phe
Val Leu Arg Ser Val Pro Trp Pro Gln Gly Ala Val His 170 175 180 Phe
Asn Leu Leu Asp Val Ala Lys Asp Trp Asn Asp Asn Pro Arg 185 190 195
Lys Asn Phe Gly Leu Phe Leu Glu Ile Leu Val Lys Glu Asp Arg 200 205
210 Asp Ser Gly Val Asn Phe Gln Pro Glu Asp Thr Cys Ala Arg Leu 215
220 225 Arg Cys Ser Leu His Ala Ser Leu Leu Val Val Thr Leu Asn Pro
230 235 240 Asp Gln Cys His Pro Ser Arg Lys Arg Arg Ala Ala Ile Pro
Val 245 250 255 Pro Lys Leu Ser Cys Lys Asn Leu Cys His Arg His Gln
Leu Phe 260 265 270 Ile Asn Phe Arg Asp Leu Gly Trp His Lys Trp Ile
Ile Ala Pro 275 280 285 Lys Gly Phe Met Ala Asn Tyr Cys His Gly Glu
Cys Pro Phe Ser 290 295 300 Leu Thr Ile Ser Leu Asn Ser Ser Asn Tyr
Ala Phe Met Gln Ala 305 310 315 Leu Met His Ala Val Asp Pro Glu Ile
Pro Gln Ala Val Cys Ile 320 325 330 Pro Thr Lys Leu Ser Pro Ile Ser
Met Leu Tyr Gln Asp Asn Asn 335 340 345 Asp Asn Val Ile Leu Arg His
Tyr Glu Asp Met Val Val Asp Glu 350 355 360 Cys Gly Cys Gly 66 20
DNA Artificial Sequence Synthetic oligonucleotide probe 66
gtctgacagc cactccagag 20 67 47 DNA Artificial Sequence Synthetic
oligonucleotide probe 67 tctccaattt ctgggcttag ataaggcgcc
ttcaccccag aagttcc 47 68 24 DNA Artificial Sequence Synthetic
oligonucleotide probe 68 gtcccaggtt atagtaagaa ttgg 24 69 20 DNA
Artificial Sequence Synthetic oligonucleotide probe 69 gtgttgcggt
cagtcccatg 20 70 20 DNA Artificial Sequence Synthetic
oligonucleotide probe 70 gctgtctccc atttccatgc 20 71 24 DNA
Artificial Sequence Synthetic oligonucleotide probe 71 cgactaccat
gtcttcataa tgtc 24 72 2849 DNA Homo Sapien 72 cactttctcc ctctcttcct
ttactttcga gaaaccgcgc ttccgcttct 50 ggtcgcagag acctcggaga
ccgcgccggg gagacggagg tgctgtgggt 100 gggggggacc tgtggctgct
cgtaccgccc cccaccctcc tcttctgcac 150 tgccgtcctc cggaagacct
tttcccctgc tctgtttcct tcaccgagtc 200 tgtgcatcgc cccggacctg
gccgggagga ggcttggccg gcgggagatg 250 ctctaggggc ggcgcgggag
gagcggccgg cgggacggag ggcccggcag 300 gaagatgggc tcccgtggac
agggactctt gctggcgtac tgcctgctcc 350 ttgcctttgc ctctggcctg
gtcctgagtc gtgtgcccca tgtccagggg 400 gaacagcagg agtgggaggg
gactgaggag ctgccgtcgc ctccggacca 450 tgccgagagg gctgaagaac
aacatgaaaa atacaggccc agtcaggacc 500 aggggctccc tgcttcccgg
tgcttgcgct gctgtgaccc cggtacctcc 550 atgtacccgg cgaccgccgt
gccccagatc aacatcacta tcttgaaagg 600 ggagaagggt gaccgcggag
atcgaggcct ccaagggaaa tatggcaaaa 650 caggctcagc aggggccagg
ggccacactg gacccaaagg gcagaagggc 700 tccatggggg cccctgggga
gcggtgcaag agccactacg ccgccttttc 750 ggtgggccgg aagaagccca
tgcacagcaa ccactactac cagacggtga 800 tcttcgacac ggagttcgtg
aacctctacg accacttcaa catgttcacc 850 ggcaagttct actgctacgt
gcccggcctc tacttcttca gcctcaacgt 900 gcacacctgg aaccagaagg
agacctacct gcacatcatg aagaacgagg 950 aggaggtggt gatcttgttc
gcgcaggtgg gcgaccgcag catcatgcaa 1000 agccagagcc tgatgctgga
gctgcgagag caggaccagg tgtgggtacg 1050 cctctacaag ggcgaacgtg
agaacgccat cttcagcgag gagctggaca 1100 cctacatcac cttcagtggc
tacctggtca agcacgccac cgagccctag 1150 ctggccggcc acctcctttc
ctctcgccac cttccacccc tgcgctgtgc 1200 tgaccccacc gcctcttccc
cgatccctgg actccgactc cctggctttg 1250 gcattcagtg agacgccctg
cacacacaga aagccaaagc gatcggtgct 1300 cccagatccc gcagcctctg
gagagagctg acggcagatg aaatcaccag 1350 ggcggggcac ccgcgagaac
cctctgggac cttccgcggc cctctctgca 1400 cacatcctca agtgaccccg
cacggcgaga cgcgggtggc ggcagggcgt 1450 cccagggtgc ggcaccgcgg
ctccagtcct tggaaataat taggcaaatt 1500 ctaaaggtct caaaaggagc
aaagtaaacc gtggaggaca aagaaaaggg 1550 ttgttatttt tgtctttcca
gccagcctgc tggctcccaa gagagaggcc 1600 ttttcagttg agactctgct
taagagaaga tccaaagtta aagctctggg 1650 gtcaggggag gggccggggg
caggaaacta cctctggctt aattctttta 1700 agccacgtag gaactttctt
gagggatagg tggaccctga catccctgtg 1750 gccttgccca agggctctgc
tggtctttct gagtcacagc tgcgaggtga 1800 tgggggctgg ggccccaggc
gtcagcctcc cagagggaca gctgagcccc 1850 ctgccttggc tccaggttgg
tagaagcagc cgaagggctc ctgacagtgg 1900 ccagggaccc ctgggtcccc
caggcctgca gatgtttcta tgaggggcag 1950 agctccttgg tacatccatg
tgtggctctg ctccacccct gtgccacccc 2000 agagccctgg ggggtggtct
ccatgcctgc caccctggca tcggctttct 2050 gtgccgcctc ccacacaaat
cagccccaga aggccccggg gccttggctt 2100 ctgtttttta taaaacacct
caagcagcac tgcagtctcc catctcctcg 2150 tgggctaagc atcaccgctt
ccacgtgtgt tgtgttggtt ggcagcaagg 2200 ctgatccaga ccccttctgc
ccccactgcc ctcatccagg cctctgacca 2250 gtagcctgag aggggctttt
tctaggcttc agagcagggg agagctggaa 2300 ggggctagaa agctcccgct
tgtctgtttc tcaggctcct gtgagcctca 2350 gtcctgagac cagagtcaag
aggaagtaca cgtcccaatc acccgtgtca 2400 ggattcactc tcaggagctg
ggtggcagga gaggcaatag cccctgtggc 2450 aattgcagga ccagctggag
cagggttgcg gtgtctccac ggtgctctcg 2500 ccctgcccat ggccacccca
gactctgatc tccaggaacc ccatagcccc 2550 tctccacctc accccatgtt
gatgcccagg gtcactcttg ctacccgctg 2600 ggcccccaaa cccccgctgc
ctctcttcct tccccccatc ccccacctgg 2650 ttttgactaa tcctgcttcc
ctctctgggc ctggctgccg ggatctgggg 2700 tccctaagtc cctctcttta
aagaacttct gcgggtcaga ctctgaagcc 2750 gagttgctgt gggcgtgccc
ggaagcagag cgccacactc gctgcttaag 2800 ctcccccagc tctttccaga
aaacattaaa ctcagaattg tgttttcaa 2849 73 281 PRT Homo Sapien 73 Met
Gly Ser Arg Gly Gln Gly Leu Leu Leu Ala Tyr Cys Leu Leu 1 5 10 15
Leu Ala Phe Ala Ser Gly Leu Val Leu Ser Arg Val Pro His Val 20 25
30 Gln Gly Glu Gln Gln Glu Trp Glu Gly Thr Glu Glu Leu Pro Ser 35
40 45 Pro Pro Asp His Ala Glu Arg Ala Glu Glu Gln His Glu Lys Tyr
50 55 60 Arg Pro Ser Gln Asp Gln Gly Leu Pro Ala Ser Arg Cys Leu
Arg 65 70 75 Cys Cys Asp Pro Gly Thr Ser Met Tyr Pro Ala Thr Ala
Val Pro 80 85 90 Gln Ile Asn Ile Thr Ile Leu Lys Gly Glu Lys Gly
Asp Arg Gly 95 100 105 Asp Arg Gly Leu Gln Gly Lys Tyr Gly Lys Thr
Gly Ser Ala Gly 110 115 120 Ala Arg Gly His Thr Gly Pro Lys Gly Gln
Lys Gly Ser Met Gly 125 130 135 Ala Pro Gly Glu Arg Cys Lys Ser His
Tyr Ala Ala Phe Ser Val 140 145 150 Gly Arg Lys Lys Pro Met His Ser
Asn His Tyr Tyr Gln Thr Val 155 160 165 Ile Phe Asp Thr Glu Phe Val
Asn Leu Tyr Asp His Phe Asn Met 170 175 180 Phe Thr Gly Lys Phe Tyr
Cys Tyr Val Pro Gly Leu Tyr Phe Phe 185 190 195 Ser Leu Asn Val His
Thr Trp Asn Gln Lys Glu Thr Tyr Leu His 200 205 210 Ile Met Lys Asn
Glu Glu Glu Val Val Ile Leu Phe Ala Gln Val 215 220 225 Gly Asp Arg
Ser Ile Met Gln Ser Gln Ser Leu Met Leu Glu Leu 230 235 240 Arg Glu
Gln Asp Gln Val Trp Val Arg Leu Tyr Lys Gly Glu Arg 245 250 255 Glu
Asn Ala Ile Phe Ser Glu Glu Leu Asp Thr Tyr Ile Thr Phe 260 265 270
Ser Gly Tyr Leu Val Lys His Ala Thr Glu Pro 275 280 74 24 DNA
Artificial Sequence Synthetic oligonucleotide probe 74 tacaggccca
gtcaggacca gggg 24 75 24 DNA Artificial Sequence Synthetic
oligonucleotide probe 75 ctgaagaagt agaggccggg cacg 24 76 45 DNA
Artificial Sequence Synthetic oligonucleotide probe 76 cccggtgctt
gcgctgctgt gaccccggta cctccatgta cccgg 45 77 1042 DNA Homo Sapien
77 gaattcggca cgagggaaga agagaaagaa aatctccggg gctgctggga 50
gcatataaag aagccctgtg gccttgctgg ttttaccatc cagaccagag 100
tcaggccaca gacggacatg gctgctcaag gctggtccat gctcctgctg 150
gctgtcctta acctaggcat cttcgtccgt ccctgtgaca ctcaagagct 200
acgatgtctg tgtattcagg aacactctga attcattcct ctcaaactca 250
ttaaaaatat aatggtgata ttcgagacca tttactgcaa cagaaaggaa 300
gtgatagcag tcccaaaaaa tgggagtatg atttgtttgg atcctgatgc 350
tccatgggtg aaggctactg ttggcccaat tactaacagg ttcctacctg 400
aggacctcaa acaaaaggaa tttccaccgg caatgaagct tctgtatagt 450
gttgagcatg aaaagcctct atatctttca tttgggagac ctgagaacaa 500
gagaatattt ccctttccaa ttcgggagac ctctagacac tttgctgatt 550
tagctcacaa cagtgatagg aattttctac gggactccag tgaagtcagc 600
ttgacaggca gtgatgccta aaagccactc atgaggcaaa gagtttcaag 650
gaagctctcc tcctggagtt ttggcgttct cattcttata ctctattccc 700
gcgttagtct ggtgtatgga tctatgagct ctcttttaat attttattat 750
aaatgtttta tttacttaac ttcctagtga atgttcacag gtgactgctc 800
ccccatcccc atttcttgat attacatata atggcatcat ataccccttt 850
attgactgac aaactactca gattgcttaa cattttgtgc ttcaaagtct 900
tatcccactc cactatgggc tgttacagag tgcatctcgg tgtagagcaa 950
ggctccttgt cttcagtgcc ccagggtgaa atacttcttt gaaaaatttt 1000
cattcatcag aaaatctgaa ataaaaatat gtcttaattg ag 1042 78 167 PRT Homo
Sapien 78 Met Ala Ala Gln Gly Trp Ser Met Leu Leu Leu Ala Val Leu
Asn 1 5 10 15 Leu Gly Ile Phe Val Arg Pro Cys Asp Thr Gln Glu Leu
Arg Cys 20 25 30 Leu Cys Ile Gln Glu His Ser Glu Phe Ile Pro Leu
Lys Leu Ile 35 40 45 Lys Asn Ile Met Val Ile Phe Glu Thr Ile Tyr
Cys Asn Arg Lys 50 55 60 Glu Val Ile Ala Val Pro Lys Asn Gly Ser
Met Ile Cys Leu Asp 65 70 75 Pro Asp Ala Pro Trp Val Lys Ala Thr
Val Gly Pro Ile Thr Asn 80 85 90 Arg Phe Leu Pro Glu Asp Leu Lys
Gln Lys Glu Phe Pro Pro Ala 95 100 105 Met Lys Leu Leu Tyr Ser Val
Glu His Glu Lys Pro Leu Tyr Leu 110 115 120 Ser Phe Gly Arg Pro Glu
Asn Lys Arg Ile Phe Pro Phe Pro Ile 125 130 135 Arg Glu Thr Ser Arg
His Phe Ala Asp Leu Ala His Asn Ser Asp 140 145 150 Arg Asn Phe Leu
Arg Asp Ser Ser Glu Val Ser Leu Thr Gly Ser 155 160 165 Asp Ala 79
798 DNA Homo Sapien unsure 794 unknown base 79 cagacatggc
tcagtcactg gctctgagcc tccttatcct ggttctggcc 50 tttggcatcc
ccaggaccca aggcagtgat ggaggggctc aggactgttg 100 cctcaagtac
agccaaagga agattcccgc caaggttgtc cgcagctacc 150 ggaagcagga
accaagctta ggctgctcca tcccagctat cctgttcttg 200 ccccgcaagc
gctctcaggc agagctatgt gcagacccaa aggagctctg 250 ggtgcagcag
ctgatgcagc atctggacaa gacaccatcc ccacagaaac 300 cagcccaggg
ctgcaggaag gacagggggg cctccaagac tggcaagaaa 350 ggaaagggct
ccaaaggctg caagaggact gagcggtcac agacccctaa 400 agggccatag
cccagtgagc agcctggagc cctggagacc ccaccagcct 450 caccagcgct
tgaagcctga
acccaagatg caagaaggag gctatgctca 500 ggggccctgg agcagccacc
ccatgctggc cttgccacac tctttctcct 550 gctttaacca ccccatctgc
attcccagct ctaccctgca tggctgagct 600 gcccacagca ggccaggtcc
agagagaccg aggagggaga gtctcccagg 650 gagcatgaga ggaggcagca
ggactgtccc cttgaaggag aatcatcagg 700 accctggacc tgatacggct
ccccagtaca ccccacctct tccttgtaaa 750 tatgatttat acctaactga
ataaaaagct gttctgtctt cccnccca 798 80 134 PRT Homo Sapien 80 Met
Ala Gln Ser Leu Ala Leu Ser Leu Leu Ile Leu Val Leu Ala 1 5 10 15
Phe Gly Ile Pro Arg Thr Gln Gly Ser Asp Gly Gly Ala Gln Asp 20 25
30 Cys Cys Leu Lys Tyr Ser Gln Arg Lys Ile Pro Ala Lys Val Val 35
40 45 Arg Ser Tyr Arg Lys Gln Glu Pro Ser Leu Gly Cys Ser Ile Pro
50 55 60 Ala Ile Leu Phe Leu Pro Arg Lys Arg Ser Gln Ala Glu Leu
Cys 65 70 75 Ala Asp Pro Lys Glu Leu Trp Val Gln Gln Leu Met Gln
His Leu 80 85 90 Asp Lys Thr Pro Ser Pro Gln Lys Pro Ala Gln Gly
Cys Arg Lys 95 100 105 Asp Arg Gly Ala Ser Lys Thr Gly Lys Lys Gly
Lys Gly Ser Lys 110 115 120 Gly Cys Lys Arg Thr Glu Arg Ser Gln Thr
Pro Lys Gly Pro 125 130 81 20 DNA Artificial Sequence Synthetic
oligonucleotide probe 81 agacatggct cagtcactgg 20 82 19 DNA
Artificial Sequence Synthetic oligonucleotide probe 82 gacccctaaa
gggccatag 19 83 924 DNA Homo Sapien 83 aaggagcagc ccgcaagcac
caagtgagag gcatgaagtt acagtgtgtt 50 tccctttggc tcctgggtac
aatactgata ttgtgctcag tagacaacca 100 cggtctcagg agatgtctga
tttccacaga catgcaccat atagaagaga 150 gtttccaaga aatcaaaaga
gccatccaag ctaaggacac cttcccaaat 200 gtcactatcc tgtccacatt
ggagactctg cagatcatta agcccttaga 250 tgtgtgctgc gtgaccaaga
acctcctggc gttctacgtg gacagggtgt 300 tcaaggatca tcaggagcca
aaccccaaaa tcttgagaaa aatcagcagc 350 attgccaact ctttcctcta
catgcagaaa actctgcggc aatgtcagga 400 acagaggcag tgtcactgca
ggcaggaagc caccaatgcc accagagtca 450 tccatgacaa ctatgatcag
ctggaggtcc acgctgctgc cattaaatcc 500 ctgggagagc tcgacgtctt
tctagcctgg attaataaga atcatgaagt 550 aatgttctca gcttgatgac
aaggaacctg tatagtgatc cagggatgaa 600 caccccctgt gcggtttact
gtgggagaca gcccaccttg aaggggaagg 650 agatggggaa ggccccttgc
agctgaaagt cccactggct ggcctcaggc 700 tgtcttattc cgcttgaaaa
taggcaaaaa gtctactgtg gtatttgtaa 750 taaactctat ctgctgaaag
ggcctgcagg ccatcctggg agtaaagggc 800 tgccttccca tctaatttat
tgtaaagtca tatagtccat gtctgtgatg 850 tgagccaagt gatatcctgt
agtacacatt gtactgagtg gtttttctga 900 ataaattcca tattttacct atga 924
84 177 PRT Homo Sapien 84 Met Lys Leu Gln Cys Val Ser Leu Trp Leu
Leu Gly Thr Ile Leu 1 5 10 15 Ile Leu Cys Ser Val Asp Asn His Gly
Leu Arg Arg Cys Leu Ile 20 25 30 Ser Thr Asp Met His His Ile Glu
Glu Ser Phe Gln Glu Ile Lys 35 40 45 Arg Ala Ile Gln Ala Lys Asp
Thr Phe Pro Asn Val Thr Ile Leu 50 55 60 Ser Thr Leu Glu Thr Leu
Gln Ile Ile Lys Pro Leu Asp Val Cys 65 70 75 Cys Val Thr Lys Asn
Leu Leu Ala Phe Tyr Val Asp Arg Val Phe 80 85 90 Lys Asp His Gln
Glu Pro Asn Pro Lys Ile Leu Arg Lys Ile Ser 95 100 105 Ser Ile Ala
Asn Ser Phe Leu Tyr Met Gln Lys Thr Leu Arg Gln 110 115 120 Cys Gln
Glu Gln Arg Gln Cys His Cys Arg Gln Glu Ala Thr Asn 125 130 135 Ala
Thr Arg Val Ile His Asp Asn Tyr Asp Gln Leu Glu Val His 140 145 150
Ala Ala Ala Ile Lys Ser Leu Gly Glu Leu Asp Val Phe Leu Ala 155 160
165 Trp Ile Asn Lys Asn His Glu Val Met Phe Ser Ala 170 175 85 2137
DNA Homo Sapien 85 gctcccagcc aagaacctcg gggccgctgc gcggtgggga
ggagttcccc 50 gaaacccggc cgctaagcga ggcctcctcc tcccgcagat
ccgaacggcc 100 tgggcggggt caccccggct gggacaagaa gccgccgcct
gcctgcccgg 150 gcccggggag ggggctgggg ctggggccgg aggcggggtg
tgagtgggtg 200 tgtgcggggg gcggaggctt gatgcaatcc cgataagaaa
tgctcgggtg 250 tcttgggcac ctacccgtgg ggcccgtaag gcgctactat
ataaggctgc 300 cggcccggag ccgccgcgcc gtcagagcag gagcgctgcg
tccaggatct 350 agggccacga ccatcccaac ccggcactca cagccccgca
gcgcatcccg 400 gtcgccgccc agcctcccgc acccccatcg ccggagctgc
gccgagagcc 450 ccagggaggt gccatgcgga gcgggtgtgt ggtggtccac
gtatggatcc 500 tggccggcct ctggctggcc gtggccgggc gccccctcgc
cttctcggac 550 gcggggcccc acgtgcacta cggctggggc gaccccatcc
gcctgcggca 600 cctgtacacc tccggccccc acgggctctc cagctgcttc
ctgcgcatcc 650 gtgccgacgg cgtcgtggac tgcgcgcggg gccagagcgc
gcacagtttg 700 ctggagatca aggcagtcgc tctgcggacc gtggccatca
agggcgtgca 750 cagcgtgcgg tacctctgca tgggcgccga cggcaagatg
caggggctgc 800 ttcagtactc ggaggaagac tgtgctttcg aggaggagat
ccgcccagat 850 ggctacaatg tgtaccgatc cgagaagcac cgcctcccgg
tctccctgag 900 cagtgccaaa cagcggcagc tgtacaagaa cagaggcttt
cttccactct 950 ctcatttcct gcccatgctg cccatggtcc cagaggagcc
tgaggacctc 1000 aggggccact tggaatctga catgttctct tcgcccctgg
agaccgacag 1050 catggaccca tttgggcttg tcaccggact ggaggccgtg
aggagtccca 1100 gctttgagaa gtaactgaga ccatgcccgg gcctcttcac
tgctgccagg 1150 ggctgtggta cctgcagcgt gggggacgtg cttctacaag
aacagtcctg 1200 agtccacgtt ctgtttagct ttaggaagaa acatctagaa
gttgtacata 1250 ttcagagttt tccattggca gtgccagttt ctagccaata
gacttgtctg 1300 atcataacat tgtaagcctg tagcttgccc agctgctgcc
tgggccccca 1350 ttctgctccc tcgaggttgc tggacaagct gctgcactgt
ctcagttctg 1400 cttgaatacc tccatcgatg gggaactcac ttcctttgga
aaaattctta 1450 tgtcaagctg aaattctcta attttttctc atcacttccc
caggagcagc 1500 cagaagacag gcagtagttt taatttcagg aacaggtgat
ccactctgta 1550 aaacagcagg taaatttcac tcaaccccat gtgggaattg
atctatatct 1600 ctacttccag ggaccatttg cccttcccaa atccctccag
gccagaactg 1650 actggagcag gcatggccca ccaggcttca ggagtagggg
aagcctggag 1700 ccccactcca gccctgggac aacttgagaa ttccccctga
ggccagttct 1750 gtcatggatg ctgtcctgag aataacttgc tgtcccggtg
tcacctgctt 1800 ccatctccca gcccaccagc cctctgccca cctcacatgc
ctccccatgg 1850 attggggcct cccaggcccc ccaccttatg tcaacctgca
cttcttgttc 1900 aaaaatcagg aaaagaaaag atttgaagac cccaagtctt
gtcaataact 1950 tgctgtgtgg aagcagcggg ggaagaccta gaaccctttc
cccagcactt 2000 ggttttccaa catgatattt atgagtaatt tattttgata
tgtacatctc 2050 ttattttctt acattattta tgcccccaaa ttatatttat
gtatgtaagt 2100 gaggtttgtt ttgtatatta aaatggagtt tgtttgt 2137 86
216 PRT Homo Sapien 86 Met Arg Ser Gly Cys Val Val Val His Val Trp
Ile Leu Ala Gly 1 5 10 15 Leu Trp Leu Ala Val Ala Gly Arg Pro Leu
Ala Phe Ser Asp Ala 20 25 30 Gly Pro His Val His Tyr Gly Trp Gly
Asp Pro Ile Arg Leu Arg 35 40 45 His Leu Tyr Thr Ser Gly Pro His
Gly Leu Ser Ser Cys Phe Leu 50 55 60 Arg Ile Arg Ala Asp Gly Val
Val Asp Cys Ala Arg Gly Gln Ser 65 70 75 Ala His Ser Leu Leu Glu
Ile Lys Ala Val Ala Leu Arg Thr Val 80 85 90 Ala Ile Lys Gly Val
His Ser Val Arg Tyr Leu Cys Met Gly Ala 95 100 105 Asp Gly Lys Met
Gln Gly Leu Leu Gln Tyr Ser Glu Glu Asp Cys 110 115 120 Ala Phe Glu
Glu Glu Ile Arg Pro Asp Gly Tyr Asn Val Tyr Arg 125 130 135 Ser Glu
Lys His Arg Leu Pro Val Ser Leu Ser Ser Ala Lys Gln 140 145 150 Arg
Gln Leu Tyr Lys Asn Arg Gly Phe Leu Pro Leu Ser His Phe 155 160 165
Leu Pro Met Leu Pro Met Val Pro Glu Glu Pro Glu Asp Leu Arg 170 175
180 Gly His Leu Glu Ser Asp Met Phe Ser Ser Pro Leu Glu Thr Asp 185
190 195 Ser Met Asp Pro Phe Gly Leu Val Thr Gly Leu Glu Ala Val Arg
200 205 210 Ser Pro Ser Phe Glu Lys 215 87 26 DNA Artificial
Sequence Synthetic oligonucleotide probe 87 atccgcccag atggctacaa
tgtgta 26 88 42 DNA Artificial Sequence Synthetic oligonucleotide
probe 88 gcctcccggt ctccctgagc agtgccaaac agcggcagtg ta 42 89 22
DNA Artificial Sequence Synthetic oligonucleotide probe 89
ccagtccggt gacaagccca aa 22 90 1857 DNA Homo Sapien 90 gtctgttccc
aggagtcctt cggcggctgt tgtgtcagtg gcctgatcgc 50 gatggggaca
aaggcgcaag tcgagaggaa actgttgtgc ctcttcatat 100 tggcgatcct
gttgtgctcc ctggcattgg gcagtgttac agtgcactct 150 tctgaacctg
aagtcagaat tcctgagaat aatcctgtga agttgtcctg 200 tgcctactcg
ggcttttctt ctccccgtgt ggagtggaag tttgaccaag 250 gagacaccac
cagactcgtt tgctataata acaagatcac agcttcctat 300 gaggaccggg
tgaccttctt gccaactggt atcaccttca agtccgtgac 350 acgggaagac
actgggacat acacttgtat ggtctctgag gaaggcggca 400 acagctatgg
ggaggtcaag gtcaagctca tcgtgcttgt gcctccatcc 450 aagcctacag
ttaacatccc ctcctctgcc accattggga accgggcagt 500 gctgacatgc
tcagaacaag atggttcccc accttctgaa tacacctggt 550 tcaaagatgg
gatagtgatg cctacgaatc ccaaaagcac ccgtgccttc 600 agcaactctt
cctatgtcct gaatcccaca acaggagagc tggtctttga 650 tcccctgtca
gcctctgata ctggagaata cagctgtgag gcacggaatg 700 ggtatgggac
acccatgact tcaaatgctg tgcgcatgga agctgtggag 750 cggaatgtgg
gggtcatcgt ggcagccgtc cttgtaaccc tgattctcct 800 gggaatcttg
gtttttggca tctggtttgc ctatagccga ggccactttg 850 acagaacaaa
gaaagggact tcgagtaaga aggtgattta cagccagcct 900 agtgcccgaa
gtgaaggaga attcaaacag acctcgtcat tcctggtgtg 950 agcctggtcg
gctcaccgcc tatcatctgc atttgcctta ctcaggtgct 1000 accggactct
ggcccctgat gtctgtagtt tcacaggatg ccttatttgt 1050 cttctacacc
ccacagggcc ccctacttct tcggatgtgt ttttaataat 1100 gtcagctatg
tgccccatcc tccttcatgc cctccctccc tttcctacca 1150 ctgctgagtg
gcctggaact tgtttaaagt gtttattccc catttctttg 1200 agggatcagg
aaggaatcct gggtatgcca ttgacttccc ttctaagtag 1250 acagcaaaaa
tggcgggggt cgcaggaatc tgcactcaac tgcccacctg 1300 gctggcaggg
atctttgaat aggtatcttg agcttggttc tgggctcttt 1350 ccttgtgtac
tgacgaccag ggccagctgt tctagagcgg gaattagagg 1400 ctagagcggc
tgaaatggtt gtttggtgat gacactgggg tccttccatc 1450 tctggggccc
actctcttct gtcttcccat gggaagtgcc actgggatcc 1500 ctctgccctg
tcctcctgaa tacaagctga ctgacattga ctgtgtctgt 1550 ggaaaatggg
agctcttgtt gtggagagca tagtaaattt tcagagaact 1600 tgaagccaaa
aggatttaaa accgctgctc taaagaaaag aaaactggag 1650 gctgggcgca
gtggctcacg cctgtaatcc cagaggctga ggcaggcgga 1700 tcacctgagg
tcgggagttc gggatcagcc tgaccaacat ggagaaaccc 1750 tactggaaat
acaaagttag ccaggcatgg tggtgcatgc ctgtagtccc 1800 agctgctcag
gagcctggca acaagagcaa aactccagct caaaaaaaaa 1850 aaaaaaa 1857 91
299 PRT Homo Sapien 91 Met Gly Thr Lys Ala Gln Val Glu Arg Lys Leu
Leu Cys Leu Phe 1 5 10 15 Ile Leu Ala Ile Leu Leu Cys Ser Leu Ala
Leu Gly Ser Val Thr 20 25 30 Val His Ser Ser Glu Pro Glu Val Arg
Ile Pro Glu Asn Asn Pro 35 40 45 Val Lys Leu Ser Cys Ala Tyr Ser
Gly Phe Ser Ser Pro Arg Val 50 55 60 Glu Trp Lys Phe Asp Gln Gly
Asp Thr Thr Arg Leu Val Cys Tyr 65 70 75 Asn Asn Lys Ile Thr Ala
Ser Tyr Glu Asp Arg Val Thr Phe Leu 80 85 90 Pro Thr Gly Ile Thr
Phe Lys Ser Val Thr Arg Glu Asp Thr Gly 95 100 105 Thr Tyr Thr Cys
Met Val Ser Glu Glu Gly Gly Asn Ser Tyr Gly 110 115 120 Glu Val Lys
Val Lys Leu Ile Val Leu Val Pro Pro Ser Lys Pro 125 130 135 Thr Val
Asn Ile Pro Ser Ser Ala Thr Ile Gly Asn Arg Ala Val 140 145 150 Leu
Thr Cys Ser Glu Gln Asp Gly Ser Pro Pro Ser Glu Tyr Thr 155 160 165
Trp Phe Lys Asp Gly Ile Val Met Pro Thr Asn Pro Lys Ser Thr 170 175
180 Arg Ala Phe Ser Asn Ser Ser Tyr Val Leu Asn Pro Thr Thr Gly 185
190 195 Glu Leu Val Phe Asp Pro Leu Ser Ala Ser Asp Thr Gly Glu Tyr
200 205 210 Ser Cys Glu Ala Arg Asn Gly Tyr Gly Thr Pro Met Thr Ser
Asn 215 220 225 Ala Val Arg Met Glu Ala Val Glu Arg Asn Val Gly Val
Ile Val 230 235 240 Ala Ala Val Leu Val Thr Leu Ile Leu Leu Gly Ile
Leu Val Phe 245 250 255 Gly Ile Trp Phe Ala Tyr Ser Arg Gly His Phe
Asp Arg Thr Lys 260 265 270 Lys Gly Thr Ser Ser Lys Lys Val Ile Tyr
Ser Gln Pro Ser Ala 275 280 285 Arg Ser Glu Gly Glu Phe Lys Gln Thr
Ser Ser Phe Leu Val 290 295 92 24 DNA Artificial Sequence Synthetic
oligonucleotide probe 92 tcgcggagct gtgttctgtt tccc 24 93 50 DNA
Artificial Sequence Synthetic oligonucleotide probe 93 tgatcgcgat
ggggacaaag gcgcaagctc gagaggaaac tgttgtgcct 50 94 20 DNA Artificial
Sequence Synthetic oligonucleotide probe 94 acacctggtt caaagatggg
20 95 24 DNA Artificial Sequence Synthetic oligonucleotide probe 95
taggaagagt tgctgaaggc acgg 24 96 20 DNA Artificial Sequence
Synthetic oligonucleotide probe 96 ttgccttact caggtgctac 20 97 20
DNA Artificial Sequence Synthetic oligonucleotide probe 97
actcagcagt ggtaggaaag 20 98 1200 DNA Homo Sapien 98 cccacgcgtc
cgaacctctc cagcgatggg agccgcccgc ctgctgccca 50 acctcactct
gtgcttacag ctgctgattc tctgctgtca aactcagtac 100 gtgagggacc
agggcgccat gaccgaccag ctgagcaggc ggcagatccg 150 cgagtaccaa
ctctacagca ggaccagtgg caagcacgtg caggtcaccg 200 ggcgtcgcat
ctccgccacc gccgaggacg gcaacaagtt tgccaagctc 250 atagtggaga
cggacacgtt tggcagccgg gttcgcatca aaggggctga 300 gagtgagaag
tacatctgta tgaacaagag gggcaagctc atcgggaagc 350 ccagcgggaa
gagcaaagac tgcgtgttca cggagatcgt gctggagaac 400 aactatacgg
ccttccagaa cgcccggcac gagggctggt tcatggcctt 450 cacgcggcag
gggcggcccc gccaggcttc ccgcagccgc cagaaccagc 500 gcgaggccca
cttcatcaag cgcctctacc aaggccagct gcccttcccc 550 aaccacgccg
agaagcagaa gcagttcgag tttgtgggct ccgcccccac 600 ccgccggacc
aagcgcacac ggcggcccca gcccctcacg tagtctggga 650 ggcagggggc
agcagcccct gggccgcctc cccacccctt tcccttctta 700 atccaaggac
tgggctgggg tggcgggagg ggagccagat ccccgaggga 750 ggaccctgag
ggccgcgaag catccgagcc cccagctggg aaggggcagg 800 ccggtgcccc
aggggcggct ggcacagtgc ccccttcccg gacgggtggc 850 aggccctgga
gaggaactga gtgtcaccct gatctcaggc caccagcctc 900 tgccggcctc
ccagccgggc tcctgaagcc cgctgaaagg tcagcgactg 950 aaggccttgc
agacaaccgt ctggaggtgg ctgtcctcaa aatctgcttc 1000 tcggatctcc
ctcagtctgc ccccagcccc caaactcctc ctggctagac 1050 tgtaggaagg
gacttttgtt tgtttgtttg tttcaggaaa aaagaaaggg 1100 agagagagga
aaatagaggg ttgtccactc ctcacattcc acgacccagg 1150 cctgcacccc
acccccaact cccagccccg gaataaaacc attttcctgc 1200 99 205 PRT Homo
Sapien 99 Met Gly Ala Ala Arg Leu Leu Pro Asn Leu Thr Leu Cys Leu
Gln 1 5 10 15 Leu Leu Ile Leu Cys Cys Gln Thr Gln Tyr Val Arg Asp
Gln Gly 20 25 30 Ala Met Thr Asp Gln Leu Ser Arg Arg Gln Ile Arg
Glu Tyr Gln 35 40 45 Leu Tyr Ser Arg Thr Ser Gly Lys His Val Gln
Val Thr Gly Arg
50 55 60 Arg Ile Ser Ala Thr Ala Glu Asp Gly Asn Lys Phe Ala Lys
Leu 65 70 75 Ile Val Glu Thr Asp Thr Phe Gly Ser Arg Val Arg Ile
Lys Gly 80 85 90 Ala Glu Ser Glu Lys Tyr Ile Cys Met Asn Lys Arg
Gly Lys Leu 95 100 105 Ile Gly Lys Pro Ser Gly Lys Ser Lys Asp Cys
Val Phe Thr Glu 110 115 120 Ile Val Leu Glu Asn Asn Tyr Thr Ala Phe
Gln Asn Ala Arg His 125 130 135 Glu Gly Trp Phe Met Ala Phe Thr Arg
Gln Gly Arg Pro Arg Gln 140 145 150 Ala Ser Arg Ser Arg Gln Asn Gln
Arg Glu Ala His Phe Ile Lys 155 160 165 Arg Leu Tyr Gln Gly Gln Leu
Pro Phe Pro Asn His Ala Glu Lys 170 175 180 Gln Lys Gln Phe Glu Phe
Val Gly Ser Ala Pro Thr Arg Arg Thr 185 190 195 Lys Arg Thr Arg Arg
Pro Gln Pro Leu Thr 200 205 100 28 DNA Artificial Sequence
Synthetic oligonucleotide probe 100 101 24 DNA Artificial Sequence
Synthetic oligonucleotide probe 101 102 41 DNA Artificial Sequence
Synthetic oligonucleotide probe 102 103 1679 DNA Homo Sapien 103
gttgtgtcct tcagcaaaac agtggattta aatctccttg cacaagcttg 50
agagcaacac aatctatcag gaaagaaaga aagaaaaaaa ccgaacctga 100
caaaaaagaa gaaaaagaag aagaaaaaaa atcatgaaaa ccatccagcc 150
aaaaatgcac aattctatct cttgggcaat cttcacgggg ctggctgctc 200
tgtgtctctt ccaaggagtg cccgtgcgca gcggagatgc caccttcccc 250
aaagctatgg acaacgtgac ggtccggcag ggggagagcg ccaccctcag 300
gtgcactatt gacaaccggg tcacccgggt ggcctggcta aaccgcagca 350
ccatcctcta tgctgggaat gacaagtggt gcctggatcc tcgcgtggtc 400
cttctgagca acacccaaac gcagtacagc atcgagatcc agaacgtgga 450
tgtgtatgac gagggccctt acacctgctc ggtgcagaca gacaaccacc 500
caaagacctc tagggtccac ctcattgtgc aagtatctcc caaaattgta 550
gagatttctt cagatatctc cattaatgaa gggaacaata ttagcctcac 600
ctgcatagca actggtagac cagagcctac ggttacttgg agacacatct 650
ctcccaaagc ggttggcttt gtgagtgaag acgaatactt ggaaattcag 700
ggcatcaccc gggagcagtc aggggactac gagtgcagtg cctccaatga 750
cgtggccgcg cccgtggtac ggagagtaaa ggtcaccgtg aactatccac 800
catacatttc agaagccaag ggtacaggtg tccccgtggg acaaaagggg 850
acactgcagt gtgaagcctc agcagtcccc tcagcagaat tccagtggta 900
caaggatgac aaaagactga ttgaaggaaa gaaaggggtg aaagtggaaa 950
acagaccttt cctctcaaaa ctcatcttct tcaatgtctc tgaacatgac 1000
tatgggaact acacttgcgt ggcctccaac aagctgggcc acaccaatgc 1050
cagcatcatg ctatttggtc caggcgccgt cagcgaggtg agcaacggca 1100
cgtcgaggag ggcaggctgc gtctggctgc tgcctcttct ggtcttgcac 1150
ctgcttctca aattttgatg tgagtgccac ttccccaccc gggaaaggct 1200
gccgccacca ccaccaccaa cacaacagca atggcaacac cgacagcaac 1250
caatcagata tatacaaatg aaattagaag aaacacagcc tcatgggaca 1300
gaaatttgag ggaggggaac aaagaatact ttggggggaa aagagtttta 1350
aaaaagaaat tgaaaattgc cttgcagata tttaggtaca atggagtttt 1400
cttttcccaa acgggaagaa cacagcacac ccggcttgga cccactgcaa 1450
gctgcatcgt gcaacctctt tggtgccagt gtgggcaagg gctcagcctc 1500
tctgcccaca gagtgccccc acgtggaaca ttctggagct ggccatccca 1550
aattcaatca gtccatagag acgaacagaa tgagaccttc cggcccaagc 1600
gtggcgctgc gggcactttg gtagactgtg ccaccacggc gtgtgttgtg 1650
aaacgtgaaa taaaaagagc aaaaaaaaa 1679 104 344 PRT Homo Sapien 104
Met Lys Thr Ile Gln Pro Lys Met His Asn Ser Ile Ser Trp Ala 1 5 10
15 Ile Phe Thr Gly Leu Ala Ala Leu Cys Leu Phe Gln Gly Val Pro 20
25 30 Val Arg Ser Gly Asp Ala Thr Phe Pro Lys Ala Met Asp Asn Val
35 40 45 Thr Val Arg Gln Gly Glu Ser Ala Thr Leu Arg Cys Thr Ile
Asp 50 55 60 Asn Arg Val Thr Arg Val Ala Trp Leu Asn Arg Ser Thr
Ile Leu 65 70 75 Tyr Ala Gly Asn Asp Lys Trp Cys Leu Asp Pro Arg
Val Val Leu 80 85 90 Leu Ser Asn Thr Gln Thr Gln Tyr Ser Ile Glu
Ile Gln Asn Val 95 100 105 Asp Val Tyr Asp Glu Gly Pro Tyr Thr Cys
Ser Val Gln Thr Asp 110 115 120 Asn His Pro Lys Thr Ser Arg Val His
Leu Ile Val Gln Val Ser 125 130 135 Pro Lys Ile Val Glu Ile Ser Ser
Asp Ile Ser Ile Asn Glu Gly 140 145 150 Asn Asn Ile Ser Leu Thr Cys
Ile Ala Thr Gly Arg Pro Glu Pro 155 160 165 Thr Val Thr Trp Arg His
Ile Ser Pro Lys Ala Val Gly Phe Val 170 175 180 Ser Glu Asp Glu Tyr
Leu Glu Ile Gln Gly Ile Thr Arg Glu Gln 185 190 195 Ser Gly Asp Tyr
Glu Cys Ser Ala Ser Asn Asp Val Ala Ala Pro 200 205 210 Val Val Arg
Arg Val Lys Val Thr Val Asn Tyr Pro Pro Tyr Ile 215 220 225 Ser Glu
Ala Lys Gly Thr Gly Val Pro Val Gly Gln Lys Gly Thr 230 235 240 Leu
Gln Cys Glu Ala Ser Ala Val Pro Ser Ala Glu Phe Gln Trp 245 250 255
Tyr Lys Asp Asp Lys Arg Leu Ile Glu Gly Lys Lys Gly Val Lys 260 265
270 Val Glu Asn Arg Pro Phe Leu Ser Lys Leu Ile Phe Phe Asn Val 275
280 285 Ser Glu His Asp Tyr Gly Asn Tyr Thr Cys Val Ala Ser Asn Lys
290 295 300 Leu Gly His Thr Asn Ala Ser Ile Met Leu Phe Gly Pro Gly
Ala 305 310 315 Val Ser Glu Val Ser Asn Gly Thr Ser Arg Arg Ala Gly
Cys Val 320 325 330 Trp Leu Leu Pro Leu Leu Val Leu His Leu Leu Leu
Lys Phe 335 340 105 1734 DNA Homo Sapien 105 gtggactctg agaagcccag
gcagttgagg acaggagaga gaaggctgca 50 gacccagagg gagggaggac
agggagtcgg aaggaggagg acagaggagg 100 gcacagagac gcagagcaag
ggcggcaagg aggagaccct ggtgggagga 150 agacactctg gagagagagg
gggctgggca gagatgaagt tccaggggcc 200 cctggcctgc ctcctgctgg
ccctctgcct gggcagtggg gaggctggcc 250 ccctgcagag cggagaggaa
agcactggga caaatattgg ggaggccctt 300 ggacatggcc tgggagacgc
cctgagcgaa ggggtgggaa aggccattgg 350 caaagaggcc ggaggggcag
ctggctctaa agtcagtgag gcccttggcc 400 aagggaccag agaagcagtt
ggcactggag tcaggcaggt tccaggcttt 450 ggcgcagcag atgctttggg
caacagggtc ggggaagcag cccatgctct 500 gggaaacact gggcacgaga
ttggcagaca ggcagaagat gtcattcgac 550 acggagcaga tgctgtccgc
ggctcctggc agggggtgcc tggccacagt 600 ggtgcttggg aaacttctgg
aggccatggc atctttggct ctcaaggtgg 650 ccttggaggc cagggccagg
gcaatcctgg aggtctgggg actccgtggg 700 tccacggata ccccggaaac
tcagcaggca gctttggaat gaatcctcag 750 ggagctccct ggggtcaagg
aggcaatgga gggccaccaa actttgggac 800 caacactcag ggagctgtgg
cccagcctgg ctatggttca gtgagagcca 850 gcaaccagaa tgaagggtgc
acgaatcccc caccatctgg ctcaggtgga 900 ggctccagca actctggggg
aggcagcggc tcacagtcgg gcagcagtgg 950 cagtggcagc aatggtgaca
acaacaatgg cagcagcagt ggtggcagca 1000 gcagtggcag cagcagtggc
agcagcagtg gcggcagcag tggcggcagc 1050 agtggtggca gcagtggcaa
cagtggtggc agcagaggtg acagcggcag 1100 tgagtcctcc tggggatcca
gcaccggctc ctcctccggc aaccacggtg 1150 ggagcggcgg aggaaatgga
cataaacccg ggtgtgaaaa gccagggaat 1200 gaagcccgcg ggagcgggga
atctgggatt cagggcttca gaggacaggg 1250 agtttccagc aacatgaggg
aaataagcaa agagggcaat cgcctccttg 1300 gaggctctgg agacaattat
cgggggcaag ggtcgagctg gggcagtgga 1350 ggaggtgacg ctgttggtgg
agtcaatact gtgaactctg agacgtctcc 1400 tgggatgttt aactttgaca
ctttctggaa gaattttaaa tccaagctgg 1450 gtttcatcaa ctgggatgcc
ataaacaagg accagagaag ctctcgcatc 1500 ccgtgacctc cagacaagga
gccaccagat tggatgggag cccccacact 1550 ccctccttaa aacaccaccc
tctcatcact aatctcagcc cttgcccttg 1600 aaataaacct tagctgcccc
acaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1650 aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1700 aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaa 1734 106 440 PRT Homo Sapien 106 Met Lys Phe Gln
Gly Pro Leu Ala Cys Leu Leu Leu Ala Leu Cys 1 5 10 15 Leu Gly Ser
Gly Glu Ala Gly Pro Leu Gln Ser Gly Glu Glu Ser 20 25 30 Thr Gly
Thr Asn Ile Gly Glu Ala Leu Gly His Gly Leu Gly Asp 35 40 45 Ala
Leu Ser Glu Gly Val Gly Lys Ala Ile Gly Lys Glu Ala Gly 50 55 60
Gly Ala Ala Gly Ser Lys Val Ser Glu Ala Leu Gly Gln Gly Thr 65 70
75 Arg Glu Ala Val Gly Thr Gly Val Arg Gln Val Pro Gly Phe Gly 80
85 90 Ala Ala Asp Ala Leu Gly Asn Arg Val Gly Glu Ala Ala His Ala
95 100 105 Leu Gly Asn Thr Gly His Glu Ile Gly Arg Gln Ala Glu Asp
Val 110 115 120 Ile Arg His Gly Ala Asp Ala Val Arg Gly Ser Trp Gln
Gly Val 125 130 135 Pro Gly His Ser Gly Ala Trp Glu Thr Ser Gly Gly
His Gly Ile 140 145 150 Phe Gly Ser Gln Gly Gly Leu Gly Gly Gln Gly
Gln Gly Asn Pro 155 160 165 Gly Gly Leu Gly Thr Pro Trp Val His Gly
Tyr Pro Gly Asn Ser 170 175 180 Ala Gly Ser Phe Gly Met Asn Pro Gln
Gly Ala Pro Trp Gly Gln 185 190 195 Gly Gly Asn Gly Gly Pro Pro Asn
Phe Gly Thr Asn Thr Gln Gly 200 205 210 Ala Val Ala Gln Pro Gly Tyr
Gly Ser Val Arg Ala Ser Asn Gln 215 220 225 Asn Glu Gly Cys Thr Asn
Pro Pro Pro Ser Gly Ser Gly Gly Gly 230 235 240 Ser Ser Asn Ser Gly
Gly Gly Ser Gly Ser Gln Ser Gly Ser Ser 245 250 255 Gly Ser Gly Ser
Asn Gly Asp Asn Asn Asn Gly Ser Ser Ser Gly 260 265 270 Gly Ser Ser
Ser Gly Ser Ser Ser Gly Ser Ser Ser Gly Gly Ser 275 280 285 Ser Gly
Gly Ser Ser Gly Gly Ser Ser Gly Asn Ser Gly Gly Ser 290 295 300 Arg
Gly Asp Ser Gly Ser Glu Ser Ser Trp Gly Ser Ser Thr Gly 305 310 315
Ser Ser Ser Gly Asn His Gly Gly Ser Gly Gly Gly Asn Gly His 320 325
330 Lys Pro Gly Cys Glu Lys Pro Gly Asn Glu Ala Arg Gly Ser Gly 335
340 345 Glu Ser Gly Ile Gln Gly Phe Arg Gly Gln Gly Val Ser Ser Asn
350 355 360 Met Arg Glu Ile Ser Lys Glu Gly Asn Arg Leu Leu Gly Gly
Ser 365 370 375 Gly Asp Asn Tyr Arg Gly Gln Gly Ser Ser Trp Gly Ser
Gly Gly 380 385 390 Gly Asp Ala Val Gly Gly Val Asn Thr Val Asn Ser
Glu Thr Ser 395 400 405 Pro Gly Met Phe Asn Phe Asp Thr Phe Trp Lys
Asn Phe Lys Ser 410 415 420 Lys Leu Gly Phe Ile Asn Trp Asp Ala Ile
Asn Lys Asp Gln Arg 425 430 435 Ser Ser Arg Ile Pro 440 107 918 DNA
Homo Sapien 107 agccaggcag cacatcacag cgggaggagc tgtcccaggt
ggcccagctc 50 agcaatggca atgggggtcc ccagagtcat tctgctctgc
ctctttgggg 100 ctgcgctctg cctgacaggg tcccaagccc tgcagtgcta
cagctttgag 150 cacacctact ttggcccctt tgacctcagg gccatgaagc
tgcccagcat 200 ctcctgtcct catgagtgct ttgaggctat cctgtctctg
gacaccgggt 250 atcgcgcgcc ggtgaccctg gtgcggaagg gctgctggac
cgggcctcct 300 gcgggccaga cgcaatcgaa cccggacgcg ctgccgccag
actactcggt 350 ggtgcgcggc tgcacaactg acaaatgcaa cgcccacctc
atgactcatg 400 acgccctccc caacctgagc caagcacccg acccgccgac
gctcagcggc 450 gccgagtgct acgcctgtat cggggtccac caggatgact
gcgctatcgg 500 caggtcccga cgagtccagt gtcaccagga ccagaccgcc
tgcttccagg 550 gcagtggcag aatgacagtt ggcaatttct cagtccctgt
gtacatcaga 600 acctgccacc ggccctcctg caccaccgag ggcaccacca
gcccctggac 650 agccatcgac ctccagggct cctgctgtga ggggtacctc
tgcaacagga 700 aatccatgac ccagcccttc accagtgctt cagccaccac
ccctccccga 750 gcactacagg tcctggccct gctcctccca gtcctcctgc
tggtggggct 800 ctcagcatag accgcccctc caggatgctg gggacagggc
tcacacacct 850 cattcttgct gcttcagccc ctatcacata gctcactgga
aaatgatgtt 900 aaagtaagaa ttgcaaaa 918 108 251 PRT Homo Sapien 108
Met Ala Met Gly Val Pro Arg Val Ile Leu Leu Cys Leu Phe Gly 1 5 10
15 Ala Ala Leu Cys Leu Thr Gly Ser Gln Ala Leu Gln Cys Tyr Ser 20
25 30 Phe Glu His Thr Tyr Phe Gly Pro Phe Asp Leu Arg Ala Met Lys
35 40 45 Leu Pro Ser Ile Ser Cys Pro His Glu Cys Phe Glu Ala Ile
Leu 50 55 60 Ser Leu Asp Thr Gly Tyr Arg Ala Pro Val Thr Leu Val
Arg Lys 65 70 75 Gly Cys Trp Thr Gly Pro Pro Ala Gly Gln Thr Gln
Ser Asn Pro 80 85 90 Asp Ala Leu Pro Pro Asp Tyr Ser Val Val Arg
Gly Cys Thr Thr 95 100 105 Asp Lys Cys Asn Ala His Leu Met Thr His
Asp Ala Leu Pro Asn 110 115 120 Leu Ser Gln Ala Pro Asp Pro Pro Thr
Leu Ser Gly Ala Glu Cys 125 130 135 Tyr Ala Cys Ile Gly Val His Gln
Asp Asp Cys Ala Ile Gly Arg 140 145 150 Ser Arg Arg Val Gln Cys His
Gln Asp Gln Thr Ala Cys Phe Gln 155 160 165 Gly Ser Gly Arg Met Thr
Val Gly Asn Phe Ser Val Pro Val Tyr 170 175 180 Ile Arg Thr Cys His
Arg Pro Ser Cys Thr Thr Glu Gly Thr Thr 185 190 195 Ser Pro Trp Thr
Ala Ile Asp Leu Gln Gly Ser Cys Cys Glu Gly 200 205 210 Tyr Leu Cys
Asn Arg Lys Ser Met Thr Gln Pro Phe Thr Ser Ala 215 220 225 Ser Ala
Thr Thr Pro Pro Arg Ala Leu Gln Val Leu Ala Leu Leu 230 235 240 Leu
Pro Val Leu Leu Leu Val Gly Leu Ser Ala 245 250 109 1813 DNA Homo
Sapien 109 ggagccgccc tgggtgtcag cggctcggct cccgcgcacg ctccggccgt
50 cgcgcagcct cggcacctgc aggtccgtgc gtcccgcggc tggcgcccct 100
gactccgtcc cggccaggga gggccatgat ttccctcccg gggcccctgg 150
tgaccaactt gctgcggttt ttgttcctgg ggctgagtgc cctcgcgccc 200
ccctcgcggg cccagctgca actgcacttg cccgccaacc ggttgcaggc 250
ggtggaggga ggggaagtgg tgcttccagc gtggtacacc ttgcacgggg 300
aggtgtcttc atcccagcca tgggaggtgc cctttgtgat gtggttcttc 350
aaacagaaag aaaaggagga tcaggtgttg tcctacatca atggggtcac 400
aacaagcaaa cctggagtat ccttggtcta ctccatgccc tcccggaacc 450
tgtccctgcg gctggagggt ctccaggaga aagactctgg cccctacagc 500
tgctccgtga atgtgcaaga caaacaaggc aaatctaggg gccacagcat 550
caaaacctta gaactcaatg tactggttcc tccagctcct ccatcctgcc 600
gtctccaggg tgtgccccat gtgggggcaa acgtgaccct gagctgccag 650
tctccaagga gtaagcccgc tgtccaatac cagtgggatc ggcagcttcc 700
atccttccag actttctttg caccagcatt agatgtcatc cgtgggtctt 750
taagcctcac caacctttcg tcttccatgg ctggagtcta tgtctgcaag 800
gcccacaatg aggtgggcac tgcccaatgt aatgtgacgc tggaagtgag 850
cacagggcct ggagctgcag tggttgctgg agctgttgtg ggtaccctgg 900
ttggactggg gttgctggct gggctggtcc tcttgtacca ccgccggggc 950
aaggccctgg aggagccagc caatgatatc aaggaggatg ccattgctcc 1000
ccggaccctg ccctggccca agagctcaga cacaatctcc aagaatggga 1050
ccctttcctc tgtcacctcc gcacgagccc tccggccacc ccatggccct 1100
cccaggcctg gtgcattgac ccccacgccc agtctctcca gccaggccct 1150
gccctcacca agactgccca cgacagatgg ggcccaccct caaccaatat 1200
cccccatccc tggtggggtt tcttcctctg gcttgagccg catgggtgct 1250
gtgcctgtga tggtgcctgc ccagagtcaa gctggctctc tggtatgatg 1300
accccaccac tcattggcta aaggatttgg ggtctctcct tcctataagg 1350
gtcacctcta gcacagaggc ctgagtcatg ggaaagagtc acactcctga 1400
cccttagtac tctgccccca cctctcttta ctgtgggaaa accatctcag 1450
taagacctaa gtgtccagga gacagaagga gaagaggaag tggatctgga 1500
attgggagga gcctccaccc acccctgact cctccttatg aagccagctg 1550
ctgaaattag ctactcacca agagtgaggg gcagagactt ccagtcactg 1600
agtctcccag gcccccttga tctgtacccc acccctatct aacaccaccc 1650
ttggctccca ctccagctcc ctgtattgat ataacctgtc aggctggctt 1700
ggttaggttt tactggggca gaggataggg aatctcttat taaaactaac 1750
atgaaatatg tgttgttttc atttgcaaat ttaaataaag atacataatg 1800
tttgtatgaa aaa 1813 110 390 PRT Homo Sapien 110 Met Ile Ser Leu Pro
Gly Pro Leu Val Thr Asn Leu Leu Arg Phe 1 5 10 15 Leu Phe Leu Gly
Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln 20 25 30 Leu Gln Leu
His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Gly 35 40 45 Gly Glu
Val Val Leu Pro Ala Trp Tyr Thr Leu His Gly Glu Val 50 55 60 Ser
Ser Ser Gln Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe 65 70 75
Lys Gln Lys Glu Lys Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly 80 85
90 Val Thr Thr Ser Lys Pro Gly Val Ser Leu Val Tyr Ser Met Pro 95
100 105 Ser Arg Asn Leu Ser Leu Arg Leu Glu Gly Leu Gln Glu Lys Asp
110 115 120 Ser Gly Pro Tyr Ser Cys Ser Val Asn Val Gln Asp Lys Gln
Gly 125 130 135 Lys Ser Arg Gly His Ser Ile Lys Thr Leu Glu Leu Asn
Val Leu 140 145 150 Val Pro Pro Ala Pro Pro Ser Cys Arg Leu Gln Gly
Val Pro His 155 160 165 Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser
Pro Arg Ser Lys 170 175 180 Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln
Leu Pro Ser Phe Gln 185 190 195 Thr Phe Phe Ala Pro Ala Leu Asp Val
Ile Arg Gly Ser Leu Ser 200 205 210 Leu Thr Asn Leu Ser Ser Ser Met
Ala Gly Val Tyr Val Cys Lys 215 220 225 Ala His Asn Glu Val Gly Thr
Ala Gln Cys Asn Val Thr Leu Glu 230 235 240 Val Ser Thr Gly Pro Gly
Ala Ala Val Val Ala Gly Ala Val Val 245 250 255 Gly Thr Leu Val Gly
Leu Gly Leu Leu Ala Gly Leu Val Leu Leu 260 265 270 Tyr His Arg Arg
Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile 275 280 285 Lys Glu Asp
Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser 290 295 300 Ser Asp
Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser 305 310 315 Ala
Arg Ala Leu Arg Pro Pro His Gly Pro Pro Arg Pro Gly Ala 320 325 330
Leu Thr Pro Thr Pro Ser Leu Ser Ser Gln Ala Leu Pro Ser Pro 335 340
345 Arg Leu Pro Thr Thr Asp Gly Ala His Pro Gln Pro Ile Ser Pro 350
355 360 Ile Pro Gly Gly Val Ser Ser Ser Gly Leu Ser Arg Met Gly Ala
365 370 375 Val Pro Val Met Val Pro Ala Gln Ser Gln Ala Gly Ser Leu
Val 380 385 390 111 22 DNA Artificial Sequence Synthetic
oligonucleotide probe 111 agggtctcca ggagaaagac tc 22 112 24 DNA
Artificial Sequence Synthetic oligonucleotide probe 112 attgtgggcc
ttgcagacat agac 24 113 50 DNA Artificial Sequence Synthetic
oligonucleotide probe 113 ggccacagca tcaaaacctt agaactcaat
gtactggttc ctccagctcc 50 114 2479 DNA Homo Sapien 114 acttgccatc
acctgttgcc agtgtggaaa aattctccct gttgaatttt 50 ttgcacatgg
aggacagcag caaagagggc aacacaggct gataagacca 100 gagacagcag
ggagattatt ttaccatacg ccctcaggac gttccctcta 150 gctggagttc
tggacttcaa cagaacccca tccagtcatt ttgattttgc 200 tgtttatttt
ttttttcttt ttctttttcc caccacattg tattttattt 250 ccgtacttca
gaaatgggcc tacagaccac aaagtggccc agccatgggg 300 cttttttcct
gaagtcttgg cttatcattt ccctggggct ctactcacag 350 gtgtccaaac
tcctggcctg ccctagtgtg tgccgctgcg acaggaactt 400 tgtctactgt
aatgagcgaa gcttgacctc agtgcctctt gggatcccgg 450 agggcgtaac
cgtactctac ctccacaaca accaaattaa taatgctgga 500 tttcctgcag
aactgcacaa tgtacagtcg gtgcacacgg tctacctgta 550 tggcaaccaa
ctggacgaat tccccatgaa ccttcccaag aatgtcagag 600 ttctccattt
gcaggaaaac aatattcaga ccatttcacg ggctgctctt 650 gcccagctct
tgaagcttga agagctgcac ctggatgaca actccatatc 700 cacagtgggg
gtggaagacg gggccttccg ggaggctatt agcctcaaat 750 tgttgttttt
gtctaagaat cacctgagca gtgtgcctgt tgggcttcct 800 gtggacttgc
aagagctgag agtggatgaa aatcgaattg ctgtcatatc 850 cgacatggcc
ttccagaatc tcacgagctt ggagcgtctt attgtggacg 900 ggaacctcct
gaccaacaag ggtatcgccg agggcacctt cagccatctc 950 accaagctca
aggaattttc aattgtacgt aattcgctgt cccaccctcc 1000 tcccgatctc
ccaggtacgc atctgatcag gctctatttg caggacaacc 1050 agataaacca
cattcctttg acagccttct caaatctgcg taagctggaa 1100 cggctggata
tatccaacaa ccaactgcgg atgctgactc aaggggtttt 1150 tgataatctc
tccaacctga agcagctcac tgctcggaat aacccttggt 1200 tttgtgactg
cagtattaaa tgggtcacag aatggctcaa atatatccct 1250 tcatctctca
acgtgcgggg tttcatgtgc caaggtcctg aacaagtccg 1300 ggggatggcc
gtcagggaat taaatatgaa tcttttgtcc tgtcccacca 1350 cgacccccgg
cctgcctctc ttcaccccag ccccaagtac agcttctccg 1400 accactcagc
ctcccaccct ctctattcca aaccctagca gaagctacac 1450 gcctccaact
cctaccacat cgaaacttcc cacgattcct gactgggatg 1500 gcagagaaag
agtgacccca cctatttctg aacggatcca gctctctatc 1550 cattttgtga
atgatacttc cattcaagtc agctggctct ctctcttcac 1600 cgtgatggca
tacaaactca catgggtgaa aatgggccac agtttagtag 1650 ggggcatcgt
tcaggagcgc atagtcagcg gtgagaagca acacctgagc 1700 ctggttaact
tagagccccg atccacctat cggatttgtt tagtgccact 1750 ggatgctttt
aactaccgcg cggtagaaga caccatttgt tcagaggcca 1800 ccacccatgc
ctcctatctg aacaacggca gcaacacagc gtccagccat 1850 gagcagacga
cgtcccacag catgggctcc ccctttctgc tggcgggctt 1900 gatcgggggc
gcggtgatat ttgtgctggt ggtcttgctc agcgtctttt 1950 gctggcatat
gcacaaaaag gggcgctaca cctcccagaa gtggaaatac 2000 aaccggggcc
ggcggaaaga tgattattgc gaggcaggca ccaagaagga 2050 caactccatc
ctggagatga cagaaaccag ttttcagatc gtctccttaa 2100 ataacgatca
actccttaaa ggagatttca gactgcagcc catttacacc 2150 ccaaatgggg
gcattaatta cacagactgc catatcccca acaacatgcg 2200 atactgcaac
agcagcgtgc cagacctgga gcactgccat acgtgacagc 2250 cagaggccca
gcgttatcaa ggcggacaat tagactcttg agaacacact 2300 cgtgtgtgca
cataaagaca cgcagattac atttgataaa tgttacacag 2350 atgcatttgt
gcatttgaat actctgtaat ttatacggtg tactatataa 2400 tgggatttaa
aaaaagtgct atcttttcta tttcaagtta attacaaaca 2450 gttttgtaac
tctttgcttt ttaaatctt 2479 115 660 PRT Homo Sapien 115 Met Gly Leu
Gln Thr Thr Lys Trp Pro Ser His Gly Ala Phe Phe 1 5 10 15 Leu Lys
Ser Trp Leu Ile Ile Ser Leu Gly Leu Tyr Ser Gln Val 20 25 30 Ser
Lys Leu Leu Ala Cys Pro Ser Val Cys Arg Cys Asp Arg Asn 35 40 45
Phe Val Tyr Cys Asn Glu Arg Ser Leu Thr Ser Val Pro Leu Gly 50 55
60 Ile Pro Glu Gly Val Thr Val Leu Tyr Leu His Asn Asn Gln Ile 65
70 75 Asn Asn Ala Gly Phe Pro Ala Glu Leu His Asn Val Gln Ser Val
80 85 90 His Thr Val Tyr Leu Tyr Gly Asn Gln Leu Asp Glu Phe Pro
Met 95 100 105 Asn Leu Pro Lys Asn Val Arg Val Leu His Leu Gln Glu
Asn Asn 110 115 120 Ile Gln Thr Ile Ser Arg Ala Ala Leu Ala Gln Leu
Leu Lys Leu 125 130 135 Glu Glu Leu His Leu Asp Asp Asn Ser Ile Ser
Thr Val Gly Val 140 145 150 Glu Asp Gly Ala Phe Arg Glu Ala Ile Ser
Leu Lys Leu Leu Phe 155 160 165 Leu Ser Lys Asn His Leu Ser Ser Val
Pro Val Gly Leu Pro Val 170 175 180 Asp Leu Gln Glu Leu Arg Val Asp
Glu Asn Arg Ile Ala Val Ile 185 190 195 Ser Asp Met Ala Phe Gln Asn
Leu Thr Ser Leu Glu Arg Leu Ile 200 205 210 Val Asp Gly Asn Leu Leu
Thr Asn Lys Gly Ile Ala Glu Gly Thr 215 220 225 Phe Ser His Leu Thr
Lys Leu Lys Glu Phe Ser Ile Val Arg Asn 230 235 240 Ser Leu Ser His
Pro Pro Pro Asp Leu Pro Gly Thr His Leu Ile 245 250 255 Arg Leu Tyr
Leu Gln Asp Asn Gln Ile Asn His Ile Pro Leu Thr 260 265 270 Ala Phe
Ser Asn Leu Arg Lys Leu Glu Arg Leu Asp Ile Ser Asn 275 280 285 Asn
Gln Leu Arg Met Leu Thr Gln Gly Val Phe Asp Asn Leu Ser 290 295 300
Asn Leu Lys Gln Leu Thr Ala Arg Asn Asn Pro Trp Phe Cys Asp 305 310
315 Cys Ser Ile Lys Trp Val Thr Glu Trp Leu Lys Tyr Ile Pro Ser 320
325 330 Ser Leu Asn Val Arg Gly Phe Met Cys Gln Gly Pro Glu Gln Val
335 340 345 Arg Gly Met Ala Val Arg Glu Leu Asn Met Asn Leu Leu Ser
Cys 350 355 360 Pro Thr Thr Thr Pro Gly Leu Pro Leu Phe Thr Pro Ala
Pro Ser 365 370 375 Thr Ala Ser Pro Thr Thr Gln Pro Pro Thr Leu Ser
Ile Pro Asn 380 385 390 Pro Ser Arg Ser Tyr Thr Pro Pro Thr Pro Thr
Thr Ser Lys Leu 395 400 405 Pro Thr Ile Pro Asp Trp Asp Gly Arg Glu
Arg Val Thr Pro Pro 410 415 420 Ile Ser Glu Arg Ile Gln Leu Ser Ile
His Phe Val Asn Asp Thr 425 430 435 Ser Ile Gln Val Ser Trp Leu Ser
Leu Phe Thr Val Met Ala Tyr 440 445 450 Lys Leu Thr Trp Val Lys Met
Gly His Ser Leu Val Gly Gly Ile 455 460 465 Val Gln Glu Arg Ile Val
Ser Gly Glu Lys Gln His Leu Ser Leu 470 475 480 Val Asn Leu Glu Pro
Arg Ser Thr Tyr Arg Ile Cys Leu Val Pro 485 490 495 Leu Asp Ala Phe
Asn Tyr Arg Ala Val Glu Asp Thr Ile Cys Ser 500 505 510 Glu Ala Thr
Thr His Ala Ser Tyr Leu Asn Asn Gly Ser Asn Thr 515 520 525 Ala Ser
Ser His Glu Gln Thr Thr Ser His Ser Met Gly Ser Pro 530 535 540 Phe
Leu Leu Ala Gly Leu Ile Gly Gly Ala Val Ile Phe Val Leu 545 550 555
Val Val Leu Leu Ser Val Phe Cys Trp His Met His Lys Lys Gly 560 565
570 Arg Tyr Thr Ser Gln Lys Trp Lys Tyr Asn Arg Gly Arg Arg Lys 575
580 585 Asp Asp Tyr Cys Glu Ala Gly Thr Lys Lys Asp Asn Ser Ile Leu
590 595 600 Glu Met Thr Glu Thr Ser Phe Gln Ile Val Ser Leu Asn Asn
Asp 605 610 615 Gln Leu Leu Lys Gly Asp Phe Arg Leu Gln Pro Ile Tyr
Thr Pro 620 625 630 Asn Gly Gly Ile Asn Tyr Thr Asp Cys His Ile Pro
Asn Asn Met 635 640 645 Arg Tyr Cys Asn Ser Ser Val Pro Asp Leu Glu
His Cys His Thr 650 655 660 116 21 DNA Artificial Sequence
Synthetic oligonucleotide probe 116 cggtctacct gtatggcaac c 21 117
22 DNA Artificial Sequence Synthetic oligonucleotide probe 117
gcaggacaac cagataaacc ac 22 118 22 DNA Artificial Sequence
Synthetic oligonucleotide probe 118 acgcagattt gagaaggctg tc 22 119
46 DNA Artificial Sequence Synthetic oligonucleotide probe 119
ttcacgggct gctcttgccc agctcttgaa gcttgaagag ctgcac 46 120 2857 DNA
Homo Sapien 120 tgaagagtaa tagttggaat caaaagagtc aacgcaatga
actgttattt 50 actgctgcgt tttatgttgg gaattcctct cctatggcct
tgtcttggag 100 caacagaaaa ctctcaaaca aagaaagtca agcagccagt
gcgatctcat 150 ttgagagtga agcgtggctg ggtgtggaac caattttttg
taccagagga 200 aatgaatacg actagtcatc acatcggcca gctaagatct
gatttagaca 250 atggaaacaa ttctttccag tacaagcttt tgggagctgg
agctggaagt 300 acttttatca ttgatgaaag aacaggtgac atatatgcca
tacagaagct 350 tgatagagag gagcgatccc tctacatctt aagagcccag
gtaatagaca 400 tcgctactgg aagggctgtg gaacctgagt ctgagtttgt
catcaaagtt 450 tcggatatca atgacaatga accaaaattc ctagatgaac
cttatgaggc 500 cattgtacca gagatgtctc cagaaggaac attagttatc
caggtgacag 550 caagtgatgc tgacgatccc tcaagtggta ataatgctcg
tctcctctac 600 agcttacttc aaggccagcc atatttttct gttgaaccaa
caacaggagt 650 cataagaata tcttctaaaa tggatagaga actgcaagat
gagtattggg 700 taatcattca agccaaggac atgattggtc agccaggagc
gttgtctgga 750 acaacaagtg tattaattaa actttcagat gttaatgaca
ataagcctat 800 atttaaagaa agtttatacc gcttgactgt ctctgaatct
gcacccactg 850 ggacttctat aggaacaatc atggcatatg ataatgacat
aggagagaat 900 gcagaaatgg attacagcat tgaagaggat gattcgcaaa
catttgacat 950 tattactaat catgaaactc aagaaggaat agttatatta
aaaaagaaag 1000 tggattttga gcaccagaac cactacggta ttagagcaaa
agttaaaaac 1050 catcatgttc ctgagcagct catgaagtac cacactgagg
cttccaccac 1100 tttcattaag atccaggtgg aagatgttga tgagcctcct
cttttcctcc 1150 ttccatatta tgtatttgaa gtttttgaag aaaccccaca
gggatcattt 1200 gtaggcgtgg tgtctgccac agacccagac aataggaaat
ctcctatcag 1250 gtattctatt actaggagca aagtgttcaa tatcaatgat
aatggtacaa 1300 tcactacaag taactcactg gatcgtgaaa tcagtgcttg
gtacaaccta 1350 agtattacag ccacagaaaa atacaatata gaacagatct
cttcgatccc 1400 actgtatgtg caagttctta acatcaatga tcatgctcct
gagttctctc 1450 aatactatga gacttatgtt tgtgaaaatg caggctctgg
tcaggtaatt 1500 cagactatca gtgcagtgga tagagatgaa tccatagaag
agcaccattt 1550 ttactttaat ctatctgtag aagacactaa caattcaagt
tttacaatca 1600 tagataatca agataacaca gctgtcattt tgactaatag
aactggtttt 1650 aaccttcaag aagaacctgt cttctacatc tccatcttaa
ttgccgacaa 1700 tggaatcccg tcacttacaa gtacaaacac ccttaccatc
catgtctgtg 1750 actgtggtga cagtgggagc acacagacct gccagtacca
ggagcttgtg 1800 ctttccatgg gattcaagac agaagttatc attgctattc
tcatttgcat 1850 tatgatcata tttgggttta tttttttgac tttgggttta
aaacaacgga 1900 gaaaacagat tctatttcct gagaaaagtg aagatttcag
agagaatata 1950 ttccaatatg atgatgaagg gggtggagaa gaagatacag
aggcctttga 2000 tatagcagag ctgaggagta gtaccataat gcgggaacgc
aagactcgga 2050 aaaccacaag cgctgagatc aggagcctat acaggcagtc
tttgcaagtt 2100 ggccccgaca gtgccatatt caggaaattc attctggaaa
agctcgaaga 2150 agctaatact gatccgtgtg cccctccttt tgattccctc
cagacctacg 2200 cttttgaggg aacagggtca ttagctggat ccctgagctc
cttagaatca 2250 gcagtctctg atcaggatga aagctatgat taccttaatg
agttgggacc 2300 tcgctttaaa agattagcat gcatgtttgg ttctgcagtg
cagtcaaata 2350 attagggctt tttaccatca aaatttttaa aagtgctaat
gtgtattcga 2400 acccaatggt agtcttaaag agttttgtgc cctggctcta
tggcggggaa 2450 agccctagtc tatggagttt tctgatttcc ctggagtaaa
tactccatgg 2500 ttattttaag ctacctacat gctgtcattg aacagagatg
tggggagaaa 2550 tgtaaacaat cagctcacag gcatcaatac aaccagattt
gaagtaaaat 2600 aatgtaggaa gatattaaaa gtagatgaga ggacacaaga
tgtagtcgat 2650 ccttatgcga ttatatcatt atttacttag gaaagagtaa
aaataccaaa 2700 cgagaaaatt taaaggagca aaaatttgca agtcaaatag
aaatgtacaa 2750 atcgagataa catttacatt tctatcatat tgacatgaaa
attgaaaatg 2800 tatagtcaga gaaattttca tgaattattc catgaagtat
tgtttccttt 2850 atttaaa 2857 121 772 PRT Homo Sapien 121 Met Asn
Cys Tyr Leu Leu Leu Arg Phe Met Leu Gly Ile Pro Leu 1 5 10 15 Leu
Trp Pro Cys Leu Gly Ala Thr Glu Asn Ser Gln Thr Lys Lys 20 25
30 Val Lys Gln Pro Val Arg Ser His Leu Arg Val Lys Arg Gly Trp 35
40 45 Val Trp Asn Gln Phe Phe Val Pro Glu Glu Met Asn Thr Thr Ser
50 55 60 His His Ile Gly Gln Leu Arg Ser Asp Leu Asp Asn Gly Asn
Asn 65 70 75 Ser Phe Gln Tyr Lys Leu Leu Gly Ala Gly Ala Gly Ser
Thr Phe 80 85 90 Ile Ile Asp Glu Arg Thr Gly Asp Ile Tyr Ala Ile
Gln Lys Leu 95 100 105 Asp Arg Glu Glu Arg Ser Leu Tyr Ile Leu Arg
Ala Gln Val Ile 110 115 120 Asp Ile Ala Thr Gly Arg Ala Val Glu Pro
Glu Ser Glu Phe Val 125 130 135 Ile Lys Val Ser Asp Ile Asn Asp Asn
Glu Pro Lys Phe Leu Asp 140 145 150 Glu Pro Tyr Glu Ala Ile Val Pro
Glu Met Ser Pro Glu Gly Thr 155 160 165 Leu Val Ile Gln Val Thr Ala
Ser Asp Ala Asp Asp Pro Ser Ser 170 175 180 Gly Asn Asn Ala Arg Leu
Leu Tyr Ser Leu Leu Gln Gly Gln Pro 185 190 195 Tyr Phe Ser Val Glu
Pro Thr Thr Gly Val Ile Arg Ile Ser Ser 200 205 210 Lys Met Asp Arg
Glu Leu Gln Asp Glu Tyr Trp Val Ile Ile Gln 215 220 225 Ala Lys Asp
Met Ile Gly Gln Pro Gly Ala Leu Ser Gly Thr Thr 230 235 240 Ser Val
Leu Ile Lys Leu Ser Asp Val Asn Asp Asn Lys Pro Ile 245 250 255 Phe
Lys Glu Ser Leu Tyr Arg Leu Thr Val Ser Glu Ser Ala Pro 260 265 270
Thr Gly Thr Ser Ile Gly Thr Ile Met Ala Tyr Asp Asn Asp Ile 275 280
285 Gly Glu Asn Ala Glu Met Asp Tyr Ser Ile Glu Glu Asp Asp Ser 290
295 300 Gln Thr Phe Asp Ile Ile Thr Asn His Glu Thr Gln Glu Gly Ile
305 310 315 Val Ile Leu Lys Lys Lys Val Asp Phe Glu His Gln Asn His
Tyr 320 325 330 Gly Ile Arg Ala Lys Val Lys Asn His His Val Pro Glu
Gln Leu 335 340 345 Met Lys Tyr His Thr Glu Ala Ser Thr Thr Phe Ile
Lys Ile Gln 350 355 360 Val Glu Asp Val Asp Glu Pro Pro Leu Phe Leu
Leu Pro Tyr Tyr 365 370 375 Val Phe Glu Val Phe Glu Glu Thr Pro Gln
Gly Ser Phe Val Gly 380 385 390 Val Val Ser Ala Thr Asp Pro Asp Asn
Arg Lys Ser Pro Ile Arg 395 400 405 Tyr Ser Ile Thr Arg Ser Lys Val
Phe Asn Ile Asn Asp Asn Gly 410 415 420 Thr Ile Thr Thr Ser Asn Ser
Leu Asp Arg Glu Ile Ser Ala Trp 425 430 435 Tyr Asn Leu Ser Ile Thr
Ala Thr Glu Lys Tyr Asn Ile Glu Gln 440 445 450 Ile Ser Ser Ile Pro
Leu Tyr Val Gln Val Leu Asn Ile Asn Asp 455 460 465 His Ala Pro Glu
Phe Ser Gln Tyr Tyr Glu Thr Tyr Val Cys Glu 470 475 480 Asn Ala Gly
Ser Gly Gln Val Ile Gln Thr Ile Ser Ala Val Asp 485 490 495 Arg Asp
Glu Ser Ile Glu Glu His His Phe Tyr Phe Asn Leu Ser 500 505 510 Val
Glu Asp Thr Asn Asn Ser Ser Phe Thr Ile Ile Asp Asn Gln 515 520 525
Asp Asn Thr Ala Val Ile Leu Thr Asn Arg Thr Gly Phe Asn Leu 530 535
540 Gln Glu Glu Pro Val Phe Tyr Ile Ser Ile Leu Ile Ala Asp Asn 545
550 555 Gly Ile Pro Ser Leu Thr Ser Thr Asn Thr Leu Thr Ile His Val
560 565 570 Cys Asp Cys Gly Asp Ser Gly Ser Thr Gln Thr Cys Gln Tyr
Gln 575 580 585 Glu Leu Val Leu Ser Met Gly Phe Lys Thr Glu Val Ile
Ile Ala 590 595 600 Ile Leu Ile Cys Ile Met Ile Ile Phe Gly Phe Ile
Phe Leu Thr 605 610 615 Leu Gly Leu Lys Gln Arg Arg Lys Gln Ile Leu
Phe Pro Glu Lys 620 625 630 Ser Glu Asp Phe Arg Glu Asn Ile Phe Gln
Tyr Asp Asp Glu Gly 635 640 645 Gly Gly Glu Glu Asp Thr Glu Ala Phe
Asp Ile Ala Glu Leu Arg 650 655 660 Ser Ser Thr Ile Met Arg Glu Arg
Lys Thr Arg Lys Thr Thr Ser 665 670 675 Ala Glu Ile Arg Ser Leu Tyr
Arg Gln Ser Leu Gln Val Gly Pro 680 685 690 Asp Ser Ala Ile Phe Arg
Lys Phe Ile Leu Glu Lys Leu Glu Glu 695 700 705 Ala Asn Thr Asp Pro
Cys Ala Pro Pro Phe Asp Ser Leu Gln Thr 710 715 720 Tyr Ala Phe Glu
Gly Thr Gly Ser Leu Ala Gly Ser Leu Ser Ser 725 730 735 Leu Glu Ser
Ala Val Ser Asp Gln Asp Glu Ser Tyr Asp Tyr Leu 740 745 750 Asn Glu
Leu Gly Pro Arg Phe Lys Arg Leu Ala Cys Met Phe Gly 755 760 765 Ser
Ala Val Gln Ser Asn Asn 770 122 25 DNA Artificial Sequence
Synthetic oligonucleotide probe 122 cttgactgtc tctgaatctg caccc 25
123 24 DNA Artificial Sequence Synthetic oligonucleotide probe 123
aagtggtgga agcctccagt gtgg 24 124 52 DNA Artificial Sequence
Synthetic oligonucleotide probe 124 ccactacggt attagagcaa
aagttaaaaa ccatcatggt tcctggagca 50 gc 52 125 1152 DNA Homo Sapien
125 cttcagaaca ggttctcctt ccccagtcac cagttgctcg agttagaatt 50
gtctgcaatg gccgccctgc agaaatctgt gagctctttc cttatgggga 100
ccctggccac cagctgcctc cttctcttgg ccctcttggt acagggagga 150
gcagctgcgc ccatcagctc ccactgcagg cttgacaagt ccaacttcca 200
gcagccctat atcaccaacc gcaccttcat gctggctaag gaggctagct 250
tggctgataa caacacagac gttcgtctca ttggggagaa actgttccac 300
ggagtcagta tgagtgagcg ctgctatctg atgaagcagg tgctgaactt 350
cacccttgaa gaagtgctgt tccctcaatc tgataggttc cagccttata 400
tgcaggaggt ggtgcccttc ctggccaggc tcagcaacag gctaagcaca 450
tgtcatattg aaggtgatga cctgcatatc cagaggaatg tgcaaaagct 500
gaaggacaca gtgaaaaagc ttggagagag tggagagatc aaagcaattg 550
gagaactgga tttgctgttt atgtctctga gaaatgcctg catttgacca 600
gagcaaagct gaaaaatgaa taactaaccc cctttccctg ctagaaataa 650
caattagatg ccccaaagcg atttttttta accaaaagga agatgggaag 700
ccaaactcca tcatgatggg tggattccaa atgaacccct gcgttagtta 750
caaaggaaac caatgccact tttgtttata agaccagaag gtagactttc 800
taagcataga tatttattga taacatttca ttgtaactgg tgttctatac 850
acagaaaaca atttattttt taaataattg tctttttcca taaaaaagat 900
tactttccat tcctttaggg gaaaaaaccc ctaaatagct tcatgtttcc 950
ataatcagta ctttatattt ataaatgtat ttattattat tataagactg 1000
cattttattt atatcatttt attaatatgg atttatttat agaaacatca 1050
ttcgatattg ctacttgagt gtaaggctaa tattgatatt tatgacaata 1100
attatagagc tataacatgt ttatttgacc tcaataaaca cttggatatc 1150 cc 1152
126 179 PRT Homo Sapien 126 Met Ala Ala Leu Gln Lys Ser Val Ser Ser
Phe Leu Met Gly Thr 1 5 10 15 Leu Ala Thr Ser Cys Leu Leu Leu Leu
Ala Leu Leu Val Gln Gly 20 25 30 Gly Ala Ala Ala Pro Ile Ser Ser
His Cys Arg Leu Asp Lys Ser 35 40 45 Asn Phe Gln Gln Pro Tyr Ile
Thr Asn Arg Thr Phe Met Leu Ala 50 55 60 Lys Glu Ala Ser Leu Ala
Asp Asn Asn Thr Asp Val Arg Leu Ile 65 70 75 Gly Glu Lys Leu Phe
His Gly Val Ser Met Ser Glu Arg Cys Tyr 80 85 90 Leu Met Lys Gln
Val Leu Asn Phe Thr Leu Glu Glu Val Leu Phe 95 100 105 Pro Gln Ser
Asp Arg Phe Gln Pro Tyr Met Gln Glu Val Val Pro 110 115 120 Phe Leu
Ala Arg Leu Ser Asn Arg Leu Ser Thr Cys His Ile Glu 125 130 135 Gly
Asp Asp Leu His Ile Gln Arg Asn Val Gln Lys Leu Lys Asp 140 145 150
Thr Val Lys Lys Leu Gly Glu Ser Gly Glu Ile Lys Ala Ile Gly 155 160
165 Glu Leu Asp Leu Leu Phe Met Ser Leu Arg Asn Ala Cys Ile 170 175
127 2557 DNA Homo Sapien 127 gccctaacct tcccagggct cagctctttg
gagctgccca ttcctccggc 50 tgcgagaaag gacgcgcgcc ctgcgtcggg
cgaagaaaag aagcaaaact 100 tgtcgggagg gtttcgtcat caacctcctt
cccgcaaacc taaacctcct 150 gccggggcca tccctagaca gaggaaagtt
cctgcagagc cgaccagccc 200 tagtggatct ggggcaggca gcggcgctgg
ctgtggaatt agatctgttt 250 tgaacccagt ggagcgcatc gctggggctc
ggaagtcacc gtccgcgggc 300 accgggttgg cgctgcccga gtggaaccga
cagtttgcga gcctcggctg 350 caagtggcct ctcctccccg cggttgttgt
tcagtgtcgg gtgagggctg 400 cgagtgtggc aagttgcaaa gagagcctca
gaggtccgaa gagcgctgcg 450 ctcctactcg cgttcgcttc ttcctcttct
cggttcccta ctgtgaaatc 500 gcagcgacat ttacaaaggc ctccgggtcc
taccgagacc gatccgcagc 550 gtttggcccg gtcgtgccta ttgcatcggg
agcccccgag caccggcgaa 600 atggcgaggt tcccgaaggc cgacctggcc
gctgcaggag ttatgttact 650 ttgccacttc ttcacggacc agtttcagtt
cgccgatggg aaacccggag 700 accaaatcct tgattggcag tatggagtta
ctcaggcctt ccctcacaca 750 gaggaggagg tggaagttga ttcacacgcg
tacagccaca ggtggaaaag 800 aaacttggac tttctcaagg cggtagacac
gaaccgagca agcgtcggcc 850 aagactctcc tgagcccaga agcttcacag
acctgctgct ggatgatggg 900 caggacaata acactcagat cgaggaggat
acagaccaca attactatat 950 atctcgaata tatggtccat ctgattctgc
cagccgggat ttatgggtga 1000 acatagacca aatggaaaaa gataaagtga
agattcatgg aatattgtcc 1050 aatactcatc ggcaagctgc aagagtgaat
ctgtccttcg attttccatt 1100 ttatggccac ttcctacgtg aaatcactgt
ggcaaccggg ggtttcatat 1150 acactggaga agtcgtacat cgaatgctaa
cagccacaca gtacatagca 1200 cctttaatgg caaatttcga tcccagtgta
tccagaaatt caactgtcag 1250 atattttgat aatggcacag cacttgtggt
ccagtgggac catgtacatc 1300 tccaggataa ttataacctg ggaagcttca
cattccaggc aaccctgctc 1350 atggatggac gaatcatctt tggatacaaa
gaaattcctg tcttggtcac 1400 acagataagt tcaaccaatc atccagtgaa
agtcggactg tccgatgcat 1450 ttgtcgttgt ccacaggatc caacaaattc
ccaatgttcg aagaagaaca 1500 atttatgaat accaccgagt agagctacaa
atgtcaaaaa ttaccaacat 1550 ttcggctgtg gagatgaccc cattacccac
atgcctccag tttaacagat 1600 gtggcccctg tgtatcttct cagattggct
tcaactgcag ttggtgtagt 1650 aaacttcaaa gatgttccag tggatttgat
cgtcatcggc aggactgggt 1700 ggacagtgga tgccctgaag agtcaaaaga
gaagatgtgt gagaatacag 1750 aaccagtgga aacttcttct cgaaccacca
caaccgtagg agcgacaacc 1800 acccagttca gggtcctaac taccaccaga
agagcagtga cttctcagtt 1850 tcccaccagc ctccctacag aagatgatac
caagatagca ctacatctaa 1900 aagataatgg agcttctaca gatgacagtg
cagctgagaa gaaaggggga 1950 accctccacg ctggcctcat cattggaatc
ctcatcctgg tcctcattgt 2000 agccacagcc attcttgtga cagtctatat
gtatcaccac ccaacatcag 2050 cagccagcat cttctttatt gagagacgcc
caagcagatg gcctgcgatg 2100 aagtttagaa gaggctctgg acatcctgcc
tatgctgaag ttgaaccagt 2150 tggagagaaa gaaggcttta ttgtatcaga
gcagtgctaa aatttctagg 2200 acagaacaac accagtactg gtttacaggt
gttaagacta aaattttgcc 2250 tataccttta agacaaacaa acaaacacac
acacaaacaa gctctaagct 2300 gctgtagcct gaagaagaca agatttctgg
acaagctcag cccaggaaac 2350 aaagggtaaa caaaaaacta aaacttatac
aagataccat ttacactgaa 2400 catagaattc cctagtggaa tgtcatctat
agttcactcg gaacatctcc 2450 cgtggactta tctgaagtat gacaagatta
taatgctttt ggcttaggtg 2500 cagggttgca aagggatcag aaaaaaaaaa
tcataataaa gctttagttc 2550 atgaggg 2557 128 529 PRT Homo Sapien 128
Met Ala Arg Phe Pro Lys Ala Asp Leu Ala Ala Ala Gly Val Met 1 5 10
15 Leu Leu Cys His Phe Phe Thr Asp Gln Phe Gln Phe Ala Asp Gly 20
25 30 Lys Pro Gly Asp Gln Ile Leu Asp Trp Gln Tyr Gly Val Thr Gln
35 40 45 Ala Phe Pro His Thr Glu Glu Glu Val Glu Val Asp Ser His
Ala 50 55 60 Tyr Ser His Arg Trp Lys Arg Asn Leu Asp Phe Leu Lys
Ala Val 65 70 75 Asp Thr Asn Arg Ala Ser Val Gly Gln Asp Ser Pro
Glu Pro Arg 80 85 90 Ser Phe Thr Asp Leu Leu Leu Asp Asp Gly Gln
Asp Asn Asn Thr 95 100 105 Gln Ile Glu Glu Asp Thr Asp His Asn Tyr
Tyr Ile Ser Arg Ile 110 115 120 Tyr Gly Pro Ser Asp Ser Ala Ser Arg
Asp Leu Trp Val Asn Ile 125 130 135 Asp Gln Met Glu Lys Asp Lys Val
Lys Ile His Gly Ile Leu Ser 140 145 150 Asn Thr His Arg Gln Ala Ala
Arg Val Asn Leu Ser Phe Asp Phe 155 160 165 Pro Phe Tyr Gly His Phe
Leu Arg Glu Ile Thr Val Ala Thr Gly 170 175 180 Gly Phe Ile Tyr Thr
Gly Glu Val Val His Arg Met Leu Thr Ala 185 190 195 Thr Gln Tyr Ile
Ala Pro Leu Met Ala Asn Phe Asp Pro Ser Val 200 205 210 Ser Arg Asn
Ser Thr Val Arg Tyr Phe Asp Asn Gly Thr Ala Leu 215 220 225 Val Val
Gln Trp Asp His Val His Leu Gln Asp Asn Tyr Asn Leu 230 235 240 Gly
Ser Phe Thr Phe Gln Ala Thr Leu Leu Met Asp Gly Arg Ile 245 250 255
Ile Phe Gly Tyr Lys Glu Ile Pro Val Leu Val Thr Gln Ile Ser 260 265
270 Ser Thr Asn His Pro Val Lys Val Gly Leu Ser Asp Ala Phe Val 275
280 285 Val Val His Arg Ile Gln Gln Ile Pro Asn Val Arg Arg Arg Thr
290 295 300 Ile Tyr Glu Tyr His Arg Val Glu Leu Gln Met Ser Lys Ile
Thr 305 310 315 Asn Ile Ser Ala Val Glu Met Thr Pro Leu Pro Thr Cys
Leu Gln 320 325 330 Phe Asn Arg Cys Gly Pro Cys Val Ser Ser Gln Ile
Gly Phe Asn 335 340 345 Cys Ser Trp Cys Ser Lys Leu Gln Arg Cys Ser
Ser Gly Phe Asp 350 355 360 Arg His Arg Gln Asp Trp Val Asp Ser Gly
Cys Pro Glu Glu Ser 365 370 375 Lys Glu Lys Met Cys Glu Asn Thr Glu
Pro Val Glu Thr Ser Ser 380 385 390 Arg Thr Thr Thr Thr Val Gly Ala
Thr Thr Thr Gln Phe Arg Val 395 400 405 Leu Thr Thr Thr Arg Arg Ala
Val Thr Ser Gln Phe Pro Thr Ser 410 415 420 Leu Pro Thr Glu Asp Asp
Thr Lys Ile Ala Leu His Leu Lys Asp 425 430 435 Asn Gly Ala Ser Thr
Asp Asp Ser Ala Ala Glu Lys Lys Gly Gly 440 445 450 Thr Leu His Ala
Gly Leu Ile Ile Gly Ile Leu Ile Leu Val Leu 455 460 465 Ile Val Ala
Thr Ala Ile Leu Val Thr Val Tyr Met Tyr His His 470 475 480 Pro Thr
Ser Ala Ala Ser Ile Phe Phe Ile Glu Arg Arg Pro Ser 485 490 495 Arg
Trp Pro Ala Met Lys Phe Arg Arg Gly Ser Gly His Pro Ala 500 505 510
Tyr Ala Glu Val Glu Pro Val Gly Glu Lys Glu Gly Phe Ile Val 515 520
525 Ser Glu Gln Cys 129 4834 DNA Homo Sapien unsure 3784 unknown
base 129 gcagccctag cagggatgga catgatgctg ttggtgcagg gtgcttgttg 50
ctcgaaccag tggctggcgg cggtgctcct cagcctgtgc tgcctgctac 100
cctcctgcct cccggctgga cagagtgtgg acttcccctg ggcggccgtg 150
gacaacatga tggtcagaaa aggggacacg gcggtgctta ggtgttattt 200
ggaagatgga gcttcaaagg gtgcctggct gaaccggtca agtattattt 250
ttgcgggagg tgataagtgg tcagtggatc ctcgagtttc aatttcaaca 300
ttgaataaaa gggactacag cctccagata cagaatgtag atgtgacaga 350
tgatggccca tacacgtgtt ctgttcagac tcaacataca cccagaacaa 400
tgcaggtgca tctaactgtg
caagttcctc ctaagatata tgacatctca 450 aatgatatga ccgtcaatga
aggaaccaac gtcactctta cttgtttggc 500 cactgggaaa ccagagcctt
ccatttcttg gcgacacatc tccccatcag 550 caaaaccatt tgaaaatgga
caatatttgg acatttatgg aattacaagg 600 gaccaggctg gggaatatga
atgcagtgcg gaaaatgatg tgtcattccc 650 agatgtgagg aaagtaaaag
ttgttgtcaa ctttgctcct actattcagg 700 aaattaaatc tggcaccgtg
acccccggac gcagtggcct gataagatgt 750 gaaggtgcag gtgtgccgcc
tccagccttt gaatggtaca aaggagagaa 800 gaagctcttc aatggccaac
aaggaattat tattcaaaat tttagcacaa 850 gatccattct cactgttacc
aacgtgacac aggagcactt cggcaattat 900 acttgtgtgg ctgccaacaa
gctaggcaca accaatgcga gcctgcctct 950 taaccctcca agtacagccc
agtatggaat taccgggagc gctgatgttc 1000 ttttctcctg ctggtacctt
gtgttgacac tgtcctcttt caccagcata 1050 ttctacctga agaatgccat
tctacaataa attcaaagac ccataaaagg 1100 cttttaagga ttctctgaaa
gtgctgatgg ctggatccaa tctggtacag 1150 tttgttaaaa gcagcgtggg
atataatcag cagtgcttac atggggatga 1200 tcgccttctg tagaattgct
cattatgtaa atactttaat tctactcttt 1250 tttgattagc tacattacct
tgtgaagcag tacacattgt ccttttttta 1300 agacgtgaaa gctctgaaat
tacttttaga ggatattaat tgtgatttca 1350 tgtttgtaat ctacaacttt
tcaaaagcat tcagtcatgg tctgctaggt 1400 tgcaggctgt agtttacaaa
aacgaatatt gcagtgaata tgtgattctt 1450 taaggctgca atacaagcat
tcagttccct gtttcaataa gagtcaatcc 1500 acatttacaa agatgcattt
ttttcttttt tgataaaaaa gcaaataata 1550 ttgccttcag attatttctt
caaaatataa cacatatcta gatttttctg 1600 ctcgcatgat attcaggttt
caggaatgag ccttgtaata taactggctg 1650 tgcagctctg cttctctttc
ctgtaagttc agcatgggtg tgccttcata 1700 caataatatt tttctctttg
tctccaacta atataaaatg ttttgctaaa 1750 tcttacaatt tgaaagtaaa
aataaaccag agtgatcaag ttaaaccata 1800 cactatctct aagtaacgaa
ggagctattg gactgtaaaa atctcttcct 1850 gcactgacaa tggggtttga
gaattttgcc ccacactaac tcagttcttg 1900 tgatgagaga caatttaata
acagtatagt aaatatacca tatgatttct 1950 ttagttgtag ctaaatgtta
gatccaccgt gggaaatcat tccctttaaa 2000 atgacagcac agtccactca
aaggattgcc tagcaataca gcatcttttc 2050 ctttcactag tccaagccaa
aaattttaag atgatttgtc agaaagggca 2100 caaagtccta tcacctaata
ttacaagagt tggtaagcgc tcatcattaa 2150 ttttattttg tggcagctaa
gttagtatga cagaggcagt gctcctgtgg 2200 acaggagcat tttgcatatt
ttccatctga aagtatcact cagttgatag 2250 tctggaatgc atgttatata
ttttaaaact tccaaaatat attataacaa 2300 acattctata tcggtatgta
gcagaccaat ctctaaaata gctaattctt 2350 caataaaatc tttctatata
gccatttcag tgcaaacaag taaaatcaaa 2400 aaagaccatc ctttattttt
ccttacatga tatatgtaag atgcgatcaa 2450 ataaagacaa aacaccagtg
atgagaatat cttaagataa gtaattatca 2500 aattattgtg aatgttaaat
tatttctact ataaagaagc aaaactacat 2550 ttttgaagga aaatgctgtt
actctaacat taatttacag gaatagtttg 2600 atggtttcac tctttactaa
agaaaggcca tcaccttgaa agccatttta 2650 caggtttgat gaagttacca
atttcagtac acctaaattt ctacaaatag 2700 tcccctttta caagttgtaa
caacaaagac cctataataa aattagatac 2750 aagaaatttt gcagtggtta
tacatatttg agatatctag tatgttgccc 2800 tagcagggat ggcttaaaaa
ctgtgatttt ttttcttcaa gtaaaactta 2850 gtcccaaagt acatcataaa
tcaattttaa ttagaaaaat gaatcttaaa 2900 tgaggggaca taagtatact
ctttccacaa aatggcaata ataaggcata 2950 aagctagtaa atctactaac
tgtaataaat gtatgacatt attttgattg 3000 atacattaaa aaagagtttt
tagaacaaat atggcattta actttattat 3050 ttatttgctt ttaagaaata
ttctttgtgg aattgttgaa taaactataa 3100 aatattattt tgtattgcag
ctttaaagtg gcacactcca taataatcta 3150 cttactagaa atagtggtgc
taccacaaaa aatgttaacc atcagtacca 3200 ttgtttggga gaaagaaaca
gatcaagaat gcatattatt cagtgaccgc 3250 tttcctagag ttaaaatacc
tcctctttgt aaggtttgta ggtaaattga 3300 ggtataaact atggatgaac
caaataatta gttcaaagtg ttgtcatgat 3350 tccaaatttg tggagtctgg
tgtttttacc atagaatgtg acagaagtac 3400 agtcatagct cagtagctat
atgtatttgc ctttatgtta gaagagactt 3450 tcttgagtga catttttaaa
tagaggaggt attcactatg tttttctgta 3500 tcacagcagc attcctagtc
cttaggccct cggacagagt gaaatcatga 3550 gtatttatga gttcaatatt
gtcaaataag gctacagtat ttgctttttt 3600 gtgtgaatgt attgcatata
atgttcaagt agatgatttt acatttatgg 3650 acatataaaa tgtctgatta
ccccatttta tcagtcctga ctgtacaaga 3700 ttgttgcaat ttcagaatag
cagttttata aattgattta tcttttaatc 3750 tataacaatt tgtgttagct
gttcatttca ggantatatt ttctacaagt 3800 tccacttgtg ggactccttt
tgttgcccct attttttttt aaagaaggaa 3850 gaaagaaaaa taagtagcag
tttaaaaatg agaatggaga gaaaagaaaa 3900 agaatgaaaa ggaaaggcag
taaagaggga aaaaaaagga aggatggaag 3950 gaatgaagga aggaagggag
gaaggggaga aggtaggaag aaagaaagga 4000 tgagagggaa ggaagaatca
gagtattagg gtagttaact tacacatttg 4050 cattcttagt ttaactgcaa
gtggtgtaac tatgtttttc aatgatcgca 4100 tttgaaacat aagtcctatt
ataccattaa gttcctatta tgcagcaatt 4150 atataataaa aagtactgcc
caagttatag taatgtgggt gtttttgaga 4200 cactaaaaga tttgagaggg
agaatttcaa acttaaagcc acttttgggg 4250 ggtttataac ttaactgaaa
aattaatgct tcatcataac atttaagcta 4300 tatctagaaa gtagactgga
gaactgagaa aattacccag gtaattcagg 4350 gaaaaaaaaa aatatatata
tatataaata cccctacatt tgaagtcaga 4400 aaactctgaa aaactgaatt
atcaaagtca atcatctata atgatcaaat 4450 ttactgaaca attgttaatt
tatccattgt gcttagcttt gtgacacagc 4500 caaaagttac ctatttaatc
ttttcaataa aaattgtttt ttgaaatcca 4550 gaaatgattt aaaaagaggt
caggttttta actatttatt gaagtatgtg 4600 gatgtacagt atttcaatag
atatgaatat gaataaatgg tatgccttaa 4650 gattctttga atatgtattt
actttaaaga ctggaaaaag ctcttcctgt 4700 cttttagtaa aacatccata
tttcataacc tgatgtaaaa tatgttgtac 4750 tgtttccaat aggtgaatat
aaactcagtt tatcaattaa aaaaaaaaaa 4800 aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaa 4834 130 354 PRT Homo Sapien 130 Met Asp Met Met
Leu Leu Val Gln Gly Ala Cys Cys Ser Asn Gln 1 5 10 15 Trp Leu Ala
Ala Val Leu Leu Ser Leu Cys Cys Leu Leu Pro Ser 20 25 30 Cys Leu
Pro Ala Gly Gln Ser Val Asp Phe Pro Trp Ala Ala Val 35 40 45 Asp
Asn Met Met Val Arg Lys Gly Asp Thr Ala Val Leu Arg Cys 50 55 60
Tyr Leu Glu Asp Gly Ala Ser Lys Gly Ala Trp Leu Asn Arg Ser 65 70
75 Ser Ile Ile Phe Ala Gly Gly Asp Lys Trp Ser Val Asp Pro Arg 80
85 90 Val Ser Ile Ser Thr Leu Asn Lys Arg Asp Tyr Ser Leu Gln Ile
95 100 105 Gln Asn Val Asp Val Thr Asp Asp Gly Pro Tyr Thr Cys Ser
Val 110 115 120 Gln Thr Gln His Thr Pro Arg Thr Met Gln Val His Leu
Thr Val 125 130 135 Gln Val Pro Pro Lys Ile Tyr Asp Ile Ser Asn Asp
Met Thr Val 140 145 150 Asn Glu Gly Thr Asn Val Thr Leu Thr Cys Leu
Ala Thr Gly Lys 155 160 165 Pro Glu Pro Ser Ile Ser Trp Arg His Ile
Ser Pro Ser Ala Lys 170 175 180 Pro Phe Glu Asn Gly Gln Tyr Leu Asp
Ile Tyr Gly Ile Thr Arg 185 190 195 Asp Gln Ala Gly Glu Tyr Glu Cys
Ser Ala Glu Asn Asp Val Ser 200 205 210 Phe Pro Asp Val Arg Lys Val
Lys Val Val Val Asn Phe Ala Pro 215 220 225 Thr Ile Gln Glu Ile Lys
Ser Gly Thr Val Thr Pro Gly Arg Ser 230 235 240 Gly Leu Ile Arg Cys
Glu Gly Ala Gly Val Pro Pro Pro Ala Phe 245 250 255 Glu Trp Tyr Lys
Gly Glu Lys Lys Leu Phe Asn Gly Gln Gln Gly 260 265 270 Ile Ile Ile
Gln Asn Phe Ser Thr Arg Ser Ile Leu Thr Val Thr 275 280 285 Asn Val
Thr Gln Glu His Phe Gly Asn Tyr Thr Cys Val Ala Ala 290 295 300 Asn
Lys Leu Gly Thr Thr Asn Ala Ser Leu Pro Leu Asn Pro Pro 305 310 315
Ser Thr Ala Gln Tyr Gly Ile Thr Gly Ser Ala Asp Val Leu Phe 320 325
330 Ser Cys Trp Tyr Leu Val Leu Thr Leu Ser Ser Phe Thr Ser Ile 335
340 345 Phe Tyr Leu Lys Asn Ala Ile Leu Gln 350 131 823 DNA Homo
Sapien 131 atagtagaag aatgtctctg aaattactgg atgagtttca gtcatacttt
50 cacatgggca caatttcaca ttcaagctcc ttatcctagg ctaattttat 100
attatgttaa atcacttgtt tttgttctca cggcttcctg cctgctatag 150
gcataattac gaggaagcag aacttctcca gaagcaagcg cacatgcgtt 200
ccaaaataag agcaaattcg ctctaaacac aggaaaagac ctgaagcttt 250
aattaagggg ttacatccaa ccccagagcg cttttgtggg cactgattgc 300
tccagcttct gcgtcactgc gcgagggaag agggaagagg atccaggcgt 350
tagacatgta tagacacaaa aacagctgga gattgggctt aaaataccca 400
ccaagctcca aagaagagac ccaagtcccc aaaacattga tttcagggct 450
gccaggaagg aagagcagca gcagggtggg agagaagctc cagtcagccc 500
acaagatgcc attgtccccc ggcctcctgc tgctgctgct ctccggggcc 550
acggccaccg ctgccctgcc cctggagggt ggccccaccg gccgagacag 600
cgagcatatg caggaagcgg caggaataag gaaaagcagc ctcctgactt 650
tcctcgcttg gtggtttgag tggacctccc aggccagtgc cgggcccctc 700
ataggagagg aagctcggga ggtggccagg cggcaggaag gcgcaccccc 750
ccagcaatcc gcgcgccggg acagaatgcc ctgcaggaac ttcttctgga 800
agaccttctc ctcctgcaaa tag 823 132 155 PRT Homo Sapien 132 Met Tyr
Arg His Lys Asn Ser Trp Arg Leu Gly Leu Lys Tyr Pro 1 5 10 15 Pro
Ser Ser Lys Glu Glu Thr Gln Val Pro Lys Thr Leu Ile Ser 20 25 30
Gly Leu Pro Gly Arg Lys Ser Ser Ser Arg Val Gly Glu Lys Leu 35 40
45 Gln Ser Ala His Lys Met Pro Leu Ser Pro Gly Leu Leu Leu Leu 50
55 60 Leu Leu Ser Gly Ala Thr Ala Thr Ala Ala Leu Pro Leu Glu Gly
65 70 75 Gly Pro Thr Gly Arg Asp Ser Glu His Met Gln Glu Ala Ala
Gly 80 85 90 Ile Arg Lys Ser Ser Leu Leu Thr Phe Leu Ala Trp Trp
Phe Glu 95 100 105 Trp Thr Ser Gln Ala Ser Ala Gly Pro Leu Ile Gly
Glu Glu Ala 110 115 120 Arg Glu Val Ala Arg Arg Gln Glu Gly Ala Pro
Pro Gln Gln Ser 125 130 135 Ala Arg Arg Asp Arg Met Pro Cys Arg Asn
Phe Phe Trp Lys Thr 140 145 150 Phe Ser Ser Cys Lys 155 133 24 DNA
Artificial Sequence Synthetic oligonucleotide probe 133 tcagggctgc
caggaaggaa gagc 24 134 28 DNA Artificial Sequence Synthetic
oligonucleotide probe 134 gcaggaggag aaggtcttcc agaagaag 28 135 45
DNA Artificial Sequence Synthetic oligonucleotide probe 135
agaagttcca gtcagcccac aagatgccat tgtcccccgg cctcc 45 136 1875 DNA
Homo Sapien 136 gtcgtgtgct tggaggaagc cgcggaaccc ccagcgtccg
tccatggcgt 50 ggagccttgg gagctggctg ggtggctgcc tgctggtgtc
agcattggga 100 atggtaccac ctcccgaaaa tgtcagaatg aattctgtta
atttcaagaa 150 cattctacag tgggagtcac ctgcttttgc caaagggaac
ctgactttca 200 cagctcagta cctaagttat aggatattcc aagataaatg
catgaatact 250 accttgacgg aatgtgattt ctcaagtctt tccaagtatg
gtgaccacac 300 cttgagagtc agggctgaat ttgcagatga gcattcagac
tgggtaaaca 350 tcaccttctg tcctgtggat gacaccatta ttggaccccc
tggaatgcaa 400 gtagaagtac ttgctgattc tttacatatg cgtttcttag
cccctaaaat 450 tgagaatgaa tacgaaactt ggactatgaa gaatgtgtat
aactcatgga 500 cttataatgt gcaatactgg aaaaacggta ctgatgaaaa
gtttcaaatt 550 actccccagt atgactttga ggtcctcaga aacctggagc
catggacaac 600 ttattgtgtt caagttcgag ggtttcttcc tgatcggaac
aaagctgggg 650 aatggagtga gcctgtctgt gagcaaacaa cccatgacga
aacggtcccc 700 tcctggatgg tggccgtcat cctcatggcc tcggtcttca
tggtctgcct 750 ggcactcctc ggctgcttct ccttgctgtg gtgcgtttac
aagaagacaa 800 agtacgcctt ctcccctagg aattctcttc cacagcacct
gaaagagttt 850 ttgggccatc ctcatcataa cacacttctg tttttctcct
ttccattgtc 900 ggatgagaat gatgtttttg acaagctaag tgtcattgca
gaagactctg 950 agagcggcaa gcagaatcct ggtgacagct gcagcctcgg
gaccccgcct 1000 gggcaggggc cccaaagcta ggctctgaga aggaaacaca
ctcggctggg 1050 cacagtgacg tactccatct cacatctgcc tcagtgaggg
atcagggcag 1100 caaacaaggg ccaagaccat ctgagccagc cccacatcta
gaactccaga 1150 cctggactta gccaccagag agctacattt taaaggctgt
cttggcaaaa 1200 atactccatt tgggaactca ctgccttata aaggctttca
tgatgttttc 1250 agaagttggc cactgagagt gtaattttca gccttttata
tcactaaaat 1300 aagatcatgt tttaattgtg agaaacaggg ccgagcacag
tggctcacgc 1350 ctgtaatacc agcaccttag aggtcgaggc aggcggatca
cttgaggtca 1400 ggagttcaag accagcctgg ccaatatggt gaaacccagt
ctctactaaa 1450 aatacaaaaa ttagctaggc atgatggcgc atgcctataa
tcccagctac 1500 tcgagtgcct gaggcaggag aattgcatga acccgggagg
aggaggagga 1550 ggttgcagtg agccgagata gcggcactgc actccagcct
gggtgacaaa 1600 gtgagactcc atctcaaaaa aaaaaaaaaa aaattgtgag
aaacagaaat 1650 acttaaaatg aggaataaga atggagatgt tacatctggt
agatgtaaca 1700 ttctaccaga ttatggatgg actgatctga aaatcgacct
caactcaagg 1750 gtggtcagct caatgctaca cagagcacgg acttttggat
tctttgcagt 1800 actttgaatt tatttttcta cctatatatg ttttatatgc
tgctggtgct 1850 ccattaaagt tttactctgt gttgc 1875 137 325 PRT Homo
Sapien 137 Met Ala Trp Ser Leu Gly Ser Trp Leu Gly Gly Cys Leu Leu
Val 1 5 10 15 Ser Ala Leu Gly Met Val Pro Pro Pro Glu Asn Val Arg
Met Asn 20 25 30 Ser Val Asn Phe Lys Asn Ile Leu Gln Trp Glu Ser
Pro Ala Phe 35 40 45 Ala Lys Gly Asn Leu Thr Phe Thr Ala Gln Tyr
Leu Ser Tyr Arg 50 55 60 Ile Phe Gln Asp Lys Cys Met Asn Thr Thr
Leu Thr Glu Cys Asp 65 70 75 Phe Ser Ser Leu Ser Lys Tyr Gly Asp
His Thr Leu Arg Val Arg 80 85 90 Ala Glu Phe Ala Asp Glu His Ser
Asp Trp Val Asn Ile Thr Phe 95 100 105 Cys Pro Val Asp Asp Thr Ile
Ile Gly Pro Pro Gly Met Gln Val 110 115 120 Glu Val Leu Ala Asp Ser
Leu His Met Arg Phe Leu Ala Pro Lys 125 130 135 Ile Glu Asn Glu Tyr
Glu Thr Trp Thr Met Lys Asn Val Tyr Asn 140 145 150 Ser Trp Thr Tyr
Asn Val Gln Tyr Trp Lys Asn Gly Thr Asp Glu 155 160 165 Lys Phe Gln
Ile Thr Pro Gln Tyr Asp Phe Glu Val Leu Arg Asn 170 175 180 Leu Glu
Pro Trp Thr Thr Tyr Cys Val Gln Val Arg Gly Phe Leu 185 190 195 Pro
Asp Arg Asn Lys Ala Gly Glu Trp Ser Glu Pro Val Cys Glu 200 205 210
Gln Thr Thr His Asp Glu Thr Val Pro Ser Trp Met Val Ala Val 215 220
225 Ile Leu Met Ala Ser Val Phe Met Val Cys Leu Ala Leu Leu Gly 230
235 240 Cys Phe Ser Leu Leu Trp Cys Val Tyr Lys Lys Thr Lys Tyr Ala
245 250 255 Phe Ser Pro Arg Asn Ser Leu Pro Gln His Leu Lys Glu Phe
Leu 260 265 270 Gly His Pro His His Asn Thr Leu Leu Phe Phe Ser Phe
Pro Leu 275 280 285 Ser Asp Glu Asn Asp Val Phe Asp Lys Leu Ser Val
Ile Ala Glu 290 295 300 Asp Ser Glu Ser Gly Lys Gln Asn Pro Gly Asp
Ser Cys Ser Leu 305 310 315 Gly Thr Pro Pro Gly Gln Gly Pro Gln Ser
320 325 138 2570 DNA Homo Sapien 138 cgagcgccaa cccgctagcg
cctgaatccg gcgtgctgcc cgctcgccgc 50 ccgccatggc ccgcgcagcc
ccgctgctcg ccgcgttgac cgcgctcctc 100 gccgccgccg ctgctggcgg
agatgccccg ccgggcaaaa tcgcggtggt 150 tggggctggg attgggggct
ctgctgtggc ccattttctc cagcagcact 200 ttggacctcg ggtgcagatc
gacgtgtacg agaagggaac cgtgggtggc 250 cgcttggcca ccatctcagt
caacaagcag cactatgaga gcggggctgc 300 ctccttccac tccctgagcc
tgcacatgca ggacttcgtc aagctgctgg 350 ggctgaggca ccggcgcgag
gtggtgggca ggagcgccat cttcggcggg
400 gagcacttca tgctggagga gactgactgg tacctgctga acctcttccg 450
cctctggtgg cactatggca tcagcttcct gaggctgcag atgtgggtgg 500
aggaggtcat ggagaagttc atgaggatct ataagtacca ggcccacggc 550
tatgccttct cgggtgtgga ggagctgctc tactcactgg gggagtccac 600
ctttgttaac atgacccagc actctgtggc tgagtccctg ctgcaggtgg 650
gcgtcacgca gcgctttatt gatgatgtcg tttctgctgt cctgcgggcc 700
agctatggcc agtcagcagc gatgcccgcc tttgcaggag ccatgtcact 750
agccggggcc caaggcagcc tgtggtctgt ggaaggaggc aataagctgg 800
tttgttccgg tttgctgaag ctcaccaagg ccaatgtgat ccatgccaca 850
gtgacctctg tgaccctgca cagcacagag gggaaagccc tgtaccaggt 900
ggcgtatgag aatgaggtag gcaacagctc tgacttctat gacatcgtgg 950
tcatcgccac ccccctgcac ctggacaaca gcagcagcaa cttaaccttt 1000
gcaggcttcc acccgcccat tgatgacgtg cagggctctt tccagcccac 1050
cgtcgtctcc ttggtccacg gctacctcaa ctcgtcctac ttcggtttcc 1100
cagaccctaa gcttttcccc tttgccaaca tccttaccac agatttcccc 1150
agcttcttct gcactctgga caacatctgc cctgtcaaca tctctgccag 1200
cttccggcga aagcagcccc aggaggcagc tgtttggcga gtccagtccc 1250
ccaagcccct ctttcggacc cagctaaaga ccctgttccg ttcctattac 1300
tcagtgcaga cagctgagtg gcaggcccat cccctctatg gctcccgccc 1350
cacgctcccg aggtttgcac tccatgacca gctcttctac ctcaatgccc 1400
tggagtgggc ggccagctcc gtggaggtga tggccgtggc tgccaagaat 1450
gtggccttgc tggcttacaa ccgctggtac caggacctag acaagattga 1500
tcaaaaagat ttgatgcaca aggtcaagac tgaactgtga gggctctagg 1550
gagagcctgg gaactttcat cccccactga agatggatca tcccacagca 1600
gcccaggact gaataagcca tgctcgccca ccaggcttct ttctgacccc 1650
tcatgtatca agcatctcca ggtgacctac tgtctgccta tattaagggt 1700
ccacacggcg gctgctgctt ttttttaagg gggaaagtaa gaaaagagaa 1750
ggaaatccaa gccagtatat ttgttttatt tatttttttt aagaagaaaa 1800
aagttcatct tcacaaggtg cttcagactt ggtttcttag ctagaaacca 1850
gaagactacg ggagggaata taaggcagag aactatgagt cttattttat 1900
tactgttttt cactacctac tcccacaatg gacaatcaat tgaggcaacc 1950
tacaagaaaa catttacaac cagatggtta caaataaagt agaagggaag 2000
atcagaaaac ctaagaaatg atcatagctc ctggttactg tggacttgat 2050
ggatttgaag tacctagttc agaactccct agtcaccatc tccaagcctg 2100
tcaacatcac tgcatattgg aggagatgac tgtggtagga cccaaggaag 2150
agatgtgtgc ctgaatagtc gtcaccatat ctccaagctt cctggcaacc 2200
agtgggaaaa gaaacatgcg aggctgtagg aagagggaag ctcttccttg 2250
gcacctagag gaattagcca ttctcttcct tatgcaaaga ttgaggaatg 2300
caacaatata aagaagagaa gtccccagat ggtagagagc agtcatatct 2350
tacccctaga tgttcatccc agcagaagaa agaagaaggt gttggggtag 2400
gattcttcag aggttagcct ggtactttct catcagacac tagcttgaag 2450
taagaggaga attatgcttt tctttgcttt ttctacaaac ccttaaaaat 2500
cacttgtttt aaaaagaaag taaaagccct tttcattcaa aaaaaaaaaa 2550
aaaaaaaaaa aaaaaaaaaa 2570 139 494 PRT Homo Sapien 139 Met Ala Arg
Ala Ala Pro Leu Leu Ala Ala Leu Thr Ala Leu Leu 1 5 10 15 Ala Ala
Ala Ala Ala Gly Gly Asp Ala Pro Pro Gly Lys Ile Ala 20 25 30 Val
Val Gly Ala Gly Ile Gly Gly Ser Ala Val Ala His Phe Leu 35 40 45
Gln Gln His Phe Gly Pro Arg Val Gln Ile Asp Val Tyr Glu Lys 50 55
60 Gly Thr Val Gly Gly Arg Leu Ala Thr Ile Ser Val Asn Lys Gln 65
70 75 His Tyr Glu Ser Gly Ala Ala Ser Phe His Ser Leu Ser Leu His
80 85 90 Met Gln Asp Phe Val Lys Leu Leu Gly Leu Arg His Arg Arg
Glu 95 100 105 Val Val Gly Arg Ser Ala Ile Phe Gly Gly Glu His Phe
Met Leu 110 115 120 Glu Glu Thr Asp Trp Tyr Leu Leu Asn Leu Phe Arg
Leu Trp Trp 125 130 135 His Tyr Gly Ile Ser Phe Leu Arg Leu Gln Met
Trp Val Glu Glu 140 145 150 Val Met Glu Lys Phe Met Arg Ile Tyr Lys
Tyr Gln Ala His Gly 155 160 165 Tyr Ala Phe Ser Gly Val Glu Glu Leu
Leu Tyr Ser Leu Gly Glu 170 175 180 Ser Thr Phe Val Asn Met Thr Gln
His Ser Val Ala Glu Ser Leu 185 190 195 Leu Gln Val Gly Val Thr Gln
Arg Phe Ile Asp Asp Val Val Ser 200 205 210 Ala Val Leu Arg Ala Ser
Tyr Gly Gln Ser Ala Ala Met Pro Ala 215 220 225 Phe Ala Gly Ala Met
Ser Leu Ala Gly Ala Gln Gly Ser Leu Trp 230 235 240 Ser Val Glu Gly
Gly Asn Lys Leu Val Cys Ser Gly Leu Leu Lys 245 250 255 Leu Thr Lys
Ala Asn Val Ile His Ala Thr Val Thr Ser Val Thr 260 265 270 Leu His
Ser Thr Glu Gly Lys Ala Leu Tyr Gln Val Ala Tyr Glu 275 280 285 Asn
Glu Val Gly Asn Ser Ser Asp Phe Tyr Asp Ile Val Val Ile 290 295 300
Ala Thr Pro Leu His Leu Asp Asn Ser Ser Ser Asn Leu Thr Phe 305 310
315 Ala Gly Phe His Pro Pro Ile Asp Asp Val Gln Gly Ser Phe Gln 320
325 330 Pro Thr Val Val Ser Leu Val His Gly Tyr Leu Asn Ser Ser Tyr
335 340 345 Phe Gly Phe Pro Asp Pro Lys Leu Phe Pro Phe Ala Asn Ile
Leu 350 355 360 Thr Thr Asp Phe Pro Ser Phe Phe Cys Thr Leu Asp Asn
Ile Cys 365 370 375 Pro Val Asn Ile Ser Ala Ser Phe Arg Arg Lys Gln
Pro Gln Glu 380 385 390 Ala Ala Val Trp Arg Val Gln Ser Pro Lys Pro
Leu Phe Arg Thr 395 400 405 Gln Leu Lys Thr Leu Phe Arg Ser Tyr Tyr
Ser Val Gln Thr Ala 410 415 420 Glu Trp Gln Ala His Pro Leu Tyr Gly
Ser Arg Pro Thr Leu Pro 425 430 435 Arg Phe Ala Leu His Asp Gln Leu
Phe Tyr Leu Asn Ala Leu Glu 440 445 450 Trp Ala Ala Ser Ser Val Glu
Val Met Ala Val Ala Ala Lys Asn 455 460 465 Val Ala Leu Leu Ala Tyr
Asn Arg Trp Tyr Gln Asp Leu Asp Lys 470 475 480 Ile Asp Gln Lys Asp
Leu Met His Lys Val Lys Thr Glu Leu 485 490 140 23 DNA Artificial
Sequence Synthetic oligonucleotide probe 140 gggacgtgct tctacaagaa
cag 23 141 26 DNA Artificial Sequence Synthetic oligonucleotide
probe 141 caggcttaca atgttatgat cagaca 26 142 31 DNA Artificial
Sequence Synthetic oligonucleotide probe 142 tattcagagt tttccattgg
cagtgccagt t 31 143 18 DNA Artificial Sequence Synthetic
oligonucleotide probe 143 ggccttgcag acaaccgt 18 144 21 DNA
Artificial Sequence Synthetic oligonucleotide probe 144 cagactgagg
gagatccgag a 21 145 26 DNA Artificial Sequence Synthetic
oligonucleotide probe 145 gcagattttg aggacagcca cctcca 26 146 18
DNA Artificial Sequence Synthetic oligonucleotide probe 146
catcaagcgc ctctacca 18 147 21 DNA Artificial Sequence Synthetic
oligonucleotide probe 147 cacaaactcg aactgcttct g 21 148 20 DNA
Artificial Sequence Synthetic oligonucleotide probe 148 cagctgccct
tccccaacca 20 149 22 DNA Artificial Sequence Synthetic
oligonucleotide probe 149 ggcagagact tccagtcact ga 22 150 22 DNA
Artificial Sequence Synthetic oligonucleotide probe 150 gccaagggtg
gtgttagata gg 22 151 24 DNA Artificial Sequence Synthetic
oligonucleotide probe 151 caggccccct tgatctgtac ccca 24
* * * * *
References